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Abstract i 
 
Living systems are overwhelmingly complex and consist of many interacting parts. Already the quantitative 
characterization of a single human cell type on genetic level requires at least the measurement of 20000 gene 
expressions. It remains a big challenge for theoretical approaches to discover patterns in these signals that 
represent specific interactions in such systems. A major problem is that available standard procedures 
summarize gene expressions in a hard-to-interpret way. For example, principal components represent axes of 
maximal variance in the gene vector space and thus often correspond to a superposition of multiple different 
gene regulation effects(e.g. I.1.4). 
Here, a novel approach to analyze and interpret such complex data is developed(Chapter II). It is based on an 
extremum principle that identifies an axis in the gene vector space to which as many as possible samples are 
correlated as highly as possible(II.3). This axis is maximally specific and thus most probably corresponds to 
exactly one gene regulation effect, making it considerably easier to interpret than principle components. To 
stabilize and optimize effect discovery, axes in the sample vector space are identified simultaneously. Genes 
and samples are always handled symmetrically by the algorithm. While sufficient for effect discovery, effect  
axes can only linearly approximate regulation laws. To represent a broader class of nonlinear regulations,  
including saturation effects or activity thresholds(e.g. II.1.1.2), a bimonotonic effect model is defined(II.2.1.2).  
A corresponding regression is realized that is monotonic over projections of samples (or genes) onto 
discovered gene (or sample) axes. Resulting effect curves can approximate regulation laws precisely(II.4.1).  
This enables the dissection of exclusively the discovered effect from the signal(II.4.2). Signal parts from other 
potentially overlapping effects remain untouched. This continues iteratively. In this way, the high-dimensional 
initial signal(II.2.1.1) can be dissected into highly specific effects. 
Method validation demonstrates that superposed effects of various size, shape and signal strength can be 
dissected reliably(II.6.2). Simulated laws of regulation are reconstructed with high correlation. Detection limits, 
e.g. for signal strength or for missing values, lie above practical requirements(II.6.4). The novel approach is 
systematically compared with standard procedures such as principal component analysis. Signal dissection is 
shown to have clear advantages, especially for many overlapping effects of comparable size(II.6.3). 
An ideal test field for such approaches is cancer cells, as they may be driven by multiple overlapping gene 
regulation networks that are largely unknown. Additionally, quantification and classification of cancer cells by 
their particular set of driving gene regulations is a prerequisite towards precision medicine. To validate the 
novel method against real biological data, it is applied to gene expressions of over 1000 tumor samples from 
Diffuse Large B-Cell Lymphoma (DLBCL) patients(Chapter III). Two already known subtypes of this disease(cf. I.1.2.1) 
with significantly different survival following the same chemotherapy were originally also discovered as a 
gene expression effect. These subtypes can only be precisely determined by this effect on molecular level. Such 
previous results offer a possibility for method validation and indeed, this effect has been unsupervisedly 
rediscovered(III.3.2.2). 
Several additional biologically relevant effects have been discovered and validated across four patient 
cohorts. Multivariate analyses(III.2) identify combinations of validated effects that can predict significant 
differences in patient survival. One novel effect possesses an even higher predictive value(cf. III.2.5.1) than the 
rediscovered subtype effect and is genetically more specific(cf. III.3.3.1). A trained and validated Cox survival 
model(III.2.5) can predict significant survival differences within known DLBCL subtypes(III.2.5.6), demonstrating 
that they are genetically heterogeneous as well. Detailed biostatistical evaluations of all survival effects(III.3.3) 
may help to clarify the molecular pathogenesis of DLBCL. 
Furthermore, the applicability of signal dissection is not limited to biological data. For instance, dissecting  
spectral energy distributions of stars observed in astrophysics might be useful to discover laws of light emission. 
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Lebende Systeme sind überwältigend komplex und bestehen aus vielen interagierenden Teilen. Bereits die 
quantitative Charakterisierung eines einzelnen menschlichen Zelltyps auf genetischer Ebene bedarf 
mindestens der Messung von 20000 Genexpressionen. Es ist nach wie vor eine große Herausforderung für 
theoretische Ansätze, Muster in diesen Signalen zu entdecken, welche spezifische Interaktionen in solchen 
Systemen repräsentieren. Ein Hauptproblem besteht darin, dass verfügbare Standardmethoden die 
Genexpressionen in einer schwierig zu interpretierenden Weise zusammenfassen. Hauptkomponenten etwa 
repräsentieren Achsen maximaler Varianz im Genvektorraum und entsprechen daher häufig einer 
Überlagerung vieler verschiedener Genregulationseffekte(e.g. I.1.4). 
In dieser Arbeit wird ein neuartiger Ansatz zur Analyse und Interpretation derartig komplexer Daten 
entwickelt(Chapter II). Er basiert auf einem Extremalprinzip, welches eine Achse im Genvektorraum identifiziert, 
zu der so viele Proben wie möglich so hoch wie möglich korreliert sind(II.3). Diese Achse ist maximal spezifisch 
und entspricht daher typischerweise genau einem Genregulationseffekt, wodurch sie deutlich einfacher zu 
interpretieren ist als Hauptkomponenten. Zur Stabilisierung und zur Optimierung der Effekterkennung 
werden analog und gleichzeitig Achsen im Probenvektorraum identifiziert. Der Algorithmus behandelt 
generell Gene und Proben symmetrisch. Obwohl sie ausreichend zur Entdeckung von Effekten sind, können 
Effektachsen Regulationsgesetze nur linear annähern. Um eine breitere Klasse nichtlinearer Regulationen wie 
Sättigungseffekte oder Aktivitätsschwellen zu repräsentieren, wird ein bimonotonisches Effektmodell 
definiert(II.2.1.2). Die entsprechende Regression ist monotonisch über die Projektionen von Proben (bzw. Genen) 
auf entdeckte Genachsen (bzw. Probenachsen). Resultierende Effektkurven können Genregulationsgesetze 
präzise approximieren(II.4.1). Das ermöglicht die ausschließliche Abtrennung des entdeckten Effekts vom 
Signal(II.4.2). Signalbestandteile anderer (möglicherweise überlappender) Effekte bleiben unangetastet. Dies 
wird iterativ fortgesetzt. Auf diese Weise kann das hochdimensionale Ausgangssignal(II.2.1.1) in hochspezifische 
Einzeleffekte zerlegt werden. 
Die Methodenvalidierung zeigt, dass superponierte Effekte von vielfältiger Größe, Form und Signalstärke 
zuverlässig zerlegt werden können(II.6.2). Simulierte Regulationsgesetze werden dabei mit hoher Korrelation 
rekonstruiert. Erkennungsgrenzen bzgl. Signalstärke oder bzgl. der Rate fehlender Messwerte(II.6.4) liegen 
oberhalb praktischer Anforderungen. Der neuartige Ansatz wird mit Standardverfahren wie der 
Hauptkomponentenanalyse systematisch verglichen. Es wird gezeigt, dass die Signalzerlegung klare Vorteile 
hat, insbesondere bei vielen überlappenden Effekten mit vergleichbarer Größe(II.6.3). 
Ein ideales Testfeld für solche Ansätze sind Krebszellen, da sie von vielen überlappenden Genregulations-
netzwerken gesteuert sein können, welche weitgehend unbekannt sind. Darüber hinaus ist die 
Quantifizierung und Klassifizierung von Krebszellen durch ihre spezifische Menge antreibender 
Genregulationen eine Voraussetzung in Richtung Präzisionsmedizin. Um die neuartige Methode gegen reale 
Daten zu validieren, wird sie auf Genexpressionen von über 1000 Tumorproben von Patienten mit diffus 
großzelligem B-Zell-Lymphom (DLBCL) angewendet. Zwei bereits bekannte Subtypen dieser Krankheit(cf. I.1.2.1) 
mit signifikant unterschiedlichem Überleben infolge derselben Chemotherapie wurden ursprünglich ebenfalls 
als Genexpressionseffekt entdeckt. Diese Subtypen können nur mit Hilfe dieses Effekts auf molekularem Level 
präzise bestimmt werden. Solche vorherigen Ergebnisse erlauben eine Methodenvalidierung, und in der Tat 
wurde dieser Effekt unüberwacht wiederentdeckt(III.3.2.2). 
Mehrere weitere biologisch relevante Ergebnisse wurden ermittelt und über vier Patientenkohorten 
validiert. Multivariate Analysen(III.2) identifizieren Kombinationen von validierten Effekten, die signifikante 
Unterschiede im Patientenüberleben vorhersagen können. Ein neuartiger Effekt besitzt sogar einen höheren 
Vorhersagewert(cf. III.2.5.1) als der wiederentdeckte Subtypeffekt und ist zudem genetisch spezifischer(cf. III.3.3.1).  
iv Kurzzusammenfassung 
 
Ein angelerntes und validiertes Cox-Überlebensmodell(III.2.5) kann signifikante Überlebensunterschiede 
innerhalb bekannter DLBCL Subtypen(III.2.5.6) vorhersagen, was zeigt, dass diese ebenfalls genetisch heterogen 
sind. Detaillierte biostatistische Auswertungen für alle Überlebenseffekte(III.3.3) können dazu beitragen, die 
molekulare Pathogenese von DLBCL zu klären. 
Darüber hinaus ist die Anwendbarkeit der Signalzerlegung nicht auf biologische Daten begrenzt. In der 
Astrophysik könnte z.B. die Zerlegung spektraler Energieverteilungen von Sternen nützlich zur Entdeckung 
von Lichtemissionsgesetzen sein. 
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 1 
 
After rooting this work in complex systems science, its biological 
context of Diffuse Large B-Cell Lymphoma is introduced.  
Summarizations of detailed measurements like human gene 
expressions are essential to discover novel effects of interactions  
and to provide an interpretable basis for high-level system modeling. 
Examples of existing summarizations by generic concepts of 
interactions are presented and the need for a more compatible 
concept for gene expressions is demonstrated. 
Next, selected biostatistical methods for analyses of typical 
experiments in molecular biology are clarified, including methods 
that can associate results with existing genomic knowledge. 
Exemplary analyses performed for several published investigations  
of DLBCL or of related biological contexts are presented. 
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I.1 Introduction 
In general terms, this work is about a complex system, the cancer cell. Theoretical concepts 
from complex system theory are used to model and detect interactions in this system in order 
to address biological and medical questions. One specific goal is to help clarifying the 
molecular pathogenesis of Diffuse-Large B-Cell Lymphoma. This disease and the pathway 
language utilized to model interactions in cancer cells are introduced. In particular, the NF-
κB pathway and its role for normal and malignant B cells is briefly presented. 
Technologies like microarrays and RNA sequencing can measure more and more parts and 
details of cancer cells. Hence, methods that can summarize observed signals by interactions 
become increasingly important in bioscience and in many other fields of science as well. Signal 
summarization is located above technology-specific signal processing and below system-
specific modeling by experts. 
For biological interactions observed by gene expressions and for similar signals, a more 
compatible summarization concept is needed, as is motivated by an intuitive 3D example. In 
particular, it is demonstrated that standard principal components analyses of such signals 
deliver misleading summaries that may prevent otherwise possible insights into underlying 
pathways. A preview illustrates the detection task and an outline concludes the introduction. 
I.1.1 What is a complex system? 
A typical complex system is fluid flow: While at lower energies laminar flow can be observed, i.e. a smooth 
flow like that of a calm river without any large local differences in movement direction or speed, at higher 
energies the same fluid may show turbulence with strong and seemingly random fluctuations over many 
scales, for example at the end of a waterfall. Between the two extremes, many interesting transitions from 
laminar to chaotic flow and vice versa can be observed and are studied in the nonlinear dynamics field of 
theoretical physics. Despite this complexity, the local behavior of systems of fluid flow can be modeled by just 
two lines of math, the Navier-Stokes equations. The same equations can also be utilized to predict fluid flow, 
given its initial conditions. For laminar flows, predictions of very high accuracy are possible even over longer 
time periods. However, turbulent flows can only be predicted with acceptable accuracy for rather short 
periods and for precise knowledge of initial conditions, because they behave completely differently over time 
for only minimal deviations in initial conditions. Mathematically, this complexity can be rooted in a nonlinear 
differential operator in the Navier-Stokes equations. Nonlinearity generally indicates that the superposition 
principle no longer holds, i.e. the system can no longer be described as a sum of easier parts without 
considering their interaction. 
For a more interdisciplinary view on complex systems, the nature of complexity needs to be extracted. From 
the fluid flow example above two things can be learned: Most importantly, all the complexity of fluid flow is 
possible, although locally every fluid molecule just follows the same simple and predictable laws of motion 
described by the Navier-Stokes equations. Hence, complexity is a result of interaction and cannot be found nor 
explained on the level of single elements of the system. Additionally, small changes at one time point can lead 
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to large qualitative and unpredictable changes as the system evolves. A more complete yet concise description 
of a complex system can be found in the Encyclopedia of Complexity and Systems Science[1]: 
“Complex systems are systems that comprise many interacting parts with the ability to generate a new 
quality of collective behavior through self-organization, e.g. the spontaneous formation of temporal, spatial or 
functional structures. They are therefore adaptive as they evolve and may contain self-driving feedback loops. 
Thus, complex systems are much more than a sum of their parts. Complex systems are often characterized as 
having extreme sensitivity to initial conditions as well as emergent behavior that are not readily predictable or 
even completely deterministic. 
The conclusion is that a reductionist (bottom-up) approach is often an incomplete description of a 
phenomenon. This recognition, that the collective behavior of the whole system cannot be simply inferred from 
the understanding of the behavior of the individual components, has led to many new concepts and 
sophisticated mathematical and modeling tools for application to many scientific, engineering, and societal 
issues that can be adequately described only in terms of complexity and complex systems.”[1] 
I.1.2 Biological Context 
The medical and biological context of this work is briefly introduced here, including the cancer type in focus, 
its known subtypes and their original definition. Some functions of the healthy ancestor cells from which this 
cancer derives are illuminated. In this context, simple pathways and exemplary known molecular causes for 
the disease are presented. Finally, the goal of precision medicine is explained. 
I.1.2.1 Diffuse Large B-Cell Lymphoma and cells as complex systems 
Throughout this work, Diffuse Large B-Cell Lymphoma (DLBCL) serves as the real-world complex system in 
focus for method development and application. Malignant lymphomas are cancers that develop from cells of 
the lymphatic system and then proliferate there. There are approximately 422.000 cases of lymphoma per 
year[2] (world-wide estimate from 2008), of which DLBCL is the most common type, accounting for 
approximately 30-40% of all adult lymphoma cases[3]. If untreated, DLBCL ultimately causes death, because 
the lymphatic system is an integral part of the human immune defense system. DLBCL is known to be a 
genetically heterogeneous disease with two dominant subtypes that are morphologically hard to distinguish: 
activated B-cell-like (ABC) and germinal center B-cell-like (GCB) DLBCL. Originally, these two subtypes were 
detected with and defined via hierarchical clustering of DLBCL gene expressions in 2000[4]. They were named 
after their shared gene expression programs with samples of activated blood B-cells respectively germinal 
center B-cells from healthy donors(Figure I.1.2.1, unterhalb); this also suggests that the malignant cells derive from these 
different normal B-cells. 
In principle, the disease is curable with a chemotherapy combining several cytotoxins (small molecule 
compounds cyclophosphamide, doxorubicin, vincristine and prednisone, in short CHOP), but the 5-years 
overall survival was only 60% for GCB DLBCL and only 30% for ABC DLBCL patients[5]. It was possible to 
improve survival significantly by 10%-15% via inclusion of an immunotherapy (Rituximab-CHOP, in short 
R-CHOP)[5]. The two subtypes found on gene expression level and validated on survival level suggest that 
different interactions with the chemotherapy take place in different patients, which encourages the search for 
subtype-specific therapies for further improvement. 
Taking a systems perspective again, there are two natural levels of abstraction here: the single cancer cell 
and the human body. Both have well-defined geometric borders in form of the cell membrane respectively the 
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human skin. Neither is a closed system as 
they obviously interact with their envi-
ronment. Both levels are valid descriptions 
and the right choice depends on the 
question. In molecular biology, the primary 
focus is to investigate the molecular 
pathogenesis, i.e. how a single cancer cell 
works. In particular, why it has started to 
proliferate in an uncontrolled way compared 
to healthy cells and how it can be 
manipulated towards apoptosis (i.e. pro-
grammed cell death). Therefore, the more 
suitable choice here is to focus on the single 
cell as the system and abstract its 
environment by functional molecules that 
can interact with it, for example by binding 
to the cell’s surface receptors. 
The cell fits the above description of a 
complex system: It is comprised of many 
functional molecules like proteins and many 
more interacting parts. In case of a cancer 
cell, they collectively self-organize a pro-
cedure of rapid cellular reproduction. They 
can adapt and evolve; for example, they 
might acquire oncogenic mutations to their 
DNA that are beneficial for their 
reproduction. It is even assumed that such 
mutations, either occurring randomly or due 
to failure in DNA maintenance and repair or 
induced by exogenous toxins, are also causal 
for cancer genesis in the first place[6]. This is also a prime example where a tiny change in the cell’s DNA (i.e. 
its “initial conditions”) causes the emergence of a qualitatively completely different anti-apoptotic re-
production behavior in the long-term. Trying to understand this complex behavior from the perspective of 
single proteins or genes is futile. Their interactions must be investigated, modeled and understood. 
I.1.2.2 Pathways, normal B cells in the immune system and NF-κB 
Molecular biology uses the language of pathways to model these interactions. One particular important 
pathway is NF-κB (nuclear factor κB) that stands for a protein family found in several species. These proteins 
act as transcription factors, i.e. they can enter the cell nucleus, bind to specific DNA sequences, recruit RNA 
polymerases and thereby initiate transcription of specific target genes. Resulting messenger RNA molecules 
(mRNAs) then leave the cell nucleus and ribosomes translate them into proteins that finally change the cell’s 
function. Central to the (classical) NF-κB pathway(Figure I.1.2.2, unterhalb) is the p50-RelA heterodimer that is normally 
bound by an independent inhibitory IκB protein in the cytoplasm and thereby inactivated, as it cannot enter 
the nucleus in this form. Via various extracellular signals that can trigger cellular responses through surface 
Figure I.1.2.1) Definition of subtypes ABC DLBCL and GCB DLBCL[4] 
Original detection and definition of the activated B-cell-like (ABC) and germinal center B-
cell-like (GCB) subtypes of Diffuse Large B-Cell Lymphoma. On the left, tumor samples from 
patient and their unsupervised hierarchical clustering by gene expressions is shown. This 
results in two distinct patient groups, orange and blue. On the right, different normal B cell 
samples from healthy donors are shown with genes aligned to the left. A similarity of the 
gene expression programs in germinal center B cells with the orange patient group, and of 
the activated blood B cells with the blue patient group, suggests a different cellular origin and 
consequently different pathogenesis of the malignant GCB-like and ABC-like subtypes of 
DLBCL. Obviously, this similarity is rough, especially with respect to genes upregulated in 
ABC DLBCL samples. 
(Reprinted by permission from Macmillan Publishers Ltd: Nature[4], copyright 2000) 
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receptors, enzymes (more precisely, the IKK complex with IκB kinases  and ) are activated and then phosphorylate IκB, thereby activating the p50-RelA 
transcription factor[7]. 
Besides many other roles, NF-κB plays an important role in the human 
adaptive immune system. For example, if a so far unknown antigen has 
entered the body, e.g. a microbial toxin or another foreign macromolecule. 
Almost certainly, there are already B-cells in the blood having antibodies 
(depicted by the large Y-shaped transmembrane protein) with antigen-
binding sites that geometrically and chemically match a candidate binding site 
in the antigen. 
This is because of somatic hypermutation in germinal centers of the 
lymphatic system, which gives rise to a stochastic repertoire of no less than 10  different antigen binding sites[8]. Together with another protein on the 
inside of the cell (CD79), an antibody that is located in the B cell’s membrane 
is called a B-cell-receptor (BCR). The BCR is an interface that allows B cells to 
react on their environment. Somatic hypermutation may also produce B cells 
with BCRs that are specific to natural macromolecules of the body (self-
antigens). Matching self-antigens cause a strong signaling at these cells’ BCRs 
already during their maturation. Normally, this either reactivates their 
recombinase machinery to generate another non-autoreactive specificity or 
sends them into apoptosis before they mature and enter the body’s 
immunocompetent B cell inventory (negative selection), thereby preventing 
autoimmune diseases[8]. 
Mature non-autoreactive B cells now react to foreign antigens in the blood. If a matching antigen comes 
sufficiently close, it chemically binds to one of the B cell’s antibodies/receptors on its surface. This activates 
the B cell: A chain of biochemical interactions inside the cell (signal transduction) is caused that also engages 
the NF-κB pathway. One possible functional response of this activated B cell is that it starts to proliferate and 
build a cell population that produces antibodies for this specific antigen, which are secreted into the blood. 
These free antibodies again bind to matching foreign antigens and thereby inactivate them. In this way, 
microbial toxins may be blocked from binding to receptors of healthy cells. If the antigen originated from a 
virus hull, resulting antibodies may also bind to such viruses. This makes it easy for phagocytic cells of the 
innate immune system to ingest them, thereby destroying these viruses.[9] 
I.1.2.3 Molecular causes of B cell malignancy 
While proliferation of activated B cells following transient NF-κB activation in response to pathogens is 
normal for a healthy immune system, lesions in the B cell’s DNA like deletions or amplifications may lead to 
an oncogenic activation of NF-κB. Such constitutive NF-κB activation also underlies the ABC DLBCL subtype[10]. 
In general, activated NF-κB signaling plays a pathogenic role in many types of cancer[10]. These tumor cells 
have a strong selective advantage compared to healthy cells, because the NF-κB pathway also blocks normal 
cell apoptosis[10]. They continue to produce copies of themselves that include the same oncogenic defects in 
their DNA and proliferate likewise. For patients this causes almost certain death in the long term, if untreated. 
A major goal concerning ABC DLBCL thus is to interrupt NF-κB signaling in a way that stops proliferation or 
even re-enables apoptosis. This is possible, for example, by a small molecule inhibitor for IκB kinase  
 
Figure I.1.2.2) Classical NF-κB pathway[7] 
Extracellular signals trigger an 
intracellular response through a 
transmembrane receptor protein, and 
then activate the IKK complex that 
subsequently phosphorylates IκB. This 
allows the p50-RelA complex to enter the 
nucleus, bind to κB sites in the DNA and 
trigger the transcription of downstream 
genes. 
(Reprinted by permission from Mac-
millan Publishers Ltd: Oncogene[7], 
copyright 2006) 
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(IKKβ)[10], because it attacks downstream of many possible NF-κB signaling pathways: It directly prevents 
phosphorylation of IκBα by IKKβ and thereby prevents the p50-RelA complex from entering the nucleus. 
However, this inhibitor is not appropriate for development of a specific treatment, as it attacks the NF-κB 
pathway in all cells. Ideally, a genetic “Achilles’ heel” could be found that specifically stops malignant ABC 
DLBCL cells. 
Experiments utilizing RNA interference (RNAi) by small hairpin RNAs (shRNAs) allow the inhibition of 
specific genes in ABC DLBCL model cell lines. For example, such experiments have shown that inhibiting 
CARD11, BCL10 or MALT1 (the CBM signaling complex) is toxic for ABC DLBCL cell lines[10]. CBM signaling is 
located upstream to the IKK complex of the NF-κB pathway(see [10].figure 1A) and thus is a more specific attack 
vector, but it is still transiently involved in and required for normal antigen response[10]. Approximately 10% 
of ABC DLBCL patients show a somatic DNA mutation that causes direct oncogenic activation of CARD11[10,11] 
and thereby NF-κB signaling, which may be one of ABC DLBCL’s pathogenic causes. For the majority of ABC 
DLBCL patients, toxicity after CBM inhibition indicates that their malignant constitutive NF-κB signaling has 
its source already upstream of the CBM complex. Even for the 10% having CARD11 mutations, there may be 
other additional upstream signaling sources. One way to find signaling sources is to directly look for genetic 
aberrations and link this information to gene expressions in the same cells; for instance, this approach allowed 
identifying SPIB as an upregulated oncogene candidate in ABC DLBCL due to chromosomal gains and 
amplifications. Indeed, SPIB is also critical for survival of ABC DLBCL cell lines, but not for GCB DLBCL cell 
lines[11]. Discovering and understanding these ABC DLBCL specific interactions is part of ongoing molecular 
investigations. 
The GCB DLBCL subtype on the other hand is not based on constitutive 
NF-κB signaling and the expression of NF-κB target genes in GCB DLBCL is 
significantly lower than in ABC DLBCL. Consequently, neither blocking CBM 
signaling nor treatment with IκB inhibitors is toxic for GCB DLBCL cell 
lines[10]. Here, looking for pathogenic aberrations revealed a loss of the 
tumor-suppressor gene PTEN[11], and immunohistochemical staining(e.g. Figure 
I.1.2.3) showed that approximately 55% of GCB DLBCL samples are PTEN 
negative, but only approximately 14% of non-GCB DLBCL samples[12]. While 
shRNAs allow the experimental inhibition of genes, it is possible to use 
cDNAs in order to overexpress specific genes in experiments. Over-
expressing PTEN in PTEN-deficient GCB DLBCL cell lines killed these cells, 
confirming PTEN’s role as tumor suppressor. Furthermore, it has been 
detected that this dependence of GCB DLBCL cells on PTEN loss is because 
of a constitutive activation of the PI3K signaling pathway[12] that is usually 
inhibited by PTEN: Overexpressing AKT, the main effector of PI3K 
signaling[13], rescued these cells despite presence of otherwise toxic PTEN 
cDNA. Additionally, using cDNAs of PTEN mutants that cannot inhibit PI3K 
signaling were not toxic. Finally, treating PTEN-deficient GCB DLBCL cell 
lines with a pharmacologic small molecule compound that is a potent 
inhibitor of PI3K kinases, significantly reduced cell viability, whereas PTEN-
positive cells were unaffected[12]. 
These are just few examples for the genetic heterogeneity of DLBCL. 
i) 
ii) 
iii) 
Figure I.1.2.3) PTEN-stained DLBCL cells[12] 
(i) PTEN-negative GCB DLBCL line HT. 
(ii) PTEN-positive ABC DLBCL line TMD8. 
(iii) A PTEN-negative DLBCL patient sample 
(with blood vessels as internal positive 
control). (Reprinted and adapted from a co-
authored paper[12].) 
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I.1.2.4 Precision medicine 
The shared goal in medicine, molecular biology, biophysics, biostatistics, bioinformatics and pharmacy in 
context of heterogeneous genetic diseases is to enable precision medicine. 
To this end, initially oncogenic drivers need to be identified. This requires genomic measurements of a 
sufficient number of cancer samples. With the Cancer Genome Atlas(see TCGA Research Network, http://cancergenome.nih.gov) 
a large and public data source already exists to this end and is steadily expanding. Next, candidate oncogenes 
and tumor suppressors need to be identified by analyzing and summarizing these huge and detailed genomic 
data. Subsequently, promising candidates need to be biologically validated. Based on validated results, the 
pathway language is utilized for modeling this atlas of oncogenic drivers; this allows a rich qualitative 
description of various kinds of discovered interactions in cells and between cells. Pathways also facilitate 
molecular reasoning on a high level and can help to generate hypotheses or to transfer knowledge from one 
cancer type to another. On pharmaceutical level, novel agents need to be developed that specifically target 
validated and biologically promising drivers in-vivo. Finally, a set of these agents that is specific to the set of 
drivers detected in an individual cancer patient could be applied as therapy; this is called precision medicine. 
This is also the next major breakthrough that is targeted for DLBCL treatment. 
The recent(January 2015) United States Government Precision Medicine Initiative also demonstrates the priority 
of this research[14]. This initiative has the aim to measure genomic data for up to one-million samples[15], an 
unprecedented amount of genomic data! 
From a certain perspective, the complexity of cancer cells may even help towards reaching this goal: The 
number of genes that can be simultaneously modified by shRNAs or cDNAs in biological validation 
experiments is limited to just a few. It is not trivial that it is actually possible to send cells into apoptosis by 
inhibiting or overexpressing just few or even just a single gene. Only by virtue of the complex interaction and 
signaling chains in tumor cells, it is possible that such Achilles’ heels indeed exist. 
 
I.1.3 Common Stages in Systems Science 
Based on examples from biosciences, similar general processing stages that are shared by many different 
fields of science are identified and presented here. In particular, the increasing need for an intermediate stage 
is demonstrated that is able to provide comprehensible summaries of more and more detailed measurements 
about parts of complex systems. 
I.1.3.1 A cascade of abstraction levels for modeling 
The added immunotherapy in form of Rituximab resulted in a DLBCL therapy with significantly more 
favorable patient outcome; this already indicates that interactions with the human immune system may play 
a likewise important role in disease progression. In the concrete case, it is understood that the antibody 
Rituximab binds to the CD20 protein on B cell surfaces, thereby marking them for ingestion and destruction 
by natural killer cells of the immune system[16]. The dynamics of this antibody-triggered cell-cell interaction 
also presents an interesting biomechanical modeling challenge: It has been observed that Rituximab causes a 
polarization of B cells by concentrating their CD20 on a single cap of the cell membrane as opposed to a 
uniform distribution on the surface. By this redistribution natural killer cells of the host are 60% more 
effective at killing the B cell[16]. This selective killing of B cells is a logical complement to the CHOP 
chemotherapy of DLBCL. 
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This example implies that the cell-cell interaction level may allow researching additional potential attack 
vectors, but this also requires a higher level of abstraction for models: So far, interactions within the cancer 
cell were considered, while the coupling to the cellular environment has been modeled by molecules or 
antigens binding to the cell’s surface receptors. Now the system is no longer the single cell, but consists of cells 
itself. Again, this is a complex system, as can be easily verified: Cells interact with each other and show self-
organization, for example by building organs in the human body. Trying to understand the death of patients 
from the perspective of a single cancer cell is again futile, even if all its intra-cellular interactions were 
understood. However, changing the initial conditions slightly, for example by implanting just a single 
cancerous cell, might cause a tumor to emerge that can interact with the host organism in such a way that it 
dies, a truly significant change in system evolvement over time. 
Obviously, both levels of abstraction could be merged, but trying to model the human body by choosing genes 
as basic elements of interaction is not as useful from a modeling perspective: Models should be of a 
manageable and comprehensible complexity. Otherwise, no useful and verifiable predictions can be made. It 
is impractical to gain any novel knowledge with help of overly detailed or too simplistic models. It makes even 
more sense for many questions to refine the modeling cascade by introducing additional intermediate levels 
of abstraction, for example organs or cell organelles. 
I.1.3.2 The measurement stage, 
 next-generation RNA sequencing and unexpected complexity 
Besides the choice of a useful top abstraction level for scientific modeling, it is essential to understand which 
parts of the system can actually be observed. In molecular biology, a single standard gene expression (GEP) 
microarray can profile the activity of the human genome at approximately 50000 genomic loci simultaneously, 
including probes for mRNA sequences from all known human genes. Newer RNA sequencing technologies can 
even deliver a detailed view of the transcriptome, i.e. of the total active RNA in measured cancer cells, based 
on millions of reads and not just for a limited number of preselected mRNA sequences probed by a microarray. 
The possibilities of RNA sequencing in particular have “become increasingly important in cancer research – 
all at a data scale that was unimagined just several years ago”[17] and have already led to “a new appreciation 
for the complexity of the transcriptome, encompassing a multitude of previously unknown coding and non-
coding RNA species”[17]. 
This complexity was somewhat unexpected, because the paradigm of gene transcription into mRNA and 
subsequent direct translation into proteins by ribosomes now seems to be a too generalized view. The 
translation into proteins is modulated by an interconnected network of mRNAs as well as short and long 
noncoding RNA molecules[18] for the majority of genes. This post-transcriptional level of regulation probably 
needs to be investigated with the same effort as the protein level in order to understand its interaction chains. 
This newfound complexity of post-transcriptional regulation may even require revisiting older interpretations 
of gene expression measurements: The basic assumption of direct protein level inference from gene 
expressions should be applied with care and when making gene expression based statements about single 
genes, independent experimental validations of the protein concentrations are mandatory. For example, gene 
expressions based on RNA sequencing technologies may show only a very weak (albeit significant) correlation 
of 0.1 to 0.4 to the gene expressions of the same cells measured by microarray technology[19, cf. figure 5]. To 
complicate things, this may also be in part caused by technological problems or by the computational methods 
utilized to process the RNA sequencing reads: The estimated expression levels of these methods vary 
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widely[20], both due to technological uncertainties as well as due to the inherent biological complexity of the 
transcriptome. 
The technological and data processing problems will however eventually be solved as the technology and 
the methods mature. The sequencing of full-length cDNA molecules (instead of short sequences via shotgun 
methods) and the direct use of RNA (instead of first converting it into cDNA) are technological steps in that 
direction[21]. Another variant of RNA sequencing that promises an important filtered view is Ribosome 
profiling: Here only the ribosome:mRNA complexes in cells are measured after halting their translation, rather 
than the total RNA. This allows to specifically measure only the mRNAs that are indeed being translated into 
functional proteins[21]. Consequently, the basic assumption of protein level inference from measured mRNA 
concentrations is perfectly valid here. 
I.1.3.3 The increasing gap, an obvious but fundamental problem 
Being able to measure more and more dimensions like RNA concentrations of a complex system is clearly 
advantageous as it leads to insights into previously underestimated levels of complexity and can provide more 
possibilities of understanding them. There are some technological, data processing and estimation challenges, 
but they seem solvable. Assuming that all these challenges have been solved, the ideal result would be a signal 
comprised of reliably estimated expression levels of all genes and of activity levels for all proteins and for all 
other functional molecules that may regulate the transcriptional or translational level.  
Even then, a fundamental problem would remain: The human working memory for thought and modeling 
processes has a limited capacity for simultaneously holding and manipulating independent information. For 
example, the visual working memory can only store 3-4 independent items in the short term[22], models for 
the verbal memory show a maximum of only five or six unrelated words and even with chunking the 
immediate memory span for sentences is only approximately 15 words[23]. This implies that the human brain 
lacks the capacity to model and understand interesting interactions directly from these huge signals that 
contemporary instruments can measure. 
This obvious gap between the amount of observable information from a complex system and the human 
working memory for modeling is steadily increasing in practically all fields of science, as measurement 
technologies advance. This is multiplied by the number of measured samples, for example by the up to one-
million samples that is prospectively measured in context of the United States Government Precision Medicine 
Initiative alone(cf. I.1.2.4). Besides biosciences, especially in astrophysics many improvements had to be 
developed in the last decade, “attempting to keep up with the vastly increased volume and quality of available 
data”[24]. Here, galaxies or quasars are the complex systems and the primary source of information is their light 
emissions, more precisely their spectral energy distributions, which are measured with large telescopes and 
spectrometers. A major, huge and fast growing signal database in this field of science is provided by the Sloan 
Digital Sky Survey(SDSS, see http://www.sdss.org) with already approximately 70 terabytes of data in the total SDSS 
volume III. The current public data release DR10 contains 927,844 galaxy spectra[25], for example. Spectra for 
the majority of the visible sky have yet to be systematically measured[26, see figure 2], so this data source 
prospectively also continues to grow (even if there were no further technological advances in spectral 
coverage). 
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I.1.3.4 Generic footprints of interactions and the summarization stage 
Because of this increasing gap, another intermediate stage of research is required. This stage is located above 
the technology-specific processing and refinement of the growing measurement data about all parts of the 
system. It is located below the system-specific higher-level modeling of their interactions by experts of the 
respective field, for example in the pathways language. The goal of this stage is to summarize the detailed 
signal about the system parts into as few as possible chunks of information that are comprehensible for 
modeling. Ideally, this summarization is unbiased, especially it should not just focus only on some portions of 
the signal, and it should be complete in the sense that all the important classes of interactions and their large-
scale effects in the signal are retained and presented to the modeler. 
To achieve this, each existing method of the summarization stage applies a generic concept of interaction, 
either via direct definitions or implicitly through algorithms. These concepts do not try to comprehend the 
interactions on a system level like in pathways for cancer cells, but rather search for the basic footprints of 
these interactions in the observed signals in order to detect them in the first place. Example concepts are: 
Concept of signal 
footprints from 
interactions 
Methods using  
these concepts 
Summarization examples 
Minimal high- 
dimensional distance  
(of various metrics) 
Hierarchical  
clustering(cf. I.2.2.1) 
Generally, all cluster algorithms summarize all measured system parts by 
relatively few clusters to support subsequent modeling. Clusters contain 
similar system parts that are distinct from other clusters. For example, the 
“ABC DLBCL > GCB DLBCL” and “GCB DLBCL >ABC DLBCL” gene signatures 
summarize gene expressions from many samples by just two flat sets. 
Orthogonal directions 
of maximal variance 
Principal  
components 
analysis(cf. I.2.2.2) 
Just a few principal components for high-dimensional data may already 
capture most of the signal’s variability. Many gene expressions may thus be 
summarized by just a few linear combinations of all genes. 
Frequency and  
periodicity over time 
Fourier trans-
formation 
The first few Fourier terms can already capture large-scale features of a 
signal. An example is image smoothing by removing noisy high-frequency 
information. 
Assuming a constant 
neighborhood over a 
predefined order axis 
Circular binary 
segmentation[27] 
Long segments of equal DNA copy number aberrations summarize millions 
of noisy reads along the genomic sequence that were measured by array 
comparative genomic hybridization (aCGH); this summary may allow 
detection and modeling of oncogenes. 
Table I.1.3.4) Example concepts of generic summarizations by interaction 
 
All examples can be viewed as a pre-modeling summarization by different effects of interactions on the 
observable signal; these summaries can then serve as a basis for higher-level system modeling. Other than 
modeling languages like pathways, these concepts are rather generic and much less specific to a certain field 
of science. Therefore, corresponding summarization methods and their underlying modeling ideas often turn 
out to be of surprisingly interdisciplinary nature, even if they were developed in the context of only a single 
field of science. The relative simple method of hierarchical clustering from computer science and its 
tremendous success in many fields of science, especially in biosciences(cf. I.2.2.1), is a good example of that. 
Another intuitive physical example is a rigid body: When applied to the positional measurements of its parts, 
principal components analysis (PCA) delivers its three principal axes of rotation, i.e. when applying a torque 
around such an axis the body begins to rotate exactly around this axis only, i.e. all its atoms that lie on this axis 
stay in space where they were before rotating. If the same torque was applied around any other non-principal 
direction this is not the case. Exceptions are perfectly spherical bodies of constant density; here all directions 
are principal (as long as the body does not already rotate). Therefore, PCA can summarize an insightful effect 
of the true interactions within a rigid body that gives rise to its rotational behavior, namely that all its atoms 
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are forced to keep a constant distance to their neighbors and that the motion of each atom is governed by 
Newton’s laws. This illustrates the differences between what can be measured (positions of atoms), how these 
measurements can be summarized (principal axes) and the true nature of interactions between system parts 
(forces keeping atomic distances to neighbors approximately constant). This summary might seem trivial, 
because a rigid body is not a complex system and it is well understood. Additionally, the positional 
measurements of its parts might still seem comprehensible even at high resolution, if visualized in 3D. 
In biology however, neither a final set of laws for cancer cells nor for DLBCL pathogenesis is known. These 
systems are far more complex, their measurements deliver signals of huge detail and these signals cannot be 
visualized intuitively in 3D, since they are not only high-resolution but also high dimensional. Modeling such 
biological systems can therefore greatly profit from signal summarization. 
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I.1.3.5 The association stage and putting it all together 
While sometimes effects from the summarization stage may be directly accessible for high-level system 
modeling, it is often helpful to associate them with existing computable knowledge first, if available. This can 
also help to prevent redundant discoveries in fields that produce a fast-growing collection of knowledge. 
In biosciences, an important computable knowledge base is the gene ontology that hierarchically associates 
genes with their already discovered molecular functions, cellular components or biological processes(cf. I.3.2). 
Additionally, large gene signature databases can help to associate experiments with related discoveries in 
scientific articles(cf. I.3.1). Bioinformatics and biostatistics methods such as overrepresentation analyses or gene 
set enrichment analyses facilitate these associations. For example, they could reveal known gene signatures 
that are significantly enriched for top regulated genes in a cell line experiment for a tested inhibitor. Simple 
supervised analyses like -tests that identify these significantly regulated top genes in the first place are also 
part of this association stage. Additionally, often system properties of different formats have been measured, 
for example gene expressions, patient gender and patient outcome following chemotherapy. It is important to 
associate these different sources of information to get a complete as possible picture of the system and to filter 
out disease-unspecific information, for example gender-specific gene expression effects. Biostatistical 
methods like Kaplan-Meier survival analyses and log-rank tests or contingency tables and -tests allow 
quantifying these associations with  values, i.e. with the probability to see a particular association or an even 
stronger one by pure chance. 
Considering everything, first, a com-
plex system in nature is observed using 
measurement technologies. Ideally, they 
deliver precise signals for all parts of the 
system. Because these signals are often 
too detailed to make directly sense of 
them, they are summarized next. If 
computable existing knowledge is avail-
able, summarized effects are associated 
with it. Finally, this yields the basis for 
modeling interactions between system 
parts in a matching modeling language. 
These models ideally provide new 
insights that lead to predictions and 
hypotheses about the analyzed system. 
Via feedback on the experimental 
design, these hypotheses can be tested. 
Once a system has been sufficiently 
understood, it may be possible to 
manipulate it towards useful goals, for 
example curing DLBCL. 
Figure I.1.3.5) Typical stages of systems research with examples, mostly from biosciences 
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I.1.4 Motivation and Goals 
First, it is illustrated why PCA may lead to hard-to-interpret signal summaries. Consequential design goals 
are presented and a 3D concept example illustrates a useful signal summary contrasting PCA results. Thereby, 
the detection task is clarified. Additionally, a real-world example for detectable high-dimensional effects of 
biological origin is provided. Finally, a brief outline concludes the introduction. 
I.1.4.1 Helpful and misleading signal summarizations 
Although all introduced concepts utilized for summarization(I.1.3.4) are rather generic and thus have 
interdisciplinary applications, it is still very important that the concept of the chosen method is compatible 
with the nature of interactions in the underlying system. Otherwise, a summarization into few effects of 
interaction might not work at all. Alternatively and worse, it might still succeed, but resulting effects are hard 
or impossible to interpret and thus not helpful or even strongly misleading when modeling the system. 
Conceptually, this can already be illustrated(cf. Figure 
I.1.4.1) with just three dimensions: For simulated ex-
pressions of three genes driven by two distinct 
pathways causing linear co-regulation(red and blue) the 
principal components(yellow) follow different 
directions (i.e. describe different laws of gene co-
regulation) and thus cannot dissect the two 
simultaneously measured effects. Even though this 
signal might be reduced from three to two 
dimensions by this PCA (as the third principle 
component explains negligible signal variance on top 
of the first two), true effects and corresponding 
groups of simulated patients are still mixed in the 
new coordinates, making the reduced two-
dimensional signal as hard to interpret as the original 
signal. This is because PCA still treats data points as if they were governed by interactions of a rigid body(cf. I.1.3.4), 
i.e. the yellow principal components still are the physically meaningful principal axes of rotation for an X-
shaped body with these points as mass elements. However, this is meaningless and misleading in the gene 
expression context. A useful summary here would instead separate both groups of patients and deliver one 
axis, i.e. one linear law of gene co-regulation, for each pathway. 
Although this seems to be an obvious insight, given this visualization and human intuition in 3D, visualization 
capabilities and human intuition for high-dimensional data are limited. Therefore and at first sight, principal 
components of high-dimensional signals like gene expressions may appear to be a perfectly valid and concise 
summary of that signal, although they actually mix many distinct true effects. Hence, the linear law described 
by a single principal component usually does not specifically describe the co-regulation mediated by a single 
pathway, making this signal summary hard or impossible to interpret biologically. This is demonstrated in 
detail when systematically applying PCA to simulated high-dimensional data for method validation and 
comparison(II.6). 
The same problem is also known in astrophysics. Here, PCA has been utilized to summarize spectral energy 
distributions measured from stars or from far galaxies. However and consistent, “The main difficulty with PCA 
 
Figure I.1.4.1) Principal components do not point into effect directions 
Points for three dimensions simulate two distinct but partly correlated (i.e. not 
perpendicular) effects for 1000 samples each (red and blue). The principal 
components returned by PCA are the three yellow perpendicular directions. 
The two longer components capture nearly all of the signal’s variance here; 
therefore, the third component that protrudes where the two longer cross in 
the center is relatively short. Further details on how the PCA works follow 
in I.2.2.2. 
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is that the interpretation of the empirically determined PC components in terms of physical properties is 
complex at best.”[24] 
Generally, methods of the summarization stage are applied to measurements in order to get ideas about 
possible laws governing interactions between parts of the underlying system. Principal components and similar 
methods essentially reformulate measured signals by spanning an alternate coordinate system. The hope is 
that some of the new coordinate axes(yellow) provide insights into interactions of the analyzed system that were 
not possible in the original units of measurement, for example by isolating a co-regulation law of a distinct 
pathway. 
This idea of a change in coordinates has also been generalized by spectral methods to spaces of functions, 
rather than finite-dimensional spaces containing measured samples. For a physical example of such a signal 
summary, fluid flow can be revisited once more: Local nonlinear interactions of this system are already 
understood, validated and summarized well in form of the Navier-Stokes equations. But resulting complex 
large-scale flow behavior is not completely understood and is not clearly described by Navier-Stokes 
equations. Hence, it makes sense to try to reformulate or re-summarize these known laws about neighboring 
fluid elements analytically in order to get ideas about how large-scale flow behavior might be generated from 
local interactions. To this end, an analytic linear expansion of a flow field for low Reynolds numbers has been 
performed[28] by a separation ansatz in a certain geometry that allowed identifying time, radial and angular 
eigenfunctions of the flow; a linear superposition can then reconstruct the complete flow field. Because 
resulting linear operators quickly gained in complexity over expansion order, benefits in understanding 
interactions based on this expansion were unfortunately limited: No obvious summarization of large-scale 
flow properties was possible in these new spectral coordinates. Finding better analytic summarization 
concepts that are more compatible with nonlinear interactions in fluid flow is a subject of ongoing research in 
nonlinear dynamics. Maybe empirical methods summarizing particle image velocimetry measurements could 
help finding them. Ideally, a simple (maybe statistical) description can be obtained, analogous to the simple 
summary of large-scale rotational behavior of complex-shaped rigid bodies by principal axes. 
In one form or another, the problem of finding useful summaries of high dimensional signals is likely to be 
known in many more fields of science. 
I.1.4.2 Design goals, the detection task and method preview 
Consequently, it is a major design goal for any novel summarization method that its summary effects are 
specific to true effects in the analyzed system. In particular, summarized effects of gene expressions should not 
mix signal parts from different pathways that may be active simultaneously in measured cells. Another design 
goal is the removal of superposed strong effects without affecting signals from overlapping weaker, but 
biologically often more important effects. This is particularly important in the presence strong lab effects 
caused by measurement technology or protocol. These and several more design goals are presented(cf. II.1.2) in 
the context of bioscience and gene expressions. In part they can be derived from problems associated with 
principal components analysis or hierarchical clustering in this context. 
Another major conceptual goal for signal dissection is the support for a broad class of non-linear effects that 
may occur in gene expression signals. For example, some genes may reach their saturation expression for 
lower average activity of the underlying pathway than other genes in the same effect. Some pathways may 
contain feedback loops that may cause some of its genes to be expressed stronger than linearly (e.g. 
quadratically) over its average activity. Yet other pathways may show unsteady switch behavior, i.e. some or 
all of its genes are expressed either at zero or immediately on a plateau of high expression. 
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A concept example with just three genes works best for 
illustrating this(Figure I.1.4.2); it is defined in detail in II.1.1. 
Briefly, besides a usual linear law of co-regulation(red), 
pathways in this example simulate a saturation effect(blue), 
a stronger than linearly regulated gene(green) and a 
threshold behavior(magenta). 
Application of PCA on this signal results in depicted 
principal components(upper panel, yellow). Again, they are not 
helpful, both due to PCA’s incompatibility with the 
underlying simulated interactions as explained 
above(I.1.4.1) and because of a fundamental conceptual 
limitation shared by all projection methods that try to 
represent the signal in new coordinates: There are four 
effects here, but only three dimensions. Whatever 
directions principal components may point to, whatever 
eigenvectors may be determined by an alternative 
spectral separation of the signal, whatever orthonormal 
rotation of the coordinate system results, after three 
projections in 3D only zero remains. Hence, at least one of 
the four distinct effects of the example cannot be properly 
described and dissected by methods based on or 
equivalent to full projections as a matter of principle. 
Thus, it is not sufficient to just represent the signal in 
another coordinate system, if the goal is discover a 
specific summary for each effect. 
The task for detection methods is to recover the laws of 
gene co-regulation for each simulated pathway empirically 
from measured points. (Of course, the color cording is not 
provided for this task.) 
A preview of four monotonic effect gene curves, one for 
each simulated effect, demonstrates that signal 
dissection(Chapter II) is able to solve this task(lower panel, yellow). 
The 3D example is useful for illustration, but the main 
goal is to dissect possibly overlapping effects in very high-
dimensional signals like 50000-dimensional gene 
expressions. Actually, the developed bimonotonic effect 
model(II.2.1.2) was inspired by ordered heatmaps of real-
world gene expression signatures that are known to be 
biologically relevant, like the cell-of-origin induced gene 
expression effect for distinguishing ABC DLBCL from GCB 
DLBCL(cf. Figure I.1.2.1 or Figure I.1.4.2.b). Only after the method was 
already operational for such high-dimensional signals, the 
above 3D example was devised for conceptual illustration 
Principal Components Analysis 
 
Signal Dissection 
 
Figure I.1.4.2.a) 3D concept example with four effects. Misleading principal 
components and precise effect curves by signal dissection (preview). 
Four simulated pathways corresponding to four distinct sample groups 
have been simulated with different governing laws of regulation for the 
same three genes. Details on the signal follow in II.1.1.  
The upper panel shows all three principal components for this signal; 
they cannot summarize this signal in an interpretable form. 
The lower panel previews all four effect gene curves detected by signal 
dissection. 
 
Figure I.1.4.2.b) Example of a roughly bimonotonic real-world effect[29] 
This heatmap is based on a supervised analysis that sorts samples of 
cohort GSE31312 based on their differential expressions between 
predefined gene signatures for ABC-like and GCB-like subtypes of 
DLBCL. (Adapted by permission from Macmillan Publishers 
Ltd: Leukemia[29], copyright 2012) 
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purposes. Hence, discovered effects for high-dimensional gene expression signals that follow this effect model 
should provide an accessible signal summary for further biological modeling of interactions in cells. Other 
than in the depicted example that is based on a supervised analysis, signal dissection discovers such effects 
unsupervised and the sum of all dissected effects rebuilds the complete measured signal, except for a noise 
term. 
I.1.4.3 Outline 
In the remainder of this chapter, several other methods from the association stage(I.3) and for supervised 
analyses(I.2.1) are introduced. They are complementary to unsupervised signal dissection and summarization 
in the typical research workflow within molecular biology, as illustrated in the stages of science diagram(Figure 
I.1.3.5, oben). Exemplary analyses from selected co-authored papers are presented. As methods for unsupervised 
gene expression analysis(I.2.2), hierarchical clustering and PCA are explained.  
In Chapter II, the previewed method for signal dissection is presented in detail. After clarifying design 
goals(II.1) and its mathematical framework(II.2), its search strategy(II.3) is explained. Subsequently, bimonotonic 
regression and effect dissection are clarified(II.4). Noise and significance measures are discussed separately(II.5). 
Among other tests, a versatility test scenario that simulates high-dimensional technical and biological effects 
of various shapes(II.6.2) is utilized to systematically validate the method and to compare it with PCA(II.6). 
In Chapter III, signal dissection is applied to gene expression measurements for samples from more than 
1000 DLBCL patients(III.1). Resulting gene expression effects are validated across four independent patient 
cohorts(III.1.2). Validated effects include the rediscovered cell-of-origin effect(III.3.2.2) and several genetically novel 
effects that show significant association with patient survival. Multivariate survival analyses allow 
construction of a Cox survival predictor that reveals significant survival differences within standard DLBCL 
subtypes(III.2.5). All top survival effects are biostatistically presented and evaluated in detail(III.3.3); they may lead 
to insights into the molecular pathogenesis of DLBCL. 
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I.2 Standard Analyses 
A common challenge in many fields of biology is to identify essential differences between 
measured samples and to relate them with their genetic origin. 
Generally, two classes of analysis methods are distinguished. Supervised analyses are 
applied in contexts with some prior knowledge about measured data. They are intended to 
answer specific questions or to test a particular hypothesis. In contrast, unsupervised analyses 
follow the aim to reveal previously unknown patterns in measured signals that may help to 
gain new insights or to infer new hypotheses. 
Methods of both types are utilized recurrently in typical research workflows in molecular 
biology. Selected examples that have been analyzed for several published studies are 
presented here. 
I.2.1 Supervised Gene Expression Analysis 
In supervised cases, it is already known what samples need to be compared to identify genes of a specific 
interest. An example is the analysis of gene expressions of cancer cells after application of a drug versus 
untreated controls. Alternatively, it may be already known what genes need to be interrogated to answer a 
specific biological question about samples. Here, several examples of such supervised analyses are presented. 
I.2.1.1 Differential expression analyses 
To quantify the significance of differential expressions of genes between two known settings, various -tests 
of loggene	expression	ratios can be computed. Expression ratios are typically computed relative to the 
average expression of all samples in the current context in order to neutralize potential offset effects and to 
focus on the differences. One has to distinguish between paired scenarios and unpaired scenarios. In the 
unpaired case, for instance, samples from cancer patients versus (an arbitrary number of) samples from 
healthy controls is compared with two-sample -tests(e.g.  [79], pages 276-279). In the paired case, for example, the same 
cell line has been measured either following treatment with an inhibitor or in untreated form for several time 
points. In this case, paired -tests(e.g.  [79], pages 522-528) are utilized to focus on the differences induced by the 
inhibitor. Pairing has the advantage to ignore additional differences that might have biologically occurred or 
technically incurred between the time points. 
As an example of a typical supervised gene expression analysis, the examination of peripheral blood 
mononuclear cell samples (PMBCs) from renal cell cancer patients (RCC patients) is briefly presented. 
Genes are depicted(cf. Figure I.2.1.1) that are significantly differentially expressed between these PMBC samples 
compared to independent control samples from healthy donors. This analysis has been performed for a study 
to investigate the immunosuppression characteristics of RCC. More precisely, a previously administered 
vaccine failed to induce clinically relevant immune responses and the aim was to elucidate the molecular 
mechanisms responsible for that. The biological analysis of differentially expressed genes revealed that 
already before treatment with the vaccine several genes associated with immune functions are expressed at 
far lower levels in RCC samples compared to healthy controls[30]. Further association analyses and their 
biological interpretation confirmed this immunological impairment(e.g. Figure I.3.1.2). 
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Figure I.2.1.1) Example for a supervised gene expression analysis that determines significantly differentially expressed genes between two known settings 
Depicted are supervisedly determined top upregulated and top downregulated genes in 9 peripheral blood mononuclear cell samples (PMBCs) from renal cell cancer 
(RCC) patients prior to vaccination (left) compared to 9 healthy control samples (right). All genes with a  value  0.001 are depicted (two-sample -tests). Labelled 
genes are involved in immunological processes. (Analysis performed for and reprinted from [30].) 
 
I.2.1.2 Application of specific gene signatures 
Once experiment-specific signatures of top-upregulated or top-downregulated genes have been ob-
tained(cf. I.2.1.1), they may be used to interrogate other experiments for the same genes or to test biological 
hypothesis. 
For instance, most genes that are top-downregulated following the IKKβ inhibitor MLN120b can be 
interpreted as NF-κB target genes, as NF-κB signaling is halted by this inhibitor before the phosphorylation of 
IκB in the classical NF-κB pathway(cf. Figure I.1.2.2). If another inhibitor candidate is assumed to inhibit NF-κB target 
genes as well, it should cause downregulation of largely the same genes. To test this, the gene signature for the 
IKKβ inhibitor can be applied to experiments with this other inhibitor. 
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In the example(cf. Figure I.2.1.2), a PI3K inhibitor is tested, and indeed it significantly decreases expression of NF-
κB target genes in two cell lines for four time points. Further experiments in the same study identify a critical 
role for PI3K (and the downstream kinase PDK1) for viability of a subset of ABC DLBCL cell lines that are 
characterized by CD79B mutations[31]. 
Figure I.2.1.2) Application of an identified NF-κB signature (left) to gene expressions following treatment with a PI3K inhibitor 
Top-downregulated genes for the IKKβ inhibitor MLN120b (left) have been supervisedly identified based on gene expression profiling for four time points and for the 
ABC DLBCL cell line HLB1 (selection criteria: at least 50% downregulation for at least three time points). Identical genes are interrogated in an identical experimental 
setup for a PI3K inhibitor[31]. Both the HLB1 cell line in the center panel and the ABC DLBCL cell line TMD8 have been tested. Signature averages are significantly 
downregulated for both cell lines in all four interrogated time points (-tests versus zero regulation). (eps denotes a numeric resolution limit of a previously utilized  distribution integration function at 2.22 ⋅ 10 . Gray pixels indicate missing values due to the spot filter.) (Analyzed for [31].) 
Similar analyses have been performed for another study[32]. Analogous to the IKKβ inhibitor above, the 
MALT1 inhibitor Z-VRPR-FMK was already known to interfere with survival of ABC DLBCL cells in vitro. 
However, Z-VRPR-FMK is not adequate for clinical applications, as it needs to be administered in very high 
concentrations. To identify small molecule inhibitors with more favorable pharmacological properties, top 
downregulated genes of Z-VRPR-FMK have been determined first(cf. I.2.1.1). The resulting MALT1 specific gene 
signature has been subsequently applied to gene expressions following treatment with the phenothiazine 
derivative Mepazine. Indeed, the MALT1 signature was downregulated significantly four time points as above, 
but with weaker average folding. Chemically, this might originate from the fact that Z-VRPR-FMK inhibits 
MALT1 by covalent binding, while Mepazine binds it in a non-covalent and reversible manner[32]. 
Such targeted applications of biologically selected gene signatures in order to ask specific questions do not 
need any multiple hypothesis corrections. On the other hand, in case of likewise applications of signatures that 
were selected e.g. by gene set enrichment analyses based on large signature databases(cf. I.3.1), corrections for 
multiple hypothesis tests should be performed(cf.I.3.1.1). 
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I.2.2 Unsupervised Gene Expression Analysis 
In the more general unsupervised scenario, the goal is to discover all yet unknown sample groups (or gene 
subsets) that show consistent differences in measured signals. In context of a disease for example, gene 
expressions of samples from many patients might be explored with the aim to identify all disease-
characteristic molecular effects of gene regulation. 
Unsupervised analyses require completely different methods and are considerably harder to perform than 
supervised analyses. Mathematically, this difficulty stems from the huge number of theoretically possible 
subsets of patients and genes that might represent biological effects. This number grows like the power set 
with 2  respectively 2 , where  is the number of genes and  the number patients. Bulk methods that try to 
enumerate all possibilities and try to compute some score for each candidate subset are therefore futile for 
typical application sizes with   20000 genes and   100 to 1000 samples. Hence, every unsupervised 
method needs a kind of search strategy or model for the interactions it tries to unveil. 
A standard method for exploring gene expressions in the search of novel effects is hierarchical clustering. It 
is utilized frequently in molecular biology and medicine for unsupervised analyses. Another standard method 
in the unsupervised context is principal components analysis (PCA). As a blind source separation method it 
reaches conceptually beyond hierarchical clustering, since it does not only reorganize genes and samples but 
also re-expresses measured gene expressions in new coordinates called principle components. In the ideal 
case, a principal component represents a biologically specific effect. For example, it may be interpreted as gene 
regulations caused by a specific pathway. Though utilized relatively seldom in biosciences, PCA has a strong 
mathematical foundation and many applications, for example in astrophysics. Both standard methods are 
briefly presented here and problems of both methods are illustrated. 
I.2.2.1 Hierarchical clustering 
This method[33] originates back to the 1950s[34,35], i.e. long before the advent of microarray technology. In life 
sciences it was established more than 15 years ago to analyze correlations in gene expressions[36]. Since then 
it has become a standard method to discover gene signatures or clusters of samples. It has helped to gain many 
important insights into molecular processes for many organisms ranging from bacteria[37,38] and plants[39,40] to 
higher animals like mice[41,42], chimpanzees[43] and, of course, humans[4,44–58]. Besides the predominant gene 
expressions[4,39–48,50–52,54–62] it has been successfully applied to other measures such as DNA methylation[53], 
micro RNA expressions[42,56], DNA copy numbers[49] and protein concentrations[37]. Consequently, it has 
contributed to a broad spectrum of objectives, e.g. understanding viral or bacterial infections[43,58,59], effects of 
cigarette smoke[46,50] or environmental toxins[41], aging research[62], molecular psychiatry[56] or industrial aims 
like new bioenergy crops[40]. 
For DLBCL(I.1.2.1), hierarchical clustering has been particularly useful, as it revealed two distinct and 
previously unknown subtypes, i.e. ABC DLBCL and GCB DLBCL(cf. Figure I.1.2.1). These subtypes coincide with 
significantly different patient outcome for the same chemotherapy. Subsequently, this discovery enabled 
researching distinct pathogenic causes(I.1.2.3) for these subtypes. 
Conceptually, hierarchical clustering takes a    data matrix and first computes the distances between 
each pair of genes (matrix rows) or each pair of samples (matrix columns). The clusterings of genes and 
samples are independent of each other. Sometimes only one of the two order dimensions is clustered. 
Agglomerative hierarchical clustering initially considers all measured points as clusters of size one. Based on 
their pairwise distances and a linkage method, the nearest clusters are merged to form a larger cluster. Then 
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distances between centers of all current clusters are computed again, and again the nearest two clusters are 
merged. This continues iteratively until only a single cluster remains that contains all genes respectively all 
samples. The remaining cluster is depicted as the root of the dendrogram, i.e. the resulting binary distance 
tree(cf. Figure I.2.2.1, unterhalb). The height of the dendrogram depicts distances between connected clusters. A method 
to cut the dendrogram is required to obtain clusters for further analysis and discussion. For example, a 
manually prescribed distance threshold could be used (i.e. cutting at a constant dendrogram height). 
Important functional parameters of hierarchical clustering are the metric for computing distances between 
genes respectively samples and the sub-method of linkage that determines how distances between clusters 
are computed, if they contain more than a single gene respectively sample. One possibility is to use the distance 
of the two nearest members of two clusters; this method is called single-linkage. Complete linkage compares 
the farthest members of two clusters. Average linkage, for another example, compares the geometric centers 
of two clusters with the distance metric.  
The default distance metric is the Euclidean distance that measures the geometric distance between points 
in   (sample columns) respectively   (gene rows). Another way to measure distances is to utilize 
correlations between points. Compared to the Euclidean distance, distances based on correlations have the 
advantage of being independent of absolute expression strengths. If for example two genes show the same 
direction of regulation for all measured samples, but one gene has a much stronger folding than the other, 
their Euclidean distance would be high, but their correlation-based distance would still be low. Since co-
regulation for all samples may already indicate that both genes are controlled by the same pathway, the 
correlation-based distance is often advantageous in biosciences. Hierarchical clustering with a correlation 
based distance metric was established for gene expression analyses in 1998[36]. 
 
 
 
 
 
The following example(cf. Figure I.2.2.1; based on my own implementation) is instructive to explain the interpretation of a typical 
hierarchical clustering result and to demonstrate potential problems. The heatmap depicts gene expressions 
for samples from a CHOP-treated DLBCL cohort (data accessible at NCBI GEO database[63], accession 
GSE10846). An existing signature has been utilized to select an initial subset of all measured genes for this 
analysis. Hence, this analysis is not completely unsupervised(cf. II.1.2.1).  
While orange and green gene clusters show strong expressions, the blue gene cluster shows relatively weak 
expressions overall and only contains a few strongly expressed genes at the top. But these genes are not 
aligned in a monotonic way, i.e. they are incompatible to the depicted sample clustering and may be regulated 
by a distinct pathway. The depicted sample clustering has been mainly determined by the first two gene 
clusters. The biological specificity and coherence of the analyzed gene signature could possibly be increased 
by filtering out the blue gene cluster. This is an example of manual focusing in the gene space. If one focused 
on the orange gene cluster only, a different sample clustering would result, as upregulated samples with 
respect to orange genes are currently split over two different sample clusters. This demonstrates the element 
of arbitrariness associated with manual focusing. Hence, it is one design goal for signal dissection(Chapter II) to 
realize a completely unsupervised effect focusing(see also II.1.2.2). 
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Figure I.2.2.1.a) Example result from bi-hierarchical clustering 
 
Sample clusters at the top are color-coded by average patient outcome. While for the red cluster 35 deaths 
were observed (with 21 censored events), in the green cluster only 12 deaths were observed (with 20 
censored events). This indicates that underlying genes might be biologically relevant for DLBCL. However, 
given the visible heterogeneity, these genes may not belong to the same biological function. In particular, non-
monotonic signals (like at the top left of the sample cluster in the center) indicate the existence of at least one 
overlapping gene regulation effect that might give rise to an alternate sample clustering. As described above, 
it could be revealed by manual focusing on exclusively the orange gene cluster and by another subsequent 
hierarchical clustering analysis.  
 
 
 
 
 
However, more complex overlapping structures cannot be represented well by hierarchical clustering, even 
with manual focusing. The hierarchical clustering illustrated below(Figure I.2.2.1.b) arranges an exemplary subset of 
gene expressions from cohort GSE31312 (data accessible at NCBI GEO database[63]). While clear sample 
clusters can still be obtained, many substructures are visible that are inconsistent with the overall gene 
expression trend. Again, manual focusing would result in different sample clusterings, but likewise manual 
focusing on sample subsets would result in different gene clusters. These ambiguities are all the more present 
if not just a tiny subset, but the whole signal matrix with over 50000 measured probesets has to be analyzed 
unsupervisedly. Hence, a concept that does not just rearrange genes and samples, but that can also dissect 
overlapping effects by modifying the signal itself seems to be indicated in order to analyze such complex data 
consistently. 
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Figure I.2.2.1.b) Example result from bi-hierarchical clustering for a more complex gene expression signal 
 
 
 
I.2.2.2 Principal components analysis (PCA) 
Historically, principal components analysis was invented by Karl Pearson in 1901[64]. Today, PCA is one of 
the most successful analysis methods in many areas of science, including e.g. chemometrics[65]. For genomic 
data, PCA has been successfully utilized e.g. for dimension reduction and for visualization of complex 
data in 3D[66]. 
Conceptually, principal components analysis goes beyond hierarchical clustering, as it does not merely 
reorganize genes and samples into distance trees, but models gene expressions themselves as a superposition 
of expressions along principal components. Essentially, a principal component is a linear combination of genes 
(i.e. a direction in ) that shows maximal variance, i.e. samples have maximally varying expressions along 
these directions. For biological interpretation, it may be assumed that each such direction corresponds to a 
pathway that causes co-regulation of its genes along that direction. Additionally, the method reduces co-
variance between the principal components to zero, i.e. no two directions are allowed to explain expressions 
of the same genes in a co-regulated or correlated way. Geometrically this is perceptible by the fact that all 
principal components are perpendicular to each other. This restriction implicitly assumes that biologically 
distinct pathways cannot contribute to gene expressions in a partially correlated way, and thus may be well 
separable by minimizing their co-variance. (This assumption is shown to be problematic when trying to 
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dissect partially correlated effects(cf. II.6.1).) Often just a few principal components suffice to explain most of the 
variance in the gene expression signal; in this way PCA allows summarizing microarray measurements by 
fewer dimensions (also called dimension reduction). 
For demonstration, all three principal 
components(yellow) for a simple 3D signal are 
depicted(Figure I.2.2.2.a). Line lengths depict the 
relative signal variance explained by each 
principal component.  
If simulated points were positional measure-
ments of all mass elements in a rigid body, these 
principal components would have the physical 
characteristics of principle axes of inertia: 
Applying a torque around either of these axes 
would cause the body to begin rotating only 
about the respective axis. I.e. when rotating 
around the axis with maximal variance, all 
points on that axis (and especially the tips of the rigid body) would stay where they are. This is generally not 
the case when applying a torque around an arbitrary direction. As one principal component already explains 
the dominant part of the variance in this simulated signal, it can be utilized to summarize the signal for all 
points. If the same points were reinterpreted as expressions of three genes in 2000 patient samples, the 
direction of this dominant principal component might represent the law of co-regulation mediated by an 
underlying pathway. This law (in form of a linear combination) could subsequently be utilized for further high-
level modeling of that pathway. This would not be feasible, if the modeler would only have a table with raw 
data values for these 2000 points, again demonstrating the advantage of summarization for modeling and 
interpretation. 
Mathematically, principal components are found by diagonalizing the covariance matrix of the signal. Every 
gene can be seen as a random variable   that corresponds to the distribution of that gene’s expressions for all 
samples. (In the above example, each gene  ,   and   was measured for 2000 samples.) The covariance 
between two genes cov ,  is defined as E  E  ⋅   E, where E is the expectancy operator. E  can be empirically estimated by the mean of all sample expressions of gene  . Similarly, empirical 
covariances  , ≡ cov ,  for every pair of genes can be estimated numerically. As covariances are 
symmetric, the resulting matrix  ∈   is also symmetric (and real-valued). The principal axes theorem of 
linear algebra[67, theorem 7.6.3] states that for every such matrix an orthogonal matrix  ∈  exists such that  ≡ is a real-valued diagonal matrix. I.e.  rotates points in such a way that their covariance vanishes in the 
new coordinate system (zero off-diagonal elements in ). Columns of  are eigenvectors of  in original 
coordinates; they define the principal components (and their directions as depicted in yellow) that span the 
new coordinate system. Their eigenvalues diag finally equal the signal’s variance along these new axes. 
Diagonalization of  is the computationally difficult part of PCA, but can be readily performed by numeric 
algorithms, for example by singular value decomposition (e.g. implemented by the svd function in MATLAB®). 
Principal component analyses have already been successfully applied to gene expression signals. For 
example, gene expressions of a synchronized yeast culture have been measured at different times in the cell 
cycle relative to an unsynchronized control. It was possible to summarize this signal by just two eigenarrays[68] 
(i.e. by principal components in the samples space). Correlation of samples to these eigenarrays correctly 
 
Figure I.2.2.2.a) Simple 3D illustration of PCA 
Points for three dimensions and 2000 samples measure a single simulated effect. 
Principal components returned by PCA are depicted as three yellow perpendicular 
lines. Line lengths are proportional to the square roots of the variances, i.e. they depict 
the standard deviations along these directions. 
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reproduced the experimental cell cycle setup. Additionally, approximately 40% of the signal’s variance could 
be explained by just two eigengenes (i.e. principal components in the gene space). Correlations to these two 
eigengenes allowed estimating the role of all genes in the cell cycle[68]. In another application, differentially 
expressed genes between drug-sensitive and drug-resistant cases have been supervisedly identified. The first 
three principal components for this signal were have been demonstrated to be already sufficient to predict 
drug sensitivity of most samples correctly[45]. 
However, compared to the ubiquitous hierarchical 
clustering, PCA seems to be utilized relatively seldom 
in the context of unsupervised gene expression 
analyses. In part, this may be caused by PCA’s 
underlying concept of interaction, i.e. to maximize 
variance per direction and to zero correlation 
between directions. This concept does not always fit 
well to effects of gene interactions that are mediated 
by pathways and observed by gene expressions. The 
problem can be illustrated(Figure I.2.2.2.b) by simulating 
two subgroups of patient samples(red and blue), each 
driven by a distinct pathway that regulates the 
expressions of the same three genes. A useful 
summary here would separate these groups of 
patients and deliver one axis (i.e. one principal 
component or one linear law) per simulated linear pathway. Principal components(yellow) however do not 
reflect directions of the blue and red pathways. PCA cannot find the correct pathway directions here, in part 
because they are not perpendicular to each other. I.e. they are partly correlated to each other, which is 
incompatible to PCA’s concept of interactions. Hence, principal components cannot dissect the two patient 
groups, but instead summarize the signal by the two longer yellow directions, i.e. by new coordinates that mix 
both groups. This mixing of distinct pathways is hard to interpret, especially for real world signals that have a 
much higher number of dimensions (i.e. genes).  
In contrast, if depicted red and blue points would again interact like mass elements in a common rigid body, 
these principal components would still point in the directions of the principal axes of rotation for this X-shaped 
body, with the above-explained physical meaning. In this context, the red and blue pathway directions would 
not be as useful for summary for rotational properties, because if a torque would be applied around them, the 
X-shaped body would inevitably rotate in a way that also moves points near the red respectively blue effect 
axes, as they are not principal axes of rotation. This demonstrates that the model of interactions that underlies 
a summarization method should be compatible with the signal context for interpretability. 
 
Figure I.2.2.2.b) Principal components do not point into effect directions 
Points for three dimensions simulate two distinct but partly correlated (i.e. not 
perpendicular) effects for 1000 samples each (red and blue). Principal 
components returned by PCA are depicted as three yellow perpendicular lines. 
The two longer principal components capture nearly all of the signal’s variance 
here; therefore, the third component that protrudes where the two longer 
cross in the center is relatively short. 
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I.2.3 Copy Number Analyses 
Besides gene expression microarrays, another important source of genomic information is array 
comparative genomic hybridization (aCGH). Instead of interrogating concentrations of transcribed mRNA, 
here the relative amount of DNA is quantified. Normally, two copies of each gene are available in the human 
genome (in case of  and  chromosomes in males, the reference is one copy). Segments of DNA may exist that 
have a lower or higher number of copies. To unsupervisedly detect these segments and to summarize aCGH 
signals, a neighborhood model can be employed(cf. Table I.1.3.4); for example, circular binary segmentation can 
detect these segments(cf. [27], see also cghcbs.m of the MATLAB® Bioinformatics Toolbox). 
These analyses may reveal, for instance, that a cell line has a double-deletion of a specific DNA segment. In 
this case, genes encoded in this segment can no longer participate in the gene regulation network in affected 
cells. Such DNA defects may be one possible origin or driver of cancer genesis. An already presented 
example(cf. I.1.2.3) is the loss of PTEN in a subset of GCB DLBCL samples[12].  
Another exemplary result from aCGH analyses shows(Figure I.2.3) amplifications of segments that include  
the MCL1 locus: 
Figure I.2.3) Exemplary aCGH analyses 
Two DLBCL cell lines(panels a and b) and an ABC DLBCL case(panel c) are characterized by high-level MCL1 amplification. 
(Analyses performed for and reprinted form a co-authored paper[3].) 
Chromosomal gains or amplifications of this locus occur in approximately 26% of ABC DLBCL samples. For 
this subset, MCL1 deregulation has anti-apoptotic characteristics and contributes to therapy resistance[3]. 
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I.2.4 Viability Curves and the IC50 
Besides whole genome analyses, several other experiments are performed in molecular biology that are 
associated with other types of analyses. For instance, viability measurements over titrated concentrations of 
a drug candidate can be utilized to quantify the sensitivity of cell lines. 
The drug is typically titrated over a logarithmic range of concentrations for the same cell line several times. 
The IC50 is defined as the inhibitory concentration where the viability has decreased to 50%. Usually, none of 
the tested concentrations in the logarithmic range matches the IC50 exactly. Hence, an interpolation between 
data points is needed to determine it. 
Such an interpolation can be determined 
with a sigmoidal model 

⋅, where  
is the logarithmic concentration,  is the 
resulting logarithmic IC50 and  determines 
the steepness of the viability decrease. To 
respect that for some cell lines an offset 
viability may remain after the strong 
decrease in viability, the model can be added 
this degree of freedom by 

⋅  . 
This model has been fitted to measured 
titration curves(with the fit.m function in MATLAB®). The 
IC50 concentration is obtained by the fitted . Visually(cf. Figure I.2.4), the IC50 corresponds to 
the intersection of the interpolated titration 
curve(gray) at 50% viability(blue). 
The example demonstrates IC50 analyses 
that have been performed for DLBCL cell lines 
OCI-Ly3(upper panel) and TMD-8(lower panel). Both 
cell lines have been treated with an antibody 
drug conjugate (ADC) that targets CD79B. 
CD79B is physiologically expressed in the 
vast majority of B cells and thus represents a 
promising target for DLBCL[69]. The cytotoxic 
agent in this ADC is the microtubule-
disrupting agent monomethyl auristatin E 
(MMAE). It induced cell death in the majority 
of DLBCL model cell lines, as depicted 
exemplary for OCI-Ly3 and TMD-8. These 
ADCs are also clinically relevant[69]. 
 
Figure I.2.4) Examples of IC50 fits for an anti-CD79B ADC 
Sigmoidal fits are utilized to determine IC50s for an antibody drug conjugate (ADC) 
targeting CD79B as described in the text. The same drug is applied to two DLBCL cell lines, 
OCI-Ly3 and TMD-8. (Analyses performed for [69].) 
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I.3 Association Methods 
An important step to gain new knowledge from experiments is to associate measurement 
results with already existing knowledge(cf. I.1.3.5). 
In molecular biology, important sources of computable genomic knowledge are public gene 
signature databases. They contain sets of genes that were discovered to function alike. 
A similar source is the gene ontology. It groups genes hierarchically by known molecular 
functions, by cellular components or by known biological processes. 
In context of patient samples, typically clinical information is available in addition to 
genomic information sources. These information can be of categorical type (like gender) or of 
metric type (like blood values). They can also be of a time-ordered censored type (like patient 
survival measured by follow-up studies). Different statistical methods exist for the association 
of each type of information with gene expressions. 
Selected examples analyzed for published studies are presented in this subchapter to 
illustrate some of these association methods. The same methods are applied systematically 
for biostatistical evaluation of discovered GEP effects(cf. III.3). Results for all 135 validated GEP 
effects are digitally provided in both tabular and graphical form(cf. page 231). 
I.3.1 Signature Analyses and Gene Set Enrichment 
Usually, genomic discoveries in bioscience have been published in the form of sets of genes that have shown 
similar behavior in analyzed biological settings. For example, they may have been identified by similar 
differential expressions between cell types or by co-regulation in response to a drug, etc. These gene 
signatures have been collected in several large public databases. For a comprehensive association with all 
existing biological knowledge encoded by these gene signatures, I have imported and combined the following 
public databases: • MolSigDB[70] (9479 signatures, v4.0, downloaded in May 2014) • GeneSigDB[71] (3138 signatures, v4.0, downloaded in September 2011) • Staudt lab signature DB[72] (253 lymphoma specific signatures, downloaded in November 2012) • HGNC gene families[73] (285 signatures, downloaded in May 2014) 
The resulting combined signatures database enables a systematic association of genomic experiments with 
13155 known gene signatures from various fields of biology. 
I.3.1.1 Gene set enrichment analysis 
Several statistical analyses can be utilized to test the association of a given biological experiment to these 
signatures. The probably most relevant statistical method to this end is gene set enrichment analysis[74].  
First, genes are ranked by the experiment in focus. Typically a supervised analysis(cf. I.2.1.1) determines these 
gene ranks, for example genes are sorted by their folding from the most upregulated to the most 
downregulated gene. For a given known gene signature, ranks of genes that are contained in this signature are 
marked next. Then it is tested, if these marked genes are distributed in a significantly non-random form.  
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Higher enrichment scores are obtained if all signature genes are located either at the downregulated side or 
all at the upregulated side of the analyzed experiment. More precisely, if all genes in a signature of size  are 
identical with the set of genes that have top ranks 1 … , then the enrichment score equals 1. If they are 
identical to the set of bottom-most genes, the enrichment score equals 1. Enrichments on either side may be 
biologically interesting, while a signature is typically relatively uninteresting, if its genes are half upregulated 
and half downregulated, or if they are all weakly regulated (corresponding to middle ranks). In these cases, 
the enrichment score is lower. For completely random (i.e. uniform) distribution of ranks, the score 
approaches zero. Gene weights may be utilized, for example, to prevent weakly or insignificantly regulated 
genes from having overdue impact on the score. The enrichment score is computed as a cumulative rank 
statistic that can be visualized as an enrichment mountain(e.g. Figure I.3.1.1). From left to right, the curve increases 
for every gene in the signature(blue lines) and decreases for every other gene. Both sets of genes are normalized 
and thus both contributions add to zero. The enrichment score is defined as the extremum of this 
curve(see [74] for details). 
To test the significance of enrichment scores, permutation tests are applied. These tests are a major factor 
for the computational cost of gene set enrichment analyses. As usually many signatures are tested 
simultaneously, a false discovery rate (FDR) is additionally computed as control for multiple hypothesis 
testing. The FDR estimates the ratio of signatures with likewise or stronger statistics that might exist by pure 
chance due to testing many signatures. Signatures can be categorized biologically. Often only signatures from 
specific categories are of interest. Hence, FDRs are typically computed separately for each category (rather 
than for the full database) to respect this external knowledge. 
In the study for which the depicted example(Figure I.3.1.1) 
has been analyzed, a murine Eμ-Tcl1 model for the 
human chronic lymphocytic leukemia (CLL) has been 
utilized to compare Eμ-Tcl1 mice with Cxcr5−/− Eμ-Tcl1 
mice[75]. The spontaneous tumor development has been 
followed for both genotypes of mice. Mice without 
CXCR5 showed a substantially delayed onset of the 
disease. For analysis, first, differentially expressed 
genes between six samples from Eμ-Tcl1 mice and five 
samples from Cxcr5−/− Eμ-Tcl1 mice have been 
supervisedly determined(cf. I.2.1.1). Ranking all genes by 
their  values for their differential expressions, the 
combined signatures database(cf. I.3.1) has been screened 
by gene set enrichment analyses. The depicted 
significant enrichment has been detected for the cell 
division cycle 2 (CDC2) signature (from the GNF2 
expression compendium obtained via the MolSigDB[70]). 
Genes are significantly downregulated in Cxcr5−/− Eμ-
Tcl1 mice. Hence, this signature predicts a proliferative 
advantage in Eμ-Tcl1 tumor cells. In total, seven 
different proliferation related signatures have been 
associated with likewise significant enrichment. Together with other experiments and analyses, the study 
clarifies steps of CXCR5-dependent tumor cell lodging and resulting proliferative stimuli to leukemia B cells[75]. 
 
Figure I.3.1.1) Significant enrichment of a proliferation related signature 
The signature CDC2 (from the GNF2 expression compendium via the 
Molecular Signature DB[70]) is significantly enriched (see text for details). 
(Analyzed for and reprinted from a co-authored paper[75].) 
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A similar analysis has been performed for an investigation of anaplastic large cell lymphoma (ALCL)[76]. First, 
genes that were significantly differentially expressed in cell lines K299, FE-PD and DEL following IRF4 
knockdown by RNA interference have been supervisedly determined(cf. I.2.1.1). For the resulting gene ranks, the 
combined signature database(cf. I.3.1) has been screened and a previously described MYC gene signature has 
been identified by significant enrichment. Together with other analyses and experiments, MYC has been 
revealed as a primary target of IRF4 in this study[76]. 
I.3.1.2 Additional signature statistics and signature heatmaps 
My analysis pipeline routinely computes additional statistics and heatmaps for enriched signatures that 
depict the actual gene expressions of samples in the current experiment. For each sample, the signature 
expression is aggregated and tested for significance (via -tests relative to baseline). If these statistics are not 
significant or if average foldings are relatively weak compared to top genes in the same experiment, results 
from enrichment analyses should be interpreted with care in my experience (even if they are significant). 
For the already briefly presented study in tumor immunology about RCC(cf. I.2.1.1 and [30]), several significantly 
enriched signatures confirm an immunological impairment. For example, the immune signature “immediate 
early” (from the Staudt lab signature DB[72]) has been identified with an enrichment score of 0.961 (  0.0007 
by permutation test, FDR  0.1%). The depicted heatmap(cf. Figure I.3.1.2) shows significant downregulation of 
signature genes in the majority of RCC patient samples prior to vaccination relative to healthy control samples. 
In four RCC samples this effect is particularly strong, leading to significant sample-wise average 
expressions(bottom), despite the low number of genes in this signature. 
Figure I.3.1.2) A immediate early immune response signature identified by gene set enrichment analyses 
The immune signature “immediate early” (from the Staudt lab signature DB[72]) has been identified by significant enrichment (enrichment score 0.961 and  0.0007 by permutation test). The depicted heatmap shows significant downregulation of signature genes in the majority of RCC patient samples (left) relative to 
healthy control samples. Additional signature statistics are a FDR for the enrichment of 0.1%  and a strong average logratio over all samples of 1.67. 
(Analysis performed for and reprinted from [30].) 
These heatmap information complement significant enrichment. Together, such statistics can provide a 
reliable basis for further biological interpretation of respective signatures. 
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I.3.2 Gene Ontology Analyses 
Gene ontology (GO) terms are similar to gene signatures, but they are organized hierarchically. There are 
three hierarchy roots: biological processes, molecular functions and cellular components([77], downloaded in June 2011). 
The deeper a term is in a hierarchy, the more specific is its biological meaning. The online source QuickGO[78] 
provides an overview of the definition of every GO term. 
Overrepresentation analyses can associate gene ontology terms with experiment-specific signatures or with 
discovered genomic effects. Typically, every term is tested for overrepresentation by a hypergeometric 
test(cf. [79], pages 369-371). Improvements to the statistical analysis that incorporate the parent-child relationship of 
terms have been suggested[80]. For all gene ontology analyses for this work(presented in III.3), I use only direct term 
annotations of genes in order to focus on the biologically most specific terms.  
A disadvantage compared to gene set enrichment analyses is that overrepresentation analyses require a 
definition of “top genes” for the experiment or effect being analyzed. I.e. a cutoff has to be specified that 
introduces an element of user-dependency. In contrast, enrichment analyses work with the ranks of all genes 
and do not require any cutoff. 
GO analyses may be useful for the identification of (re)discovered effects of already known biological 
functions. For example, a relative large GEP effect in DLBCL has been unsupervisedly discovered is 
significantly associated with gene ontology terms from all three term trees(cf. III.3.3.4). In context of new effects, 
especially for smaller effects induced e.g. by RNA interference experiments, GO analyses often do not result in 
significantly overrepresented terms in my experience. 
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I.3.3 Kaplan Meier Survival and Log Rank Tests 
Kaplan-Meier survival curves(cf. [79], pages 760-767) estimate survival over time from right-censored event data. In 
case of analyzing overall patient survival, observed deaths are the events and censored events correspond to 
patients that were lost to follow-up before their death occurred. Not only observed events but also censored 
events carry important information, as censored patients lived at least until the last recorded follow-up time. 
Resulting Kaplan-Meier survival estimates respect both types of information. Survival curves e.g. for  
two different subsets of patients, can be compared and tested for significant differences by log rank  
tests(cf. [79], pages 767-773). 
For multivariate survival analysis of combinations of GEP effects, Cox survival models(cf. III.2.1.1) are employed. 
Kaplan Meier survival estimates are then utilized extensively(in III.2) to visualize survival differences(e.g. Figure 
III.2.5.3.b) that are predicted by unsupervisedly discovered gene expression effects or by multivariate 
combinations thereof. 
The same analyses can be utilized in supervised contexts to test specific biological hypothesis. For example, 
a cross-species investigation based on mouse lymphoma models[81] has identified a subgroup of GCB DLBCL 
patients defined by high BCL2 expression. This subgroup is associated with significantly more favorable 
outcome for high NF-κB expression(cf. Figure I.3.3). In contrast, constitutively active NF-κB signaling also 
characterizes the ABC DLBCL subtype(cf. I.1.2.3, [10]) that is associated with significantly adverse outcome(cf. Figure 
III.2.1.8) relative to GCB DLBCL. Hence, the NF-κB pathway plays opposing roles, depending on the cellular 
context[81]. 
 
Figure I.3.3) Kaplan-Meier survival analyses show significantly more favorable outcome for high NF-κB expressions in a GCB DLBCL subset with high BCL2 expression 
Kaplan-Meier survival analyses for samples in GSE10846.R-CHOP(cf. III.1.1.1, [5]) are depicted for eight sample subsets. First, samples have been stratified by their BCL2 
gene expression and by their previously assigned DLBCL subtypes[5]. For each of the four resulting patient subsets, patients have been grouped further by their NF-κB 
expression (as quantified by the average expression of the signature “NFkB_Up_all_OCILy3_Ly10” from the Staudt lab signature database[72]). For GCB DLBCL patients 
with high BCL2 expression, a significantly more favorable survival was identified for high NF-κB expressions (p=0.005, log rank test, 49 samples). (Analyzed for [81].) 
Interestingly, BLC2 has also been unsupervisedly (re)discovered based on signal dissection results and 
multivariate survival analysis as one of the top DLBCL survival effects(effect validation index ν=75, cf. III.2.5). Biostatistical 
analyses for this effect(cf. III.3.3.7) help to determine a subset of patients with low BCL2 expressions and high 
expressions of a T cell co-stimulation related effect(cf. III.3.3.6). This discovered subset is associated with 
significantly different survival for different expressions of a zinc related effect(cf. III.3.3.8). 
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Modern technologies can measure many parts of a system 
simultaneously. For example, human whole genome microarrays 
provide approximately 50000 gene expressions per tumor sample. 
To bridge the gap between information about all system parts 
and the high-level modeling of their interactions, there is an 
increasing need to summarize these measurements. 
In principle, a signal can be separated in many ways like a sum 
into summands, but a specific dissection is required to identify 
summands that represent distinct true effects of interactions in 
the underlying system. An ideal summary represents the complete 
high-dimensional multi-sample signal by as few as possible, yet 
easily interpretable and statistically significant effects. 
This chapter presents a novel signal dissection method that 
utilizes a correlation maximization principle and bi-monotonic 
regression to this end. Various biological effects are simulated to 
validate the method and to systematically compare it with 
principal component analysis and hierarchical clustering. 
 MIC 0.a KÜ 
 MIC 1.a KÜ 
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II.1 Design Goals 
To exemplify a basic detection task, first, a simulated 3D signal is presented. It serves 
throughout this chapter for geometric illustrations of method concepts like effect curves that 
are difficult to imagine in high-dimensional signal spaces. 
When developing a novel algorithm it is instructive to reflect existing problems that ideally 
should be solved. To this end, characteristics of gene expression signals or requirements by 
the analytical workflow in life sciences are reflected, together with present problems of 
hierarchical clustering or principal components analysis. Corresponding conceptual 
improvements that are implemented by signal dissection are briefly previewed. 
II.1.1 Introductory 3D Example 
Although the method is designed and optimized for high-dimensional signals, an example with just three 
dimensions can be more illustrative. It provides a geometrical perception of how the method works, based on 
visualizations in the familiar 3D space. Furthermore, the simulated signal mimics four basic biological 
regulation concepts. High-dimensional effects that resemble real-world gene expression signatures with many 
genes are simulated later for method validation and systematic comparison(II.6.2.1). 
II.1.1.1 A simple linear effect 
In the easiest case, genes controlled by a pathway are co-regulated in a linear 
way, i.e. samples follow a line in gene space. The red effect on the right simulates 
this using a gene axis of  red  ≡ 0.2, 0.2, 1  for   , , , i.e. gene  is the top 
gene of that pathway with gene  being five-fold weaker co-regulated and gene  
being also five-fold weaker, but regulated with opposite sign. If  denotes the 
average pathway strength or activity in samples, then sample points follow the 
effect via |red , where |red  ≡ |red  red   is its normalized gene axis. To 
construct a typical gradual effect for which extreme expressions are less probable 
than weaker regulations, simulated pathway strengths  for all depicted 1000 red 
samples(Figure II.1.1.1) follow a normal distribution ~0,1; this also explains the 
solitary outlier at the bottom. To simulate measurement noise, each sample  
point was added normally distributed expressions of standard deviation 0.1 for 
each gene. 
Real-world gene expressions are usually analyzed as logratios relative to 
control samples or relative to the average of all measured patients. Hence, zero 
indicates no pathway activity relative to this baseline, positive values represent up-
regulated genes and negative values represent downregulated genes relative to 
baseline. In general, a pathway may simultaneously modulate gene expressions 
towards upregulation for a set of genes (here ,  with   0) and towards 
downregulation for another set of genes (here only  with   0). For samples with negative pathway 
activity   0, “up” and “down”regulation change roles. Whether |red  or |red  is the positive direction of a 
 
Figure II.1.1.1) 3D example; red 
effect: a linear law of gene regulation 
All three genes are regulated 
linearly. Gene  dominates with 
five-fold higher regulation 
strength as the other two genes. 
(1000 samples were simulated as 
explained din the text.) 
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pathway is a matter of convention and cannot be decided by the method. In any case, both sets of genes are 
anti-correlated to each other by virtue of the underlying connecting regulation law. 
II.1.1.2 Supported nonlinear biological effects and three examples 
Although the assumption of linearity is a standard first attempt for modeling in physics and biosciences, 
nature is not always linear. For example, feedback loops in pathways that may lead to nonlinearities and 
maybe even oscillations over time. 
In case of gene expressions, a snapshot of average mRNA expressions in a cell ensemble is measured, i.e. no 
dynamics over time are recorded. To see nonlinearities like oscillations I such signals would likely correspond 
to an unnatural effect. For example, consider a subset of samples that shows co-regulation for a set of pathway 
genes, while one half of these genes are regulated stronger than the other half. Additionally, there are other 
samples with stronger average activity of the same pathway, but for them the initially weaker half of genes is 
now regulated stronger than the other half. For samples with even stronger pathway activity, the relative 
expression of the gene halves is flipped again and thus equals the initial set of samples with relatively low 
average pathway. Such oscillatory behavior seems biologically implausible in the gene expressions context. 
Even if such an effect was measured, it would probably be more constructive for system modeling to detect 
both halves of genes separately as two partially correlated effects. Besides, no general-purpose method that is 
able to detect and properly dissect superposed effects of all imaginable nonlinear forms can exist, because this 
task is highly ambiguous and has no unique solution. 
Still, there are non-linear biological effects in typical gene expression signals. One example are pathways 
including genes that reach their saturation expression before other genes regulated by the same pathway (i.e. 
they reach their maximum expression for lower average pathway activity). Other pathways may regulate 
some genes sub-proportionally or over-proportionally (e.g. quadratically) relative to their overall pathway 
activity. Yet others might show a switch behavior, e.g. some of their genes are either switched off or 
immediately expressed on a constant high level for some activity threshold. All these nonlinearities have one 
thing in common: They are monotonic over the average pathway activity. And they extend along a guiding 
linear gene axis, over which they are monotonic. Projections of sample points on this gene axis quantify their 
average pathway activities. Three basic examples illustrate such monotonic effects: 
 
Figure II.1.1.2) 3D example; blue, green and magenta effects: monotonic non-linear laws of gene regulation 
Blue effect) Gene  saturates over the average pathway activity proportional to the logistic function, while genes  and  follow linear laws (500 samples). 
Green effect) Gene  shows quadratic increase respectively decrease, while genes  and  follow linear laws (500 samples); top point densities are relatively low here. 
Magenta effect) A one-sided effect with an offset that simulates a pathway with a threshold activity (500 samples, but only the top 100 have nonzero signal before 
adding simulated noise). 
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Precise definitions are as follows:  • The blue saturation effect uses  blue  ≡ 0.5, 0.75, 0.2  as its dominant linear gene axis, simulates 
500 activities 	~	0,1 and uses a centered logistic function  ≡ 3 ⋅ 0.5   to simulate a 
saturation of gene .  • The green effect extends along  green  ≡ 0.8, 0.2, 0.5 , again simulates 500 samples with 
activities 	~	0,1 and regulates gene  quadratically via  ≡ sign ⋅ .  • Finally, the magenta effect extends linearly along gene axis  magenta  ≡ 0.4, 0.7, 0.7 , but only 
the top 20% of all 500 simulated pathway activities		~	0,1 are kept; all others are set to zero in 
order to mimic a one-sided threshold behavior. To simulate measurement uncertainties, all simulated 
sample points are added normal noise with standard deviation 0.1 for each gene. 
II.1.1.3 Merged 3D signal and an exemplary detection task 
In this example, all four simulated effects take place in different sample subsets that could represent disease 
subtypes. Initially, it is unknown, which sample belongs to which subtype. Neither is known how many effects 
are contained in the signal. Like in a real measurement setting, only the merged signal (without color-coding) 
is available as input for detection(Figure II.1.1.3). The task is to detect and dissect all four effects correctly. 
Furthermore, empirically discovered laws of gene regulation should be provided for each one in an 
interpretable form. More precisely, the method should yield an effect curve in the space spanned by genes ,  
and  for each effect, together with correlations and effect weights that assign samples to subtypes. 
 
Figure II.1.1.3) Merged 3D example with four effects 
Four simulated basic pathways correspond to four distinct sample subsets. They are regulated by different laws for the same three genes, as defined above. (Sample 
points are plotted in a perspective that has been chosen to show all effects with as few as possible overlap.) 
The task for detection methods is to recover all four simulated pathway laws empirically from the points. (The color-coding is not part of the input for detection 
methods, as illustrated on the right.) 
Although based on only three dimensions, this example is difficult to dissect from a certain conceptual 
perspective: The signal contains four effects, but its gene space has only three dimensions. Mathematically 
consequently and visually obvious, these effects are partially correlated to each other. This also implies that 
they cannot be dissected by usual projections, because after three projections in 3D only zero remains. In high-
dimensional gene expression measurements, pathways usually only regulate some shared genes, but not all 
of their genes are shared. This makes their dissection easier. Still, visually the 3D effects are clearly separated 
by their point density. In addition, their guiding linear gene axes point in clearly distinct directions, despite 
their partial correlation. This can be utilized to dissect them as is illustrated when explaining the search 
strategy(II.3). 
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II.1.2 Method Design Goals 
Several characteristics of signals in life sciences are listed in this subchapter. Associated problems from 
methodological perspective are presented. Primarily, examples based on hierarchical clustering are provided, 
as this method is the quasi-standard for unsupervised analyses in biosciences(cf. I.2.2.1). Additionally, problems 
are presented in the context of principal components analysis(I.2.2.2), as PCA is conceptually more comparable 
to signal dissection. Corresponding method design goals are clarified and method concepts reaching these 
goals are briefly previewed. 
II.1.2.1 Effect focusing should be unsupervised 
Whole genome microarrays measure many different effects, including obvious differences like gender or 
race. Hence, a single sample clustering cannot summarize all measured sample characteristics simultaneously, 
as most effects are independent and their signals may overlap. 
Per design, hierarchical clustering tries to derive just a single sample clustering based on a simultaneous 
comparison of all genes in its input signal. This usually leads to noisy and unreliable results when applied to 
the complete measurement signal. To some extent this is still the case for too loosely focused signals[e.g. 55.figure 
1]. To overcome this problem, usually the analysis is focused on a tight subset of measured genes 
only[44,47,48,51,54,57,60,61]. For example, it might be focused on the most variable genes in a given context or with 
help of a previously defined gene signature. However, these interventions make resulting clusterings 
dependent on the chosen focus and thus are an incomplete summary with respect to the complete signal. 
In brief, a direct application of the method to the full measurement signal should be possible and should not 
require any supervised restrictions of the gene or sample space, as they can make results incomplete and 
maybe even biased. 
Signal dissection can be applied to the full signal, as its search strategy(cf. II.3) realizes an automatic, unbiased 
and adaptive focusing of effects. 
II.1.2.2 Discovered effects should be specific to true effects 
Even after an initial (either supervised or unsupervised) general focusing, typically several yet unknown 
disease-specific effects remain in the focused signal. Often their underlying biological pathways still overlap 
each other independently like ordinary human features such as gender, skin color and blood groups, i.e. they 
do not stand in any hierarchical context to each other. To dissect these biological effects properly, one ideally 
needs an individual sample clustering for each independent true effect. 
Conceptually, hierarchical clustering tries to organize samples in a tree structure that is simultaneously 
based on all remaining effects in the focused signal. The resulting sample clustering then may constitute an 
automated mixture of biologically yet unidentified and potentially independent effects, which makes resulting 
dendrograms[as in 44,47,60] harder to interpret and hard to compare. One might extract sub clusters from a larger 
dendrogram to finally arrive at single effects[e.g. 47], but this is only possible if those effects were not overlapped 
and split by other effects in the first place. Furthermore, these results are dependent on yet another supervised 
focusing decision. It is legitimate and often statistically significant to just use the dominant effect, i.e. to cut the 
dendrogram at a top level and to define just few sample clusters[e.g. 61], but this is again systematically 
incomplete. In the extreme case of manual focusing, one might uses external information to focus directly on 
the context in question, for example, on genes that are differentially expressed in tumor samples that have 
different drug sensitivity[45.fig.2]. This may be useful to construct predictive models, but it is only available in 
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supervised scenarios and thus cannot reveal any previously unknown biological groups of samples or genes as 
a matter of principle.  
PCA does not try to represent overlapping effects as a hierarchical distance tree, but it assumes that effects 
correspond to directions of maximal variance. This can also lead to a mixture of multiple true effects by each 
principal component as illustrated in I.2.2.2. This is also confirmed in method validation(II.6.3) and again makes 
principal components hard or even impossible to interpret. This problem is also known in astrophysics, a field 
where PCA has been applied more frequently compared to bioscience: “The main difficulty with PCA is that 
the interpretation of the empirically determined PC components in terms of physical properties is complex at 
best.”[24]  
Rather than coping with signal summaries that mix real effects, it is usually more constructive to first 
unsupervisedly detect and identify each single effect separately and then let an expert combine them later to 
generate an interpretable compound model, for example by multivariate survival analyses(III.2) based on 
discovered gene expression effects. 
In brief, biologically independent effects should not be mixed automatically in any form as this makes results 
hard to interpret and difficult to compare. 
Signal dissection uses a general superposition model for the signal(cf. II.2.1.1) that supports effect hierarchies, 
but is not limited to them and also supports independently overlapping effects. A correlation maximization 
principle is utilized by the search strategy(II.3) to detect and robustly identify effect axes that are specific to 
distinct true effects.  
II.1.2.3 Partial correlations should be properly resolved 
Special cases of overlapping effects are partially correlated yet distinct effects, e.g. the four effects in the 3D 
concept example(Figure II.1.1.3). Methods like PCA that require orthogonality of resulting effect axes (i.e. principal 
components) cannot properly resolve such partially correlated effects(cf. II.6.1). The same is true for all methods 
that are based on (or can be equivalently formulated as) a series of projections of the signal.  
Especially in context of genetically heterogeneous diseases like DLBCL, it is important that the method is 
able to dissect overlapping and partially yet not fully correlated sets of genes. Underlying distinct biological 
pathways can then be inferred from resulting subsets of highly correlated genes. This inference is considerably 
harder, if a single and relatively large set of only moderately correlated genes is returned that corresponds to 
a mixture of these partially correlated effects. 
In brief, methods should not be restricted detecting only 100% uncorrelated effects (i.e. to orthogonal effect 
axes), because this leads to hard to interpret summaries of signals containing partially correlated yet distinct 
true effects. 
Dissection strengths(cf. II.4.2.1) are utilized to precisely dissect the signal parts that are most correlated with the 
respective discovered effect, thereby keeping distinct or only partially correlated signal parts for later 
discovery as separate effects. These separate effects are usually correlated higher to these signal parts and 
thus represent them with more specificity, which makes their interpretation easier. 
II.1.2.4 Symmetry of genes and samples 
In general, a biological effect causes expressions in an initially unknown subset of genes and in an initially 
unknown subset of samples. As outlined above(II.1.2.1, II.1.2.2), it is useful to focus on a gene subset in order to 
determine affected samples. Analogously, it increases precision to focus only on the affected samples when 
42 Chapter II - Signal Dissection 
 
trying to determine participating genes in the first place. Both focusing needs are interdependent and 
therefore should be handled simultaneously. 
Hierarchical clustering can either cluster samples based on their expressions of all presented genes or it can 
cluster genes based on their expressions in all presented samples. Often both resulting dendrograms are 
displayed simultaneously, but they can only be computed independently from each other, as hierarchical 
clustering can only compare objects (i.e. genes or samples) of the same type at a time (and only with a 
predetermined fixed number of features). It may be possible to first compute gene clusters based on all 
samples (ignoring that effects may only affect a subset of them) and then utilize the resulting dendrogram to 
focus within the gene space, i.e. to compute sample clusterings separately for each identified gene cluster. 
However, this iterative procedure assigns different roles to genes and samples and makes results additionally 
dependent on the sequence of those roles. 
In brief, genes and samples should be treated symmetrically and simultaneously by the method in order to 
optimally focus on an effect. 
Signal dissection realizes this symmetrization immediately after selecting an initial representative gene or 
sample(cf. II.3.1.3) for a potential effect. Henceforth, roles of genes and samples are interchangeable during 
detection to avoid any bias. Effect eigensignals are modeled(cf. II.2.1.2) and determined(cf. II.4) as two-dimensional 
functions, thereby detecting and representing correlations between genes and between samples 
simultaneously. 
II.1.2.5 Removal of overlapping strong effects 
Gene expression experiments can only measure the sum of all superposed effects, and stronger effects may 
shine out weaker but more important ones. Strong effects may be of biological origin, for example racial 
differences[57]. Often they are unintended cohort-specific lab effects of unknown cause; some of which may be 
identified retrospectively, for example differences in experimental labeling protocols[5]. 
Hierarchical clustering effectively splits the cohort by the strongest effect, for example by cell subtype(e.g. B- or 
T-cell based ALL; cf. [45.supp.fig.1]). Consequently, parts of independently overlapping weaker effects are only detectable as 
sub-clusters within each cluster of the strong effect, making true causes of the weaker effect harder to infer, as 
demonstrated in II.6.2.6. Furthermore, in such a case the effective cohort size is reduced, eventually preventing 
detection of biologically more meaningful yet smaller and weaker effects, e.g. gene expression effects with 
prognostic value[45.fig.2]. PCA on the other hand, usually can handle a single overlapping strong and linear effect 
well, as such effects define a clear direction of maximal variance due to their strength(cf. II.6.2.5). The information 
along this direction is then projected away by the first principal component, which makes initially overshined 
effects detectable by further principal components. However, detection precision breaks down in presence of 
more than one strong effect of similar size(cf. II.6.3). 
In brief, unimportant strong effects should be prevented from dominating results and they should be 
removed without affecting information from weaker yet potentially more important effects. 
Signal dissection detects the empirical eigenorder(cf. II.4.1.2) of the strong effect and utilizes bimonotonic 
regression(cf. II.4.1.3) to estimate signal parts caused by it. This enables its later dissection without losing 
information about overlapped weaker effects. Later detection iterations can thus detect these weaker effects 
based on all samples and without any artificial reduction in the sample size due to the strong effect. As large 
overlapping effects often are just uninteresting lab effects, their removal can also be seen as a type of advanced 
signal normalization that is complementary to global signal preprocessing (e.g. by quantile normalization). 
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II.1.2.6 Compatibility with gradual effects 
Most biological effects are gradual in nature, i.e. some samples are affected stronger than others, and their 
gene expressions effectively sort them in a gap-free continuous way. The same holds for genes participating 
in an effect. 
Usual gene signatures or sample clusters are represented as flat sets with hard borders that were determined 
by e.g. partitioning methods or were inferred from dendrograms of hierarchical clustering. This 
representation is a consequence from the underlying cluster concept that assumes high similarity within 
clusters and large gaps between clusters. Gradual effects cannot be represented well by this concept and cut 
points thus become unreliable and hard to reproduce. 
PCA results are more precise relative to flat gene signatures, as principal components can describe directions 
along which linear gradual effects extend. The coordinates of samples along this principal component then 
reflect gradual effect strengths, i.e. average pathway activities. However, gradual biological effects like 
saturations(cf. basic examples in II.1.1.2) that deviate from a linear axis cannot be properly described by a single principle 
component. Instead, the effect’s non-linear signal part is represented by one or several perpendicular principal 
components. Again, this makes it hard to infer the effect’s underlying biological law of gene regulation from 
PCA’s signal summary. 
In brief, flat sets and hard cuts are an unsuitable model for gradual effects and should be replaced by more 
flexible forms of effect representation that can also describe non-linear gradual effects without artificially 
splitting them. 
Signal dissection uses a generic bimonotonic effect model(cf. II.2.1.2) that supports gradual effects. In the special 
case that the effect is truly of binary nature (and thus could be represented by a traditional hard cut as well), 
this information is retained in form of a steep signal change in the regressed effect curve(cf. II.2.2.3 and II.4.1). 
II.1.2.7 Number of effects and user-dependency of results 
It is a common yet difficult question, where one effect ends and another one starts and thus how many effects 
make up a signal in total. The same question occurs when deciding if a given signal part still makes up an effect 
or is merely noise. 
Hierarchical clustering just returns a dendrogram (i.e. a distance tree) and leaves it to the user to read 
clusters from it, i.e. to define the number of effects and their borders. This can strongly influence results[82], 
making sample clusterings harder to reproduce and harder to compare. This problem is amplified in the 
context of gradual effects(II.1.2.6) or when hierarchical clustering is utilized iteratively to realize a manual effect 
focusing as explained above(II.1.2.4). 
PCA returns a full orthonormal rotation of the coordinate system underlying the signal space, i.e. it always 
returns as many principal components as there are signal dimensions. Usually there are much more 
dimensions than true effects. (In case of partial correlations in subspaces of the signal it may also be less than 
required for proper dissection of true effects(cf. II.1.2.3).) Usually principal components are sorted descending by 
the amount of signal variance explained by them. Then only those are retained that explain more than a 
selected threshold. In this case, the number of effects again is determined manually and retrospectively. 
Preferably, user parameters should all be defined before effect detection starts and should be kept to a 
minimum. In particular, the number of effects in the signal should be determined unsupervisedly and not by 
retrospective user action. 
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Signal dissection estimates the true noise level(cf. II.5.1.1). Based on this estimation, the significance of the signal 
strength in an effect’s focus can be computed(cf. II.5.1.2). Additionally, the significance of correlations between 
genes and samples in an effect is computed(cf. II.5.2). Based on prescribed significance thresholds, this can be 
utilized for effect qualification(cf. II.3.1.8). Only few parameters are defined for this effect qualification and all are 
prescribed. As soon as no more gene or sample qualifies, the method terminates, thereby determining the 
number of effects in the signal unsupervisedly. 
II.1.2.8 Completeness of results 
Ideally, an analysis method can detect all consistent interactions that were measured in a given signal and 
represent them 1:1 by interpretable effects. 
Hierarchical clustering can only return a single sample clustering for presented data. The only way to get 
towards completeness is to use it multiple times via sequential focusing as explained(II.1.2.4), with all associated 
problems outlined above. In case of principal components, they represent 100% of the measured signal in new 
coordinates per construction. But as explained above, principal components do not necessarily match true 
effects and in case of high-dimensional signals, most of them usually explain just different aspects of 
signal noise. 
Preferably, effects that explain noise (i.e. false positives) should be prevented, but simultaneously a strong 
statement about the remaining unexplained signal should be made with respect to the non-existence of further 
true effects in it (i.e. no false negatives, either).  
The signal model(cf. II.2.1.1) and the generic bimonotonic effect model(cf. II.2.1.2) can represent a broad class of 
effects and signals comprised of such effects. With respect to preventing false positives while simultaneously 
discovering true positives, again effect qualification(cf. II.3.1.8) is utilized based on the significance of an effect 
candidate’s signal strengths and correlations. Method validation demonstrates that this works reliably with a 
high rate of discovered true positives while only accepting occasional false positives(cf. II.6.2.5). 
II.1.3 Needed Capabilities beyond Detection 
Additional to solving discussed conceptual problems of previous detection methods(II.1.2), the typical 
workflow in molecular biology requires several capabilities beyond unsupervised effect discovery, for 
example their cross-cohort validation. These capabilities are out of scope for detection methods like 
hierarchical clustering or PCA, but they should be included as part of a comprehensive solution. They are 
presented and applied in Chapter III, but ideally, the detection stage is already designed with these subsequent 
requirements in mind, as briefly introduced below. 
II.1.3.1 Comparability and validation of effects across sample cohorts 
Often, gene expression signals for a single patient cohort contain cohort-specific lab effects, e.g. systematic 
properties of the utilized microarray, experimental setup or protocol. Resulting effects on the signal are 
statistical true positives, but biological false positives. Therefore, it is mandatory in life sciences to validate 
any discovered gene expression effects, however significant they may be. This is also helpful to filter out false 
positives that might have been detected due to imperfect dissections or due to underestimated noise. 
To realize this validation, a comparison method for detected effects is required. For the detection stage this 
implies that effects should already be discovered and stored in a form that is suitable for later comparison. 
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Effects discovered by signal dissection can be compared directly by weighted correlations(cf. II.2.3.1) of their 
axes. This cutoff-free comparison does not only test whether flat sets of top genes are compatible, but precisely 
quantifies the consistency of the relative order and of all regulation strengths of genes respectively samples. 
These correlations can be associated with a  value for statistical assessment(cf. II.5.2). Based on these 
comparisons, effects can be validated(cf. III.1.2) by looking for multiple unsupervised discoveries of the same 
genomic effect in independent cohorts. Alternatively, effects may be validated by supervisedly testing their 
existence in signals from other cohorts (similar to effect application for classification; cf. II.1.3.3). 
II.1.3.2 Cohort-independent genomic consensus effects 
If the same biological phenomenon has been discovered in multiple patient cohorts, then the information 
from all available sample cohorts should be used to represent this genomic effect in its most general way. To 
this end, a procedure should combine all individual discoveries to a consensus gene effect that is as cohort-
independent as possible. 
Consensus gene effects can be readily computed from multiple discoveries of the same biological effect by 
averaging their gene axes, gene correlations and gene weights returned by signal dissection(cf. III.1.3). 
II.1.3.3 Patient classification in new cohorts by genomic consensus effects 
Once consensus gene effects have been constructed, a typical application is to sort or classify new samples 
of new cohorts by them, thereby predicting their association with the discovered genomic effect. For example, 
patients could be sorted by an effect that describes the gene expression differences of particular disease 
subtypes. Resulting correlations of samples with subtypes and associated  values might be useful for 
determining the optimal therapeutic strategy for these patients in precision medicine contexts. 
All algorithmic parts of signal dissection except for the search strategy can be identically reused to compute 
consensus sample effects(cf. III.1.4), thereby quantifying and predicting effect strengths in samples from new 
cohorts. To this end, the search strategy is replaced by the respective consensus gene effect that should be 
used for sample classification. 
II.1.3.4 Specific biostatistical evaluation of discovered effects 
To help experts characterize and identify consensus effects biologically, ideally all available computable 
biological knowledge that is significantly associated with an effect should be summarized in an easily 
retrievable form. To this end, effects should retain as much as possible information. Only then, specific 
associations can be found and misleading false-positive associations can be prevented. 
For example, in case of clustering and partitioning methods, statistical association methods are limited to 
flat sets, again. This essentially restricts to categorical statistical tests. Sample clusters may be associated with 
e.g. clinical covariates and gene clusters could be analyzed in context of known gene signatures by 
overrepresentation analyses. However, more sophisticated statistical association methods like gene set 
enrichment analyses(I.3.1) require more information like a continuous quantification of the involvement of every 
single gene in a particular effect. 
All effects discovered by signal dissection and constructed consensus effects can be tested directly by gene 
set enrichment analyses. More precisely, several scores for gene ranking are available to this end(cf. III.1.3.2). 
Additionally, effects can be biostatistically associated with several other sources of computable genomic 
respectively clinical knowledge(cf. III.3). 
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II.2 Mathematical Framework 
Signal dissection is based on a superposition model for the signal and an unrestrictive 
bimonotonic effect model. After clarifying and motivating this approach, basic concepts to 
formalize the algorithm like gene and sample vector spaces and effect curves are defined. 
The concept utilized for quantification and later detection of interactions(cf. I.1.3.4) is motivated 
and corresponding functions like uncentered weighted correlations are defined. For 
illustration, an equivalent geometric interpretation is provided as well. 
II.2.1 Model 
Like principal components analyses(cf. I.2.2.2) that search for maximal variance in the signal or hierarchical 
clustering(I.2.2.1) that is based on a distance metric and a linkage method, every unsupervised method needs a 
compatible model for the specific type of interactions that it tries to unveil(cf. I.1.3.4). Ideally, this model leads to 
an unambiguous dissection of the signal into interpretable effects of interaction, while simultaneously making 
as few as possible assumptions and demanding as few as possible constraints. 
II.2.1.1 Signal model 
The complete measured signal for  genes (or features) and  samples can be represented as a matrix  ∈ , where  ≡ …,… 	 ∈  is the signal space. The lower index zero indicates the initial 
signal before the first detection and dissection iteration. 
To dissect the signal into its generating effects, I assume that the 
measured signal   is the result of a superposition of different effects  . 
Like  , all   are matrices ∈ . Together with a random matrix  of 
the same size and with normally distributed components, the signal 
model as matrix equation is a simple sum(Eqn. II.2.1.1). 
As effects   are dissected iteratively by the method,  ≡  ∑   denotes the remaining signal at the end of detection and 
dissection iteration . Hence,  is the initial signal for the following iteration and   is the initial signal for 
the first iteration. 
In molecular biology, the method is applied to log-transformed gene expression ratios. Hence, the model is 
multiplicative instead of additive for raw signal intensities. This is intended, because folding is the biologically 
relevant measure and e.g. 8-fold upregulation versus healthy controls is about as important as downregulation 
to 

, whereas the addition of a constant amount of mRNA expression by itself has no clear biological meaning 
without knowing the base concentration. For example, adding  mRNA molecules to a reservoir of already 100  mRNAs of the same sequence in the same cell usually has biologically insignificant functional 
consequences compared to adding the same  mRNA molecules to a cell that did not express this sequence at 
all so far. With help of log-transformations, absolute numerical values become the same for the same 
biological importance. For the above example, log 8  3 and log   3. Consequently, the method should 
search for additive effects in this log-scale, rather than searching for additive effects on signal intensity level. 
   


  
Eqn. II.2.1.1) Signal model 
The initial signal   is modeled as a sum of 
effects   plus normally distributed noise . 
This matrix equation is valid for all genes   and 
all samples . The total number of effects   is 
initially unknown, as are all  . 
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II.2.1.2 Bimonotonic effect model and effect eigensignals 
Dissecting a sum into summands is ambiguous without further information or constraints. Hence, an effect 
model is required. While effects are visually clear in the 3D example(Figure II.1.1.3), this needs to be generalized in 
a formal way to guide detection and regression of high-dimensional effects. 
Let  ≡ 1,2, … ,  be the measurement order of genes and  ≡ 1,2, … ,  be the measurement order of 
samples. These external reference orders are needed for formal reasons when resorting a signal matrix 
according to an effect. They usually do not correspond themselves to any effect of interaction. For sort vectors , , i.e. for a permutation  of   and a permutation  of , let ,  ≡ , …,…  denote the 
correspondingly resorted matrix. 
The effect model was inspired by the looks of typical 
real-world heatmaps that have been sorted by differential 
gene expression(examples: Figure II.2.1.2, Figure I.1.2.1, [83].Figure 1A, [45].Figure 2). 
The model should be able to represent nonlinear laws of 
gene regulation that are monotonic over the average 
pathway activity, as illustrated for basic 3D effects(II.1.1.2).  
For generalization and for definition, I demand that each 
effect   has an eigenorder  ,  of gene and sample 
permutations such that the resorted effect signal  ≡ ,  is bimonotonic, i.e. monotonic for both genes 
and samples. This definition is utilized later(II.4) to 
empirically regress an effect’s own contribution to the 
signal and to dissect it from any superposed foreign effects 
or noise. Hence,   is named the eigensignal of effect . 
Writing bimonotonicity out, the effect model reads: 
∀:	∃  ∈ perm	∃  ∈ perm:	
∧ ∀ ∈ 1, : ∨ ∀ ∈ 1,   1: ,   1  , ∨ ∀ ∈ 1,   1: ,   1  , 	
∧ ∀ ∈ 1, : ∨ ∀ ∈ 1,   1:   1,   , ∨ ∀ ∈ 1,   1:   1,   ,  
Eqn. II.2.1.2) Effect Model 
 permX Full permutations of a finite set , i.e. perm ≡ |:  → 	bijective 
Other than a supervised sorting of gene expressions(e.g. Figure II.2.1.2), signal dissection utilizes this bimonotonic 
effect model to unsupervisedly discover effects and to determine their co-regulated and anti-regulated genes in 
the first place. More precisely, correlations (or anti-correlations) between all genes and between all samples 
of an effect are a consequence of bimonotonicity (except for unregulated genes or samples at the effect’s zero 
transition). This is utilized for effect detection by searching for high correlations in the signal(cf. II.3). Empirical 
sample and gene eigenorders are determined for each discovered effect. These empirical eigenorders presort 
expressions approximately bimonotonic for the effect’s top genes and samples. Then the bimonotonic model 
is applied to regress the effect’s eigensignal(cf. II.4.1). Finally, the eigensignal is dissected(cf. II.4.2), which potentially 
reveals previously overlapped effects for discovery in subsequent detection iterations. 
Although bimonotonicity is a sufficient constraint to be able to regress the signal of detected effects(II.4), it is 
a rather generic effect model compared to models that involve specific functional forms or explicit parameters. 
 
Figure II.2.1.2) Example of a roughly bimonotonic real-world effect[29] 
This heatmap is based on a supervised analysis that sorts samples of 
cohort GSE31312 based on their differential expressions between 
predefined gene signatures for ABC-like and GCB-like subtypes of 
DLBCL. Originally, this subtype prediction has been developed and 
applied to an older DLBCL cohort[83], which also resulted in a roughly 
bimonotonic signature. (Adapted by permission from Macmillan 
Publishers Ltd: Leukemia[29], copyright 2012) 
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This allows fitting a wide range of regulation laws, including gradual effects like saturations, sub-proportional 
(e.g. square root like) or super-proportional (e.g. quadratic) regulations as well as unsteady step functions 
(e.g. between gender groups). 
Conceptually, bimonotonicity links the signal of both genes and samples. This type of intrinsic two-
dimensionality is an advantage over methods or distance measures that compare either genes or 
samples(cf. II.1.2.4), especially for dissection tasks in the context of strong(cf. II.1.2.5) or many(cf. II.6.3) overlapping effects. 
In summary, I model the initial signal   as a superposition of effects  . Each effect has an eigenorder  ,  
in which its eigensignal   is perfectly bimonotonic. Eigensignals represent and idealize distinct laws of gene 
regulation or other interactions in the underlying system. 
II.2.2 Basic Concepts 
The mathematical framework is set up here to prepare the formalization of signal dissection. Basic 
descriptive concepts and their notation are defined and motivated. 
II.2.2.1 Gene and sample vector spaces 
The gene space   is a vector space spanned by  genes |  1 … . Every | has coordinates  … ∈   in the gene reference order   (where   is the Kronecker delta, i.e.   1, if    and zero 
otherwise). For clarity, the upper index 	 is used to indicate elements of this space or information tokens about 
all genes. For each sample, all genes have been measured and hence samples are points in this vector space 
spanned by all genes. Let |  ∑  ||  denote the th sample vector with expressions  | ≡ ,  
for gene indices  ∈ 1, … , . 
The sample space   is a vector space spanned by  samples |  1 … . Every |  has coordinates … ∈   in the sample reference order . The upper index 	 indicates elements of this space or 
information tokens about all samples. For each gene, all samples have been measured and hence genes are 
points in this vector space spanned by all samples. Let |   ∑  |  | denote the  th gene vector with 
expressions  |  ≡ ,  for sample indices  ∈ 1, … , . 
Generally, a gene vector can be expressed in terms of all contextual sample vectors via |   ∑  	||  
and vice versa via |  ∑  	| | , if they share the same underlying signal matrix. Later, additional lower 
indices may be used to clarify the underlying signal matrix or the patient cohort. 
If the signal matrix and vector components are not clear from context or for definition purposes, I use 
abbreviations like | ,  or |, . They define vectors by directly specifying their coordinates in the 
respective canonical base, i.e. formally ∀:   ,  ≡ ,   ,  and ∀:  ,  ≡,   , . 
II.2.2.2 Gene and samples axes 
Let | ∈   be an arbitrary nonzero vector. Its components  | for all genes define a specific direction 
or axis in the gene space. Every direction can be interpreted as a linear approximation of a specific gene 
regulation law. If a pathway mediating this type of interactions exists in the underlying system, affected 
samples form a point cloud around this axis. 
The search strategy(cf. II.3.1) screens and scores many candidate directions to discover such dominant linear 
directions, i.e. to discover gene axes pointing to effects(see II.1.1.2 for 3D examples). Every effect compatible with the 
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effect model has a gene axis, as monotonicity is always associated with an axis, over which the function is 
monotonic.  
Likewise, let | ∈   denote the sample axis of an effect, i.e. its dominant linear direction in sample space. 
Here,  | can quantify involvement of samples in an effect. 
II.2.2.3 Effect curves 
While a pair of a gene and a sample axis can already pinpoint an effect, they are only linear approximations 
of its law of regulation. After regression of an effect’s eigensignal  , this approximation can be improved by 
replacing axes with effect curves that are monotonic over these axes. (More precisely, if using projections on 
effect axes as scalar curve parameter, then coordinate functions of effect curves are monotonic for all 
dimensions.) 
An effect’s gene curve completely describes the empirically regressed law of gene regulation for each sample 
and its sample curve completely describes regulation differences between samples for each gene. Hence, both 
are different descriptions of the same information. Indeed, both are just re-parameterizations of the effect’s 
eigensignal. 
An effect’s gene curve is a vector-valued function over sample indices  with components   ≡, . In eigenorder   of effect , each component of  is monotonic, i.e. ∀: ∀ ∈ 1,  1:    1    ∨ ∀ ∈ 1,   1:    1   . Gene curves for 
effects in the 3D example are regressed and illustrated in II.4. 
Analogously, an effect’s sample curve is a vector-valued function over gene indices  with components   ≡ , . In eigenorder   of effect , each component of | is monotonic, i.e. ∀: ∀ ∈1,   1:    1    ∨ ∀ ∈ 1,   1:    1   . 
In brief, effect curves re-parameterize an effect’s eigensignal, run through the effect’s point clouds in gene 
respectively sample space and generalize linear approximations by gene or sample axes to more precise 
monotonic approximations. 
II.2.2.4 Effect focus 
Normally, an effect neither regulates all measured genes nor does it necessarily exist in all measured 
samples. When using scalar measures based on all genes and all samples, small effects are hard to 
detect(cf. II.1.2.1). If, for example, 20000 genes were measured for each sample, but only 10 genes are truly and 
strongly correlated, then corresponding correlations between samples are typically heavily diluted and not 
significant when using all 20000 measured expressions for their calculation. Masses of noise genes would 
dominate the computation of correlation coefficients. However, if gene weights were utilized to focus on only 
a small subset of genes that contains all 10 true positives, resulting correlation coefficients would become 
strong and significant, as noisy information from unimportant genes would be excluded. Hence, I focus on gene 
and sample subspaces in which an effect exists in order to detect it(cf. II.3.1). Additionally, discovered effect foci 
are utilized for effect dissection(II.4.2.1). They help to prevent the modification of signal parts from foreign effects, 
i.e. from effects that represent gene regulations outside of the current effect’s focus. 
Collecting weights as vectors, the effect focus consists of gene and sample weights | and | with 
components ∈ 0,1 ⊂ . Weights are initially estimated based on the standardized signal(cf. II.3.1.3) and are 
iteratively refined based on correlations(cf. Eqn. II.3.1.4.b) during search strategy. 
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II.2.3 Measures of Interaction 
To pinpoint bimonotonic effects, the search strategy needs a measure of interaction that can be computed 
from the perspective of single genes |  or single samples |. Fortunately, (nonzero) bimonotonic effect 
eigensignals have high correlations between genes and between samples as a consequence. Hence, a type of 
correlation can be utilized to quantify interactions and to search for bimonotonic effects. This measure is 
compatible to previous methods in biosciences, including the common form of hierarchical clustering for 
microarray data[36]. 
An “effect” in molecular biology typically is observed as the co-regulation of many genes in many samples. 
From co-regulated gene expressions, it might be concluded that participating genes take part in the same 
biological function of measured cells. While co-regulation is to my knowledge just a descriptive term without 
any formal definition, correlation is formally well defined and can quantify co-regulation. It goes beyond just 
demanding regulation “in the same direction” (i.e. either all upregulated or all downregulated relative to a 
reference) and also tests whether differences in regulation strength are related. Hence, correlation is a specific 
form of co-regulation and can be used to quantify the consistency of interactions that cause correlations 
between measured gene expressions in the first place. To detect biologically specific effects, I additionally 
combine correlations with the effect focus(cf. II.2.2.4). To this end, a weighted form of correlations is needed. 
II.2.3.1 Weighted uncentered correlations aka the cosine distance 
To quantify the interaction of a sample respectively a gene | with other samples respectively genes in an 
effect, I utilize weighted uncentered Pearson correlations to the effect’s representative gene respectively 
sample axis |, i.e. to its linearized law of regulation in the respective signal space(cf. II.2.2.1). 
As already explained(cf. II.2.2.4), using weights is necessary to focus on an effect and to prevent computed 
correlations from being washed out by inclusion of many non-effect dimensions. Additionally, using 
uncentered correlations respects that a logratio of zero already indicates no regulation and thus defines the 
global baseline. (In this context, “pre-centered” may be a more intuitive term than the usual “uncentered” is.) 
Pre-centering has the advantage that the score can also identify points as highly correlated if they are located 
in the same direction far off from baseline, even if these points show no correlation relative to the center of 
their common offset. The usual centered Pearson correlation would instead ignore this offset in a common 
direction and thus would drop important information. 
Let | denote gene respectively sample weights in the current effect 
focus. Then the weighted uncentered correlation of | with | in focus | can be easily defined with scalar products(Eqn. II.2.3.1).  
In the unweighted case (|  |1, i.e. ∀:    1) and if 
components of | and | have zero means, this definition is identical 
to the usual Pearson correlation coefficient; hence the name. (In this 
case, . |.   |  ∑   equals the uncentered covariance of components from | and from |, times 
the number of components. Likewise, ‖. ‖‖. ‖  ‖‖‖‖  || equals the product of the 
uncentered standard deviations of components in | and in |, times the number of components. The number 
of components cancels and uncentered equals centered for zero means, resulting in the usual Pearson 
correlation coefficient that is defined as covariance over the product of standard deviations.) 
This measure also has an illustrative geometric interpretation: The cosine in a right-angled triangle is 
defined as the quotient of its adjacent side to its hypotenuse. In the unweighted case (i.e. again |  |1),  
|| ≡ . |. ‖. ‖‖. ‖ 
Eqn. II.2.3.1) Weighted uncentered correlation 
Dots denote component-wise multiplication 
(Hadamard product). 
This measure ∈ 1,1 ⊂  is utilized by signal 
dissection for quantification of interactions between 
genes or between samples. 
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‖‖ can be seen as the length of the hypotenuse, while the length of its projection on |, i.e. | ‖‖⁄ , is the 
length of the adjacent side. Therefore, uncentered correlation is equivalent to the cosine of the angle between 
the two compared vectors: ||  cos∢|, |. Hence, || can be thought of a generalized cosine 
between two vectors in the weighted subspace cut by |. 
Like usual correlations, weighted correlations assume values ∈ 1,1. Together with the above geometric 
interpretation, 1 can be interpreted as 100% parallelism of | and |, while 1 indicates perfect anti-
parallelism. Zero designates perpendicular vectors, i.e. uncorrelated effects. Consequently, if | describes an 
effect axis, perpendicularity implies that no parts of the signal of | can be explained by the linear law of gene 
regulation encoded by |. 
Again, vectors may be specified directly by their coordinates from a signal matrix; abbreviations like , | | or , || denote correlations with |,  respectively |,  (cf. II.2.2.1). 
II.2.3.2 Weighted projections 
Let | denote a projection target, | a vector from the same space and | weights for all dimensions of this 
space. The projection target typically is a gene or a sample axis of an effect again, i.e. it linearly encodes a 
specific law of regulation. Already defined correlations(Eqn. II.2.3.1) are neither proportional to ‖‖ nor to ‖‖. 
Hence, correlations can only compare directions. Sometimes the absolute signal strength of | that is 
explained by a specific law of regulation | is of interest, i.e. the signal strength of | in direction of |. 
To this end, weighted projections of | in direction of | can be 
defined(Eqn. II.2.3.2). They are identical to weighted correlations, except for 
the factor for the weighted norm of |. (The upper index zero is used 
to avoid confusion with the usual scalar product that does not 
normalize by the norm of |.) 
 
|| ≡ . |. ‖. ‖  
Eqn. II.2.3.2) Weighted projections 
Dots denote component-wise multiplication 
(Hadamard product). This measure is similar to 
weighted correlations(cf. Eqn. II.2.3.1), but it scales with 
the signal strength of |. 
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II.3 Search Strategy 
At the beginning of each detection iteration, the signal is screened for effect candidates that 
qualify relative to significance thresholds for their signal strength and correlation.  
If an effect exists, it affects some genes and some samples. This is utilized to discover an initial 
representative that roughly points in an effect’s direction. Once an initial gene or sample has 
been identified, additional genes or samples of the same effect are searched and incorporated 
into its definition. A maximum principle guides this search towards effect axes to which as 
many as possible genes and samples are correlated as high as possible. This continues 
iteratively until the estimated effect axes have converged. 
After convergence, effect axes can be considered independent of individual features from 
single representatives and hence are representative for the effect as a whole. They linearly 
approximate its laws of gene regulation and serve as starting point for the precise regression 
of its eigensignal(II.4). 
As soon as no gene and no sample qualify any longer, the method declares that no significant 
effects remain in the signal and terminates. 
II.3.1 Finding Effects 
It is hard to directly search for bimonotonic effects: In principle, one could enumerate all possible pairs of 
gene subsets and sample subsets from the joint power set   , sort them by their average expressions 
and directly score them. However, this is not viable for typical  and , since |  |  2. Hence, a 
search strategy is required. My search strategy is based on measures for interactions(II.2.3) that can be computed 
from the perspective of a single gene or single sample and that can be summarized by an effect score(II.3.1.6). In 
brief, the more genes and samples participate in an effect and the higher correlated they are to this effect, the 
larger is this score. 
For performance reasons, a deterministic lookahead scheme based on a presorting(II.3.1.7) is utilized to 
efficiently screen genes and samples for a good initial representative, i.e. for a new effect  with locally maximal 
score. The initial representative is either a gene with index ,  
and gene expressions , ≡ ,,  or a sample with 
index ,  and gene expressions , ≡  , ,. To 
immediately symmetrize the situation(II.3.1.3), gene and sample 
axes are computed for either type of initial representative. 
Initial axes already point in the direction of the newly 
discovered effect , but usually can approximate its law of 
regulation only roughly. For example, the gene axis(yellow) based 
on the marked initial sample for the blue effect(Figure II.3.1) is only 
a good approximation for its outmost tips. 
Next, all steps leading to a discovered effect’s initial axes are 
presented in processing order, thereby explaining the 
 
Figure II.3.1) 3D concept example, first detection iteration, initial 
representative for the blue effect and its associated initial gene axis 
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algorithm’s structure. Again, components of genes and samples are always implicitly taken from the contextual 
signal matrix(cf. II.2.2.1). Here, this is   for the first detection iteration and in general it is the remaining 
signal(cf. II.2.1.1), i.e.     ∑  . For example,  ,  ,, . 
II.3.1.1 Standardization against outliers 
One conceptual goal of the method is to be robust against outliers. To this end and also as a basis for initial 
weights (as defined in the next section), the standardized signal   is computed from the remaining signal  at the beginning of every detection iteration . These standardizations are associated with the loss of one 
signal dimension (for 3D examples, the signal is embedded into a 2D surface). Hence they should not be 
utilized as surrogate for the unstandardized signal, but they can be used for scoring or weighting. 
An iterative standardization is utilized that converges uncentered variances E  0 for all genes 
respectively all samples to one, where  denotes the random variable sampled by the components of a 
particular gene or sample vector. The empirical estimation  of this variance for a sample | with components  | equals ∑  | ⁄ 	and hence is proportional to its squared Euclidean norm ‖‖  | ∑  | |  ∑  | , but is normalized such that it is independent of the number of genes . A result 
of this proportionality is that for any standardized sample |  ≡ | , , the Euclidean norm equals ‖‖  	 ⁄  √, as   1 after standardization. 
For the 3D example this implies that all standardized 
sample vectors lie on the   sphere(Figure II.3.1.1.a) in gene 
space with radius √3. Similarly, all three standardized 
gene vectors have norm √ and thus lie on S  with 
radius √2500  50 in the associated sample space. As 
uncentered variance equals one for all  
columns (and all rows) of  , it follows ∑ ∑  ,  ⁄  1 for the whole matrix. If 
the input signal matrix was centered (which is a usual 
preprocessing step for log-transformed gene 
expressions), this implies that the standard deviation 
from one pixel to another in   is 1, too. Hence, all 
possible signal strength fluctuations have been 
equalized. 
The implementation of this standardization is 
straightforward: Uncentered variances are 
empirically estimated for every gene row and every 
sample column as above, resulting in gene variances  ∈  and the sample variances  ∈ . The 
signal matrix is then divided component-wise by the 
component-wise square roots of the matrix product  ∈  . This is iterated until uncentered 
variances of all genes and all samples equal one 
within an epsilon that is determined as 1/1000 of the 
current noise level(cf. II.5.1.1). Convergence is usually 
reached within few tens of iterations.  
Figure II.3.1.1.a) Standardization results   in gene space for the 3D example via 
equalization of uncentered variances 
 
 
Figure II.3.1.1.b) Standardization results in gene space for the 3D example when 
equalizing absolute norms 
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Notably, this procedure equalizes norms in both the gene and the sample space, while dividing genes by their 
norms (or samples by theirs) only equalizes norms in either space, but not in both spaces simultaneously. 
The same iterative procedure can be utilized to equalize by other measures instead of uncentered variance, 
for example by the absolute norm ∑ | | . For the 3D example this would result in a projection onto 
diamonds(cf. Figure II.3.1.1.b) in both the gene and the sample space. However, to eliminate signal strength fluc-
tuations and for initial weights, the sphere seems to be the more natural choice for standardization. 
II.3.1.2 The effect focus and its initial estimation 
Finding a formula for an adaptive effect focus that is as general-purpose as possible has been the second-
hardest task after realizing bimonotonic regression(cf. II.4.1), because every processing step depends on the effect 
focus and they do so in an iterative way with self-feedback.  
For example, a too narrow effect focus may seem sharp and well-defined locally, but may lead to seeing only 
a fraction of the true effect when computing correlations and projections. This could iteratively grow into far 
too narrow “stripe-like” false positive effects. These stripes look like true positives in their narrow focus, but 
are essentially ordered noise. For combinatorial reasons, sort orders that arrange a small fraction of samples 
in such a way that hundreds of measured probesets seem to be co-regulated always exist in large signal 
matrices with ~50000 probesets(e.g. Figure II.6.4.2.d). On the other hand, a too broadly defined gene focus includes 
too many noise genes and thus correlations or projections of samples based on this focus are washed 
out(cf. II.1.2.1). Iteratively, this can grow into narrow false positives as well, because weights are dependent on 
correlations of previous convergence iterations for effect axes(cf. II.3.2.2). Consequently, sample weights may be 
washed out towards zero for all but those few samples, whose genes can be ordered in such a way that a non-
vanishing signal remains despite the over-broad gene focus. This is similar to defining the sample focus too 
sharp or over-optimized in the first place.  
Furthermore, effect focus formulas working perfectly in one scenario, for example in the versatility 
scenario(II.6.2), might produce artefacts in other scenarios, for example for the 3D example. Therefore, the aim 
should be to find a common and balanced formula for the effect focus that simultaneously works in all method 
validation scenarios including real world cohorts in order to advance towards a general-purpose method. 
A working though recursive formula for focusing weights has been found based on correlations with the 
effect and based on the significance of these correlations. For an initial gene or sample candidate, neither 
correlations nor their  values are available. The effect focus is therefore defined and refined in several steps 
during a detection iteration. Here, only initial weights are defined; the correlation based formula for all 
following refinements is provided in II.3.1.4. 
 Initial weights estimation 
Initially, no information other than the signal strength (in original or standardized units) is available to 
define weights. For an initial (and rough) approximation of the effect focus, I use weights based on the 
standardized signal(II.3.1.1). Compared to the signal in original units this has the advantage of being relatively 
outlier-robust. More importantly, very strong non-standardized signals often are indicative for multiple 
constructively overlapping effects. However, with an interpretable dissection in mind, genes or samples that 
are exclusively affected by a single effect are preferred as initial effect representatives. Standardized gene 
expressions are larger if the original signal of a sample is concentrated in fewer genes, and lowest, if all genes 
are expressed with approximately the same strength. This can be utilized to tighten the effect focus for 
representatives with expressions pointing to more specific effects. Still, the effect focus should neither become 
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too narrow for reasons explained above. Otherwise and in the extreme case, effect candidates would be 
dominated by only one top gene or top sample; this would be neither informative nor could it achieve a 
qualifying effect score.  
I therefore utilize the absolute standardized signal as initial weights, but cap it at 80%: 
For an initial gene ,, initial sample weights are:    ≡ min 1,  ,,.⋅  ,, 
For an initial sample ,, initial gene weights are:    ≡ min 1,  ,,.⋅   ,, 
Eqn. II.3.1.2) Initial effect focus based on the standardized signal 
 
The main goal of these initial weights is just to prevent too many noise dimensions in context of high-
dimensional spaces, as they could wash out scores, wash out the twin axis computed below and thus prevent 
effect detection.  
Practically all dimensions that could be true effect dimensions still have full weights due to the 80% cap. 
When a single dimension dominates the original signal, this dimension has maximal value in the standard 
vector; let  denote this value. The minimal possible value of a component in a standardized vector is obtained 
for the hyperdiagonal, i.e. when all dimensions equally contribute to the original signal. Via Pythagoras for  
dimensions it holds ∑    . Thus, the dimension-dependent minimal ratio of components in a 
standardized vector equals 
||||  √. Hence and in general, the more dimensions the standardized signal has, 
the more possibilities exist to get below the 80% cap. Hence, initial weights based on standardized signals 
prevent washed-out scores in a way that is adaptive to signal dimensionality. 
More precise weights for the effect focus are defined as soon as correlations have been computed(cf. II.3.1.4). 
II.3.1.3 Initial effect axes and symmetrization by twin axes 
One design goal is to symmetrize roles of genes and samples(cf. II.1.2.4). To symmetrize as early as possible, gene 
and sample axes need to be defined for either type of initial candidate.  
Naturally, an initial gene , defines its own sample axis | and an initial sample , defines its own 
gene axis |.  
To compute the respective twin axis in the other vector space, weighed projections(cf. II.2.3.2) of all other genes 
on |   |,  respectively of all other samples on    ,  can be computed, using respective 
initial weights(cf. Eqn. II.3.1.2): 
The twin gene axis | ∈   for an initial gene ,  is defined by  | ≡  |,  ‖ ‖ . 
The twin sample axis | ∈   for an initial sample , is defined by  | ≡ |,    . 
Eqn. II.3.1.3) Initial twin axes for symmetrization 
 
This results in a pair of initial axes |, |  for either type of initial candidate. Initial weights for 
components of the twin axis are computed by repeating twin axis computation for the standardized signal   and then capping at 80% again(cf. Eqn. II.3.1.2). Together with initial weights for the initial candidate, they 
complete the initial effect focus  , | . Initial axes and the initial focus provide a symmetric basis 
for all following computations and scores. 
Analogous projections are also utilized when updating twin axes based on refined weights(cf. Eqn. II.3.1.4.b) during 
effect axes convergence(II.3.2). 
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II.3.1.4 Correlations and the refined effect focus 
Initial axes |, | are already a rough linear approximation of an effect candidate. In order to score this 
effect, correlations of all genes and all samples with its initial axes are computed next. Using the initial effect 
focus as weights, uncentered correlations(cf. II.2.3.1) can be utilized to this end. All resulting correlations can be 
collected as two vectors: 
Gene correlations | ∈   are defined by  | ≡  |   , | . 
Sample correlations |  ∈   are defined by  | ≡       , |  . 
Eqn. II.3.1.4.a) Initial correlations 
 
For each correlation, a  value can be calculated(cf. II.5.2.1) to quantify its significance. Resulting | and | are 
utilized together with computed correlations to focus on the effect more precisely than it was initially possible 
based on the standardized signal(Eqn. II.3.1.2): 
Refined sample weights: Let  ≡  | ⋅ 1   |  and  ≡ min 1, .⋅ , then 
  ≡  , if	  .  |  0	otherwise .  Refined gene weights: Let  ≡  | ⋅ 1   |

 and 
 ≡ min 1, .⋅ , then 
  ≡  , if	  . | |  |0	otherwise .  The effect focus is |, |. 
Eqn. II.3.1.4.b) Refined effect focus based on correlations 
 
In words, I replace the initial effect focus by weights that are based on absolute correlations times a factor 
that goes down to zero quadratically with the noise probability of these correlations. Final weights are defined 
relative to the maximum and all  that are  50% get full weight. Hence, the order of top genes in an effect is 
not influenced by different weights. Additionally, weights that are less than 0.67 times the quantile axis are set 
to zero exactly. Hence, any unspecific influence of (potentially very many) low weights is prevented.  
The purpose of the effect focus remains the same after this refinement: Exclude dimensions that have 
nothing to do with the effect in order to compute as effect-specific as possible scores via weighted projections 
or correlations. Except for the initial focus, the effect focus |, | is always computed as defined here. 
This includes all focus updates following effect axes updates later during axes convergence in II.3.2. 
For effect size estimation and qualification thresholds, mapping all -values above 50% to full weight is not 
optimal; instead I would like to keep the dynamic range of weights for these tasks. To this end, I additionally 
define the extended effect focus |, | by increasing the upper threshold from 50% to 100% (i.e.  ≡ ) 
and by decreasing the lower threshold from 0.67 to 0.4. 
II.3.1.5 Focusing step 
The refined effect focus | , |   is utilized next to also refine twin axes(Eqn. II.3.1.3), correlations(Eqn. II.3.1.4.a) and 
 values of correlations. Updated scores are focused more precisely on the effect and hence are more 
representative for it. 
Due to the recursive nature of the refined effect focus formula(Eqn. II.3.1.4.b), this focusing step could be iterated. 
It is iterated during axes convergence(II.3.2). However, during screening for a new effect, a single focusing step 
suffices. Besides, multiple focusing steps for every screened candidate would have a massive negative impact 
on performance, as every focusing step requires weighted correlations with all measured genes and all 
measured samples to be recomputed. 
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II.3.1.6 Scalar effect score 
To compare effect candidates and determine the best one, a scalar effect score is computed. During 
development, this score was effectively a functional degree of freedom whose formula had to be identified by 
trial and error in the context of test scenarios with synthetic data. This process was guided by two ideas: a) the 
higher correlations of genes and samples are to an effect, the more interesting is this effect and b) the more 
genes and samples are correlated to an effect, the more interesting it is. 
To estimate effect sizes in each order dimension, i.e. to estimate the number of underlying genes or samples, 
the effect focus is summated:  ≡ ∑    and  ≡ ∑    . To determine a single scalar that 
represents the effect’s size,   and   need to be combined. This should be done multiplicatively, because   is proportional to the number of the measured values underlying the effect, i.e. the number of pixels in 
the signal matrix belonging to genes and samples with high correlation to the effect. To prevent the effect size 
factor from dominating the score, a square root is utilized below to balance its contribution relative to the 
correlation factor. To boost scores for effects that have broad and robust support in both order dimensions, I 
assign 90% geometric weight to the minimum of   and   and only the remaining 10% to their maximum. 
This causes broad effects in all order dimensions to be preferred over effect candidates that are broad in one 
but narrow in the other order dimension. The rationale behind this is that it is usually easier to interpret 
narrow effects after overlapping broad effects have already been dissected from the signal, rather than vice 
versa. Hence, the final effect size factor reads min , . max , .. 
The correlation information from | and | is also summarized by a representative scalar. This is realized 
by weighted averages of absolute correlations in the effect’s focus. Abbreviating components  ≡  ,  ≡  ,  ≡    and  ≡  , these averages are:  ≡ ∑     ⁄  and  ≡∑     ⁄ . To determine a single scalar representing the effect’s average correlation, another average 
using effect sizes as weights is computed:  ≡   /  . Herein,   and   are weighted 
with the number of points supporting the correlations in | respectively |. This weighting is important 
when one order dimension has much higher resolution than the other. For instance, there are only three genes 
in the 3D example and their correlations   have been robustly determined by many samples, while sample 
correlations   are only computed over three points each and thus relatively unreliable. 
Using effect scores that are directly proportional to   did not provide enough dynamic range, i.e. there was 
not enough difference between high and merely moderate correlations. This difference is required when 
multiplying with the effect size in order to prevent that a larger effect with only moderate correlations gets a 
higher score than a bit smaller effect with high correlations. The aim is to value specificity over size; this also 
helps dissecting overlapping effects. To solve this problem, I transform correlations via  1   ⁄⁄ ; this 
emphasizes correlations near one. (This transformation was inspired by and adapted from the transformation 
of a correlation into a corresponding -statistic when determining its significance(cf. II.5.2.1).) 
The final scalar effect score is the product of the effect’s transformed average correlation and its 
summarized size as explained above. 
 ≡ 1   ⁄ min , . max , . 
Eqn. II.3.1.6) Scalar effect score (average correlation times effect size) 
   Representative scalar correlation of the effect (see above). 
  ,   Effect size in the gene respectively sample space (see above). 
The score can be computed independent of the type of the initial candidate. Whether a gene or a sample is 
the better choice as initial representative for an effect depends on the effect’s shape, i.e. how it extends to other 
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genes and other samples. In the 3D example, samples are always better representatives, as none of the three 
genes is specific to only one of the four effects. In high-dimensional signals(cf. II.6.1), often genes are better initial 
representatives. The algorithm keeps treating roles of genes and samples symmetrically and both have equal 
chances of being selected as initial effect representative in every detection iteration. 
II.3.1.7 Search complexity, presorting candidates and a lookahead scheme 
Finding the gene or sample with the globally maximal effect score has the following complexity: There are    possible initial candidates. Every gene candidate spawns a gene and a sample axis. Correlating the gene 
axis with all  samples has complexity , as every single correlation is linear in the number of values per 
sample, i.e. . Correlating the gene candidate’s sample axis with all  genes results in  as well. 
Likewise, a sample candidate spawns a gene axis and a sample axis that need to be correlated with all samples 
respectively with all genes to compute the effect score. Altogether, finding the globally maximal effect score 
has complexity    ⋅        ⋅ . While this is much faster than the naïve approach 
that tries to enumerate the joint power set(cf. II.3.1), this cubic complexity is still too slow for typical  and  in 
practice. 
To facilitate a successful and fast lookahead for a local (and ideally the global) score maximum, a presorting 
of all genes and samples is needed that ideally sorts representatives by descending effect scores. This 
presorting should be based on local scores only that can be computed fast, i.e. scores that can be computed 
with just linear complexity from perspective of a single gene or sample. Hence, presorting cannot be perfect, 
as it only utilizes local information about each gene or sample rather than their interactions in form of 
correlations. However, this sorting does not need to be precise, as it does not determine subsequent qualifica-
tion of genes or samples as effect candidates, but just the order in which promising candidates are presented. 
A speed advantage is gained together with a lookahead scheme that breaks processing early, if no better 
score has been found for a certain amount of presented candidates (in the default 200). The better the 
presorting (i.e. ideally descending in effect scores), the faster this early break is reached. Hence, the factor    in the complexity gets replaced by a number  that in the theoretical worst case is still   , but in 
practice typically  ≪    for large , . The lookahead scheme itself is straight forward: When processing 
the presorted list, every candidate gene or sample has to qualify first(cf. II.3.1.8). Then it competes with scores of 
other already qualified effect candidates within the lookahead interval. If no stronger candidate is found for 
the next 200 ranks in the presorting order, the candidate is accepted as initial representative. 
The following presorting score has proven to provide a good speedup without hampering quality. It is based 
on the maximum of two local information sources about the initial gene respectively initial sample. The first 
local score is the candidate’s uncentered standard deviation  (where  stands for the random variable 
sampled by all components of the initial candidate). Uncentered instead of usual standard deviations are 
utilized again for the same reason I chose uncentered correlations(cf. II.2.3.1), i.e. since zero indicates baseline 
expression and a consistent offset from zero should lead to a higher effect score. The second local score is the 
candidate’s maximal component in its absolute standardized signal, e.g. max  ,  for gene candidate . 
This maximal component is a purity score as explained(cf. II.3.1.2), i.e. it is larger for effects that are concentrated 
in fewer dimensions rather than spread equally over many dimensions. Purer effects prospectively have 
higher average correlation, leading to higher effect scores. For each gene and each sample, both local scores 
can be computed in linear time, as they only need the signal for the respective gene or sample. Both are 
computed for all genes and all samples at the beginning of each detection iteration (complexity ). 
Resulting scores are -transformed (i.e. centered and divided by their usual standard deviation) to make both 
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sources of local information comparable. Finally, the maximum of these two  scores for each gene and each 
sample is employed to presort all genes and all samples by their descending scores. This results in a common 
list of candidates of length   . This list is then processed by the lookahead scheme as explained above. 
II.3.1.8 Qualification of candidates 
Several qualification scores and corresponding thresholds determine, whether a gene or sample is eligible 
as initial representative of an effect. 
Effect scores only facilitate a relative ranking of initial candidate genes or samples, but they are not suitable 
for effect qualification. Qualification cutoffs need to be easy-to-configure based on easy-to-interpret properties 
of candidate effects.  values quantifying the significance of correlations or of signal strengths in the effect 
focus are natural choices for qualification. Both are approximated based on  statistics(cf. II.5). (As no noise 
distribution has been estimated before the first effect detection(cf. II.5.1.1), only correlation based significance is 
checked in iteration   1. Still, the effect’s significance with respect to its signal strength can be assessed 
retrospectively at the end of iteration   1.) 
Additionally, thresholds for the average correlation in the effect focus and for the effect size are defined for 
qualification. They can be used to exclude statistically significant, yet uninteresting effects. Default thresholds 
have been developed in context of synthetic data(cf. II.6) and with the aim to still detect even weak true positives, 
while terminating before the onset of many false positives. With real-word applications in mind, occasional 
false positives are considered less problematic compared to false negatives (i.e. non-detections), because 
cross-cohort validation of effects(cf. III.1.2) will filter these false positives out again. This additional validation step 
has to be performed anyway for real-world applications, as systematic errors in the signal like lab effects may 
be statistical true positives, but are biological false positives. (Hence, they cannot be excluded here by effect 
qualification as a matter of principle.) 
The following table summarizes all parameters utilized for qualification of effect candidates. 
Qualification 
parameter 
Default 
threshold 
Comments 
correlation  
significance   10

   
As  values for correlations within an effect focus(II.5.2.1) decrease rapidly over effect size, a very strong 
significance threshold can be chosen. Because up to    initial candidates are tested, the threshold is further 
decreased by applying the Bonferroni correction for multiple hypothesis testing. Corresponding  values are 
defined in II.5.2. 
signal strength  
significance   10

   
The significance of the signal strength in the effect focus(II.5.1.2) is determined relative to the estimated noise 
level(II.5.1.1). Again, the threshold is decreased by applying the Bonferroni correction of multiple hypothesis 
testing.  
minimal correlation 
 in the effect focus min  0.4 
The average correlation in the effect focus  (cf. II.3.1.6) can be utilized to exclude significant effects that are 
uninteresting, as their signal is too rough and inconsistent for interpretation purposes (even if it is still 
significant, i.e. if it cannot be explained by noise alone). 
minimal number of genes min  participating in an effect 0.5 ⋅ log   
The number of genes in an effect   is defined in II.3.1.6. With the intention to define defaults that are as general 
as possible, I utilize a formula that is adaptive to the signal size. The more samples  are measured, the more 
combinatorial possibilities exist to arrange them in a way such that a sample subset looks like a true effect for 
few genes. Hence, I require more genes in an effect, if there are more samples to choose from. The precise 
functional dependency has been derived from experience with the noise genes test scenario(cf. II.6.4.2) and the few 
samples test scenario(cf. II.6.4.3). 
minimal number of samples min  participating in an effect 0.5 ⋅ log  
The number of samples in an effect   is defined in II.3.1.6. With the intention to define defaults that are as 
general as possible, I utilize a formula that is adaptive to the signal size. The more genes  were measured, the 
more combinatorial possibilities exist to arrange a subset of them in a way that looks like a true effect for a few 
samples. Hence, I require more samples in an effect, if there are more genes to choose from. For a typical real-
world   50000 this results in min  8 samples as minimum to qualify as “interesting” effect. The precise 
functional dependency has been derived from experience with the noise genes test scenario(cf. II.6.4.2) and the few 
samples test scenario(cf. II.6.4.3). 
Table II.3.1.8) Qualification thresholds for effect candidates 
Default thresholds have been defined based on experience with synthetic test scenarios(cf. II.6) and have been optimized to prevent most false positives, while keeping 
sensitivity even for small and weak effects in all but very noisy contexts(cf. II.6.4 for details). 
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The gene or sample that has qualified relative to all these thresholds and that has the best effect score of all 
other candidates in the lookahead interval(cf. II.3.1.7) is finally selected as initial representative. Its gene and 
sample axes |, | already point to the discovered effect that is regressed and dissected in this detection 
iteration. As a first step towards this dissection, effect axes are refined by convergence as described in the 
following section. 
II.3.2 Effect Axes Convergence 
To optimize axes for the discovered effect and especially to 
become independent of potentially unreliable individual 
features of the initial representative, additional represen-
tative genes and/or samples are searched for and combined 
for effect axes estimation until convergence. Resulting 
converged axes are considered the final linear approximation 
of the effect’s law of regulation. These axes usually put an 
emphasis on strong regulations by the effect, as they are often 
associated with higher correlations. Effect axes serve as basis 
for later bimonotonic regression(II.4). 
Their convergence and in particular the search for 
additional representative genes or samples must be guided. 
Samples from possibly overlapping foreign effects should not 
be selected to prevent uninterpretable mixtures of true 
effects. In case of suboptimal initial candidates that are located between two effects, convergence should guide 
away from the intermediate space and towards a single particular effect to dissect it and only it. I again utilize 
effect scores(II.3.1.6) and select those representatives that maximize it, i.e. I utilize maximization of both 
correlation and effect size as guide for convergence. 
In the example(Figure II.3.2) the converged gene axis(yellow) is nearer to all blue points compared to the gene axis 
based only on the initial representative(Figure II.3.1). Due to the nonlinear shape of the blue effect, no linear 
approximation can be a perfect match, but it can serve as starting point for regression of precise bimonotonic 
effect curves(II.4.1). If an effect’s law of regulation is actually linear like for the red effect, effect axes and effect 
curves are equal. 
II.3.2.1 Iterative selection of representatives 
Let | , | denote current effect axes based on  representatives, |, | the current effect focus and |, | current correlations. For   1, these vectors equal the initial effect axes(Eqn. II.3.1.3) respectively the 
refined effect focus(Eqn. II.3.1.4.b) respectively the initial correlations(Eqn. II.3.1.4.a). 
At the beginning of each iteration, all genes and all samples are sorted descending by their absolute 
correlations  ,  respectively ,  in a single joint list (again using component abbreviations , ≡   and , ≡  ). Points in the gene or sample space that most likely belong to the same effect are thus sorted to 
the top. Roles of genes and samples continue to be symmetric. 
For a lookahead(similar to II.3.1.7) interval, top correlated points from this list (in the default 20) are candidate-
added to the current set of effect representatives and are accumulated(detailed in II.3.2.2 unterhalb); this results in 
 
Figure II.3.2) 3D concept example, first detection iteration, genera-
lizing representatives and converged gene axis for the blue effect 
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candidates for the next effect axes | , | , the next effect focus | , |  and the next correlations | , | .  
Again, the effect score(Eqn. II.3.1.6) is computed for these updated axes. The candidate leading to the best effect 
score is selected as next representative. Often points with stronger folding are selected, as they are more likely 
to reach higher correlations to each other assuming a constant noise level and thus can lead to higher effect 
scores. However, the effect size factor in the score prevents selection of top-folded points, if they have no 
correlated partners. 
Iterations continue until axes have converged and sufficiently many representatives have been selected(as 
defined in II.3.2.3 unterhalb). Then the algorithm passes these converged axes on to effect regression and dissection(II.4). 
II.3.2.2 Accumulating representatives and the update step 
Let | ,   denote initial gene and 
sample axes(Eqn. II.3.1.3) for each so far selected 
representative gene or sample   1 …  1, including the currently selected candidate   1. (The constant effect index  is 
suppressed for readability.) Then the 
updated accumulated axes are defined as 
their weighted arithmetic averages, using 
correlations to current accumulated axes as 
weights. This is more precise than assigning 
equal weights to all representatives, 
because effect axes may wander during 
convergence and, hence, previously se-
lected representatives may become less correlated and thus less representative for the effect. Representative 
genes or samples may be either highly correlated or highly anti-correlated to the effect and to each other. To 
always accumulate them constructively, correlation signs are kept and utilized to align all representatives to 
each other in the sum(Eqn. II.3.2.2). 
Next, correlations | , |  for all genes and samples are computed for updated axes, analogous to initial 
correlations(Eqn. II.3.1.4.a), but using the current effect focus |, |  as weights.  
Finally, the effect focus is updated with the same formula that refined the initial effect focus(Eqn. II.3.1.4.b), using 
current correlations | , |  and their significance.  
Then the effect score is computed(Eqn. II.3.1.6) that also facilitates the identification of the best candidate for 
representative  from the lookahead interval(cf. II.3.2.1). 
II.3.2.3 Checking for sufficient representatives and for convergence 
Two criteria must be met before linear axes are considered sufficiently reliable and representative for 
an effect. 
The convergence criterion checks that the change by addition of the last representative is below a threshold 
parameter  ≡ 10 . The change can be quantified by one minus the correlation to the preceding axis:  ≡1   |   respectively  ≡ 1   |   . (The correlations are always positive per construction of 
accumulated axes.) The precise condition is    2⁄ ! . In words, axes are considered converged, if 
The accumulated sample axis |  ∈   for individual sample  
axes |  of all so far selected representatives is defined as: 
|  ≡
∑   
∑  
 
 
The accumulated gene axis   ∈   for individual gene  
axes |  of all so far selected representatives is defined as: 
  ≡
∑   
∑   
 
Eqn. II.3.2.2) Accumulated effect axes over  effect representatives 
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adding another representative gene or sample keeps them correlated with preceding axes  0.999 on average. 
As every additional representative can only change axes with a maximal weight of 1 ⁄ (cf. Eqn. II.3.2.2), this always 
converges sooner or later in practice. (For the theoretical possibility of a convergence point      that 
never occurred for any test scenario(cf. II.6), all genes and samples are selected and a warning is issued.) 
The second criterion demands a minimum amount of selected representatives. This is important, because if 
two nearly identical candidates exist in the raw signal by accident, the convergence criterion might already be 
reached for   2, but this is usually not yet representative nor robust. In the default, the minimum of fifteen 
and of 20% of the estimated effect size is required. The effect size is estimated as for the effect score(II.3.1.6). 
20% are considered sufficiently representative for any effect. Fifteen has proven to be already sufficient in all 
test cases and there is no point to add more representatives and waste computation resources, if axes have 
converged. The relative cut at 20% is also important to demand less than fifteen representatives for very small 
effects that might not even have this many members (in this case, forcing more representatives would make 
effect axes less specific and less representative). 
Once both criteria are met for a certain , effect axes |,   are considered the final linear approximation 
of the effect’s law of regulation and thus are fixed hereafter. They are passed on to bimonotonic regression, 
where they serve as axes over that precise effect curves are monotonically regressed(II.4). 
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II.4 Regression and Dissection 
Once an effect has been pinpointed by its gene and sample axes as determined by the search 
strategy, the next step is to estimate and extract its and only its contributions to the signal in 
order to dissect it. This extraction must be precise, because if the effect’s eigensignal is 
underestimated, hard-to-interpret shadows of the same effect would be detected later. If it is 
over-compensated, artifacts would be introduced, likewise leading to hard-to-interpret 
secondary effects. If it is compensated in a too fine-grained way, information about other 
overlapping effects would be lost, preventing their detection. 
The bimonotonic effect model(cf. II.2.1.2) allows for a precise regression of the effect’s 
eigensignal. Together with dissection strengths determined by correlations to the effect, the 
effect can be removed from the signal in a way that leaves signals from overlapping and even 
partially correlated foreign effects untouched. Additionally, effect curves based on the 
eigensignal can replace previous linear approximations with more precise monotonic 
approximations of the effect’s law of gene regulation. 
II.4.1 Regression and Effect Curves 
Based on discovered and representative effect axes |, (cf. II.3.2.3), the bimonotonic effect model(cf. II.2.1.2) is 
utilized to realize a corresponding regression of the effect’s 
eigensignal. This eigensignal can be re-parameterized as effect 
curves(cf. II.2.2.3) in the gene or sample space. The resulting gene 
curve for the blue effect in the concept example demonstrates a 
much more precise approximation of the effect’s nonlinear law 
of gene regulation(Figure II.4.1) compared to its previous linear 
approximation by effect axes(cf. Figure II.3.2). 
An overview of this important sub-algorithm is presented 
here, then individual steps are clarified in detail below. 
Eigensignals are regressed by one outer and one inner 
convergence loop. Every outer regression iteration  is 
structured as follows: • II.4.1.1: Compute effect strengths for genes ,  and for samples ,  • II.4.1.2: Resort the current signal  to the effect’s empirical eigenorder , , , (as determined by 
effect strengths) in order to obtain a roughly bimonotonic presorting. • II.4.1.3: Inner loop (index ) for bimonotonic regression of the empirical eigensignal , , ,. 
Results in ,    for convergence iteration     . • II.4.1.4: Adaptive smoothing  by rescaling to the effect strength space and by 2D Fourier transforms. • II.4.1.5: Convergence check. As soon as converged (index   ), the result    ,     is passed on to 
compute the final eigensignal and to dissect the effect(II.4.2). 
 
 
Figure II.4.1) 3D example, blue effect curve in gene space 
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II.4.1.1 Effect strengths for genes and samples 
Before the first bimonotonic regression (  0), effect strengths are computed by projecting all genes on the 
effect’s representative sample axis   and all samples on the effect’s representative gene axis | that were 
determined by the search strategy. The current signal context for these projections and for genes | 	 and 
samples  is still the signal matrix . (For clarity, definitions below are also written out in terms of matrix 
based vector components.) 
Initial effect gene strengths ,  ∈   are defined by weighted projections(II.2.3.2) in the sample focus  :  ,  ≡  
  ,  
   
Initial effect sample strengths ,  ∈   are defined by weighted projections(II.2.3.2) in the gene focus  :  ,  ≡ 
   , 
   
Eqn. II.4.1.1.a) Effect strengths by weighted projections on effect axes for   1 
 
Of note, these projections may effectively also be viewed as classifications of genes respectively samples with 
respect to an effect. Alternatively, correlations to the effect could be utilized for later classification 
purposes(cf. III.1.4). 
For regression iterations   1, effect curves(II.2.2.3) are employed instead of effect axes for higher precision. 
These curves are based on the smoothed and regressed eigensignal version , ≡ ,    from the 
previous iteration   1 (as defined and computed in the following sections; the corresponding matrix in 
reference order is again denoted without tilde, i.e. ,, , ,   ,.) 
Refined effect gene strengths ,  ∈   are defined by weighted projections(II.2.3.2) in the sample focus  :  ,  ≡  |   , ,, 
   
Refined effect sample strengths ,  ∈   are defined by weighted projections(II.2.3.2) in the gene focus :  ,  ≡  
   , ,, 
   
Eqn. II.4.1.1.b) Effect strengths by weighted projections on effect curves for   1 
 
 
II.4.1.2 The empirical eigenorder 
I utilize defined effect strengths(II.4.1.1) as empirical estimate for the effect eigenorder: 
The empirical gene eigenorder ,  of the effect orders genes by their effect strengths  |, , i.e. 
∀	 ∈ 1,   1: ,  ,   ,  , . 
The empirical sample eigenorder ,  of the effect orders samples by their effect strengths  |, , i.e. 
∀	 ∈ 1,   1: ,  ,   ,  , . 
Eqn. II.4.1.2) Empirical effect eigenorder based on effect strengths 
 
The correspondingly permuted signal matrix , , ,  orders genes and samples by the discovered 
effect, resulting in a roughly bimonotonic signal already. This raw eigensignal provides the basis for precise 
regression below(II.4.1.3). Notably, the final eigensignal cannot be defined with this empirical signal directly, 
because after subtracting it, the remaining signal would equal zero. Hence, all information about other possibly 
overlapping effects with different eigenorders would be lost. 
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II.4.1.3 Bimonotonic regression 
Bimonotonic regression is realized based on 1D monotonic regressions, weighted averages and a 
convergence loop of the following structure: • weighted monotonic 1D regression of each gene in the sample eigenorder ,  of the effect • weighted monotonic 1D regression of each sample in the gene eigenorder ,  of the effect • 2D Fourier smoothing of the signal (utilized for points with no or low weight in the effect focus) • compute weighted averages • check for convergence. 
To realize 1D monotonic regressions for each gene and for each every sample, an established isotonic 
regression algorithm is utilized called Generalized Pool Adjacent Violator (GPAV)[84]. The algorithm has  
(respectively ) computational complexity in the worst case, but approaches linear complexity  for 
already monotonically presorted data. Hence and in practice, it is much faster than the worst case, because 
genes and samples are already roughly presorted in the signal matrix , , , . Importantly, this 
algorithm supports weights, which is utilized to put regression emphasis on signals in the effect focus. 
Let  denote the iteration index of this inner convergence loop. Rather than using gene weights  for the 
regression of each sample (or sample weights   for the regression of each gene), every gene and every 
sample gets its own weights vector for regression as follows. Let  ∈  represent sample weights for 
each gene and let  ∈  denote gene weights for each sample. (The tilde indicates matrices in eigenorder 
rather than in reference order; see their following definition.) Both weight matrices are initialized at   0 (i.e. 
before the first regression) with the symmetric outer product of the effect focus:  
The product effect focus  ∈   (of effect ) is defined as components of the outer product ⨂  of the 
final effect focus ,  (cf. II.3.2). 
Regression weights for the initial inner iteration   0 are initialized with this product effect focus in the current 
eigenorder , , , :    ≡ , , , . 
Eqn. II.4.1.3.a) The product effect focus and initial weights for 1D regressions 
 
These product weights work like a logical AND-condition. Only gene, sample pixels associated with high gene 
weight    and high sample weight    also get high weights for regression and subsequent 
averaging (as detailed below). 
Let ,  denote the signal of outer iteration  and at the beginning of inner regression iteration . Before the 
first regression (  0), , is initialized as the roughly bimonotonic signal  , , ,  in the empirical 
effect eigenorder. (For readability, the outer index  is suppressed for all local variables like weight matrices 
in this section.) 
Now GPAV is applied to every gene row in , , using corresponding rows in   as regression weights. This 
results in monotonically regressed genes that can be collected as matrix  ∈  . Each gene row in  is 
a step function that consists of blocks of constant regressed gene expressions, while expressions of 
neighboring blocks are all either monotonically increasing or all monotonically decreasing. Each block 
corresponds to a sample interval in the sample eigenorder ,  of the effect. GPAV also updates sample weights 
(for each gene) by averaging input weights for each block; they can be collected as rows of a matrix  . 
Likewise, regressions of sample columns in ,  are realized with GPAV, using corresponding columns of   
as regression weights. This results resulting in a matrix of monotonic columns  ∈   and updated gene 
weights for each sample  ∈ . 
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To interweave gene and sample regressions over iterations , weights are mixed. To realize a soft 
convergence, additionally an average with a history of one iteration is computed. This average respects 
 
Figure II.4.1.3) Illustration of bimonotonic regression (inner convergence loop) 
Starting from the presorted signal matrix , , ,  in effect eigenorder, first genes and samples in the effect focus are monotonically regressed (bottom left). 
Results are combined via weighted averaging to obtain , (center row, second panel). This continues until the final iteration      4 that is depicted in the right half. 
The top row illustrates differences ,  , ; color bars indicate the scaling. Provided   values are pixel standard deviations of depicted matrices in the effect 
focus. (Most of the 1000 simulated genes are not depicted, as they have zero weight in the effect focus. Hence, the effect eigensignal for them is determined solely by 
adaptive smoothing. Similarly, gray lines indicate genes and samples with zero weights because of their relatively low correlation to the effect’s sample or gene axis 
compared to existing top correlated genes respectively samples.) 
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imbalances in gene and sample counts (to prevent weights based on just a few samples to overwrite much 
more granular information from many genes, for example). The concrete definition of mixed weights reads: 
 ≡ 
   2   
   2    
Eqn. II.4.1.3.b) Interweaved regression weights for genes and samples 
 
Typically effects do not affect all genes and all samples in the signal. Often only a fraction of all measured 
genes are correlated to an effect. Hence, the effect focus ,  typically assigns zero weights to many 
genes and maybe also several samples. For zero weights, an adaptive smoothing of , , ,  is employed 
instead of regressions to define the effect’s eigensignal. In this way, usually most genes do not need to be 
regressed at all, which increases performance considerably. To this end, the same smoothing operator  is 
applied to , as for final eigensignal polishing(cf. II.4.1.4). This support for zero weights also has the useful side 
effect to support missing values in the input signal(cf. II.6.4.4). 
Finally and using the same interweaved weights as above, the next estimate for the bimonotonic eigensignal 
is formed as weighted average: 
,  
   2   ⋅  
   2   ⋅   1    ⋅ , 
Eqn. II.4.1.3.c) Bimonotonic regression step 
 
The third summand gradually fills in the adaptively smoothed signal for all weights less than one. Hence, all 
pixels keep their norm, irrespective of how strongly correlated they are to the effect. 
To illustrate this regression procedure, the first and last iterations of eigensignal regression for the 
discovered pattern #3 of a versatility test(cf. II.6.2) are depicted(Figure II.4.1.3). 
For convergence estimation, the pixel standard deviation of ,  , can be utilized (weighted with the 
product effect focus  (Eqn. II.4.1.3.a)). Let      denote the iteration as soon as this standard deviation is 	̂, 
where  ≡ 10  and ̂ is the current estimated noise level(cf. II.5.1.1). Then ,    is considered bimonotonically 
regressed to sufficient precision and passed on towards signal polishing(II.4.1.4). 
 
II.4.1.4 Adaptive smoothing by 2D Fourier transforms 
Bimonotonic regression has already resulted in a signal matrix ,    that fulfills the effect model(II.2.1.2). 
Adaptive smoothing alone could not have provided this, as monotonicity is a global property and smoothing 
is a local operation. Even for very large smoothing kernels, bimonotonicity could in general only be 
approximated and furthermore such blurry smoothing would prevent a precise dissection (in the limit of ever 
larger smoothing kernel sizes, the result would simply approach a constant). However, for relatively small and 
adaptive kernel sizes as explained below, smoothing has been found to increase quality over the step-function-
like pure bimonotonic regression result ,   . As smoothing cannot change monotonicity, bimonotonicity is 
kept by this operation. Additionally and as explained in the last section, the same smoothing operation is also 
utilized for performance reasons when replacing the relatively slow regression by this smoothing for genes 
and samples with zero weight in the effect focus. 
It is counterproductive to directly smooth ,    (or , , ,  before regression), because neighboring 
genes or samples in the empirical eigenorder might have strongly different effect strengths. Smoothing such 
neighbors would result in an eigensignal that, if subtracted, undercompensated the stronger neighbor and 
overcompensated the weaker. Both would result in inaccurate approximations of the effect’s law of regulation 
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and trigger hard-to-interpret secondary detections of signal remnants from this effect after its inevitable 
imprecise dissection. Hence, in case of rapid signal changes a very small (and for abrupt signal changes even 
zero-width) smoothing kernel is required to obtain a sharp eigensignal for the effect.  
Furthermore, in eigenorder intervals with nearly constant effect strengths, it makes more sense to employ a 
large kernel that smooths many neighbors, because all of them contribute equally to the effect and hence 
should result in the same eigensignal for balanced dissection.  
Unfortunately, the direct computation of a smoothing operation with an adaptive kernel size is 
computationally quadratic in the number of pixels and hence not feasible for practical purposes. 
To realize this adaptive smoothing fast, ,    is first rescaled using effect strengths ,  and , (cf. II.4.1.1). 
A constant smoothing kernel in this rescaled effect strengths space then corresponds to the requirement of an 
adaptive smoothing in the original eigenorder index space. For performance reasons, the resolution of this 
rescaled space is set to  ≡ 512 rows and  ≡ 512 columns respectively. This is sufficiently precise to 
represent a bimonotonic signal for all practical purposes. (Choosing resolutions as powers of two allows an 
 
Figure II.4.1.4) Illustration of adaptive signal smoothing (realized by rescaling and 2D Fourier transformation) 
Starting from the presorted signal matrix , , ,  in eigenorder, first the signal is rescaled and downscaled by aggregation and interpolation in the space with 
equidistant effect strengths (resolution: 512x512 pixels). To avoid border artefacts from 2D Fourier transforms the signal is circularly padded with sign alignment as 
depicted. With a Gaussian kernel and the convolution theorem described in the text, the smooth result on the lower right is obtained (i.e. the convolution). After 
unpadding and rescaling back to original coordinates by interpolation, the smoothed version of the start signal is obtained. 
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optimally efficient fast Fourier transformation below.) Coordinates of this rescaled and downscaled space 
correspond to equidistant effect strengths: 
Basis vectors  of the rescaled and downscaled gene space correspond for  ∈ 1,  to equidistant  
gene effect strengths , , 1  , , 1  , ,  ⋅ . 
Basis vectors  of the rescaled and downscaled sample space correspond for  ∈ 1,  to equidistant 
sample effect strengths , , 1  , , 1  , ,  ⋅ . 
Eqn. II.4.1.4.a) Rescaled and downscaled gene and sample space for smoothing 
 
The rescaled and downscaled signal ,   ∈   can be computed from ,    by averaging in the 
corresponding effect strength grid cells (that are bordered on the right by defined effect strength cuts). In case 
of empty grid cells (i.e. no gene and no sample has an effect strength in the corresponding intervals), nearest-
neighbor interpolation is employed. 
This coordinate change does not only increase the resolution at steep changes of effect strengths (i.e. where 
the eigensignal also needs to change rapidly) but also reduces resolution for intervals with relatively flat effect 
strengths (i.e. where the eigensignal should also change little). Therefore, ,    can now be smoothed in this 
rescaled space using a constant window width, while still fulfilling the requirement of adaptive widths in the 
original index space. 
Let  , ∈   denote the Gaussian kernel (centered at indices  ,  ) with effect strength standard 
deviations corresponding to eight pixels:  ≡ , , 1  , ,  ⋅  and   ≡, , 1  , ,  ⋅ . Eight pixels are sufficiently many to avoid numeric artefacts. And  is 
small enough to avoid problems with over- and under-compensation in the original space as explained above. 
The smoothing result is the convolution ,   ∗  , . Unfortunately its naïve computation has still a 
complexity that is quadratic in the number of points. Therefore, the convolution theorem[85 §15.3.1.3] is applied: 
,   ∗  ,   ,    	.  , 
Eqn. II.4.1.4.b) Application of the convolution theorem reduces the smoothing task to 2D Fourier transforms and component-wise multiplication 
 
This reduces the smoothing task to the component-wise multiplication of two Fourier-transformed matrices 
plus one inverse Fourier transform of the result. Fast Fourier transform implementations for  and  
(provided by fft2 and ifft2 functions in MATLAB®) are employed that only have log-linear complexity.  
To avoid numeric artifacts from border effects, ,    is circularly continued for half its size with sign 
alignment. This is implemented by padding of the signal matrix and corresponding unpadding after the inverse 
transformation(see Figure II.4.1.4).  
Finally, the unpadded convolution result is scaled back to original coordinates via 2D interpolation at effect 
strengths  ,  and  , . For abbreviation, let ,   summarize this smoothing operation. 
Notably, while the result is already a good approximation of the eigensignal (and was even employed to 
estimate it in an earlier development stage of the algorithm), this approximation it is not necessarily 
bimonotonic and may contain hard to interpret parts, e.g. the visible red stripes(Figure II.4.1.4). Especially for strong 
effect strengths (where eigensignals are also strong) precision is paramount to avoid introduction of artifacts 
that might be discovered as “pseudo effects” in later iterations. Additionally, this smoothing operation is not 
weighted, i.e. it cannot respect the effect focus. Only by enforcing bimonotonicity via weighted regression in 
the effect focus(II.4.1.3) and by using dissection strengths(II.4.2.1) in order to zero the eigensignal outside of the 
effect focus, the aspired precision and interpretability of resulting effects was obtained. 
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II.4.1.5 Check for convergence 
Convergence of the outer regression loop is finally checked by correlating all pixels of ,   with the result 
from the previous iteration ,   , again using the symmetric product effect focus(Eqn. II.4.1.3.a) as weights. The 
eigensignal is considered converged as soon as this correlation is 0.99. Let     denote this iteration; then    ,    is passed on to the computation of the final eigensignal for effect dissection(II.4.2). 
Convergence is always reached, as the only change between outer iterations is the update of the empirical 
eigenorder by projections on regressed effect curves. In practice, often only the first iteration (from effect axes 
to the first effect curves) is associated with a relatively large change. After that, it usually takes only one 
additional outer iteration to reach the correlation threshold. If the effect is linear, it may even converge after 
the first outer iteration, as in this case effect curves equal effect axes. 
 
 
 
 
 
 
 
 
 
 
 
II.4.2 Effect Dissection 
After having bimonotonically regressed and smoothed the signal in the discovered effect eigenorder,    ,     
is multiplied by dissection strengths based on the effect focus to obtain the final effect eigensignal. 
The effect focus ,  obtained by the search strategy(cf. II.3.2) serves not only a purposes during 
regression but also during dissection. The first purpose was to define weights for regression(II.4.1.3) in order to 
estimate effect curves in the ideal case exclusively based on genes and samples in the effect, i.e. by those that 
are indeed significantly regulated by the discovered effect. 
The second purpose during dissection concerns partially correlated effects, i.e. effects that share dimensions 
with partially co-ordered eigenorders. (For example, green samples in the 3D example(see e.g. Figure II.4.1) may show 
strong effect strengths when projected on the red effect axis, but simultaneously have high distance from the 
red effect.) In this case, even with a perfectly regressed effect curve for the current effect, effects cannot be 
dissected cleanly, as is demonstrated in this subchapter(Figure II.4.2.2.b). Hence, the second purpose of the effect 
focus is to prevent explaining signal parts by for genes or samples that are significantly out of the current 
effect. Only then, these partially correlated effects can be detected and dissected in later iterations with effect 
curves that are specific to their original signal (rather than with hard to interpret effect curves that only fit 
remnants of their signal and effectively depend on all previously dissected effects). 
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II.4.2.1 Dissection strengths, final eigensignal and remaining signal 
Dissection strengths are essentially 
identical to the effect focus and guarantee 
that no signal is modified outside of the 
effect’s focus. Like regression weights 
before(Eqn. II.4.1.3.a), dissection strengths are 
defined as the symmetric product effect 
focus in eigenorder. 
Now the final eigensignal of effect  can be defined. 
The effect eigensignal in the discovered eigenorder is defined as the component-wise product:  ≡  .    ,     
Eqn. II.4.2.1.b) Eigensignal of the discovered effect 
 
Sorting back to reference orders   and  via ,   , ,    ≡  defines the final eigensignal  ∈   that is 
compatible with signal matrices. 
At this point, dissection is merely a matrix subtraction of the eigensignal. 
This results in the remaining signal  . It is the input for the next detection 
iteration   1 that starts with the search strategy(cf. II.3), again. 
 
 
 
 
 
II.4.2.2 Effective clustering and conceptual limits of projection based methods 
Implicitly, dissection realizes an iterative soft 
clustering of the signal. Even partially correlated 
effects can be properly dissected. 
This is also demonstrated by the 3D example(Figure 
II.4.2.2.a). The blue effect has been successfully 
explained by its discovered and regressed eigen-
signal(see its gene curve in Figure II.4.1). All signal parts that 
remain from the blue effect are scattered around 
zero with distances that approximately correspond 
to the noise level. 
In contrast, signals from all three other effects are 
still untouched. (The gene curve depicting the 
eigensignal for the green effect is already shown 
here as well. It will be dissected in the second 
iteration. All dissection steps for this 3D example 
are shown in II.6.1.) 
Dissection strengths  ∈   for effect  are defined as 
square roots of the components of  ⨂ , i.e. of the outer 
product of the final effect focus  ,  (cf. II.3.2). 
 ≡ ,   , ,    denotes dissection strengths in the final 
eigenorder. 
Eqn. II.4.2.1.a) Dissection strengths 
 
 ≡     
Eqn. II.4.2.1.c) Remaining signal after dissection 
of the discovered effect  
 
 
Figure II.4.2.2.a) 3D example, remaining signal   after dissection of the blue effect  
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Conceptually, this effective clus-
tering by dissection goes beyond PCA 
and other methods that are equivalent 
to projections or to orthogonal co-
ordinate transformations. For the 3D 
example, such methods could maxi-
mally provide three orthogonal gene 
axes, because after three projections 
only a point signal remains. However, 
there are four distinct effects in this 3D 
signal. Hence, these methods cannot 
dissect all four effects and, thus, 
original effects are hard to infer from 
resulting axes, e.g. from principal 
components(cf. II.6.1.2). 
To demonstrate these limits of 
projections and the importance of the 
effect focus in particular, the upper 
example uses only the regressed and 
smoothed    ,    for dissection(Figure 
II.4.2.2.b, upper panel). This is compared with 
the dissection based on the final eigen-
signal  .    ,     that cuts regression 
results with the effect focus(lower panel). 
Whenever partial correlations 
between effects are present in the 
signal, as in this example, then not only 
samples regulated by the current 
effect(blue) have a nonzero projection on 
the effect’s gene axis(orange) but also 
samples from foreign effects. Hence,    ,    is not zero for samples 
regulated by foreign effects. Its 
subtraction moves points from these 
foreign effects towards a perpendi-
cular plane, similar to a projection 
along the gene axis(see upper panel). 
This should be prevented in order to 
be able to detect and interpret original 
laws of gene regulation for the green, 
red and magenta effects, without any 
information loss or warping by other 
previously detected effects. 
 
 
Figure II.4.2.2.b) Dissection with and without using the effect focus as dissection strengths 
Upper panel: Naïve dissection based on the regressed effect curve. All points with nonzero 
projection on the effect axes are changes. Lower panel: Dissection in the effect focus based on the 
final eigensignal. Signals from partially correlated yet distinct effects are untouched, while the blue 
effect is removed. 
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In contrast, when using the final eigensignal   that makes use of the effect focus(cf. II.4.2.1), signal parts from all 
other effects are untouched and only blue samples are moved by this dissection(Figure II.4.2.2.b, lower panel), as intended. 
II.4.2.3 Visualization of high-dimensional eigensignals: the coordinate view 
So far, most examples were visualized within their 3D gene space. This type of direct visualization is 
unfortunately not possible for high-dimensional signals. To still visualize the raw signal and the regressed 
effect curves for high-dimensional signals, coordinates of all gene and sample vectors and of the regressed 
effect curves can be depicted as heatmaps. 
This is explained below for the second iteration of the 3D example that detects and dissects the green effect. 
The blue effect has already been dissected in the first iteration: 
Figure II.4.2.3.a) Coordinate view for high-dimensional visualization; exemplary dissection of the green effect for the 3D example 
 
This coordinate view is henceforth employed for visualization of all detections and dissections of high-
dimensional effects. Higher dimensions simply correspond to more gene rows (or sample columns) in 
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heatmaps. A detailed explanation follows that clarifies the equivalence of this coordinate view to the gene and 
sample spaces: 
i) The original gene expressions   are depicted; they include signals form all four simulated effects. 
Columns correspond to samples and rows to genes.   is already presented in the empirical eigenorder  ,  of the currently detected green effect. 
ii) The already explained parts of the signal are depicted in the empirical eigenorder for the detected green 
effect. Generally, this is the sum of all so far dissected effects. Here, it is just the final eigensignal   of 
the blue effect that was detected and dissected in the first iteration. As samples regulated by the blue 
effect have a signal near zero now, they are centered in the sample eigenorder  for the green effect. 
iii) The initial signal   for the current detection iteration is shown, again in the detected empirical 
eigenorder of the green effect. This ordered signal is already roughly bi-monotonic for top sample effect 
strengths (i.e. leftmost and rightmost columns). The green effect is partially correlated to the red effect 
with respect to the  direction. However, it is anti-correlated with respect to gene . Only those samples 
that are co-regulated (i.e. that have the same color) for genes  and  belong to the green effect. Red 
samples may still have strong effect strengths (as quantified by their projections on the green effect 
axis), i.e. red and green samples are mixed by the empirical eigenorder. 
iv) This panel shows the eigensignal, i.e. the bimonotonically regressed signal of the green effect times 
dissection strengths. Points outside of the effect focus, as determined by relatively low correlations to 
the effect(cf. II.3.2.2 and Eqn. II.3.1.4.b), are greyed out. Their signal is not modified by dissection. In particular, red 
samples are successfully filtered out, despite their partial correlation to the green gene axis. 
v) The final result of detection iteration   2 is the remaining signal   after dissection of the detected 
green effect. Top samples of the green effect at the left and right end of the heatmap are now noticeably 
zeroed. The signal still contains the red and magenta effects; they are detected and dissected in 
subsequent iterations(cf. II.6.1). (For instance, columns in the right half of this heatmap that show 
negative(blue) expression for all three genes  correspond to samples regulated by the magenta effect.) 
vi) The initial signal   for the current iteration is shown in the 3D gene space. Every sample point has 
coordinates depicted by one column in panel iii. The eigensignal of the green effect is shown in form of 
the yellow gene curve of the effect. Points along this curve correspond to columns in panel iv. 
vii) Lastly, the final dissection result in shown 3D view. Every sample point corresponds to one column 
in panel v. 
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II.4.3 Remaining Signal and Termination 
Because every eigensignal is locally comparable to a signal average, dissection modifies the signal towards 
zero on average and ultimately only a zero signal can remain. Hence, termination is always guaranteed. 
Typically, already long before that, no effects with significant correlation and signal strengths remain in the 
signal. This is recognized in the search strategy when no gene or sample qualifies any longer(cf. II.3.1.8). In this 
way, the method unsupervisedly determines the number of effects  in the signal(cf. II.2.1.1). 
For the 3D concept example, the method correctly detects that after four iterations the remaining signal does 
no longer contain any relevant effects. Hence, the number of effects in the simulated 3D signal is determined 
to be   4 and the method terminates. More precisely, no candidate qualifies any longer with respect to the 
significance threshold for the signal strength(cf. II.3.1.8). This is a relative statement and depends on the empirical 
noise estimation(cf.II.5.1). This termination by remaining signal strength is visually clear in case of the 3D example 
when comparing the original simulated signal with the remaining signal after four dissection iterations: 
 
Figure II.4.2.3.a) 3D example, remaining signal after all four dissection iterations 
 
 
76 Chapter II - Signal Dissection 
 
II.5 Noise and Significance 
A vital part of a statistical solution for unsupervised detection of so far unknown effects is a 
statement of how reliable its findings are. This is typically quantified by  values, i.e. 
probabilities of observing detected effects (or even stronger effects) based on noise alone. 
To obtain these probabilities, observables like correlations of genes with the effect’s gene 
axis or correlations of samples with the effect’s sample axis are tested for their significance. 
Likewise, the significance of observed signal strengths in the effect’s focus is tested relative to 
the estimated noise level. 
Based on these  values for observed signal strengths and correlations, effect candidates are 
qualified or disqualified by the search strategy(II.3.1.8). As soon as no gene or sample qualifies 
any longer, the remaining signal is considered as noise and detection stops. Hence, noise 
estimation should be as precise as possible in order to minimize false negatives (due to 
overestimated noise) as well as false positives (due to underestimated noise). 
II.5.1 Significance of Observed Signal Strengths 
To calculate  values with respect to the signal strength of effects, first the true noise level of the overall 
signal needs to be estimated. This noise estimation is related to the field of blind denoising. It is a non-trivial 
sub problem, especially for signals containing many effects. 
With the estimated noise distribution as reference, several statistical tests can be utilized to evaluate the 
observed signal in an effect’s focus for significance. These tests differ in computation speed and how robust 
they are in practice against deviations from their theoretical assumptions by the actual signal. 
II.5.1.1 Estimating the true noise level 
A naïve approach might utilize global estimates like the empirical standard deviation of measured gene 
expressions ̂ ≡ ∑ ,    , ⁄  ⁄ . However, this can strongly overestimate the true noise level, 
because   still contains all true effects, including maybe strong and broad effects with a strong influence on 
such global estimators. In the 3D example, for instance, σ  0.600, whereas the true simulated noise level 
is only 0.1. Hence, this reference would prevent the detection of weaker true effects (false negatives). On the 
other hand, using the standard deviation of the remaining signal σ as reference at the beginning of each 
iteration  would ultimately strongly underestimate the true noise level in the initial signal, as dissecting effects 
propagates the remaining signal  ever nearer towards zero. Hence, using this estimate may lead to 
detection of many false positives. 
Estimating the true noise level in a signal of unknown structure is a difficult problem that is also studied in 
the field of blind denoising. If the signal represents an image, one idea[86] is to first find patches of weak texture 
in this image and only utilize these patches as basis for noise estimation. However, this approach is based on 
the prescribed spatial order of image rows and columns. Another idea from blind denoising is to model 
projections of theoretical noise on all conceivable effect axes in a theoretical effect alphabet. These projections 
should be distributed normally and the supremum of these projections over the alphabet provides a useful cut 
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line between true effects and noise. This can then be utilized as stop criterion for denoising as demonstrated 
by the BIRD algorithm[87]. However, this approach needs a known and fixed alphabet of effects. 
In order to adapt these two ideas for the unsupervised scenario with an initially empty effect alphabet and 
initially unknown and unfixed order of genes and samples, one needs to identify “weak textures” in this 
context. Let ,  , ,  denote the final effect focus for converged effect axes(cf. II.3.2) of a detected effect . 
Gene expressions that are significantly correlated(cf. II.5.2) to this effect’s axes are not noise. They are “textured” 
in the image analogy and thus should be excluded for noise estimation. To deselect them, I demand that 
dissection strengths(cf. II.4.2.1)   for the current effect are near zero via   10  (the relation is taken 
component-wise, resulting in a Boolean mask ∈ true, false). 
This condition alone is not yet sufficient to exclusively select noise, because there might exist many other 
effects with strong signals that are perpendicular (or partially correlated) to currently discovered effect axes. 
To deselect them as well, I utilize the standard assumption of a constant global noise level (rather than noise 
that varies for each effect). This allows testing for perpendicular effects based on standard  scores for the 
radial distances of genes and samples to the respective current effect axis. A cutoff condition of less than three 
noise standard deviations ̂(defined below) has worked well in practice. From iteration   2 onwards, the 
noise standard deviations can be estimated reliably based on the noise distribution  . However, initially 
when   1, no noise distribution has been estimated yet. In this case, and again with the assumption of a 
global noise level, the standard deviation (weighted with dissection strengths ) of pixels in   around the 
regressed eigensignal   can approximate the initial noise standard deviation. 
 
Together, both conditions select only those gene expressions in  that are most probably “untextured” 
noise. These values are added to the initially empty estimated noise distribution  . Every selected value for 
gene  and sample  in the noise distribution is assigned 1  ,  as weight. The same is done for every 
detected effect, making the estimated noise distribution   larger and more reliable with every dissection. For 
memory performance,   and its weights matrix   are implemented as matrices of the same size as  . 
Pixels never selected as noise samples get weight zero. Pixels selected as noise estimates in multiple detection 
iterations are averaged in   and the maximum of their corresponding weights is retained in  . 
Now the true noise standard deviation of measured gene,	sample pixel around zero can be estimated by ̂ ≡ ∑ ,  ⋅ ,   0 , ∑ , ,  ⁄ . I utilize the uncentered standard deviation that is 
always computed relative to zero (and not relative to the empirical mean), as zero already represents the 
theoretically known mean for globally pre-centered data. 
For the blue, green, red and magenta effects in the 3D concept example, this procedure yields estimates for 
the noise level of ̂  0.100, ̂  0.108, ̂  0.103 and ̂  0.097 respectively(cf. Figure 
II.5.1.2, page 79), while the true simulated noise level is sim  0.1. 
Besides providing a reference for significance estimation, the noise distribution can also be utilized to define 
signal-adaptive error thresholds. For example,  ≡ ̂/1000 is used for bi-monotonic regression; there is 
no point in regressing the signal more precise than this. (For   1, error thresholds are estimated using ̂; a probable overestimation is uncritical for this purpose.) 
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II.5.1.2 Significance of signal strengths 
To answer whether an effect has significant signal strength, it is now possible to test the signal in the final 
effect focus against the obtained sampling   for the true noise distribution. As the signal is signed, signal 
averages are not useful for this comparison. Instead the signal power (i.e. quadratic values) or signal 
amplitudes (i.e. absolute values) can be utilized. Several tests and statistics can be employed to this end, with 
different advantages and disadvantages.  
 Permutation tests are non-deterministic and have too high computational cost 
A straight-forward approach would be a permutation test. Some distance statistic could be defined between 
signal amplitudes in the effect focus and noise amplitudes. Then the effect focus, i.e. gene weights and samples 
weights, could be randomly permuted among all available genes and samples. If the observed statistic for the 
effect focus is stronger than for sufficiently many permutations, the effect’s signal strength may be called 
significant. This approach has two problems. First, it is non-deterministic because of random permutations. 
Secondly, it is far too slow in practice, because the significance with respect to signal strength has to be tested 
for every effect candidate during the search strategy(cf. II.3.1.8). 
 Kolmogorov-Smirnov tests are deterministic, but still too slow and not sensitive enough 
As a sample of   was obtained (instead of just a scalar estimation of ), one deterministic possibility 
to obtain a  value is to employ Kolmogorov-Smirnov (KS) tests. They can directly compare distributions of 
signal amplitudes. To this end, first the cumulative distribution function (CDF) for the current absolute signal 
matrix || ≡ |, |,  is empirically estimated, using dissection strengths   as weights. Secondly, the 
weighted CDF for absolute signals of all noise samples || is empirically estimated, using   as weights. For 
a one-tailed test, whether signal amplitudes in the effect focus are higher than noise amplitudes, the KS statistic 
is simply the maximum of all point-wise differences of these two CDFs. Notably, the effect focus(Eqn. II.3.1.4.b) only 
utilizes correlations and their significance, but not signal strengths to define weights; otherwise weighting 
with   would be biased towards stronger expressions, which could lead to underestimated  values. 
Effectively, the KS test looks for larger counts (or larger weight mass) of higher expressions in the effect focus 
as can be expected by the sampled noise. Only the relative order of values is important for this test, rather than 
their absolute numeric values. Hence, this test is robust against outliers. To finally compute corresponding  
values, the asymptotic upper tail of the Kolmogorov-Smirnov distribution(D statistic in table 1 of [88]; also see kstest2.m of the 
MATLAB® Statistics Toolbox for implementation details) can be integrated.  
Though this KS test is robust and deterministic and utilizes all available information, it has a disadvantage: 
For strong yet small effects that differ only in the upper distribution tail when compared to  , it might cause 
false negatives. This insensitivity with respect to tails is a known weakness of Kolmogorov-Smirnov tests; a 
solution using inverse signal variances as weights to focus on tails has been suggested[89], but it is difficult to 
estimate the signal variance precisely. Additionally, for the search strategy weighted CDFs of the signal in 
every candidate effect focus would have to be estimated for these Kolmogorov-Smirnov tests. While this is 
practically possible, a faster alternative is presented next. 
 Weighted t-tests are fast, deterministic and have other practical properties 
A relatively simple weighted -test has been found to provide all needed properties for practice. It can be 
computed fast and deterministically. Additionally, it is robust and forgiving with respect to slight over- or 
underestimations of the true noise level. Most importantly, together with a significance threshold that can be 
chosen tightly as signal ≡ 10, these -tests can correctly sort out false positives with respect to signal strength 
in most test cases, while still qualifying simulated weak true positives(cf. II.6). This was confirmed over many 
simulations(e.g. II.6.2.5).  
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In contrast, for instance, -tests were relatively sensitive to the correct estimation of the true noise level. 
(These tests were also examined during development to compare signal powers between the effect’s signal 
and the noise distribution.) -tests caused both false positives and false negatives in several simulations. This 
corresponds to the known sensitivity of -tests against non-normality[90], while -tests are known to be robust 
against moderate deviations from normality[91,92].  
 
 
Figure II.5.1.2) Signal significance in the 3D example 
Each panel shows the empirical density over signal strengths of (gene, sample) pixels in the focus of the discovered effect. The area under each colored curve 
corresponds to the sum of the product effect focus, i.e. the sum of the detected effect’s dissection strengths ∑ ∑ ,  . Theoretical half Gaussian distributions are 
depicted with the same mass and for the respective noise standard deviation ̂ ( abbreviates ̂  in these plots). Standard deviations of   initially strongly 
overestimate the simulated noise level sim  0.1 and in the end underestimate it (̂  0.079). Approximate  values based on -tests are provided in 
panel titles in log  scale. All are very small, as the signal of all four effects is clearly stronger than the simulated noise level. Additionally, all effects are carried by 
sufficiently many samples (Inf corresponds to a numeric underflow to   0). 
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The central limit theorem[85 §16.2.5.2] states that the arithmetic mean of many independent random variates 
from the same distribution (with finite mean and variance) is distributed approximately normal. This and the 
above-mentioned robustness of -tests allow their application to only half-normally distributed values. More 
precisely, I utilize them to compare many half-normally distributed signal amplitudes in || in the effect 
focus against many half-normally distributed noise amplitudes in || (the absolute value is taken component-
wise, again). 
For computation, -tests require only empirical means, empirical standard deviations and weight sums for 
both distributions to compare. In the unweighted case, weight sums simply equal the number of points. All 
these measures can be computed fast. For ||, this even needs to be computed only once per detection 
iteration and can then be reused for all effect candidates visited by the search strategy. Let ̂| |, , ̂||,  and  ≡ ∑ ,  denote the empirical weighted mean, the empirical weighted standard 
deviation and the weights sum for ||. Identical to dissection strengths  (Eqn. II.4.2.1.a), let focus  denote the 
product effect focus of some effect candidate. Then ̂||, focus denotes the weighted mean of signal 
amplitudes in this focus, ̂||, focus is the weighted standard deviation of it and focus ≡ ∑ focus,  is its 
weights sum. As all weights are ∈0,1, each pixel can contribute at maximum 1 to this weights sum, i.e. no 
single independent measurement is allowed to count more than once. With the assumption of a constant 
global noise level, variances of both distributions can also be assumed equal. The  statistic for this comparison 
is now defined analogous to the unweighted two-sample -test for independent samples with equal variance(cf. 
[79], eqn. 8.11) by replacing sample counts with weight sums:  ≡   focus  2 
 ≡   1 ⋅ ̂||,    focus  1 ⋅ ̂||, focus   
 ≡ ̂||, focus  ̂| |,  
 1  1focus
 
Eqn. II.5.1.2.a)  statistic for the difference between the mean signal amplitude in the focus of an effect and the mean noise signal amplitude 
 
For signals stronger than noise, this  statistic for the effect is positive. To compute the  value for this 
statistic, the upper tail of the  distribution with  degrees of freedom is integrated(as implemented by the tcdf.m function of the 
MATLAB® Statistics Toolbox). This  value for an effect candidate or detected effect finally quantifies the significance of 
the observed signal strengths in the respective effect’s focus relative to the estimated noise level. 
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II.5.2 Significance of Observed Correlations 
Weighted correlations(cf. II.2.3.1) are utilized as base measure to detect interactions. For effect candidate 
qualification(cf. II.3.1.8) and to determine the effect focus(cf. II.3.2.2 and Eqn. II.3.1.4.b), significance estimates for these 
correlations are essential. 
II.5.2.1 Significance of weighted correlations 
 A -statistic based approximation 
In case of an unweighted Pearson correlation , a corresponding  statistic can be derived from a two-
dimensional normal distribution(see [93], section 12-8 for details). It is computed as   √ √1  ⁄ (see [93] eqn. 12-93 or [79] 
eqn. 11.20), where  is the number of degrees of freedom that equals the number of correlated points minus two. 
For interpretation,  values should quantify the probability to observe stronger correlations of the same sign 
due to chance. The corresponding one-tailed  value can be computed by integrating the  distribution with  
degrees of freedom in ,∞ (if   0) respectively in ∞,  (if   0). 
In the following, let | denote an observed gene vector from the contextual signal matrix, let |  be a sample 
effect axis to which it is correlated, let | denote sample weights of the contextual effect focus and finally let || be the weighted correlation(cf. II.2.3.1) for this gene with the effect axis. A  value for this correlation 
needs to be computed. (Obtaining  values for correlations of samples with effect gene axes is analogous.) 
By setting   ∑     2 and   || in the above formula for the  statistic, an approximation of  
values for weighted correlations can be obtained by assuming that the resulting statistic is distributed like a  
statistic with  degrees of freedom. Whether this approximation is well-defined, is tested next. 
 Comparison with null distribution based p values 
Similar to significance computation for signal strengths, random sampling techniques for the null 
distribution like permutation tests have the disadvantage to make the algorithm non-deterministic and 
relatively slow. Therefore, they cannot be utilized for practical purposes. However, they have the advantage 
to determine correct  values with ever higher precision over sample size of the null distribution, without 
needing to know its analytical form.  
To test the applicability of the above  statistic based approximation, I sampled the null distribution of 
weighted correlations and then compared  values obtained by both methods. 
One possibility to obtain a sampling of the null distribution is to randomly permute sample columns before 
computing gene correlations. Resulting weighted correlations represent correlations that could be explainable 
due to noise alone. A more direct approach is to simulate theoretically pure normal noise. (As correlations are 
scale invariant, the standard deviation of this noise signal can be chosen freely.) Then the same weighted 
correlations(cf. II.2.3.1) are computed with these simulated noise genes like before with the actually observed gene |, i.e. using the same effect axis | and the same weights |. The resulting sampling of the null distribution 
is utilized next to approximate the  value directly, as in permutation tests. More precisely, the  value for || is the ratio of stronger correlations in the null distribution (i.e. correlations that are nearer to +1 
respectively to -1, depending on the correlation sign). As correlations are signed, the minimal achievable  
value by this sampling method is 2 sampling	resolution⁄ . 
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A detection iteration of effect pattern #3 from a versatility test(II.6.2.1) has been selected for this 
comparison(Figure II.5.2.1). For all 1000 genes(upper panel) and for all 100 samples(lower panel),  values for their 
correlations to the respective effect axis in the effect focus have been computed by both methods. On the 
vertical axis,  values based on a null distribution with sampling resolution 1.000.000 are depicted. On the 
horizontal axis,  values are obtained via the approximate  statistic(see above). While  values based on the null 
distribution are truncated at 2 sampling	resolution⁄ , a nearly linear agreement above that resolution threshold 
provides confidence that the  statistic based approximation formula from unweighted correlations is still 
valid for weighted correlations. (No closed form of the precise analytical PDF for correlations using arbitrary 
weights seems to be known yet. A stochastical derivation of  values for weighted correlations could help to 
solidify this significance measure. Maybe it could be derived similar to the unweighted case(see [93], pages 188-199) 
under the null hypothesis of uncorrelated signals by introducing weights as another random variable that is 
constrained by a constant weights sum.) 
 
 
 
 
Figure II.5.2.1) Comparison of  value computation methods for weighted correlations  
For this comparison, genes and samples simulated for a versatility test(cf. II.6.2.1) are correlated with effect axes discovered for effect pattern #3. This pattern regulates 
200/1000 simulated genes and 50/100 samples.  
Non-deterministic  values based on a sampled null distribution (vertical axis, with sampling resolution 1.000.000) are compared to deterministic  values based on 
approximate  statistics as for weighted correlations. The former are truncated at 2 sampling	resolution⁄  (correlations are signed and  values are estimated 
separately for both tails; hence the factor two).  
Above this resolution threshold, both methods agree nearly linearly, which provides confidence that the  statistic formula from unweighted correlations is still 
applicable to weighted correlations. 
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II.5.2.2 Significance of all gene and sample correlations for an effect 
In the last section,  statistics and  values have been obtained for weighted correlations of each single gene  ≡  || to an effect’s sample axis | in its sample focus | . Likewise, correlations  ≡ |  and 
their significance for each single sample  are computed. For effect qualification(cf. II.3.1.8) these results need to be 
summarized in form of a scalar  value for all correlations.  
As confirmed by the sampled null distribution(cf. II.5.2.1), all corresponding   gene statistics approximately 
follow a  distribution with ∑     2 degrees of freedom and all   sample statistics follow a  distribution 
with ∑    2 degrees of freedom.  
If all observed ||  1 …  for genes or all observed | |  1 …  for samples are significantly higher 
than absolute values expected by the respective  distribution, then the effect is carried by significant 
correlations. This can be tested by two Kolmogorov-Smirnov tests in the gene respectively sample effect 
focus(cf. II.5.1.2), resulting in , for all gene correlations (that is for their || statistics) and in ,  for all 
sample correlations.  
Finally,  ≡ min, , , provides a scalar  value for all correlations with the current effect axes |, | and is tested for significance during effect qualification(cf. II.3.1.8). 
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II.6 Method Validation and Comparison 
To validate that the method is capable of dissecting signals into meaningful effects, several 
test scenarios have been designed. 
The main scenario tests the versatility of the method by simulating 13 different effects for 
randomly selected genes and patient. These effects comprise seven distinct patterns that 
imitate different real world gene expression effects of biological nature or lab effects(II.6.2). The 
second scenario tests the superposition limit of still dissectible overlapping effects for three 
different patterns(II.6.3). 
Finally, several detection limits are tested(II.6.4): the minimal signal strength relative to the 
noise level that is required for detection, the maximally tolerable ratio of missing values, the 
exclusion of false positives in the few samples limit and the exclusion of false positives in the 
many noise genes limit. 
II.6.1 3D Concept Example 
Before starting with high-dimensional effects, an overview of all results for the concept example is provided 
here. Principal components for the same signal are also provided for a comparison and to illustrate why they 
are hard to interpret in terms of original simulated effects. 
II.6.1.1 Overview of all dissection steps 
 
Figure II.6.1.1) 3D concept example, all detected gene curves, all dissection steps and the remaining signal 
Four simulated pathways corresponding to four distinct sample groups that are governed by different regulation laws for the same three genes have been 
simulated (cf. II.1.1). First the blue effect is detected, regressed and dissected. This is followed by the green, the red and the magenta effect. The remaining signal has a 
strength below the estimated noise level and hence signal dissection terminates after four iterations. (Details for all steps are explained in II.3, II.4 and II.5.) 
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II.6.1.2 Comparison with PCA 
 Principal Components Analysis Signal Dissection 
   
Figure II.6.1.2) 3D concept example, comparison of final detected gene curves and principal components 
 
Clearly, depicted principal components are not strongly correlated to any of the four simulated effect axes. 
Hence, no principal component represents a simulated law of gene co-regulation. Instead, all four effects have 
non-zero projections on all three principal components. Hence, every principal component (i.e. the new 
coordinate defined by it) represents a mixture (i.e. a linear combination) of four distinct effects. This is the 
reason, why these principal components are hard to interpret and not helpful when the goal is to discover new 
and distinct effects in an unknown signal. 
In contrast, signal dissection detects and regresses all four simulated (monotonically nonlinear) effects, i.e. 
empirically derives the original laws of gene co-regulation. Every effect is dissected iteratively(cf. Figure II.6.1.1) and 
its associated effect focus defines the samples in it, thereby effectively realizing a clustering of the signal, on 
top of explaining laws of gene regulation. 
The interpretability of a simulated effect based on detection results can be quantified by the best correlation 
of the simulated effect axis to any of the detected effect axes (respectively principal components). This can be 
used to illustrate the interpretability of method results for high-dimensional multi-effect signals, as is defined 
in II.6.2.3. 
 
 
 
 
 
II.6.1.3 Comparison with hierarchical clustering 
As it is used often for unsupervised effect discovery in biosciences(cf. I.2.2.1), results of hierarchical clustering 
for the 3D concept example are illustrated next. Hierarchical clustering can be configured with various 
distance metrics and linkage methods. First, results for the default Euclidean distance and for average linkage 
are demonstrated. In this case(cf. Figure II.6.1.3.a), most of the samples are grouped by a zero-centered large cluster, 
while tips of simulated effects are separated by several smaller clusters. 
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One conceptual problem of 
hierarchical clustering for this 
signal is its distance-based 
model for interactions: Points 
from different simulated 
effects are near to each other 
at the zero crossing, but points 
from opposite tips of the 
identical effect are geome-
trically far from each other. 
The correlation based 
distance (instead of the 
Euclidean distance) is a step 
towards solving this problem 
and results in a more balanced 
dendrogram, but it still cannot 
make out true simulated 
effects(cf. Figure II.6.1.3.b). 
Other linkage methods and 
distance metrics have been 
tested (data not shown); they 
lead to similar uninterpretable 
results for this signal. 
Another comparison with 
hierarchical clustering for 
high-dimensional data follows 
in II.6.2.6; all other com-
parisons are performed with 
PCA, as it seems to be  
the more powerful competitor 
compared to hierarchical 
clustering. 
 
 
   
Figure II.6.1.3.a) 3D concept example, results from 
hierarchical clustering (Euclidean distance metric, 
average linkage) 
 
 
 
   
Figure II.6.1.3.b) 3D concept example, results from 
hierarchical clustering (Correlation distance metric, 
average linkage) 
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II.6.2 Versatility 
The purpose of the versatility test is to challenge the method a wide variety of different effect forms that 
imitate different real world biological effects or lab effects. These effects may overlap each other. After defining 
simulated effect patterns, an exemplary run demonstrates how the method works for these high-dimensional 
signals. For method comparison, detection statistics are computed for signal dissection and for PCA. In 
addition, a brief comparison with hierarchical clustering is provided. 
II.6.2.1 Scenario definition and 7 distinct effect patterns 
A signal with   1000 genes and   100 
samples is simulated by superposition of seven 
effects and normal noise with standard deviation   0.5. 
The seven simulated effects differ in size, form 
and signal strength. For every effect, first genes 
and patients are randomly permuted. For 
predefined effect sizes (percentages), a bi-
monotonic signal has been generated at the top 
of these permutation orders, as depicted(cf. Figure 
II.6.2.1) (for other genes and samples, the simulated 
effect has zero eigensignal). 
To test the dissection of outshining broad and 
strong effects, pattern #1 mimics different 
experimental setups (e.g. the labeling protocol 
effect in GSE10846[5]). Due to its size, it is 
relatively easy to detect, but important to dissect 
without information loss. Pattern #2 simulates a 
strong binary cluster for only 10 measured 
genes; this is typical for, e.g., gender specific gene 
expressions. To test the detection of subclass-
only effects, pattern #3 simulates a broad biological effect that only exists in half of the samples. Pattern #4 
simulates a medium sized one-sided effect that is also typical for real-world biological effects. Pattern #5 
simulates a small gradual signal of medium strength. It is mainly a one-sided effect, but includes one anti-
correlated gene to test detection specificity. To test detection sensitivity with respect to noise, pattern #6 adds 
a weak effect that has a maximum absolute signal at the noise level and that gradually declines to zero. Finally, 
pattern #7 tests the sensitivity with respect to narrow effects by only affecting 5% of all simulated samples. 
The superposition of all seven effects in a common gene and patient reference order plus normal noise with 
standard deviation   0.5 serves as the input signal   for detection methods. The detection task is to recover 
simulated effect axes and depicted eigensignals for the respective random subsets of genes and samples.  
Besides this test scenario with 7 effects, and in order to increase detection and dissection difficulty, another 
larger versatility scenario is defined with 13 effects. To this end, the biologically most typical patterns #2, #3 
and #4 are simulated three times each (for different random permutations of all genes and all samples). 
 
Figure II.6.2.1) Versatility test, 7 simulated effect patterns and the superposed signal 
(a) Seven effects of depicted size and signal shape are simulated for randomly 
selected genes and samples. They are detailed in the text. Smaller effects are zoomed. 
(b) Superposed effects are depicted in a common reference order for all genes and 
samples, including simulated normal noise of standard deviation  ≡ 0.5. 
88 Chapter II - Signal Dissection 
 
II.6.2.2 A detection walkthrough for 1000 dimensions 
To illustrate how signal dissection works for high-dimensional signals, several detection and dissection 
iterations for the versatility test scenario with 7 effects are depicted and explained in this section. 
First, the large superposed lab effect #1 has to be dissected. Because of its dominant size (resulting in a 
dominant effect score; cf. II.3.1.6) it is always discovered first: 
 
Figure II.6.2.2.a) Versatility test with 7 effects, detection and dissection of the large overlapping lab effect (pattern #1, iteration   1) 
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Labels of top genes are depicted; each label lists all patterns that influence a particular gene. Plus and minus 
signs indicate whether they are co-regulated or anti-regulated by an effect. Clearly, genes that are correlated 
to the detected effect (“#1+”) are sorted to the top, while bottom ranks are exclusively occupied by genes that 
are anti-correlated to the effect (“#1-“). Final gene strengths ,   (center panel, green curve; cf. II.4.1.1) for this effect 
correctly reflect its linear gradual signal and sample effect strengths ,   (center panel, light orange curve) reflect the 
constant and strong signal in two different sample groups of size 2:1. Dissection of this effect results in a 
remaining signal(panel e) that is indistinguishable between those sample groups for strong effect strengths. 
Towards zero signal (and hence towards low correlation) a slight shadow remains due to decreasing 
dissection strengths(cf. II.4.2.1). This is intended, because in general this shadow could also be just ordered noise. 
And with dissection of partially correlated effects in mind, dissection should not extend into the uncorrelated 
regime(cf. II.4.2.2). 
Next, the remaining signal is screen for other simulated effects. Pattern #3 is detected at rank #2(cf. Figure II.6.2.2.b, 
page 90), because it has the next-highest effect score. (Genes and samples with very weak effect strengths are 
hidden from the plot to zoom on the effect.) The already explained and dissected signal from pattern #1 is 
presented in the eigenorder of the currently detected effect(panel b). Due to the first dissection iteration, the 
empirical signal of pattern #3(center panel) is much clearer than it was in the original signal(panel a). By virtue of low 
or zero dissection strengths(gray shading), its eigensignal(panel d) does not extend to samples that are not affected by 
this effect. Hence, in a real-world gene expression signal comprised of genetically heterogeneous samples, 
effects that are specific to only a subset of samples (e.g. to a yet unknown disease subtype) can also be detected 
and dissected. The signal of samples belonging to other subtypes does neither disturb this subtype-specific 
detection nor is it disturbed by subsequent dissection of this detected effect. This effectively allows a flexible 
detection of partly overlapping or partly hierarchical effects that may be shared by several but not necessarily 
by all samples. 
To demonstrate the specificity of the method, the small pattern #5 is depicted next(cf. Figure II.6.2.2.c, page 91). It 
simulates only one anti-regulated gene (of 1000 measured genes). This particular gene occupies the top rank 
of the detected empirical eigenorder. As the same gene was also regulated by effects #1 and #3 in this 
simulation(see its gene label), its correlation to other genes regulated by effect #5 is hardly visible in the original 
signal(panel a), but clearly revealed in the current signal(center panel). Detecting this single anti-regulated gene of 
pattern #5 is more difficult when many additional noise genes are simulated(cf. II.6.4.2). 
The pattern with the weakest simulated signal is detected last(cf. Figure II.6.2.2.d, page 92). Due to overlapping foreign 
effects, it is barely visible in the original signal(panel a), but still robustly detected(center panel). 
 
Detection and dissection iterations for patterns #2, #4 and #7 are similar. Definition plots and tables of all 
seven effects are available at  Method Validation\versatility7.single (nG=1000, nP=100)\sim 001\B=detected 
orders. 
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Figure II.6.2.2.b) Versatility test with 7 effects, detection and dissection of pattern #3 (in iteration   2) 
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Figure II.6.2.2.c) Versatility test with 7 effects, detection and dissection of pattern #5 (in iteration   6) 
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Figure II.6.2.2.d) Versatility test with 7 effects, detection and dissection of pattern #6 (in iteration   7) 
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II.6.2.3 Comparison of detected and true simulated effects and results 
To quantify detection quality and to facilitate a comparison with simulated effects, I utilize the same 
uncentered weighted correlations(cf. II.2.3.1) that were already used for effect detection. 
With a fair comparison to PCA results in mind, I correlate effect axes, i.e. the linear approximations of 
detected laws of gene regulation. They are directly comparable to principal components. Monotonically 
regressed effect curves may be more precise approximations of effects, but PCA has no analogue for a direct 
comparison. Likewise, PCA has no concept of an effect focus. Hence, the detected effect focus should not be 
used to define correlation weights as there is no analogue when testing PCA results. Instead, identical 
correlation weights should be used for both, i.e. for correlations of effect axes detected by signal dissection to 
simulated axes as well as for correlations of principal components to simulated axes. These correlations are 
defined below based on simulated and detected effect axes. As PCAs always return as many principal 
components as input dimensions (i.e. they do not determine the number of effects in the signal), only those 
principal components that show the best correlations with simulated effects are used for comparison. In case 
of signal dissection, always all detected effects are compared and displayed (even if they have only a weak 
correlation to all simulated effects). (This is a slight bonus for PCA in the presentation of comparison results.) 
Correlation weights should include all genes respectively samples that are strongly involved in the effect 
with full weight. They should exclude those with weak or zero regulation, because otherwise noise might make 
the correlation unspecific with respect to the tested effect. As the simulated gene axis |, of 
pattern  is known, it can be utilized to define full weights for all genes with  50% simulated  
signal strength  |,. Below this threshold, weights decrease linearly. (Formally, let  ,, ≡ |,  max  |,  denote relative signal strengths. Then |, ≡ ∑ min100%,  ,, 50%⁄   .) 
Let | denote the actual gene axis of the   detected effect (respectively principal component). The 
correlation should not only test the sensitivity of the redetection within the simulated focus |, . 
Correlations should also become weaker, if the detected effect axis | is strong outside of the simulated 
effect (i.e. if there are false positive genes). To this end, let |, denote analogously defined gene weights 
based on the detected gene axis |. Balanced weights |,  defined by the maxima  | ,  ≡max  |, ,  |, can finally be utilized to facilitate a both sensitive and specific correlation. (For 
example, if a gene has only 25% weight in |, because of a relatively weak simulated signal strength, but 
has a strong false positive signal in a detected effect, it will still be weighted with 100% in the comparison.) 
With these balanced weights, finally weighted correlations(cf. 
II.2.3.1) to quantify the rediscovery of simulated gene axes are 
computed. Analogously,  correlations between simulated and 
detected sample axes can be obtained. 
For the dissected simulation of the versatility test scenario 
presented in the last section, correlations between all simulated 
and all detected gene axes are depicted(cf. Figure II.6.2.3.a). These 
correlations demonstrate that each simulated effect has been 
redetected by exactly one detected effect with a correlation near 
one(red diagonal). No detected effect axis tries to explain parts of other 
effects(black off-diagonal pixels). (Results are depicted in best match order; 
the actual detection order of effects is shown by the respective 
values of  on the left of the matrix.) 
 , , , 	 , ,   
Eqn. II.6.2.3) Correlations of detected and simulated effect axes 
 ,,	, Simulated effect axes for pattern  
  , |  Detected effect axes for effect  
  , ,  ,  Balanced weights (see text above).  
 
Figure II.6.2.3.a) Versatility test with 7 effects, correlation of 
detected and simulated gene axes 
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Analogously and likewise, correlations  , | ,  compare 
simulated and detected sample axes(cf. Figure II.6.2.3.b). They are 
redetected with similar quality in this simulation. 
 
 
 
 
 
 
While correlations of effect axes are useful for 
comparison and validation, they summarize 
(re)detection quality by only one scalar per effect. To 
visualize the achievable detection quality with respect 
to the full signal caused by effects, all detected effect 
eigensignals are presented here(Figure II.6.2.3.c). They are not 
depicted in their respective detected eigenorder (where 
they are perfectly bimonotonic per construction), but in 
their true simulated eigenorder. Indeed, simulated 
gradual signals are retrieved with high similarity(cf. Figure 
II.6.2.1). Only for pattern #6 that has a true signal at or 
below the noise level, the reconstructed signal is 
relatively rough. This was expected, because this effect 
is nearly invisible in the original signal(cf. Figure II.6.2.2.d). Still, 
it was robustly detected. (The corresponding detection 
limit with respect to minimal signal strength relative to 
the noise level is analyzed in II.6.4.1.) 
Altogether, these results for the presented detection 
run(cf. II.6.2.2) already are a first validation of signal 
dissection against the versatility scenario. 
 
 
 
 
II.6.2.4 Comparison with PCA (versatility scenario with 7 effects) 
A more comprehensive validation for the small versatility scenario with 7 effects is presented in this section. 
Additionally, a first systematic comparison with PCA results is provided. 
To cover the randomness of effect simulation(cf. II.6.2.1), each scenario has been simulated 49 times (hence, 
results can be presented compactly as 7x7 block matrices). Each simulated signal has been dissected. Detected 
gene and sample axes are compared to simulated ones as explained(cf. II.6.2.3). 
 
Figure II.6.2.3.b) Versatility test with 7 effects, correlation of 
detected and simulated sample axes 
 
 
Figure II.6.2.3.c) Detected effect eigensignals in their true simulated 
eigenorder for the versatility test with 7 effects 
Eigensignals are bimonotonic per construction in their respective 
discovered empirical effect eigenorders. To visualize the compatibility of 
these empirical eigenorders with the actually simulated ones, regressed 
eigensignals are displayed here in the respective true effect eigenorders. 
(a) Empirically estimated eigenorders clearly reproduce all simulated 
large-scale signal differences of effects. However,  local gradual signals are 
not perfectly reproduced because of noise. (b) The remaining signal does 
not contain any true positive effects any more, as all 7 simulated effects 
have been detected and dissected. 
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Identical simulated signals have been passed to principal components analyses. Resulting gene axes(aka 
eigengenes in [68]; cf. I.2.2.2) and sample axes(aka eigenarrays in [68]) are likewise correlated to simulated effect axes(cf. II.6.2.3). 
For the 7-effect versatility test, results are summarized by the following block matrices. Each block 
corresponds to one simulation and shows correlations as before(cf. II.6.2.3). Blocks at the same position 
correspond to the same input signal; hence a direct visual comparison to results form PCA is possible. 
 Signal dissection, correlation of gene axes PCA, correlation of gene axes  
             
 
 Signal dissection, correlation of sample axes PCA, correlation of sample axes  
             
Figure II.6.2.4.a) Versatility test with 7 effects, 49 runs, correlations of effect axes and comparison of signal dissection with PCA 
 
While signal dissection results are precise and consistent, also PCA detects most effects reliably in this test 
scenario. 
Sometimes signal dissection finds more than 7 effects(e.g. row 6, column 7), i.e. the remaining signal is considered as 
noise later than the optimum. However, minimizing false negatives is a higher priority than minimizing false 
positives, especially with cross-cohort validation for real-world data in mind(cf. III.1.2). In case of PCA, always the 
top correlated principal components are displayed (from all  respectively  returned principal components), 
because PCA cannot determine the number of effects in the respective signal. 
Looking at details, principal components much more frequently mix two or more distinct simulated effects 
compared to signal dissection (as depicted by high correlations that are not on the diagonal). This problem 
gets more severe for more complex signals, as tested next. 
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II.6.2.5 Comparison with PCA (versatility scenario with 13 effects) 
To increase the detection and dissection difficulty, the same simulations and comparisons as presented in 
the last section are repeated for the versatility scenario with 13 effects(cf. II.6.2.1). 
While the quality of signal dissection stays approximately constant, PCA results are considerably less reliable 
for this more complex signal. In all simulations, several principal components represent mixtures (i.e. linear 
combinations) of more than one simulated effect. This is analogous to 3D examples before(see Figure II.6.1.2 and cf. Figure 
II.4.2.2.b). Supposedly, the higher rate of overlapping effects causes directions in gene space to show highest 
variance where effects overlap. Hence, principal components follow these directions instead of effect axes along 
which simulated laws of gene regulation really extend. This is the case for both gene axes(cf. Figure II.6.2.5.a, page 97) and 
for sample axes(cf. Figure II.6.2.5.b, page 98). 
To summarize and quantify these visual comparison results, two questions are tested: 
1) Does signal dissection show significantly higher correlation to the respective true simulated effect? 
2) Does signal dissection show significantly lower correlation to other effects? 
The first question effectively asks for a form of detection 
sensitivity, while the second asks for detection specificity. 
These questions can be answered with paired -tests for each 
simulated effect. Correlations to simulated axes(cf. Eqn. II.6.2.3) for 
signal dissection results and PCA results are compared (and 
paired by simulation runs, i.e. by identical input signals). For 
the first question, correlations of the best-matching effect axis 
(respectively principal component) with the respective 
simulated effect(as depicted by diagonal pixels in Figure II.6.2.5.a and Figure II.6.2.5.b) are 
compared between signal dissection and PCA over all 
simulation runs. For the second question, average correlations 
to all other simulated effects(as depicted by all non-diagonal pixels in the same 
column) are compared. Results for each simulated effect are listed 
to the right(cf. Table II.6.2.5). (For each question,  values for both 
methods add to one.) 
Due to its signal strength and size, pattern #1 defines a clear 
direction of maximal variance that coincides with its simulated 
effect axis. Hence, PCA is excellent at detecting this overlapping 
lab effect. For example, in all 49/49 simulations a principal 
component exits with a correlation  0.95 to the gene axis of 
pattern #1, while this in only the case in 37/49 simulations for 
signal dissection. However, both methods detect this strong 
effect with gene axes correlations  0.9 in all 49/49 
simulations.  
Additionally, PCA is better at detection of the weak signal 
pattern #6 (e.g. gene axes correlations are  0.8 in 38/49 runs 
for PCA, but only in 26/49 runs for signal dissection). Due to its 
weak signal relative to the noise level, neither method can 
 
Gene axes correlations 
sim. 
effect 
sim. 
pattern 
sensitivity 
(question 1) 
specificity 
(question 2) 
Sig. diss. PCA Sig. diss. PCA 
1 1 0.9963 0.0037 1.0000 7.2E-24 
2 2 1.6E-08 1.0000 2.8E-24 1.0000 
3 3 1.2E-12 1.0000 0.0029 0.9971 
4 4 3.8E-17 1.0000 9.5E-12 1.0000 
5 5 0.3803 0.6197 1.8E-17 1.0000 
6 6 0.9999 7.6E-05 7.6E-13 1.0000 
7 7 2.3E-09 1.0000 7.1E-10 1.0000 
8 2 2.4E-10 1.0000 3.2E-26 1.0000 
9 3 3.8E-12 1.0000 1.5E-05 1.0000 
10 4 1.5E-13 1.0000 1.6E-09 1.0000 
11 2 1.5E-08 1.0000 6.8E-22 1.0000 
12 3 4.7E-12 1.0000 0.0013 0.9987 
13 4 9.0E-17 1.0000 7.6E-24 1.0000 
Sample axes correlations 
sim. 
effect 
sim. 
pattern 
sensitivity 
(question 1) 
specificity 
(question 2) 
Sig. diss. PCA Sig. diss. PCA 
1 1 1.0000 1.9E-05 1.0000 1.1E-17 
2 2 3.6E-22 1.0000 1.0E-21 1.0000 
3 3 6.7E-18 1.0000 5.4E-05 0.9999 
4 4 1.7E-26 1.0000 2.8E-23 1.0000 
5 5 2.5E-15 1.0000 5.2E-16 1.0000 
6 6 0.3351 0.6649 1.8E-10 1.0000 
7 7 0.7967 0.2033 4.6E-17 1.0000 
8 2 1.3E-22 1.0000 3.4E-19 1.0000 
9 3 3.6E-15 1.0000 8.5E-07 1.0000 
10 4 3.1E-19 1.0000 1.3E-20 1.0000 
11 2 9.2E-23 1.0000 5.2E-19 1.0000 
12 3 2.5E-19 1.0000 2.6E-11 1.0000 
13 4 1.4E-27 1.0000 2.5E-18 1.0000 
 
Table II.6.2.5) Versatility test scenario with 13 effects, 49 runs, 
comparison between signal dissection and PCA results 
Based on depicted correlations between simulated and 
detected gene axes(cf. Figure II.6.2.5.a) respectively sample axes(cf. 
Figure II.6.2.5.b), signal dissection and PCA are compared. For 
detection sensitivity with respect to each simulated effect, 
correlations of the best-matching detected effect axis 
respectively of the best-matching principal component are 
compared over all 49 simulation runs (question 1). For 
detection specificity, average correlations of the same detected 
effect axis respectively principal component to all other 
simulated effects are compared (question 2). Both comparisons 
are realized by one-tailed paired -tests (paired by simulation 
runs, i.e. by identical input signal). 
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Signal dissection, correlation of gene axes 
 
PCA, correlation of gene axes 
 
Figure II.6.2.5.a) Versatility test with 13 effects, 49 runs, correlations of gene axes and comparison of signal dissection with PCA 
 
98 Chapter II - Signal Dissection 
 
Signal dissection, correlation of sample axes 
 
PCA, correlation of sample axes  
 
Figure II.6.2.5.b) Versatility test with 13 effects, 49 runs, correlations of sample axes and comparison of signal dissection with PCA 
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detect the original simulated gene axes with high precision (0/49 for correlations  0.95 for both methods). 
With respect to the narrow pattern #7, the correct 5% of samples influenced by this effect are detected by 
both methods with similar reliability (sample axes correlations  0.95 in 43/49 runs for signal dissection and 
in 42/49 runs for PCA). 
All other effects are detected significantly better by signal dissection. For example, all three simulated instances 
of the strong yet small signal pattern #2 are detected by PCA with correlations  0.8 only in 3/49, 1/49 
respectively 3/49 runs. Signal dissection detects the same effects in 45/49, 45/49 respectively 44/49 runs. 
For a correlation cutoff  0.95 still 30/49, 34/49 respectively 34/49 detections remain, while PCA detects zero 
effects of pattern #2 with this correlation. 
Additionally, PCA results for most effects are significantly less specific, as principal components are also 
correlated with several other effects instead of exclusively with their best-matching simulated effect(cf. p values on 
the right side in Table II.6.2.5). I.e. effects cannot be cleanly dissected in coordinates of these principal components(visible by 
off-diagonal correlations in Figure II.6.2.5.a and Figure II.6.2.5.b). 
 
In brief, these results thoroughly validate signal dissection against the 13-effect versatility test. PCA returns 
for identical input signals comparably unreliable and hard to interpret results. 
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II.6.2.6 Comparison with hierarchical clustering 
To compare with hierarchical clustering, it has been applied to the versatility simulation with 7 effects that 
has been presented and dissected in II.6.2.2. Based on 3D results for hierarchical clustering(cf. II.6.1.3) and its 
typical configuration for gene expression signals(cf. I.2.2.1), the correlation distance is chosen (with average 
linking). 
As expected, the distance metric is dominated by the overlapping strong lab effect (pattern #1) and resulting 
dendrograms organize genes and samples accordingly(cf. Figure II.6.2.6). Hence, pattern #1 can be considered 
detected. As discussed for method design goals(cf. II.1.2), the overlapping effect dominates the clustering and 
cannot be removed by hierarchical clustering as a matter of method concept. Hence, all other effects are split 
by this independent lab effect. 
Additionally, they split each 
other into sub clusters, if they 
overlap. This is visible in form 
of red or blue “blocks”. Genes 
belonging to the same 
simulated effect are clustered 
together in these blocks, but 
only in a fragmented form. 
In practice, it may be possible 
to manually focus on sub 
clusters in the gene dendro-
gram and then apply hierar-
chical clustering recursively in 
order to obtain a sample 
clustering for each gene sub 
cluster(cf. II.1.2.2). But this leads to 
hard-to-compare results, as the 
manual or visual determination 
of gene sub clusters is often 
difficult to reproduce. 
As hierarchical clustering has 
no concept of gene or sample 
axes, it cannot be compared 
directly and systematically with 
signal dissection as is possible 
for PCA. Therefore and because 
PCA is conceptually more 
competitive, all subsequent test 
scenarios are compared with 
PCA only. 
Figure II.6.2.6) Versatility test with 7 effects, results from hierarchical clustering (corr. distance, average linking) 
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II.6.3 Superposition Depth 
Besides a versatile detection of effects, dissection should work even if the same genes and samples are 
affected by multiple superposed effects.  
Using the same size of the signal matrix as in the versatility scenario (1000 genes, 100 samples), this is tested 
here by simulating one to 20 instances of effects of the same form (either pattern #3, pattern #4 or pattern #6 
from the versatility scenario; cf. II.6.2.1).  
For higher superposition depths, all genes or samples are regulated by multiple simulated effects eventually. 
This stresses dissection. These scenarios also stress the estimation of the true noise level(cf. II.5.1.1), because 
initially the signal standard deviation is much higher than the actual noise level. 
Results from signal dissection and from PCA are again correlated to all simulated gene and sample axes and 
are depicted as before(e.g. Figure II.6.2.5.a).  
Interestingly, PCA fails completely for these superposition scenarios, even for relatively few superposed effects. 
This can possibly be explained by PCA’s model for interactions again, namely that it searches and computes 
directions of maximal variance. Maximal variance is found where signals of effects overlap constructively. 
Hence, these directions of maximal overlapping are returned by PCA (rather than simulated effect axes). 
Additionally, no variance difference due to different effect sizes exits any longer compared to the versatility 
scenario. Given that in real-world gene expression signals effects of similar size are common, PCA’s inability 
to deal with these scenarios is this is a major disadvantage with biological interpretability of discovered gene 
expression effects in mind. 
 
II.6.3.1 Results and comparison with PCA for one to 20 times pattern #3 
Results from signal dissection and PCA for simulated signals comprised of one to 20 times pattern #3 are 
presented(cf. Figure II.6.2.1). The same noise level as for the versatility scenario is simulated (  0.5). 
While signal dissection detects precise and highly correlated effect axes for all simulated effects in all 
simulations, PCA fails to provide interpretable results in any simulation except for the single-effect 
signal(cf. Figure II.6.3.1.a and Figure II.6.3.1.b). 
For higher superposition depths, signal dissection often detects more effects than simulated. These are 
either false positives (if they are correlated to no simulated effect) or duplicates. The reason for the former is 
that the true noise level is hard to estimate for busy signals with many overlapping true positive effects. 
Besides, it is typically more useful to accept few false positives rather than accepting false negatives, because 
false positives can be sorted out in real-world scenarios via cross-cohort validation later(cf. III.1.2). PCA does not 
provide any noise estimate and always returns as many principal components as input dimensions (including 
many false positive axes). Only top correlated principal components are selected and depicted. 
The high overlapping rate causes correlations to degrade, resulting lower dissection strengths(cf. II.4.2.1). Hence, 
only effect genes with relatively low overlapping grade are dissected first. The remaining parts of the same 
effect are detected and dissected in later iterations, after overlapping and disturbing signals from other effects 
have been dissected, i.e. after the signal has been “cleaned”. This is visible as duplicate detections. These 
duplicates could be easily identified and merged via post-processing, as their detected effect axes are highly 
correlated. Hence, duplicate detections are preferable over overoptimistic dissection strengths that might 
result in larger detected effects that represent mixtures of overlapping simulated effects. 
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Signal dissection, correlation of gene axes 
 
 
PCA, correlation of gene axes 
 
Figure II.6.3.1.a) Superposition tests based on pattern #3, 1 to 20 instances, correlations of gene axes and comparison of signal dissection with PCA 
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Signal dissection, correlation of sample axes(landscape view) 
 
 
PCA, correlation of sample axes(landscape view) 
 
Figure II.6.3.1.b) Superposition tests based on pattern #3, 1 to 20 instances, correlations of sample axes and comparison of signal dissection with PCA 
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To demonstrate the grade of overlapping up to which effects are detected here, the following figure shows 
the detection of the 19th instance of pattern #3 (detected in iteration   20). Gene labels at the top and bottom 
list all effects that regulate these genes simultaneously in the original signal. Subtracting already detected 
effects(panel b) reveals the cleaned effect (as depicted in its discovered eigenorder in the center panel). 
 
Figure II.6.3.1.c) Superposition test based on pattern #3, dissection of the signal with 20 superposed effect instances,  detection iteration 20 
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II.6.3.2 Results and comparison with PCA for one to 20 times pattern #4 
In the last section, the two-sided effect pattern #3 (having both correlated and anti-correlated genes) has 
been simulated and dissected. To demonstrate that this still works for one-sided effects (that regulate all genes 
in the same direction and have no anti-correlated genes), the superposition test has been repeated with effect 
pattern #4(cf. Figure II.6.2.1). 
Correlations of detected and simulated gene axes(cf. Figure II.6.3.2.a) again show that signal dissection reliably 
discovers simulated effects in most simulations, while PCA cannot compete. Exceptions are signals with four 
or less effects as explained below. (Correlations for sample axes are similar. Corresponding plots are available 
at  Method Validation\depthTest.pat4 (nG=1000, nP=100), together with all other effect dissection plots for 
each simulation of this test scenario.) 
Superposing many effects of this one-sided pattern accumulates a global nonzero offset. I purposely keep it 
in the signal for additional difficulty and to test how the method can handle it. From five effect instances 
onwards, the first detected effect represents the combined global offset(gray rows). After dissecting it, all simulated 
effects are detected with high correlation(red pixels). Hence, signal dissection realizes a signal normalization on 
the fly by dissecting an offset effect. A depicted example(cf. Figure II.6.3.2.b) shows that top genes of this offset effect 
are the most-overlapped genes, as expected. For only three or four instances of #4 in the simulated signal 
however, there is an ambiguity. Does the emerging constructive global offset already have higher (uncentered) 
correlation or still any single simulated effect? For this ambiguity, the method is as unsuitable as PCA for three 
or four instances of the effect. Hence typical normalization steps (e.g. subtracting the median expression per 
gene) should not be omitted in general. 
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Signal dissection, correlation of gene axes 
 
PCA, correlation of gene axes 
 
Figure II.6.3.2.a) Superposition tests based on pattern #4, 1 to 20 instances, correlations of gene axes and comparison of signal dissection with PCA 
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Figure II.6.3.2.b) Superposition tests based on pattern #4, 20 instances, detection and dissection of the accumulated offset effect 
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II.6.3.3 Results and comparison with PCA for one to 20 times pattern #6 
To approach the limits of signal dissection, the superposition scenario has been repeated with pattern #6, 
i.e. with effects that have a signal at or below the simulated noise level everywhere. This signal is gradual and 
linearly decreases from top regulated genes respectively samples to zero(cf. Figure II.6.2.1). 
Here, signal dissection can no longer reliably dissect all simulated effects. Like for the other superposition 
tests before, PCA cannot compete.  
(Results are displayed for gene axes correlations only; sample axes correlations are comparable and can be 
found at  Method Validation\depthTest.pat6 (nG=1000, nP=100). All other effect dissection plots for each 
simulation of this test scenario are provided in subfolders.) 
Detection limits are investigated more systematically in the next section. 
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Signal dissection, correlation of gene axes 
 
PCA, correlation of gene axes  
 
Figure II.6.3.3) Superposition tests based on pattern #6, 1 to 20 instances, correlations of gene axes and comparison of signal dissection with PCA 
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II.6.4 Detection Limits 
To systematically test detection limits of signal dissection, several specialized test scenarios have been 
devised. Again, PCA results for each scenario are provided for comparison. 
II.6.4.1 Weak signals 
To quantify the detection limit with respect to signal strength, signals are simulated that contain a single 
effect of decreasing signal strength relative to the constant simulated noise level . Only a single effect is 
simulated per signal matrix (still of size 1000 genes and 100 samples). 
First, effects of the same shape as pattern #6 are simulated. In the versatility test, this pattern has the 
weakest signal of all effects. More precisely, its absolute signal equals 1 for its top regulated genes and 
samples and then decreases linearly to zero(cf. Figure II.6.2.1). Below, this shape is simulated 100 times with 
decreasing top signal strength, as indicated in units of the simulated noise level (horizontal axis). 
Signal dissection, correlation of gene axes  
Signal dissection, correlation of sample axes  
 
Figure II.6.4.1.a) Detection limit with respect to signal strength, effect pattern #6, signal dissection results 
 
Signal dissection detects the effect down to approximately 0.5. Below that, more often than not signal 
dissection terminates without any detected effect. 
It is possible to extend this limit by increasing the significance threshold for effect signal strengths(cf. Table II.3.1.8). 
However, this would not only result in detections of the simulated effect but also of many noise effects (i.e. 
false positives). 
Already before 0.5 , correlations of detected axes to true simulated axes break down. Hence, the detection 
limit for practice is approximately 0.75, because in practice not just a detection is required but also a high 
correlation to true effect axes for interpretability. 
Hence, the chosen significance threshold has been configured as intended, as it enables detection of true 
positives as long as effect axes may be determined with sufficient correlation, but stops short before accepting 
many false positives. 
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PCA has no concept of noise estimation and does not determine the number of effects in the signal. Instead, 
it always returns as many principal components as input dimensions. In the following comparison, always the 
principal component with maximal variance is selected and its correlation with the respective simulated effect 
axis is depicted. 
Because simulated signals only contain one true positive effect in this test scenario, axes of maximal variance 
and simulated effect axes would coincide, if there was no noise. Hence, these PCA results can be seen as the 
empirical optimum for this scenario. Indeed, correlations are higher than for signal dissection, although 
differences become negligible for higher signal strengths. 
PCA, correlation of gene axes  
PCA, correlation of sample axes  
 
Figure II.6.4.1.b) Detection limit with respect to signal strength, effect pattern #6, PCA results 
 
 
 
 
 
The same test has been repeated for effects shaped like pattern #3 in the versatility test, i.e. a two-sided 
signal that starts at a nonzero offset(cf. Figure II.6.2.1). As this effect only affects 50% of simulated samples, 
correlations to its effect axes decrease faster with the simulated signal strength as for the pattern tested above. 
Hence, also the onset of missing detections is reached earlier at approximately 0.75 . As before, PCA shows 
higher correlations and the correlation breakdown is prolonged to weaker signal strengths. Again, correlation 
differences become negligible for stronger signals. 
Signal dissection, correlation of gene axes  
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Signal dissection, correlation of sample axes  
 
PCA, correlation of gene axes  
  
PCA, correlation of sample axes  
 
Figure II.6.4.1.c) Detection limit with respect to signal strength, effect pattern #3, signal dissection and PCA results 
 
 
II.6.4.2 Many noise genes 
Besides finding true positives and preventing false positives in the limit of weak signals, the same goals need 
to be targeted in the limit of many noise genes. 
Discovering small true effects that exist only in few of all measured genes is demanding. For example, a small 
effect with a moderate signal strength for e.g. 10 genes may be robustly detectible without inviting any false 
positives in a measured signal matrix of 1000 genes. If the same effect was embedded in a signal matrix of 
20000 measured genes, it may still be detectible using constant significance thresholds, but at the cost of also 
detecting many false positives due to multiple hypothesis testing and due to more possibilities for 10 genes to 
be correlated by chance. To correct for that, significance thresholds are defined adaptively to the signal size 
using Bonferroni corrections(cf. II.3.1.8). 
To investigate this limit and to test these adaptive significance thresholds, the versatility scenario with 7 
effects (that is simulated for 1000 genes and 100 samples as before) is now embedded in a larger signal matrix. 
More precisely, noise genes are appended, i.e. genes that are affected by the same global noise level, but that 
are not regulated by any of the simulated effects. Starting with the unchanged versatility scenario, noise genes 
are added in steps of 2000 up to a signal size with 55000 simulated genes. 
Results are depicted for gene axes correlations(cf. Figure II.6.4.2.a). Sample axes correlation are comparable and are 
available in  Method Validation\versatility7.overNoiseGenes (nP=100). All detected effects by signal 
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dissection are depicted, including false positives. As PCA has no concept of noise estimation, its seven 
top correlated principal components for the respective simulation are selected and depicted for comparison. 
Signal dissection, correlation of gene axes 
 
PCA, correlation of gene axes  
 
Figure II.6.4.2.a) Versatility test with 7 effects, 1000…55000 genes, correlations of gene axes and comparison of signal dissection with PCA 
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 Comparison with PCA for each simulated pattern 
For zero added noise genes, signal dissection and PCA have already been systematically compared(cf. II.6.2.4 and 
II.6.2.5). Results are similar for relatively few added noise genes, i.e. both signal dissection and PCA discover all 
seven simulated effects with high correlation in most simulations. Differences in the context of many noise 
genes are discussed below for each simulated pattern(cf. Figure II.6.2.1). 
Pattern #1: As expected and due to its size, pattern #1 is detected reliably in all simulations with high 
correlation by both methods. 
Pattern #2: The strong but small pattern #2 is reliably detected by signal dissection. Likewise, PCA always 
returns a principal component with high correlation to this effect’s gene axis. But often this principal 
component is not specific. This can be seen by its simultaneous correlation to either pattern #3 or 
pattern #4(two red pixels in column 2).  
Pattern #3: Like pattern #2, this effect is reliably and specifically detected by signal dissection, while top-
correlated principle components often mix it with pattern #2 or pattern #4. Hence, underlying laws of gene 
regulation are hard to interpret, again. 
Pattern #4: (Like patterns #2 und #3.) 
Pattern #5: For the narrow pattern #5 the difference between the two methods is striking. While signal 
dissection discovers this effect reliably even for highest amounts of noise genes, PCA returns unreliable 
correlations from 12000 noise genes onwards and does not detect this effect at all for 26000 noise genes 
onwards. This effect is only comprised of 19 correlated and 1 anti-correlated genes. Probably this effect is too 
small to detect it without adaptive effect focusing in a sea of noise genes. 
Pattern #6: While pattern #5 was hard to detect in context of many noise genes due to its small size, pattern 
#6 is hard to detect due to its weak signal strength. For 10000 noise genes and lower, both methods still detect 
it reliably, albeit with weakening correlation. While signal dissection detects it in approximately every second 
simulation even for highest numbers of simulated noise genes, PCA fails to discover it from approximately 
22000 noise genes onwards.  
Pattern #7: From 16000 added noise genes onwards, signal dissection does not discover the narrow-shaped 
effect pattern #7 reliably. Either it is not detected at all or with low gene axis correlation to the simulated effect 
and with unspecific correlations to other effects. Likewise, PCA cannot always discover this effect and often 
discovers it with only moderate correlation(light red or gray in column 7), but tends to be more specific for this pattern 
(i.e. corresponding principle components have less correlation to other effects). 
 
 Dilution of top genes by noise genes 
Lower correlations between gene axes correspond to higher dilution of top genes by noise genes. This 
dilution can be observed especially for the weak-signal pattern #6 and for the narrow pattern #7. Increasing 
dilution by false positives generally causes increasing difficulty for effect interpretation. Unfortunately, these 
false positives top genes cannot be circumvented, as they have signal properties equal to true positives.  
Especially for pattern #7 that only regulates 5/100 simulated samples, it is relatively easy to simulate noise 
genes that are correlated by chance. These false positives with high correlation to true positives naturally 
become more frequent if more noise genes are simulated. An exemplary discovery of pattern #7(cf. Figure II.6.4.2.b) 
illustrates this problem. While top ranks at the bottom are occupied by true positives(non-black signal in panel b), all 
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other genes are actually ordered noise. All are correlated to true positive genes for the correctly focused 5/100 
samples: 
 
Figure II.6.4.2.b) Detection of the narrow pattern #7 with many false positive genes (in a versatility test with 7 effects embedded in a noise signal with 39000 genes) 
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 Specific discovery of small effects despite many present noise genes 
The most striking difference between signal 
dissection and PCA in the current scenario has been 
observed for the small pattern #5, as explained 
above. PCA is unable to detect it in the presence of 
many noise genes, probably because PCA lacks a 
concept for adaptive effect focusing. As small 
biological effects measured by large whole genome 
microarrays are typical, this is a major drawback 
of PCA. 
An exemplary discovery (cf. Figure II.6.4.2.c) of pattern #5 
demonstrates the accuracy of signal dissection and 
effect focusing in context of many noise genes: Only 
19 correlated and one anti-correlated true positive 
genes exist in this simulated signal of 55000 genes. 
This signal size is typical when measuring gene 
expressions on probeset level(cf. III.1.1.1). While again 
several false positives(black in panel b) are correlated to 
the empirically derived effect axes, all 20 true 
positives are discovered(see gene labels). Furthermore, 
they occupy top ranks in this effect without 
interruption by any false positives. Especially the 
fact that the solitary anti-correlated true positive 
gene has higher effect strength than all false 
positives was unexpected, as pattern #5 has only 
moderate signal strength and only affects 50% of all 
simulated samples. Additionally, this gene was 
overlapped by patterns #1 and #6 in the depicted 
simulation. Hence, its obvious signal correlation in 
the center panel is barely visible in the original 
signal(panel a). 
 
 
 A false positive example 
An exemplary false positive discovery(cf. Figure II.6.4.2.d) 
shows significant signal strength as well as 
significant correlations. This is expected, as it passed 
effect qualification(cf. II.3.1.8). In fact, its original signal 
in the empirically discovered eigenorder looks like a 
solid true positive effect. Typically however, such 
false positives are relatively small, either with 
respect to the number of involved genes or with 
respect to the number of involved samples.  
Figure II.6.4.2.c) Versatility test with 7 effects embedded in a noise signal with 55000 
genes, detection and dissection of the small pattern #5 
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However, “small” has 
to be understood 
relative to the size of 
the input signal. Hence, 
very large input signals 
may produce larger 
and more frequent 
false positive effects.  
This is also the 
reason, why effect size 
cutoffs used for effect 
validation have been 
defined adaptively to 
the size of the input 
signal(cf. II.3.1.8). 
Naturally, it is in-
creasingly harder for 
such strong and 
correlated signals to 
emerge from pure 
noise for many genes 
and many samples. 
Hence, they could be 
easily excluded by 
sufficiently high effect 
size qualification 
thresholds. Still, this is 
a tradeoff, as too high 
thresholds would also 
exclude small true 
positives. 
 
 
 
 
 
 
 
 
 
 
Figure II.6.4.2.d) Example of a false positive discovery (from a versatility test embedded in a noise signal with 51000 genes) 
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II.6.4.3 Few samples 
Related to the problem of false positives due to many noise genes(cf. previous section), false positives may also 
emerge in the limit of few samples. In this limit, genes have a higher chance to be correlated to each other by 
pure chance. This is similar to false positive genes for narrow effect foci within larger signals(cf. Figure II.6.4.2.b).  
To systematically test the detection performance over the number of available samples, the versatility 
scenario(cf. Figure II.6.2.1) has been simulated for 20 to 2000 samples (and again 1000 genes). Detection results and 
the comparison to PCA results are shown below(cf. Figure II.6.4.3.a). As expected, both methods return more reliable 
and more robust results for high sample counts. Consistent with previous simulations(cf. Table II.6.2.5), the weak 
signal pattern #6 was missed by signal dissection for simulations with 766 and 1363 samples, but not so 
by PCA. 
For only 20 samples, the small or weak patterns #5, #6 and #7 are no longer detected by signal dissection. 
It is possible to detect them with lower significance thresholds for effect qualification, but this would invite 
unwanted false positives. The simulation for 52 samples demonstrates that the chosen configuration(cf. II.3.1.8) is 
already near the onset of many false positives and should not be lowered much more. PCA still computes 
principal components that are weakly correlated to patterns #5 respectively #7 for the same 20 samples 
signal. However, as PCA does neither determine the noise level nor the number of effects in the signal, depicted 
seven top principal components are not comparable in terms of false positives and detection thresholds. 
To illustrate the problem of false positive genes in detected effects for in the few samples limit, the detection 
iteration for pattern #4 is depicted(cf. Figure II.6.4.3.b, page 120). While top-correlated genes at the bottom are true 
positives, all anti-correlated genes at the top and several correlated genes in the middle are false positives(cf. gene 
labels). Results are comparable to false positive genes in the many noise genes limit(e.g. Figure II.6.4.2.c). 
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Signal dissection, correlation of gene axes 
 
 
PCA, correlation of gene axes  
 
Figure II.6.4.3.a) Versatility test with 7 effects, 20…2000 samples, correlations of gene axes and comparison of signal dissection with PCA 
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Figure II.6.4.3.b) Versatility test with 7 effects simulated for only 20 samples, detection and dissection of pattern #4 with several false positive genes 
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II.6.4.4 Missing values and their imputation 
An important consideration for practical applications is often that measurement devices do not yield reliable 
results for some probes. For example, 5% of all measured sequences on a microarray may be not be readable 
or fail in QC checks. In this case, still 95% are available per sample, but only the intersection, i.e. typically 
considerably less information is be available with robust readouts for all samples. Hence, analysis methods 
that can handle missing values are needed to make use of all non-missing information. 
PCA does not support missing values and hence is not compared with signal dissection in this context. In 
general, an external imputation method for missing values might be utilized to make signals with missing 
values compatible to PCA. However, global imputation methods (e.g. replacing missing values by zero) might 
introduce a bias to results. 
Correlations underlying signal dissection are weighted(cf. II.2.3.1) and thus natively support missing values: they 
are treated identically to non-missing values with zero weight. For example, expressions from genes outside 
of the effect focus have zero weight and are commonplace for signal dissection already. Furthermore, 
bimonotonic regression(cf. II.4.1.3) is weighted as well and thus supports missing values, too. This regression also 
effectively imputes missing values from neighboring values in the empirical effect eigenorder(cf. II.4.1.2). Hence, this 
imputation is dependent on the local effect context and thus does not introduce any bias. In this way, imputed 
values are effectively inferred from correlations in the non-missing signal. In principle, this might also be used 
to predict missing signals. 
 
To quantify detection performance over missing values, the versatility scenario(cf. Figure II.6.2.1) is simulated in its 
usual size (i.e. for 1000 genes and 100 samples), but simulated (gene, sample) pixels are deleted in steps of 
5% from 0% to 100%. Detection results show(cf. Figure II.6.4.4.a) that the strong effect pattern #1 is reliably detected 
even up to 90% missing values. For smaller effects, not enough information is left at such high rates of missing 
values and thus they cannot be detected. Unexpectedly, all effect patterns are detected for up to 35% of missing 
values. As expected, the weak signal pattern #6 is lost to missing values first (from a rate of 40% onwards). 
Effect patterns #2, #3 and #4 that imitate typical biological gene expression effects are detected for up to 80% 
of missing values, again more than expected. The narrow pattern #7 is detected for up to 75% missing values 
and the small pattern #5 up to approximately 55%. 
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Signal dissection, correlation of gene axes 
 
 
Signal dissection, correlation of sample axes 
 
Figure II.6.4.4.a) Versatility test with 7 effects, 0%…100% missing values, correlations of detected gene and sample axes with simulated ones 
 
To demonstrate the imputation of effect signals, a detection and dissection of pattern #3 in context of 80% 
missing values is presented next(Figure II.6.4.4.b). Despite only relatively few remaining information, the effect is 
reliably detected with high correlation the simulated law of gene regulation(see the block for 80% NaNs in Figure II.6.4.4.a). 
Consistently, top and bottom genes in the definition plot are all labelled by “#3+” respectively “#3-“, indicating 
that they are regulated by the simulated pattern #3. Despite the high rate of missing values, still no dilution by 
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false positive genes is visible for top correlated ranks. However, the eigensignal(panel d) does not have sharp 
borders towards the center, as would be normal for this pattern if no values were missing(cf. Figure II.6.2.2.d). 
 
Figure II.6.4.4.b) Detection of effect pattern #3 for the versatility test with 7 effects and 80% missing values 
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Comparison of all simulated effects(cf. Figure II.6.4.4.c) 
with discovered and recovered eigensignals(cf. Figure 
II.6.4.4.d) shows that imputed values can predict many 
missing value correctly. However and as expected 
due to 80% missing values and due to simulated 
measurement noise, this signal reconstruction is 
not perfect. Still, it is not as worse relative to the 
same test without missing values(cf. Figure II.6.2.3.c) as 
could have been expected for 80% missing values. 
Additionally, neither global imputation methods 
nor imputation methods using a neighborhood 
concept (based on gene and sample reference 
orders) could have predicted such consistent 
expressions with simulated effects, as these 
methods do not have any knowledge of actual 
effects or correlations in the signal. 
 
Figure II.6.4.4.c) Versatility test with 80% missing values 
Simulation of a versatility scenario with 7 effects for 1000 genes and 100 samples. 
(a) Seven effects of depicted size and signal shape are simulated for randomly se-
lected genes and samples as before (cf. II.6.2.1).  (b) Superposed effects are 
depicted in a common reference order, including simulated noise ( ≡ 0.5).  80% 
of all (gene, sample) pixels were randomly selected and their signal was deleted. 
 
Figure II.6.4.4.d) Imputed eigensignals (versatility test, 80% missing values) 
(a) 5/7 simulated effects are detected, despite 80% missing values. Originally 
simulated effect signals are imputed for missing values. The detected eigensignal 
for pattern #3 in its empirically determined eigenorder is depicted in Figure 
II.6.4.4.b, for example. 
(b) The remaining signal still contains the simulated signals (as depicted in Figure 
II.6.4.4.c above) for the small pattern #5 and for the weak-signal effect #6. 
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Based on human whole genome profiling, gene expressions of 
more than 1000 patient samples of Diffuse Large B-Cell 
Lymphoma are dissected for four independent patient cohorts. 
Cross-cohort validation yields 135 GEP effects. Each effect can 
distinguish between patients by significantly differentially 
expressed genes. To illuminate their biological nature, all are 
systematically associated with clinical and genomic knowledge. 
The cell of origin(COO) effect that can distinguish between known DLBCL 
subtypes is rediscovered and redefined in a filtered form. A novel and 
genetically distinct effect is discovered that can predict DLBCL patient 
outcome more consistently compared to the COO effect. Multivariate 
survival analyses reveal novel hierarchical survival dependencies. 
Additionally, a combination of five GEP effects can predict strong and 
significant survival differences even within known subtypes and within 
clinical risk classes by international prognostic index. 
 MIC 0.a KÜ 
 MIC 1.a KÜ 
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III.1 Application to DLBCL 
Gene expression microarray measurements for samples from four DLBCL patient cohorts 
have been obtained via NCBI GEO[94]. Signal dissection(Chapter II) is independently applied to each 
cohort. Single cohorts may contain lab effects, for example caused by different experimental 
labelling protocols. Only effects representing molecular mechanisms in cells are of interest 
here and, therefore, effects are validated across cohorts to filter out non-biological effects. 
Gene axes of validated effects that were discovered in multiple cohorts are then combined to 
form consensus gene axes that represent detected effects in their most general and cohort-
independent form. Application of these consensus gene axes yields corresponding consensus 
sample axes that arrange patients according to an effect’s impact on them. This could also be 
utilized to classify patients in future DLBCL cohorts that were not used for effect detection. 
Backed by successful method validation(II.6), resulting 135 validated effects are expected to 
represent specific interactions in measured cells that are biologically comprehensible. 
Comprehensive biostatistical analyses have been computed for each validated effect 
(available via  DLBCL Master Table 2015, main overview.xlsx). In subsequent subchapters, 
these effects are systematically associated with patient survival(III.2) and top effects are 
biostatistically evaluated in detail(III.3). 
III.1.1 Detection in Single Patient Cohorts 
The dissection algorithm presented in Chapter II is applied to gene expression signals from four cohorts of 
DLBCL patients. Identical detection settings(e.g. qualification thresholds; cf. II.3.1.8) that were used for method validation(II.6) 
are now applied for dissection of these real world signals. 
III.1.1.1 Available gene expressions cohorts 
Gene expression microarrays for the following four cohorts and samples have been obtained via NCBI 
GEO[94]: 181 samples from GSE10846.CHOP[5], 166 from GSE4475.CHOP[95], 233 from GSE10846.R-CHOP[5] and 
498 from GSE31312.R-CHOP[29]. (With clinical analyses and validation in mind, GSE10846 has been split in 
two sub cohorts by the applied chemotherapy(cf. I.1.2.1).) 
All GEP measurements took place before start of therapy. GSE31312.R-CHOP is based on formalin-fixed, 
paraffin-embedded tissue (FFPE), while all other cohorts measure fresh frozen cell material from patients. 
Generally, gene expressions of FFPE material tend to be noisier because of mRNA degrading effects[96]. 
However, with clinical applications in mind, discovered effects should be robustly identifiable for FFPE based 
samples as well, as no freezing of patient cell material is available for routine clinical work due to cost and 
infrastructure reasons. Indeed, all relevant GEP effects discovered by this work exist and validate in this FFPE 
based cohort. One particularly important survival effect has even been discovered based on this cohort. This 
also indirectly confirms that HighPure Paraffin RNA Extraction Kits(Roche Diagnostics, Basle, Switzerland) utilized for 
measuring GSE31312 have worked reliably. 
Cohorts GSE10846 and GSE31312 were measured with GeneChip® Human Genome U133 Plus 2.0 
microarrays (Affymetrix Inc., Santa Clara, California, United States) and GSE4475 with former GeneChip® 
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Human Genome U133A microarrays. These microarrays are based on probesets that quantify mRNA 
concentration for genomic clusters. U133 Plus 2.0 arrays contain 54675 probesets for coding and non-coding 
mRNA sequences, U133A arrays contain a subset of 22283 probesets thereof. Annotations of probeset 
sequences with 21686 unique human genes are provided by the manufacturer (NetAffxTM,[97] v33). In general, 
analyzing gene expressions on the probeset level is more specific than analyzing on aggregated gene level. 
Hence, all dissections are computed for probeset level gene expressions. Sequences of single probes 
underlying a probeset are available from the manufacturer (they might help to construct specific shRNAs or 
cDNAs for further experimental investigations of probesets that have been identified by discovered effects and 
that are of biological interest). 
Except for the two sub cohorts of GSE10846, all cohorts were studied and measured by mutually 
independent teams and labs. Even sub-cohorts in GSE10846 are based on different experimental labelling 
protocols. Hence, validation of discovered effects across cohorts can be utilized to sort out lab effects and to 
exclusively keep effects of biological origin. 
III.1.1.2 Dissection overview for single cohorts 
Raw signal dissection has discovered 221 (GSE10846.CHOP), 82 (GSE4475.CHOP), 161 (GSE10846.R-CHOP) 
and 105 (GSE31312.R-CHOP) significant gene expression effects before the respective remaining signal has 
been considered noise(II.4.3). 
When compared to GSE10846.R-CHOP, lower numbers of detected effects were expected for the FFPE based 
cohort (due to the higher noise level) as well as for GSE4475.CHOP (due to the relatively small cohort size). It 
is surprising that GSE10846.CHOP yields more effects. However, several of these effects are very narrow (with 
respect to their number of top genes or top samples) and thus are probably lab effects that will be identified 
as such and sorted out by cross-cohort validation next. 
All discovered and dissected effects for raw signals are available in graphical and tabular from in cohort sub 
folders in  A=Detection. 
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III.1.2 Validation of Effects across Cohorts 
Ideally, GEP effects are independently discovered by signal dissection in all four cohorts. Only very strong 
and genetically unambiguous effects reach this quad-discovery. To find them, gene axes of all detected effects 
in all cohorts are systematically compared by correlation. Tuples of highly correlated effects from different 
cohorts are identified.  
Most true positive effects are not independently discovered in all four cohorts, probably because of alternate 
dissections. However, even an effect that has been discovered in just two cohorts can already be considered 
as strongly validated, because it was unsupervisedly rediscovered in an independent patient cohort.  
A weaker yet still sufficient form of GEP effect validation is supervised validation, i.e. an effect has been 
discovered in just one cohort, but its supervised application to initial signals from other cohorts proves its 
existence there, too. Alternatively, GEP effects discovered only in single cohorts can be considered validated if 
they are significantly associated with non-GEP covariates of the same cohort, like patient survival. 
Generally, the aim of validation is to extract and validate as many as possible discovered effects and only 
filter those out that are cohort-specific effects and thus disease-unspecific lab effects. 
III.1.2.1 Comparison between two cohorts by correlation of effect gene axes 
Let   and   denote two dissected cohorts and let  ,  denote indices of detection iterations. Let |,  and | ,  denote the converged gene axes of corresponding detected effects. Let |,  and | ,  denote the final 
gene correlations with the effect’s converged sample axis for the respective cohort. Finally, let | ,  and | ,  denote the effect gene weights in the final effect focus. All these vectors are results from effect axes 
convergence in II.3.2. (The index  that indicated the convergence iteration in II.3.2 is suppressed here for 
better readability.) 
As both the signal strength in effect direction and the consistency of regulations (i.e. correlations) should be 
similar for discovered effects that originate from the same biological effect, I compare the following product 
gene scores: 
| |.  ≡  	 	


 
Eqn. III.1.2.1.a) Gene scores (combining signal strength and correlation information) 
 
I.e. | , |. ,  is compared with | , |.  , . Notably, these gene scores indirectly contain information 
from all samples in the respective cohorts, as gene correlations are computed to effect sample axes. 
For the comparison of two discovered effects, all genes are relevant that are regulated by the potentially 
common biological effect. Additionally, both effects should extend to the same set of genes in both cohorts, if 
they represent the same biological interactions. Hence, the comparison should be computed for the outer 
effect focus |,; ,  defined as the maximum of respective gene weights. Then, the actual comparison 
score  ,; , is again computed by uncentered weighted correlations(cf. II.2.3.1): 
 , ;, ≡ | , |.  , | , |.  , ,; , 	with	|,; ,  ≡ max   , ,   ,  


 
Eqn. III.1.2.1.b) Comparison of effects from two cohorts by correlation 
 
For cross-cohort validation, all pairwise correlations are computed (for all pairs of cohorts and for all 
discovered effects in these cohorts). Additionally, corresponding  ,; ,-values for these correlations are 
computed as before(cf.II.5.2.1). 
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These computations presuppose that the same gene space is shared by all cohorts. In practice, this is always 
attainable by aggregating microarray results on gene level. Genes that were not measured by a particular 
microarray are assigned zero weights. For current cohorts(cf. III.1.1.1), the higher-resolution probeset space of the 
U133 Plus 2.0 microarray platform with   54675 dimensions has been selected. As U133A microarray 
utilized for GSE4475.CHOP contain a direct subset of these probesets, it was possible to join them by direct 
probeset ID lookup. 
III.1.2.2 Validation by independent discovery in several cohorts 
Four cohorts are available and in the ideal case the same biological effect has been discovered in all cohorts. 
This corresponds to a 4-tuple of detection ranks  ,  , ,  such that all pairwise correlations  ,; ,(III.1.2.1) are strong and significant.  
For every candidate tuple, pairwise correlations can be collected as a 4x4 matrix  ,,, ≡ ,; ,,… . Diagonals equal one (self-comparison) and thus for      cohorts,         cross-cohort 
correlations remain (the factor 

 is due to the symmetry of correlations). 
Next, the count of significant pairwise correlations is computed for each tuple. More precisely, a four-
dimensional count matrix  ∈      (where   denotes the final number of effects discovered for 
cohort  (cf. III.1.1.1)) is computed such that  , ,  ,  equals the number of pairwise absolute correlations of 
effects  ,  , ,  that are stronger than 0.5 and have a  value  0.001. The same pairwise absolute 
correlations are geometrically averaged for each tuple, resulting in  ∈ 0,1    . 
To estimate the count of additional cohorts, wherein an effect has been unsupervisedly rediscovered, 
pairwise correlation counts are scaled via             ⁄ . For      4, the maximum count is three independent 
rediscoveries and the minimum is zero (if the effect was only discovered in one cohort and no significantly 
correlated partner effect exists). 
To determine a list of validated effect tuples, all tuples are sorted descending by their  scores. The list is cut 
with the same threshold 0.5 that was applied to pairwise correlations above. In principle, an effect from one 
cohort may be significantly correlated to more than one effect in another cohort. Hence, this list may contain 
redundancies like  , ,  ,  and ,  , ,  (i.e. the effect was not detected in cohort three, and it 
was detected by two alternative effect axes in cohort two, while the same discovered effects are selected for 
cohorts one and four). Both tuples probably represent the same “outer” effect whose dissection into smaller 
and more coherent effects may be intrinsically ambiguous. I purposely permit such redundancies during 
validation, i.e. I permit discovered effects from one cohort to be included in more than one tuple. This enables 
finding different equally valid “views” on a true effect, i.e. views from partially correlated yet not identical 
consensus gene axes(cf. III.1.3). At this point, it cannot be decided which view is “the best”, because all are 
statistically significant and have high  scores. Later statistical associations e.g. with patient survival may 
reveal, which views are better, i.e. which are biologically more specific. Here, it is only important to keep all 
validated alternatives for further analysis. 
In total, 133 effect tuples with effects from at least two different cohorts validate in this way. The validation 
index  is used to refer to these effects henceforth. 
Another more demanding validation score can be defined based on the renormalized count of significant 
pairwise correlations times their geometric average:  ≡  .             ⁄ . The theoretical maximum for analyzed 
DLBCL cohorts (i.e. for      4) is still three. The maximal observed validation score was 8,124,9,17  2.84, 
followed by 3,4,6,6  2.64 for the gender-induced GEP effect(cf. III.3.2.1). However, most real-world biological 
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effects are not so clearly defined like the gender effect, because their foldings are weaker. Hence, their signal 
is nearer to the noise level and thus correlations are lower, too. Depending on the chosen cutoff, many effects 
thus do not validate when requiring highly correlated independent rediscoveries. For example, if one would 
require a validation score of at least 1, only 37 would be validated (of the above 133 effect tuples with 
significantly correlated effects from at least two cohorts). These 37 effects are strongly validated, as they have 
at least one independent rediscovery that is correlated with 1 (which is only theoretically achievable) or have 
multiple independent rediscoveries with correlations 0.5    1 (which is always the case in practice). These 
validation scores are also available in the  DLBCL Master Table 2015, main overview.xlsx. While this strong 
form of unsupervised validation is nice to have, it should not be required. This would exclude many discovered 
effects that can be validated in a supervised form(cf. III.1.2.3) and that are actually biologically important, as is 
evidenced by later biostatistical analyses(cf. III.3). 
III.1.2.3 Supervised Validation 
 ,  denotes the final gene axis of an effect  that was discovered when dissecting gene expressions for 
cohort  . It suffices for validation to supervisedly check the existence of the same effect in other cohorts   . 
To this end, the same procedure is utilized as for classification of samples by consensus gene effects(details follow 
in III.1.4). In brief,  ,  is accepted as final gene axis, its twin axis is computed, correlations are computed and the 
effect focus is updated. These vectors replace results from the search strategy(II.3) and are directly passed to 
regression and dissection(II.4). If this leads to a significant(cf. II.5.1.2 and II.5.2.2) effect in  (e.g. Figure III.3.3.1.b), the effect in (e.g. 
Figure III.3.3.1.a) can be considered validated in  . This is a weaker form of validation than unsupervised 
rediscovery, but effect eigensignals in   may still be strong and highly significant. 
Alternatively, effects can be supervisedly validated by associating them with non-GEP covariates. For 
example, detected effects with ranks #27 and #47 in the FFPE cohort GSE31312 were significantly associated 
with patient survival in the same cohort (#  2.1 ⋅ 10 and #  4.2 ⋅ 10, log rank tests between Kaplan-
Meier survival estimates for samples partitioned at   standard deviations of effect eigensignal strengths; cf. 
III.3.1.1). This is also the reason, why I performed biostatistical analyses for these two effects (indexed with   134 and   135 respectively) in addition to all 133 effect tuples validated above(cf. III.1.2.2). (Effect   134 
even turned out to have the most consistent association with survival of all effects in all cohorts(cf. III.2.5.1), while   135 showed still significant yet relatively weak survival association in other cohorts; cf.  DLBCL Master 
Table 2015, main overview.xlsx.) 
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III.1.3 Genomic Consensus Effects 
To define an effect on genomic level, i.e. independent of concrete samples underlying its original discoveries 
in possibly several different patient cohorts, consensus gene axes are computed. Likewise, consensus gene 
correlations can be computed. They serve for definition of gene scores used for genomic biostatistical analyses 
of effects. Additionally, they are the basis for effect application to potentially new cohorts and computation of 
consensus sample axes(in III.1.4). 
III.1.3.1 Consensus gene axes 
Let  be the index of an effects tuple with validated effects from 		  cohorts(cf. III.1.2.2). In the optimal case, the 
effect has been rediscovered in all cohorts (		    ). For only supervisedly validated effects, 		  equals one. 
Let  ,   1 … 		 denote the corresponding set of gene axes for effects   in respective  
cohorts  . Likewise, let  ,   1 … 		 denote their gene correlations (with the effect’s sample axis in the 
respective cohort). Their gene weights of the final effect focus are denoted by  ,   1 … 		. 
To combine these genomic information over all available cohorts  , weighted arithmetic averages of the 
above vectors are computed. This results in the consensus gene axis respectively in consensus gene 
correlations for this set of effects. Pairwise cross-cohort correlations  ,; , between effects(cf. III.1.2.1) are 
respected in form of weights when computing these averages. Additionally, they are utilized to align gene axes 
as they may be anti-correlated (an unaligned summation would cancel signal strengths). As for pairwise 
correlations(cf. III.1.2.1), the gene focus for the combined effect is again defined as the maximum of respective gene 
weights. 
The consensus gene axis for a tuple …		  of effects from 		  cohorts with validation index (cf. III.1.2.2) equals 
, ≡   , 
		

, 
where the signs  ≡ sign , ;	 , align axes to each other and geometrically averaged  
weights  ≡ ∏  , ;	 ,		
		
 respect the correlation of gene axis  to all others(cf. III.1.2.1). 
The consensus gene correlations for the same effects tuple is defined likewise as  
,  ≡   , 
		

. 
Finally, consensus gene weights are defined as the maximum of the gene foci in respective cohorts: 
 , ≡ max…		   ,  
Together, ,, ,, ,  describe a particular genomic consensus effect. 
Eqn. III.1.3.1) Consensus gene axis, consensus gene correlations and consensus gene weights for a validated effect   describe a genomic consensus effect 
 
The procedure of consensus axis computation can be viewed like a soft form of intersection for effects that 
were detected in multiple cohorts. If a gene is strongly correlated to the common effect in only one of several 
detection cohorts, it is assigned lower consensus signal strength  , and weaker consensus correlation  ,  than genes that are strongly correlated to the same effect in more cohorts. Thus, potential false 
positive genes (with respect to the common effect) are sorted down and hence true positives (from 
perspective of all participating cohorts) are sorted to the top. This definition should further increase the 
biological specificity of multiply rediscovered consensus effects. 
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In the special case of a supervisedly validated effect that was only discovered in a single cohort(cf. III.1.2.3), its 
consensus gene axis and its consensus correlations are identical to its gene axis and its gene correlations in its 
detection cohort. From a processing point of view, this makes no difference. However, relative to effects based 
on multiple discoveries, top genes are usually less robustly determined here and thus some top genes may still 
be cohort-specific. Hence, when the effect is applied to other cohorts(cf. III.1.4), some of its top genes may turn out 
to be false positives, i.e. they are no longer significantly correlated to the effect’s sample axis in this other 
cohort. Still, if the effect has already been supervisedly validated as a whole against the GEP signal of this other 
cohort(cf. III.1.2.3), only a minority of its top genes can be such false positives. 
While all cohorts measure the same genes, they measure different samples. Hence, no common consensus 
sample axis can be computed here. Notably, consensus sample axes could be computed for data scenarios 
where the same set of samples has been measured several times (preferably by independent labs or teams). 
Still, cohort-specific sample axes based on consensus gene axes can be and are computed for sample 
classification by genomic consensus effects(cf. III.1.4.2). 
III.1.3.2 Consensus gene scores and their correlation 
While consensus gene axes , encode information about folding strengths of genes in effects, consensus 
gene correlations , encode the consistency of gene regulations with the effect’s sample axes in the 
respective cohorts. It is an interesting question, whether genes with a stronger differential signal or with 
higher correlation to an effect (and thereby on average also to other top genes of this effect) are biologically 
more relevant. I assume that biologically highly correlated genes may also be important to understand the 
underlying pathway, even if they have a relatively weak differential signal. Like for effect validation 
before(cf. III.1.2.1), both sources of information may be important. I assume that the combination of both 
information sources maximizes biological specificity of gene rankings. Hence, consensus gene scores are 
defined based on the component-wise product: 
|, |. ,  ≡  , 	 ,	


 
Eqn. III.1.3.2.a) Consensus gene scores for a validated effect   (combining signal strength and correlation information) 
 
These scores are also used for genomic analyses of consensus effects, in particular for gene set enrichment 
analyses(cf. III.3.1.2 and III.1.5). 
To quantify the genetic similarity of two consensus effects   and  , their consensus gene scores are 
correlated. Again the maximum effect focus is used for comparison, analogous to cross-cohort comparison of 
discovered effects for validation(cf. III.1.2.1).  ; ≡ 		|,|. , 			|,|. , 	;,  , where	
| ;,  ≡  max ,,  ,  


 
Eqn. III.1.3.2.b) Correlation of consensus gene scores 
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Pairwise correlations  ;  of consensus gene scores for all pairs  ;  ∈ 1,135  of validated effects are 
depicted below: 
 
Figure III.1.3.2.a) Pairwise correlation ;   of consensus gene scores for all validated effects 
 
The permitted redundancies for alternate views(cf. III.1.2.2) are visible as strong(red or blue) correlations outside of 
the diagonal. These genetic similarities between some of the consensus effects are respected during 
biostatistical evaluation(III.3). Sometimes they are utilized to make statements about a group of several 
equivalent consensus effects at the same time(e.g. III.3.3.2). 
Most validated effects have uncorrelated or only partially correlated consensus gene scores, i.e. these effects 
probably represent biologically unrelated effects, e.g. independent gene regulation networks. (Depicted 
correlations are also provided in tabular form within  DLBCL Master Table 2015, main overview.xlsx.) 
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III.1.4 Application of Genomic Effects 
While cohorts measure the same genes, they measure different samples. Therefore, consensus gene axes of 
validated effects are applied to each cohort individually in order to compute effect strengths for their 
respective samples. Based on these effect strengths, samples can be arranged and classified by a particular 
effect. This classification can be applied to dissected cohorts in which consensus gene axes have been 
discovered and learned in the first place, as well as to new patient cohorts (for which the same gene 
expressions have been measured). Additionally, these classifications are utilized for biostatistical associations 
of effects with sample covariates (e.g. gender or survival). 
To realize this classification, large portions of signal dissection(Chapter II) can be reused. Essentially, the search 
strategy is skipped and replaced by learned consensus gene axes of the respective effect. 
III.1.4.1 Cleaned signal 
All discovered effects(cf. III.1.1.2) that were not validated(cf. III.1.2.2 and III.1.2.3) are cohort-specific effects. They are 
considered lab effects that are not of biological origin. To make gene expression signals of different cohorts 
more comparable, these cohort-specific effects should be removed. 
Let   denote the number of effects discovered by 
dissection of the initial gene expression signal  ,  of 
cohort  . Let  , ⊂ 1,   ⊂  be the index set for all 
detected effects in this cohort that did not validate(cf. 
III.1.2.2 and III.1.2.3). Then the cleaned signal for this cohort is 
obtained by subtraction of all these lab effects(cf. Eqn. III.1.4.1). 
 
III.1.4.2 Application of consensus gene axes  
 and sample classification by eigensignal strengths 
Application of a validated effect  to a cohort  computes the eigensignal of this effect in the cleaned signal  , (cf. Eqn. III.1.4.1) of this cohort. This eigensignal can be utilized for sample classification by the effect. Precise 
steps are detailed next. 
For a consensus gene effect given by its gene axis ,  and its gene correlations ,(cf. Eqn. III.1.3.1) first the 
significance of gene correlations is estimated and the gene focus  is updated in the same way as during 
detection(cf. Eqn. II.3.1.4.b). Then the twin sample axis  ,,  for cohort  is computed from the gene axis , using 
weights  (cf. Eqn. II.3.1.3), i.e. its components   ,,  equal weighted projections of samples ,|, | . 
Additionally, consensus sample correlations  ,,  for cohort  with the gene axis , are computed using 
weights  (cf. Eqn. II.3.1.4.a), i.e.   ,,   , ,| . Finally, the cohort-specific sample focus  ,  is computed 
from these correlations(cf. Eqn. II.3.1.4.b). Together, these effect axes, correlations and weights provide the same 
information in the same format as determined by the search strategy(cf. II.3) for a discovered effect during 
detection. This format identity is utilized to replace the search strategy. All other parts of signal dissection are 
identically reused for effect application. 
The resulting regressed eigensignal  , (cf. II.4.2.1) for consensus effect  in cohort  can be utilized to infer 
sample scores. They can subsequently be used for sample classification purposes or for biostatistical 
associations of effects with sample covariates. For example, the eigensignal ., (see Figure III.3.3.1.b, 
panel d) can be utilized to quantify sample involvements in this effect for subsequent survival analyses. 
 ≡   ,
∈	,
	
 , ≡  ,    
Eqn. III.1.4.1) Gene expression signal after dissecting cohort-specific effects 
  , Indices of effects detected in cohort  that did not  
  validate(cf. III.1.2.2 and III.1.2.3). 
  ,  Final eigensignal of effect  in cohort (cf. II.4.2.1). 
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To this end and more precisely, I define sample 
eigensignal strengths as column averages of these 
eigensignal matrices  , , weighted with the consensus 
gene focus  of the effect(Eqn. III.1.4.2), and using 
correlation signs to sum correlated and anti-correlated genes constructively. 
Other than sample effect strengths used for regression(cf. II.4.1.1), sample eigensignal strengths are relatively 
robust against outliers in raw sample signals and do no longer contain signal parts of partially correlated 
foreign effects (as dissection strengths are zero for them). Hence, I assume that eigensignal based sample 
scores are the purest with respect to an effect. I also utilize them for sample partitioning for clinical association 
analyses and survival analyses. (This assumption has been supported by experience with several alternate 
sample scores and with multivariate survival analyses during development: Sample orders based on sample 
eigensignal strengths resulted in the lowest  values for survival associations.) 
 
 
 
 
 
 
 
III.1.5 Overview of Scores 
To clarify gene and sample scores utilized for biostatistical analyses of consensus effects and to compare 
them with scores used for other purposes in signal dissection, the following table provides an overview of all 
gene and sample scores that are available for validated effects. 
Gene scores 
,  The cohort-independent consensus gene axis of validated effect   is a weighted average of gene axes in underlying detection cohorts(cf. Eqn. III.1.3.1). Components can be interpreted as the differential expression strengths of individual genes (in logratios units) between samples of 
patients that were ordered and distinguished by corresponding effects in underlying detection cohorts(cf. III.1.2.2). 
,  
Likewise, the cohort-independent consensus gene correlations of validated effect   are based on weighted averages of gene correlations in 
underlying detection cohorts(cf. Eqn. III.1.3.1). Components can be interpreted as the consistency of an individual gene’s expressions with sample 
eigenorders of the effect in underlying detection cohorts(cf. III.1.2.2). The nearer a gene’s correlation is to 1, the more likely it is that the gene is 
regulated by the underlying biological program that is represented by this effect. The nearer towards zero, the less likely it is that expressions 
of the gene can be explained by the current effect. 
|, |. , 
Consensus gene scores are defined as the gene-wise product of the effect’s absolute consensus gene axis with its consensus gene correlations(cf. 
Eqn. III.1.3.2.a). Hence, top genes when ranking by these scores are both strong and consistent with respect to effect  . Using both information is 
assumed to result in biologically most specific effect genes at top and bottom. Therefore, this ranking is utilized as basis for all genomic 
analyses of effects (i.e. primarily for gene set enrichment analyses and for gene ontology analyses). 
,,  
During application of a consensus gene effect to a specific cohort , signal dissection computes gene effect strengths for regression iterations  
as during detection(cf. II.4.1.1). These gene effect strengths are utilized to determine the gene eigenorder for the next bimonotonic regression 
iteration and to determine the final gene eigenorder. In effect definition plots, final gene effect strengths  ,,    are depicted in the center 
panel. 
 ,  
After determining the final eigensignal  ,  for validated effect   in cohort (cf. III.1.4.2), gene eigensignal strengths in cohort  can be computed to 
quantify the cohort-specific gene involvement in the effect, using sample correlation signs and the effect’s sample focus as weights: ,  ≡∑ sign ,,.  ,  , ,  , . Other than gene effect strengths  ,,    before, gene eigensignal strengths are relatively robust against 
outliers in raw signals of single genes | , and do no longer contain signal parts of partially correlated foreign effects (as dissection strengths 
are zero for them). They would also be a justifiable candidate for genomic analyses of effects, but they are only available in a cohort-dependent 
context, requiring a method to merge scores from different cohorts. In contrast, consensus gene scores above are already based on merged 
consensus axes and correlations. 
| ,  ≡ sign,.   , , 	 


 
Eqn. III.1.4.2) Sample eigensignal strengths 
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Sample scores 
 ,,  The consensus sample axis for validated effect   in cohort  is the twin axis of 
,(cf. Eqn. II.3.1.3). It is computed as weighted projections of all 
samples in  on the consensus gene axis, i.e. its components equal  , |,| (cf. III.1.4.2). They can be interpreted as the differential expression 
of samples (in logratios units) between co- and anti-regulated genes in the effect. 
 ,, Consensus sample correlations for validated effect   in cohort , i.e. components equal  ,,   ,,|(cf. III.1.4.2).  For interpretation, see , above. 
,,  
During application of a consensus gene effect to a specific cohort , signal dissection computes sample effect strengths for regression iterations  as during detection(cf. II.4.1.1). These sample effect strengths are utilized to determine the sample eigenorder for the next bimonotonic 
regression iteration and to determine the final sample eigenorder. In effect definition plots, final sample effect strengths  ,,    are depicted in 
the center panel. 
| ,  
After determining the final eigensignal  ,  for validated effect   in cohort (cf. III.1.4.2), sample eigensignal strengths in cohort  can be computed 
to quantify the cohort-specific sample involvement in the effect, using gene correlation signs and the effect’s gene focus as weights: | ,  ≡∑ sign,.  ,  , 	 (Eqn. III.1.4.2). Other than sample effect strengths  ,,    before, sample eigensignal strengths are relatively 
robust against outliers in raw signals of single samples | , and do no longer contain signal parts of partially correlated foreign effects (as 
dissection strengths are zero for them).  
Hence, I assume that eigensignal based scores are the purest with respect to an effect and utilize them for sample partitioning for all clinical 
association analyses and survival analyses. (This assumption has been supported by experience with several alternate sample scores and 
with multivariate survival analyses during development: Sample orders based on sample eigensignal strengths resulted in the lowest  values 
for survival associations.) 
Table III.1.5) Overview of available gene and sample scores for validated effects 
Several gene and sample scores are available for validated consensus effects. For genomic analyses, only consensus gene axes and consensus gene correlations are 
needed (the same global gene space is shared by all cohorts). For ordering and classifying samples in a concrete cohort, an effect is applied to it(cf. III.1.4.2), resulting in 
cohort-dependent sample eigensignal strengths for clinical association analyses. This overview lists all available scores and explains their differences. 
Different scores are utilized for different types of effect presentation. Effect definitions in tabular form are 
available in  DLBCL Master Table 2015, gene orders.xlsx; they show all genes and provide columns for,, ,  and |,|. ,. Effect overview plots(e.g. Figure III.3.2.1) are always presented in the empirical 
eigenorder(cf. II.4.1.2), for which the respective eigensignal is regressed (i.e. they are ordered by final effect 
strengths  ,,    and ,,    respectively). Additionally, plots apply a filter to exclude strongly folded yet 
uncorrelated genes from the view. This filter demands that absolute consensus correlations  ,  are   50% of their maximum. Gene tables for biostatistical evaluations(III.3) are presented in descending order of 
the combined scores |,|. ,, as these scores are also utilized for all genomic analyses. Hence, these gene 
tables list genes at top ranks that have both strong folding and high correlation (if available for the respective 
effect). For abbreviation, let ,, ≡  ,  and ,, ≡  , ; consequently |,, | ⋅ ,,   |,|. , . 
(The gene index  may be suppressed in the context of an arbitrary gene, e.g. for gene table headers. Or it may 
be replaced by the gene name in the text for clarity.) 
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III.2 Multivariate Survival Prediction 
Gene expression effects associated with patient outcome are probably most informative 
towards understanding the molecular pathogenesis of DLBCL. To reveal these effects, 
multivariate Cox survival models are trained. All validated GEP effects are systematically 
analyzed for their individual and combined predictive performance. 
Many GEP effects can explain significant portions of patient outcome. Several genetically 
distinct effects can explain the same portions. Some effects can explain hierarchical survival 
dependencies after patients have been stratified by other effects. In principle, all of these 
effects could contain genes that are causal to the disease or its subtypes, reflecting the genetic 
heterogeneity and complexity of DLBCL. 
Results reveal that a particular unsupervisedly discovered GEP effect(index ν=134, evaluated in III.3.3.1) 
can predict patient outcome exceptionally well with   4.5 ⋅ 10 , while the unsupervisedly 
rediscovered cell-of-origin induced effect(ν=129, evaluated in III.3.2.2) follows only at rank two(Figure 
III.2.5.1.a) with   1.1 ⋅ 10 . Additionally, another GEP effect can improve predictions on top 
of effect 134 in a hierarchical manner, while the same is not possible on top of the COO 
induced effect. This might indicate that genes in 134 are a more natural choice to identify 
subtypes of DLBCL. So far, many genes that have been investigated with respect to their 
contribution to DLBCL lymphomagenesis belong to the COO induced effect. Given that the 
discovered effect 134 is not only more consistently associated with patient outcome but 
also has fewer top genes with higher correlation(cf. Figure III.3.3.1.a) relative to the larger and less 
specific COO induced effect(cf. Figure III.3.2.2.b), its top genes might be interesting for further 
experimental investigation. 
 
 
 
III.2.1 Survival Model and Effect Selection 
Before fitting concrete models and presenting predictor results, a brief recap for Cox proportional hazard 
models is provided here. 
Available data and follow-up types are listed, the choice of sample scores utilized for predictions is motivated 
and the iterative selection procedure for GEP effects that significantly explain patient outcome is clarified. 
III.2.1.1 Cox Proportional Hazard Models 
All fits in this subchapter are based on Cox proportional hazard survival models[98]. For a selected training 
set of samples, these models test the association of survival data with a selection of explanatory variables  . 
These   correspond to measured information about training samples, for example their average expression 
of validated GEP effects. Cox models(Eqn. III.2.1.1) estimate a baseline hazard function  from survival data, and 
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regress on coefficients   for selected explanatory effects  . Fitted estimates   utilize selected explanatory 
variables to predict patient risk ratios relative to baseline risk. 
 ≡  ⋅ exp  
∈
 
Eqn. III.2.1.1) Cox proportional hazard models 
 ,  Explanatory effect index and the selected set of indices. All   1 correspond to indices of selected validated GEP effects(cf. III.1.2),  
  while   0 correspond to prescribed temporary model variables like patient age(cf. III.2.1.4). 
   Explanatory variable with index  . (For example, the average gene expressions of a validated GEP effect for all samples.) 
   Coefficients. Numeric values are obtained by regression and are denoted as  . In case of standardized variables  ,  
    can be compared directly to estimate the relative impact of explanatory variables on survival. 
  Baseline hazard function. Estimated empirically by the model. High hazards are equivalent to high risk and correspond to adverse outcome. 
   Hazard rate at  ≡   at time . Substitute   by numeric values for concrete samples  to predict their hazard rate. Ratios of hazard rates  
  quantify how much more probable an event is for one sample compared to the other. 
 exp, The predicted hazard ratio relative to baseline for patient  due to its value , for effect  . 
 ∑ ,∈  The predicted loghazard	ratio for patient  based on its values , for all effects in the model. 
The aim is to find gene expression effects that allow the prediction of significantly different hazard ratios 
between patients. Generally, high hazard rates, i.e. high risks correspond to adverse patient outcome. 
Predictions are computed relative to estimated baseline hazards and are described by loghazard	ratios, 
similar to using logratios when comparing sample gene expressions to cohort average expressions. Kaplan 
Meier survival estimates for risk intervals of loghazard	ratios will be utilized to visualize survival differences 
predicted by particular trained Cox models. All fits of Cox models are computed with the coxphfit function of 
the MATLAB® Statistics toolbox. 
Conceivable nonlinear dependencies (for example, an effect might only influence outcome if expressed 
above a threshold) cannot be fitted exactly by Cox models, but are linearly approximated in the exponential. 
Symmetric dependencies (e.g. if average expression of an effect maps to baseline survival, but both 
upregulation and downregulation cause adverse outcome) cannot be fitted or revealed by such models. 
 
III.2.1.2 Available survival data and its limited information 
Survival data from patients for samples  are available in form of follow-up times   after diagnosis and 
Boolean flags   that indicate whether an event (a death or a progression) was observed (  1) or if a patient 
was lost to follow-up before it was observed (  0, right censoring). In total, 947 DLBCL samples with follow-
up events are available: 181/181 in GSE10846.CHOP[5], 76/166 in GSE4475.CHOP[95], 220/233 in GSE10846.R-
CHOP[5] and 470/498 in GSE31312.R-CHOP[29]. 
Observed deaths are used when estimating overall patient survival. These events are different from 
observed disease progressions that do not necessarily lead to deaths, but are significantly associated with 
these later events. Progression events have the statistical advantage that they usually can be observed even 
within relatively short follow-up studies, while deaths may appear as relatively uninformative censored 
events, especially if the follow-up is too short. Therefore, progression events can potentially convey more 
information about survival than the usually fewer death events for the same follow-up duration; this is 
especially useful for cohort GSE10846.R-CHOP due to its relatively short follow-up. While death events were 
recorded for all cohorts, only in R-CHOP treated cohorts progression events are available. 
It should be illuminated before fitting any survival model that except for time information and even when 
combining all four cohorts, survival data comprises just 947 bits of information. Their primary use is to 
serve as a biologically independent validation of already discovered and validated effects on GEP level. If only 
survival information was used as primary information source, for example to supervisedly find genes with 
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expressions associated with these bits(as done for signature definition in [5]), this could result in many false positive genes, 
since the information base is too low. Even if these genes are arranged and filtered via hierarchical clustering 
to find related subsets of genes(as also done in [5]), the information base is much smaller than for unsupervised 
dissection of the full GEP signal; hence, I utilize survival data only for independent validation rather than for 
direct supervised learning of interesting genes or GEP effects. 
For the same reason, survival data should not be used to exclusively select only those GEP effects that are 
most consistently associated with DLBCL patient outcome. That would exclude many also significantly 
associated GEP effects that might contain biological true positive genes that are causal to the disease. While it 
is necessary to make a selection of effects for predictor construction (and only the most consistent effects are 
selected to this end), it should be kept in mind that in principle all effect candidates with significant survival 
association might describe important and causal parts of this genetic disease. 
A third problem tied to having 947 bits of information is the problem of “overlearning”: It is relatively easy 
to inadvertently learn 947 bits “by heart” with a model based on many variables; such a predictor would 
produce perfect results for the 947 samples it was trained with, but would not generalize well or at all to new 
patients. Herein this study this is less problematic, as predictors are based only on already validated GEP 
effects that are biological true positive effects and are usually supported by many correlated genes (or 
probesets). Still, the construction procedure for predictors should and will be validated to quantify and prove 
their predictive performance. 
 
 
III.2.1.3 Choosing sample scores 
Given a validated GEP effect , several sample scores(cf. III.1.5) could be utilized for  , for example correlations 
of samples to the effect’s consensus gene axis. Alternatively, sample projections on its consensus gene axis, its 
consensus gene weights or effect strengths based on its eigensignal in the respective cohort could be utilized. 
While all are based on the validated gene order from the effect’s consensus gene axis, only eigensignal 
strengths | , (cf. Table III.1.5) are also based on bimonotonic regression in the respective cohort. This may be the 
reason why multivariate survival analyses performed during development indicated that sample orders based 
on sample eigensignal strengths resulted in the lowest  values for survival associations. I therefore consider 
them the highest-quality sample scores available and choose them for fitting all survival predictors in this 
subchapter. 
Visually and for direct interpretation, a component , ,  is simply a constructively weighted average 
expression of sample column  in the eigensignal heatmap of the respective effect application plot(e.g. Figure III.3.3.1.a, 
panel d). The selected sample score allows for later practical applications of predictors, as consensus gene 
weights |  needed for its computation have already been learned and are readily available for each validated 
GEP effect in  DLBCL Master Table 2015, gene orders.xlsx. Additionally, the effect’s eigensignal can be 
computed from learned and available consensus gene axes even for future DLBCL cohorts(cf. III.1.4). 
Each sample of every cohort should have the same weight when training survival predictor models. To this 
end and to compensate for scaling differences between cohorts, I additionally standardize eigensignal 
strengths  ≡ ,  ,   1 …   by dividing with their standard deviation in the respective cohort  . I.e. 
the final predictor variables are , ≡ , ,  ̂⁄   1 …  , where   is the number of samples in 
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cohort  . This standardization also allows resulting   of fitted Cox models to be compared directly, as they all 
multiply effect variables distributed with standard deviation one.  
Sample scores are not shifted by their cohort mean before predictor training (as in standard  
transformations), as zero already represents the theoretical global baseline (zero logratio indicate cohort-
average gene expressions). Hence, samples with zero eigensignal (i.e. baseline expression) for a particular 
effect also map to baseline survival of fitted Cox models, since their products  are zero, irrespective of 
fitted  . 
III.2.1.4 Correcting for survival factors that are not specific for DLBCL 
Patient age is known to influence patient outcome, but it is not specific for DLBCL. Thus, assignment of 
significant explanatory value to GEP effects that are accidentally related to age should be avoided. To this end, 
I temporarily prescribe centered patient age as first explanatory variable   during GEP factor selection. 
For a maximal training base, I merge all available survival events across all four patient cohorts. To this end, 
another factor should be prescribed: Two cohorts were treated by the current standard therapy of R-CHOP, 
whereas the other two were treated by the former standard of CHOP. These therapies are associated with 
different average survival. In addition, follow-up event types are different for the same pairs of cohorts. To 
prevent selection of GEP effects that are accidentally related to therapy or follow-up type, I prescribe  as 
centered binary grouping variable for R-CHOP and CHOP events, whenever samples from both groups are 
used for predictor training. 
After having selected all significant explanatory GEP effects, factors for age and therapy are removed again 
from predictor models to only keep factors that are specific for DLBCL. 
 
III.2.1.5 Effect selection procedure and likelihood ratio tests 
The procedure for selecting explanatory GEP effects is iterative. For each effect selection iteration, each of 
the 135 validated GEP effects is candidate-added to the current Cox model and it is quantified, how well it can 
explain survival on top of already explained dependencies, initially only on top of age and (if needed) therapy 
dependent outcome. 
This can be computed via likelihood ratio tests, comparing the larger age, effect} model with just the {age} 
model: Let   be the log-likelihood of the larger model and   be the log-likelihood of the smaller nested model 
(both are determined by the fitting procedure coxphfit from the MATLAB® Statistics toolbox). Then 2 ⋅
   is asymptotically 
  distributed with one degree of freedom as per Wilks’ theorem[99]. Hence,  values 
readily can be approximated by integrating the respective upper tail of the   distribution. 
GEP effects are filtered by their  values with respect to a tightly chosen error threshold of  ≡ 10. If 
significant effects remain, the one with the best  value is selected and added to the Cox model. 
In the next iteration, again all GEP effects are candidate-added to the now larger model. Already selected 
effects can no longer provide any significant additional explanatory value; hence no effect can be selected 
twice. Again, the most explanatory effect is added to the model. This selection procedure continues as long as 
increasing model size by a particular GEP effect can fit survival data significantly better than the preceding 
smaller Cox model. 
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III.2.1.6 Validation techniques 
To prevent and quantify the problem of overlearning, trained Cox proportional hazard models should be 
validated with other observed survival data. 
Three validation scenarios will be applied: first, a model is trained with R-CHOP-treated patients and 
validated with CHOP-treated ones. Secondly, a model is trained with CHOP-treated patients and validated with 
R-CHOP-treated ones. Besides these two classical validation schemes, thirdly a leave-one-out validation will 
be employed to estimate generalization performance of a model trained with all available samples. 
Validation of fitted Cox models is only required to test their generalization performance and to confirm that 
the predictor did not learn observed survival data “by heart”. This model validation should not be confused 
with validation of effects on GEP level (either by applying them to other cohorts or even by their independent 
unsupervised detection in multiple cohorts). It is also different from validating discovered single GEP effects 
by their significant association with patient outcome. 
 
III.2.1.7 Interpreting ambiguities 
Both the genetic heterogeneity of DLBCL and the low information base of only 947 bits cause that many GEP 
effects can explain significant portions of observed survival. Different GEP effects may appear as “the best 
ones”, given a particular set of training samples. In principle, every significant GEP effect has the potential to 
contain biological true positive genes that are causal to the disease’s pathogenesis. 
To represent the most important ambiguities, several predictors are trained and validated:  • A bivariate predictor resulting from training with only R-CHOP-treated patients will be validated in the 
CHOP treated subset(III.2.2). • For comparison, another bivariate predictor will be presented that uses the rediscovered COO induced 
effect as primary explanatory variable. It also emerges from training with R-CHOP-treated patients, but 
only if manually excluding the strongest survival effect(III.2.3). • Similarly, a different bivariate predictor results from training with CHOP-treated patients only; it will 
be validated in the R-CHOP-treated subset(III.2.4). • Using the same significance thresholds for effect selection, additionally and finally a five-effect predictor 
is obtained when training with all samples(III.2.5). 
 
The number of effects that could contain causal genes for observed differences in patient outcome following 
chemotherapy can be reduced from 135 to approximately 20(cf. Figure III.2.5.1.a). Of these 20, some are genetically 
correlated, and some explain only weak survival dependencies, probably affecting only few patients. Nine 
effects are used in the various predictor models and can explain significant portions of observed survival, 
albeit in part they explain the same portions. This cannot be further reduced because of the genetic 
heterogeneity that is intrinsic to DLBCL (several smaller patient subsets seem to show different outcome 
depending on their gene expressions in different effects).  
All GEP effects selected for predictors will be presented and biostatistically evaluated in III.3 towards finding 
out the biologically most relevant gene expression differences and to sort out indirect effects about the tumor 
microenvironment. 
III.2 - Multivariate Survival Prediction 143 
 
III.2.1.8 Survival for ABC DLBCL and GCB DLBCL for comparison 
For later comparison, survival differences between known subtypes ABC DLBCL and GCB DLBCL are of 
interest. The cell of origin induced GEP effect that underlies classification into ABC DLBCL and GCB DLBCL has 
been unsupervisedly rediscovered in a filtered form(cf. III.3.2.2), but here and for reference survival differences 
based on published sample classifications are depicted(Figure III.2.1.8) for each of the four analyzed patient 
cohorts(cf. III.1.1.1). 
 GSE10846.CHOP GSE4475.CHOP 
 
 GSE10846.R-CHOP GSE31312.R-CHOP 
 
Figure III.2.1.8) Survival spread for standard classifications in ABC DLBCL, unclassified and GCB DLBCL in all four analyzed patient cohorts for comparison 
 
Predictors should ideally show a survival spread at least as strong as between these known subtypes. 
Additionally, it would be interesting if predictors could reveal significant survival dependencies within ABC 
DLBCL or within GCB DLBCL. 
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Differences in the survival spread between ABC DLBCL and GCB DLBCL for the two R-CHOP treated cohorts 
demonstrate that the current classification procedure either does not generalize well or that it is not robust 
when transferring it from a cohort based on frozen cell material like GSE10846 to a FFPE based cohort like 
GSE31312. 
 
III.2.1.9 Revisiting binary subtype classifications and associated cutoffs 
The established Bayes classification for ABC DLBCL and GCB DLBCL(as defined in [83] and applied to GSE31312, cf. Figure II.2.1.2) 
implicitly assumes that every patient is either of the ABC DLBCL or of the GCB DLBCL subtype. Only patients 
that cannot be significantly assigned to either group under this assumption are called unclassified. Thus, the 
noise level in the data and the chosen error cutoff determine the size of the unclassified group. If for example 
only two thirds of all patients were truly either ABC-like or GCB-like, while another third was neither, this 
assumption would be violated and the classifier would tend to underestimate the number of unclassified 
patients with respect to the COO induced effect, i.e. it would produce false positive classifications. 
Average GEP effect strengths or loghazard	ratios are able to encode more information about samples 
compared to binary subtype classifications. In particular, they represent the gradual nature of observed 
survival dependencies(see also II.1.2.6). Given the straight-forward interpretation of hazard ratios for patients 
relative to baseline risk and with clinical precision in mind, it is tempting to replace hard-cut clinical subtypes 
by gradual GEP effect strengths in the midterm towards precision medicine, rather than forcing patients into 
a two-class model. The importance of a more accurate description than binary subtype classifications is 
confirmed by the existence of several genetically distinct GEP effects that are all significantly associated with 
DLBCL subtypes(cf. III.3.2.2), but have strongly varying predictor capabilities with respect to patient outcome. 
For this reason, hard cutoffs during effect detection are not used and all effects are defined in a cutoff-free 
way with correlations and weights for all measured genes. I only utilize cutoffs for presenting top-correlated 
genes or for visualization of predicted survival spreads via Kaplan Meier estimates. Even here, cutoffs are 
based on correlations with the effect respectively based on risk intervals for predicted loghazard	ratios. 
Consequently, all samples with predicted hazards near baseline are combined in the same Kaplan Meier curve.  
Thus, if a predictor can only predict strong survival dependencies for a few patients, most patients are in the 
baseline Kaplan-Meier curve, rather than trying to minimize the size of the effect’s “unclassified” group over 
the limit that is justifiable based on GEP regulation strengths. Additionally, these hazard-based cuts can 
visualize predictor performance more naturally than, for example, quartile Kaplan Meier plots. This is 
especially true in presence of small patient subgroups that highly express a given effect and show significantly 
different outcome relative to other patients. 
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III.2.2 Bivariate Model for R-CHOP 
Using progression events from cohorts GSE10846.R-CHOP and GSE31312.R-CHOP as training base, two GEP 
effects are iteratively identified and selected that can explain significant survival dependencies. Validation in 
both CHOP-treated cohorts is successful. As selected GEP effects are genetically highly specific and distinct 
from the larger COO induced effect, these effects could yield novel biological insights into molecular causes of 
DLBCL. 
The second explanatory variable (  127) is shown to affect only patients in the lower risk partition with 
respect to the first effect (  134), i.e. in terms of standard subtypes, GCB DLBCL patients are affected 
predominantly, while ABC DLBCL patients seem not to be affected by its underlying pathway. Because of an 
anti-aligned survival trend, effect   127 is not significant if selected as primary effect, but highly significant 
as secondary effect, i.e. a multivariate analysis was necessary to reveal it. 
III.2.2.1 Selection of validated GEP effects as predictor variables 
Centered age is prescribed as initial factor in this Cox model to prevent potential selection advantages for 
GEP effects that are related to patient age; this factor has   0.004 over all R-CHOP-treated patients. 
Next, each of the 135 validated GEP effects is candidate-added to the model as described(III.2.1) and likelihood 
ratio tests are utilized to quantify significance of their added explanatory value. With   10  as tight 
significance threshold, eight GEP effects(Figure III.2.2.1.a) qualify as primary predictor variable: 
 
Figure III.2.2.1.a) Selection of the best primary GEP effect for survival prediction based on all 690 available R-CHOP-treated patients 
Shown are all 8 GEP effects with a  value  10 for their additional explanatory value of observed patient outcome (likelihood ratio test). The matrix shows 
whether they are genetically associated with each other (correlations of their consensus gene scores; cf. III.1.3.2). Indices of pre-consensus effects detected in the four 
source cohorts GSE10846.CHOP, GSE10846.R-CHOP, GSE4475.CHOP.nonMBL and GSE31312.R-CHOP are displayed on the left in square brackets; NaNs indicate that 
no sufficiently correlated gene axis was used for dissection of the respective cohort’s signal. 
With   3.9 ⋅ 10 , effect   134 can explain survival most consistently, followed by the COO induced effect   129 on rank #2 with   1.8 ⋅ 10 . Genetically,   134 is weakly correlated to all four following effects, 
but only has 69 top genes (unique gene IDs with  ,  0.4), while following top effects are larger (151 
genes for   129, 95 for   100 and 435 for   25, using same gene correlation cutoffs). This might indicate 
that it can capture survival-relevant genes with a higher biological specificity. 
During detection, dissection of GSE31312.R-CHOP revealed   134 in iteration #27, while no highly 
correlated gene axes were used for dissection of the other three cohorts. The reason for this cannot be an 
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ambiguous dissection of the larger COO induced effect, since it has also been rediscovered in dissection 
iteration #12 in GSE31312.R-CHOP. Probably different cell material (GSE31312 is FFPE based, while all three 
other cohorts are based on frozen cell material) makes an alternate dissection of signal parts more probably 
that remain after the COO induced effect has been dissected. Anyway,   134 has been supervisedly validated, 
i.e. it has been shown to exist on GEP level in all four cohorts irrespective of cell material by applying its 
consensus gene axis(cf. III.3.3.1). 
On rank #4 (  25), an alternate view onto the standard COO induced effect follows; its consensus gene 
scores are correlated to rank #2 with ;  0.85(cf. Eqn. III.1.3.2.b). From GEP validation perspective,   25 
would have been preferred over   129, as it was independently discovered in three cohorts rather than in 
just two cohorts. This proves that the decision was right to allow redundancies in validation(III.1.2) in order to 
let survival (or other covariates) decide which alternate high-dimensional gene axis can represent true 
biological effects best. 
After addition of   134 as explanatory variable to the Cox model, only three effects(Figure III.2.2.1.b) remain that 
can explain additional significant survival dependencies: 
 
Figure III.2.2.1.b) Selection of the best secondary GEP effect for survival prediction based on all 690 available R-CHOP-treated patients 
Three GEP effects can explain significant additional survival dependencies ( value  10 , likelihood ratio test). The matrix shows whether they are genetically 
associated with each other (correlations of their consensus gene scores; cf. III.1.3.2). 
All three qualified effects are genetically similar; the first two have a consensus gene scores correlation of ;  0.80, i.e. their top genes overlap strongly. Effect   127 can explain remaining survival slightly 
better (  5.6 ⋅ 10  opposed to   6.3 ⋅ 10) and is therefore selected here as second GEP effect for 
the predictor model. 
With only   7.4 ⋅ 10  the COO induced effect   129(III.3.2.2) follows at rank #13 here (not shown in the plot, 
as this is no longer significant with respect to   10). This indicates that   134 can explain most of the 
survival dependencies explained by   129. Vice versa, this is not the case(cf. Figure III.2.3.1). 
To find a potential third explanatory effect, again all 135 validated GEP effects are candidate-added to the 
model, but none is able to significantly explain additional survival dependencies with respect to error 
threshold   10 . 
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III.2.2.2 Fit results, prediction performance and validation 
Taken together, two validated GEP effects  ∈ 134, 127 have been selected as predictors and can explain 
survival independently and on top of age. Removing the DLBCL-unspecific age variable again and fitting a 
bivariate Cox proportional hazard model  ⋅ exp∑ ∈,  for described sample scores(III.2.1.3) results 
in listed final statistics(Table III.2.2.2) for the two 
selected GEP effects. (Final  values are not 
directly comparable to  values used during 
effect selection, since the latter were based on 
likelihood ratio tests to measure the 
additional explanatory value of an increased 
model size, rather than absolute predictive 
capability in presence of all selected predictor 
variables.) 
Kaplan-Meier survival estimates for risk intervals based on predicted loghazard	ratios are used to visualize 
a spread from 36% to 86% average survival(Figure III.2.2.2) in the R-CHOP training set. As expected, this is highly 
significant (  3.1 ⋅ 10 between the first and last risk interval, log rank test, 100+109 patients). Application 
of this bivariate predictor to the CHOP-treated validation set proves its generalization capabilities (survival 
spread from 9.7% to 65% with   5.2 ⋅ 10 between the first and last risk interval, log rank test, 31+31 
patients). Compared to standard DLBCL subtypes(Figure III.2.1.8), explanatory GEP effects   134 and   127 can 
predict wider survival spreads. 
 R-CHOP CHOP 
 
Figure III.2.2.2) Bivariate predictor  ∈ 134,127; performance in the R-CHOP training set and generalization to the CHOP validation set 
Survival predictions for 690 R-CHOP-treated patients (left, training set) and 257 CHOP-treated patients (right, validation set). Chosen split points to present the 
survival spread in five risk intervals equal multiples -1.5, -0.5, 0.5 and 1.5 of a loghazard	ratio	of	150%). 
 
GEP effect   134   127 
  -0.658 0.395 
Hazard ratios [0.52, 1.93] [0.67, 1.48] 
 values 1.4 ⋅ 10  1.2 ⋅ 10 
links to evaluation III.3.3.1 III.3.3.2 
Table III.2.2.2) Bivariate Cox model  ∈ 134,127 , final statistics for the R-CHOP training set 
  are the fitted Cox coefficients of the log(hazard	ratios) for the explanatory variables 
 ∈ 134,127 . Hazard ratio intervals equal exp  , exp . They are useful for a 
comparison of the relative impact on survival explained by different GEP effects. Cox  
values are for individual GEP effects in the final model (not directly comparable to 
likelihood ratio based  values for effect selection). 
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III.2.2.3   127 is a GCB-DLBCL-only survival effect 
If effect   127 is used alone in a univariate Cox model, it also shows a “higher expression is better” trend 
like effect   134 before, albeit relative weakly and inconsistently with  only 0.009 (for the R-CHOP training 
set). Hence, it was no candidate as primary predictor variable with respect to   10 . Interestingly, after  
134 has been added to the Cox model,   127 is able to explain much of the observed survival on top of that 
with   5.6 ⋅ 10 (likelihood ratio test) and with anti-aligned survival trend (  0 and   0). Only a 
multivariate survival analysis can reveal such dependencies. 
To elucidate this hierarchical survival dependency, I partition R-CHOP treated patients by their expression 
of   134 into negative log(hazard	ratios) (i.e. lower risk and relatively favorable outcome) and positive 
log(hazard	ratios) (i.e. higher risk and relatively adverse outcome). Then the explanatory value of adding  
127 to the model is separately quantified for each risk partition by   134. Again   127 conveys significant 
explanatory value for the lower risk partition, even with   1.0 ⋅ 10 despite the reduced sample set (this is 
better than   5.6 ⋅ 10 before for the full R-CHOP training set). On the other hand, it is not significant for the 
higher risk partition (  0.15). This indicates that   134 can partition patients cleanly into two biologically 
distinct phenotypes. 
Fitting a univariate Cox model based only on   127 to the lower risk partition of   134 results in  
  0.59 (  1.9 ⋅ 10); applying this predictor to both partitions visualizes the one-sidedness of this 
effect(Figure III.2.2.3.a). 
 R-CHOP & higher risk by     R-CHOP & lower risk by     
 
Figure III.2.2.3.a) Univariate predictor based on  127 applied to risk partitions of  134 
Survival predictions for 408 R-CHOP-treated patients in the higher risk partition of   134  and for 282 R-CHOP-treated patients in the lower risk partition of   134. 
Chosen split points to present the survival spread in three risk intervals equal  log(hazard	ratios	of	150% . 
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For a better comparability with previously defined subtypes in DLBCL, I also applied the univariate   127 
predictor separately to ABC DLBCL and GCB DLBCL subsets of all R-CHOP treated patients(Figure III.2.2.3.b). Here, 
GCB DLBCL roughly corresponds to the lower risk partition of   134. 
 R-CHOP & ABC DLBCL R-CHOP & GCB DLBCL 
 
Figure III.2.2.3.b) Univariate predictor based on 127 separately applied to GCB DLBCL and ABC DLBCL 
Survival predictions for 288 R-CHOP-treated patients classified as ABC DLBCL and for 327 R-CHOP-treated patients classified as GCB DLBCL. Again, chosen split 
points to present the survival spread in three risk intervals equal  log(hazard	ratios	of	150%.  
As expected, effect   127 can explain significantly different survival within GCB DLBCL, while it does not 
have any significant additional explanatory value for the ABC DLBCL subtype. 
 
 
 
 
 
 
 
III.2.2.4 Predictions within risk partitions of   134 
Knowing that   127 only applies to one class of patients and that it displays an opposite survival trend 
relative to the primary effect, it might further increase predictive performance when applying the bivariate 
predictor separately to these primary classes. (Otherwise expressions of   127 for patients in the higher risk 
partition of   134 might wash out their predicted log(hazard	ratios).) Partitioning by   134 does not make 
the primary predictor variable completely superfluous, because it is still able to predict some survival 
dependencies within each partition (a binary partitioning cannot capture its full explanatory value). Still, 
remaining survival dependencies on   134 are weaker after partitioning, and sample counts in the low risk 
predictor interval for the high risk partition of   134 as well as in the high risk predictor interval for the low 
risk partition of   134 are thinned out. 
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 CHOP & higher risk by     CHOP & lower risk by     
 
 R-CHOP & higher risk by     R-CHOP & lower risk by     
 
Figure III.2.2.4) Bivariate predictor  ∈ 134,127 , predictor performance within risk partitions of   134 
Survival predictions for higher and lower risk partitions of   134, separately for R-CHOP and CHOP cohorts. Chosen split points to present the survival spread in 
three risk intervals equal  log(hazard	ratios	of	150%. 
Significant survival dependencies remain within both partitions, but most show only a weak spread. In the 
lower risk partition of   134 for R-CHOP therapy however, a subset of DLBCL patients with significantly 
adverse outcome because of their expression of effect   127 exists, despite showing relatively low risk based 
on   134 alone.  
This is not clearly reflected following CHOP therapy, which is consistent with univariate survival analyses in 
GCB DLBCL for   127 in individual cohorts. They neither showed significance for the former standard CHOP 
therapy, but were significant in both R-CHOP treated cohorts(cf. III.3.3.2). 
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III.2.2.5 Predictions within ABC DLBCL and GCB DLBCL subtypes 
For a better comparability with previously defined subtypes, the bivariate predictor is also applied 
separately to ABC DLBCL and GCB DLBCL. ABC DLBCL roughly corresponds to the higher risk partition of  134 and GCB DLBCL to its lower risk partition. 
 CHOP & ABC DLBCL CHOP & GCB DLBCL 
 
 R-CHOP & ABC DLBCL R-CHOP & GCB DLBCL 
 
Figure III.2.2.5) Bivariate predictor  ∈ 134,127, performance in subtypes ABC DLBCL and GCB DLBCL 
Survival predictions for ABC DLBCL and GCB DLBCL, separately for R-CHOP and CHOP cohorts. Chosen split points to present the survival spread in three risk 
intervals again equal  log(hazard	ratios	of	150%. 
While a strong survival dependency in R-CHOP treated GCB DLBCL exists again, survival prediction tends to 
be more consistent for risk partitions of   134(cf. Figure III.2.2.4) (for example, it displays a wider survival spread 
compared to R-CHOP & GCB DLBCL and reached significance between neighboring risk intervals when 
comparing to R-CHOP & ABC DLBCL). 
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III.2.3 Bivariate Model for the COO Induced Effect 
For a comparison, the bivariate analysis(III.2.2) is repeated, this time excluding the top GEP effect   134 as 
primary explanatory factor. In this case, the rediscovered COO induced effect   129(cf. III.3.2.2) is selected. Again, 
one secondary effect qualifies and no tertiary, using progression events from GSE10846.R-CHOP and 
GSE31312.R-CHOP as training base. 
This alternative bivariate survival model can also explain significant portions of observed patient outcome. 
However, both models are based on genetically only partially correlated GEP effects. This ambiguity 
demonstrates that survival dependencies can only be used to filter out unassociated GEP effects, but several 
equally valid GEP effects remain for explanation. In principle, all these effects could contain genes and represent 
pathways that might impact outcome differences following current therapy and for the molecular 
pathogenesis of DLBCL. Survival data alone cannot exclusively pinpoint a single GEP effect that is causal for 
certain. This also implies that the COO induced effect is just one among many(also see Figure III.2.5.1.a). 
Unlike before, the best secondary survival effect for the alternate model is shown to affect both GCB DLBCL 
and ABC DLBCL. This might indicate that the primary COO induced effect is not able to separate patients into 
biologically distinct survival subtypes as clear as effect   134. 
III.2.3.1 Selection of validated GEP effects as predictors 
Again, centered age is prescribed as initial factor in the Cox model to prevent advantages for GEP effects that 
are related to patient age by accident. As   134 is excluded,   129 with   1.8 ⋅ 10 is selected as primary 
explanatory GEP effect(cf. Figure III.2.2.1.a). 
Only three effects(Figure III.2.3.1) show additional significant explanatory value and thereby qualify as secondary 
predictor variable: 
 
Figure III.2.3.1) Selection of the best secondary GEP effect for survival prediction based on all 690 available samples from R-CHOP-treated patients 
Three GEP effects can explain significant additional survival dependencies ( value  10 , likelihood ratio test). The matrix shows whether they are genetically 
associated with each other (correlations of their consensus gene scores; cf. III.1.3.2). 
The first two effects are dominated by different single genes,   105 by KIAA1217 and   96 by FCRL5. 
Consequently, their consensus gene scores are perpendicular to each other with (;)  0.03(cf. Eqn. III.1.3.2.b) 
and to the multi-gene effect   134.  
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Even after explaining survival by the COO induced effect   129, survival effect   134 can still explain 
significant additional survival dependencies with   1.2 ⋅ 10 (rank #3). This was not the case vice 
versa(cf. Figure III.2.2.1.b). This difference in predictive capabilities is even more pronounced when learning with all 
samples, rather than only with samples from R-CHOP-treated patients(cf. III.2.5.1). Effect   127, i.e. the secondary 
explanatory variable for the primary bivariate model(cf. III.2.2.2), follows at rank #5 with   4.65 ⋅ 10, i.e. just 
over the prescribed error threshold of   10 . 
Effects that are dominated by single gene effects have the advantage of being very specific and the 
disadvantage of not having the support of a broad co-regulated genetic network. Still, as validated GEP effects 
they do not represent only noise, as there are several independently measured and correlated probesets 
pointing to the same gene; furthermore both   105 and   96 were unsupervisedly discovered in two 
independent cohorts.  
Consistently applying the selection procedure, I select the most explanatory effect for the model. However, 
in terms of  values both single gene effects provide nearly equal additional explanatory value here, i.e. they 
are practically both equally valid. 
None of the 135 validated GEP effects qualifies for addition as tertiary predictor variable on top of  ∈
129, 105 for the R-CHOP-treated training set (error threshold   10). 
 
 
 
 
 
III.2.3.2 Fit results, prediction performance and validation 
Taken together, this procedure selects two 
validated GEP effects  ∈ 129, 105 that can 
explain survival independently and on top of age. 
Fitting a bivariate Cox proportional hazard model 
() ⋅ exp∑ ∈,  for described sample 
scores(III.2.1.3) results in final statistics for the two 
selected GEP effects(Table III.2.3.2). 
Comparison with final fit statistics for 
 ∈ 134, 127(Table III.2.2.2) already shows that the COO 
based predictor has larger  values and can only predict weaker survival dependencies (lower ). To 
visualize this, again Kaplan-Meier survival estimates for risk intervals based on predicted log(hazard	ratios) are 
used(Figure III.2.3.2). 
The survival spread following R-CHOP reaches from 45% to 92% (  3.1 ⋅ 10, log rank test, 84+82 
patients) and from 21% to 58% in the CHOP validation set (  0.001, log rank test, 28+33 patients). Though 
still significant, both survival spreads are more narrow compared to before and prediction is less 
homogeneous for the inner risk intervals(compare Figure III.2.2.2). However, the top R-CHOP curve has a bit higher 
average survival compared to before (92.5% instead of 89%; not significant). 
GEP effect   129   105 
  0.525 -0.321 
Hazard ratios [0.59, 1.69] [0.73, 1.38] 
 values 2.1 ⋅ 10  3.0 ⋅ 10 
links to evaluation III.3.2.2 III.3.3.3 
Table III.2.3.2) Bivariate Cox model  ∈ 129,105 , R-CHOP training set 
  denote fitted Cox coefficients of the log(hazard	ratios) for the explanatory 
variables  ∈ 129,105 . Hazard ratio intervals equal exp  , exp . They 
are useful for a comparison of the relative impact on survival explained by different 
GEP effects. Cox  values are for individual GEP effects in the final model (not directly 
comparable to likelihood ratio based  values for effect selection). 
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 R-CHOP CHOP 
 
Figure III.2.3.2) Bivariate predictor  ∈ 129, 105, performance in the R-CHOP training set and generalization to the CHOP validation set 
Survival predictions for 690 R-CHOP-treated patients (left, training set) and 257 CHOP-treated patients (right, validation set). Chosen split points to present the 
survival spread in five risk intervals equal multiples -1.5, -0.5, 0.5 and 1.5 of a loghazard ratio of 150%. 
 
III.2.3.3 Subtype-specific analysis of   105 
To investigate whether   105 only influences one risk partition of   129 in a hierarchical fashion (like 
  127 did before(III.2.2.3) with respect to   134), I trained another univariate predictor for   105 based on 
R-CHOP-treated patients from the lower risk partition of   129 (i.e. predominantly based on GCB DLBCL 
samples). This resulted in   9.7 ⋅ 10 and rank #12 for   105 only. Training with the higher risk partition 
resulted still in rank#1 for   105, but only   1.6 ⋅ 10. This is a weaker association than when training 
with the full R-CHOP set (  4.5 ⋅ 10). In contrast, significance for effect   127 increased when fitting in 
the lower risk partition with respect to   134, despite the reduction in sample size. 
Hence, no clear-cut hierarchical survival dependency as seen for risk partitions of   134(cf. III.2.2.3) does exist 
here and outcome for both ABC DLBCL and GCB DLBCL depends on the selected secondary predictor variable 
  105. With the assumption that patients from the same true biological phenotype show identical survival 
dependencies over their average gene expressions, this result is another indication besides lower  values that 
the predictor based on  ∈ 134, 127(III.2.2) is a more natural fit of survival data and for subtypes within DLBCL 
compared to predictors based on the COO classification 
Still, as   105 is a highly specific effect based exclusively on KIAA1217 and as it can reveal a significant 
survival dependency on top of the standard COO induced effect, it will also be evaluated in detail(cf. III.3.3.3). 
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III.2.4 Bivariate Model for CHOP 
So far, fitted models were trained with samples from R-CHOP treated patients. Alternatively, samples from 
patients treated with the former standard CHOP therapy can be utilized. Again two effects iteratively qualify 
as significant explanatory variables with respect to   10 . While GEP effects selected as primary 
explanatory variables before are still in the front ranks for the CHOP training set as well, genetically distinct 
effects have higher explanatory value here.  
As all GEP measurements occurred before treatment, it can be assumed that they are similar to the R-CHOP-
treated cohorts. Hence, differences in explanatory value of GEP effects are probably caused by the 
retrospective follow-up information. This indicates that Rituximab did not increase survival uniformly for all 
DLBCL patients. It also shows again that several genetically distinct GEP effects exist that all may contain genes 
that are causal for the disease or maybe important to understand its consequences, for example for the tumor 
microenvironment. 
III.2.4.1 Selection of validated GEP effects as predictors 
Again, centered age is prescribed as initial factor in the Cox model to prevent advantages for GEP effects that 
are related to patient age by accident. While previously selected primary effects   134 and   129 can also 
explain CHOP survival significantly with   1.3 ⋅ 10 respectively   7.6 ⋅ 10, a group of four genetically 
highly correlated GEP effects occupies the top ranks, with   5 in the lead (  2.2 ⋅ 10): 
 
Figure III.2.4.1.a) Selection of the best primary GEP effect for survival prediction based on all 257 available samples from CHOP-treated patients 
In total 13 GEP effects can explain significant survival dependencies on top of patient age ( value  10 , likelihood ratio test). The matrix shows whether they are 
genetically associated with each other (correlations of their consensus gene scores; cf. III.1.3.2). 
Effect   5 is interesting, because it contains many genes with strongly differential signal and is detected at 
rank one in all three cohorts with frozen cell material and at rank two in the FFPE cohort; its biostatistical 
evaluation revealed(III.3.3.5) that it is significantly related to the extracellular matrix and collagen biosynthesis. 
However, this may also indicate that it is no direct measure of expressions of DLBCL cells. 
156 Chapter III - Dissecting DLBCL Gene Expressions 
 
Only two more GEP effects qualify as secondary explanatory variable for patient outcome following CHOP 
therapy after incorporating   5 in the model: 
 
Figure III.2.4.1.b) Selection of the best secondary GEP effect for survival prediction based on all 257 available samples from CHOP-treated patients 
Two GEP effects can explain significant additional survival dependencies ( value  10 , likelihood ratio test). The matrix shows whether they are genetically 
associated with each other (correlations of their consensus gene scores; cf. III.1.3.2). 
The primary effect in the best-performing predictor model for R-CHOP (  134) is still significant for CHOP 
treated patients on top of effect   5 (on rank #2 with   7.1 ⋅ 10); this is another indirect validation of  
134. In contrast, the COO induced effect   129 cannot explain any significant additional survival 
dependencies here (  0.025 and rank #32 only). 
Effect   44(III.3.3.5) provides only slightly better explanatory value (with   2.5 ⋅ 10) compared to   134. 
Sticking to the selection procedure, it becomes the secondary explanatory variable here. 
After incorporating   44 into the model, no tertiary effect qualifies for this CHOP based predictor. 
 
 
 
 
 
III.2.4.2 Fit results, prediction performance and validation 
Taken together, two validated GEP effects  ∈
5, 44 were selected that can explain CHOP 
survival independently and on top of age. Fitting 
a bivariate Cox proportional hazard model () ⋅
exp∑ ∈,   for described sample 
scores(III.2.1.3) results in final statistics for the two 
selected GEP effects(Table III.2.4.2). 
For visualization, again Kaplan-Meier survival 
estimates for risk intervals based on predicted 
GEP effect   5   44 
  -0.723 0.475 
Hazard ratios [0.48, 2.07] [0.62, 1.61] 
 values 9.0 ⋅ 10  2.6 ⋅ 10 
links to evaluation III.3.3.4 III.3.3.5 
Table III.2.4.2) Bivariate Cox model  ∈ 5,44 , CHOP training set 
  are the fitted Cox coefficients of the log(hazard	ratios) for the explanatory 
variables  ∈ 5,44 . Hazard ratio intervals equal exp  , exp. They are 
useful for a comparison of the relative impact on survival explained by different GEP 
effects. Cox  values are for individual GEP effects in the final model (not directly 
comparable to likelihood ratio based  values for effect selection). 
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loghazard	ratios are used. They show(Figure III.2.4.2) a spread from 17% to 63% (  2.2 ⋅ 10, log rank test, 53+46 
patients) of predicted survival in the CHOP training set and from 38% to 77% in the R-CHOP validation set 
(  8.3 ⋅ 10, log rank test, 106+106 patients): 
 CHOP R-CHOP 
 
Figure III.2.4.2) Bivariate predictor  ∈ 5,44; performance in the CHOP training set and its generalization to the R-CHOP validation set 
Survival predictions for 257 CHOP-treated patients (left, training set) and 690 R-CHOP-treated patients (right, validation set). Chosen split points to present the 
survival spread in five risk intervals again equal multiples -1.5, -0.5, 0.5 and 1.5 of a log(hazard	ratio	of	150%). 
The CHOP-trained predictor clearly validates for samples from R-CHOP treated patients. The highest risk 
interval containing 106 patients is strongly separated in the R-CHOP validation cohort (  1.6 ⋅ 10 to the 
neighboring lower risk interval). However, survival of most R-CHOP treated patients cannot be resolved as 
homogeneously by the CHOP-trained predictor as by the best R-CHOP trained predictor(cf. Figure III.2.2.2). The 
survival spread in the CHOP training cohort is even slightly lower compared to the predicted spread for the 
same patients by the best-performing R-CHOP-trained predictor (for identical risk intervals). 
Taken together, the best R-CHOP trained predictor(III.2.2) works approximately as well for CHOP as the CHOP-
trained predictor, but is more powerful and resolves survival more homogeneously for the current standard 
therapy. While significant GEP effects that qualified for the CHOP predictor may also contribute insightful 
information about molecular causes of DLBCL, the R-CHOP trained model should be preferred for predictive 
purposes. In part, this could be expected, as the R-CHOP training set consists of 690 events opposed to only 
257 available events for CHOP-treated patients. 
 
III.2.4.3 Hierarchical survival analysis of   44 
Partitioning CHOP-treated patients by the selected primary predictor variable   5 (at baseline 
eigensignal), shows that effect   44 can only predict significant additional survival dependencies for the high 
risk partition of   5 (still at rank #1 with   1.24 ⋅ 10), while for the lower risk partition of   5 it only 
ranks #12th with   0.024. 
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Similar to analyzing   127 in context of   134(cf. Figure III.2.2.3.a), this hierarchical survival dependency can be 
visualized by Kaplan Meier survival estimates for risk intervals of effect   44 in risk partitions by   5. This 
also confirms the hierarchical survival dependency in the R-CHOP validation set(Figure III.2.4.3).  
Counting patients outside of the respective baseline risk interval, approximately 36/131≈27% of CHOP-
treated and 98/384≈26% of R-CHOP-treated patients in the high risk partition of   5 seem to be influenced 
by this hierarchical effect: 
 CHOP & higher risk by     CHOP & lower risk by     
 
 R-CHOP & higher risk by     R-CHOP & lower risk by     
 
Figure III.2.4.3) Univariate predictor based on   44 applied to risk partitions of  5 
For CHOP-treated patients (upper panels), survival predictions show a dependency that exclusively exists in the higher risk partition of effect 5. This is confirmed 
in the R-CHOP-treated validation set (lower panel). 
Chosen split points to present the survival spread in three risk intervals equal  log(hazard	ratios	of	150% . 
 
III.2 - Multivariate Survival Prediction 159 
 
III.2.4.4 Subtype-specific analysis of   44 
The majority of patients in the higher risk partition of   5 are classified as ABC DLBCL. Hence the same 
hierarchical survival dependency might still exist when applying the univariate predictor based on   44 to 
DLBCL subtypes separately.  
While the trend is still noticeable(Figure III.2.4.4), survival differences are washed out. Hence,   44 probably does 
not stand in a biological hierarchical relation to the COO induced effect, but only to effect   5. 
 CHOP & ABC DLBCL CHOP & GCB DLBCL 
 
 R-CHOP & ABC DLBCL R-CHOP & GCB DLBCL 
 
Figure III.2.4.4) Univariate predictor based on   44 applied to DLBCL subtypes 
The hierarchical survival dependency(cf. III.2.4.3) is still visible when splitting by subtypes, because ABC DLBCL patients are overrepresented in the higher risk partition 
of 5; however, it is washed out. Chosen split points to present the survival spread in three risk intervals again equal  loghazard	ratios	of	150% . 
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III.2.5 Quinvariate Model for All Samples 
To extract the maximum information from available data, a Cox model is trained now with all available 
samples. For the same significance threshold   10 , five genetically independent GEP effects qualify for 
selection and can explain different dependencies of observed patient outcome. The resulting quinvariate 
model for survival prediction is validated by leave-one-out validation. 
The model confirms the predictive advantage of   134 (rank #1 as primary factor,   4.5 ⋅ 10) over the 
COO induced effect (  129, rank #2 as primary factor,   1.1 ⋅ 10).  
Prediction performance based on leave-one-out validation shows a homogeneous spread from 29% to 89% 
average survival(cf. Figure III.2.5.3.b). Comparison with outcome differences predicted by standard DLBCL 
subtypes(III.2.1.8) shows an obvious and strong increase in predicted survival spreads, both for CHOP and R-
CHOP therapy. Significant survival differences are also predicted within standard subtypes(cf. Figure III.2.5.6) and 
within risk partitions of the primary survival effect   134(cf. Figure III.2.5.7). Additionally, significantly different 
survival within risk classes by international prognostic index(cf. Figure III.2.5.8) is predicted. 
Together, these results indicate that GEP effects selected as predictor variables in the quinvariate model 
probably contain novel and not yet molecularly understood mechanisms with significant impact on DLBCL 
patient outcome and that known standard DLBCL subtypes are intrinsically heterogeneous. Therefore, all 
selected GEP effects will be biostatistically evaluated in III.3.3. 
 
III.2.5.1 Selection of validated GEP effects as predictors 
To prevent selection advantages for GEP effects that are accidentally associated with DLBCL-unspecific 
factors, centered age is prescribed as first predictor variable again; it explains survival dependencies with  
5.5 ⋅ 10 over all patients. Additionally and as two cohorts were treated with the former standard CHOP 
chemotherapy, therapy is prescribed as second predictor variable (  4.1 ⋅ 10 over all patients). This also 
prevents finding GEP effects that are accidently associated with the type of follow-up event. 
For   10 , 21 GEP effects show(Figure III.2.5.1.a) significant additional explanatory value. Like for the best-
performing bivariate predictor that was only trained with R-CHOP events(III.2.2), effect   134(III.3.3.1) is again the 
most explanatory variable for observed patient outcome (  4.5 ⋅ 10). On rank #2 and with a distance, the 
well-known COO induced effect(III.3.2.2) follows (  1.1 ⋅ 10). The top effect for the CHOP-trained bivariate 
model (  5) follows at rank #3 (  2.6 ⋅ 10). Other effects already seen during factor selection for CHOP-
trained(Figure III.2.4.1.a) and R-CHOP-trained(Figure III.2.2.1.a) models follow, plus some effects that have not been 
revealed when learning with a reduced sample base. 
It should be stressed again that all these unsupervisedly detected GEP effects are hereby validated on 
survival level, i.e. in principle all of them could contain genes that are causal for the disease, not just the 
strongest ones selected for the predictor model. 
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With   134 as primary explanatory variable in the predictor, 16 GEP effects can provide significant 
explanatory value on top of that(Figure III.2.5.1.b). As before(Figure III.2.2.1.b), the COO induced effect   129 is no longer 
significant as secondary factor (  5.3 ⋅ 10 and rank #35 only), as   134 can already explain most survival 
dependencies explained by it. Vice versa, if   129 was selected as primary factor here (not plotted),   134 
would still be significant as secondary explanatory variable (with   1.4 ⋅ 10  on rank #2), again 
demonstrating that it is the more natural choice as primary DLBCL survival effect. 
 
Figure III.2.5.1.b) Selection of the secondary GEP effect for survival prediction based on all 947 available events 
Training with all samples, 16 validated GEP effects can explain significant additional survival dependencies ( value  10 , likelihood ratio test). The matrix shows 
whether they are genetically associated with each other (correlations of their consensus gene scores; cf. III.1.3.2). 
 
Figure III.2.5.1.a) Selection of the primary GEP effect for survival prediction based on all 947 available events 
In total, 21 GEP effects can explain significant survival dependencies on top of age and therapy ( value  10 , likelihood ratio test). The matrix shows whether they 
are genetically associated with each other (correlations of their consensus gene scores; cf. III.1.3.2). 
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As for the R-CHOP-based model(Figure III.2.2.1.b), the genetically correlated effects   131 and   127 occupy 
ranks #1 and #2 for the secondary explanatory variable, but this time   131 is slightly in the lead (  1.6 ⋅
10 instead of   2.0 ⋅ 10). The correlation of their consensus gene scores equals (;)  0.80(cf. Eqn. 
III.1.3.2.b), i.e.   127 and   131 are genetically similar and also share many top genes like IRF4 and BATF, as 
they are based on the same discovered effect in one of the four DLBCL cohorts. Consistently applying the 
selection procedure,   131 becomes the secondary explanatory variable for the predictor trained with all 
samples. 
Like before, two effects can explain the strongest survival trends. However, using all samples as learning set 
has the power to reveal some additional genetically independent effects with significant explanatory value, 
albeit their influence on survival is not as strong as for the first two variables. Probably they play a role only 
relatively small patient subsets. The best tertiary explanatory variable is the quad-discovered effect   19 
(with   7.5 ⋅ 10). Effect   75 follows at rank #2 (with   9.1 ⋅ 10): 
 
Figure III.2.5.1.c) Selection of the tertiary GEP effect for survival prediction based on all 947 available events 
Shown are two validated GEP effects with a p value  10 (likelihood ratio test) for their additional explanatory value of observed patient outcome. Again, the 
matrix shows whether they are genetically associated with each other (correlations of their consensus gene scores; cf. III.1.3.2). 
 
In selection iteration four,   75 is still significant and now at rank #1 (with   3.6 ⋅ 10). This indicates 
that it explains different survival dependencies compared to the last selected effect   19; otherwise, it would 
no longer be significant. The  value for   75 even decreases a bit after adding   19 to the model (this can 
happen if already selected effects can stratify samples in a way such that additional independent survival 
dependencies are revealed, as has been seen(III.2.2.1) for   127 on top of   134). 
In selection iteration five, another quad-discovered effect qualifies (  3 with   2.5 ⋅ 10). 
After selecting it, no more GEP effect can convey any additional significant explanation of observed patient 
outcome (relative to the chosen significance threshold of   10). 
 
III.2.5.2 Fit results 
Taken together, the selection procedure yields five validated GEP effects  ∈ 134, 131, 19, 75, 3 that can 
explain survival independently and on top of DLBCL-unspecific factors age and therapy. All of them will be 
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biostatistically evaluated and genetically discussed in detail(III.3.3). Fitting a Cox proportional hazard model 
 ⋅ exp∑ ∈,,,,  with all five selected effects for described sample scores(III.2.1.3) results in the 
following final statistics: 
GEP effect   134   131   19   75   3 
  -0.739 0.421 -0.287 0.232 0.257 
Hazard ratios [0.48, 2.09] [0.65, 1.52] [0.75, 1.33] [0.79, 1.26] [0.77, 1.29] 
 values 2.8 ⋅ 10 1.1 ⋅ 10  2.5 ⋅ 10 9.1 ⋅ 10 6.3 ⋅ 10 
link to evaluation  III.3.3.1 III.3.3.2 III.3.3.6 III.3.3.7 III.3.3.8 
Table III.2.5.2) Quinvariate Cox model, final statistics for the complete training set based on available samples and follow-up data for all DLBCL patients 
  are the fitted Cox coefficients of the log(hazard	ratios) for the five explanatory variables. Hazard ratio intervals equal exp , exp . They are useful for 
a comparison of the relative impact on survival explained by different GEP effects. Cox  values are for individual GEP effects in the final model (not directly 
comparable to likelihood ratio based  values for effect selection). 
Like before(Table III.2.2.2), the first two effects are associated with opposing survival trends, as sign 
sign. As consensus gene scores of effects   131 and   127 are strongly correlated ((;)  0.80), 
effect   131 stands in a similar hierarchical context(cf. III.2.2.3) to   134. Signs of   are also different for other 
variates and further hierarchical dependencies might exist (for example, effects  ∈ 19, 75, 3 might only affect 
some 2D risk partitions by both   134 and   131). One additional hierarchical dependency of   3 in 
partitions by  ∈ 19, 75 is illuminated in III.3.3.8. 
 
III.2.5.3 Leave-one-out cross-validation and predictor performance 
As the model has been trained using all available samples, no validation set remains. Therefore, leave-one-
out cross-validation is employed to test the predictive performance of the quinvariate model. 
For the five selected GEP effects, I fit   1 … 947 models of type  ⋅ exp∑ ∈,,,, , based on 
946 samples each. For example ,  are eigensignal strengths in effect   134 for all patients   2 … 947, 
except for the first one. Each fit is then used to predict the log(hazard	ratio) for the left-out sample only. I.e. for 
  1 the prediction reads ∑ ∈,,,,  , where   are the fitted coefficients without using   1 and 
  are the eigensignal strengths in all five GEP effects for the left-out patient   1. 
Taken together, this procedure results in predictions for every sample, but never uses a particular sample for 
its own prediction. Resulting distributions of   over all 947 fits are tight, which already indicates an effective 
generalization performance: 
 
Figure III.2.5.3.a) Distributions of   over all 947 leave-one-out fits 
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To test and quantify predictive performance, seven risk intervals based on predicted loghazard	ratios from 
leave-one-out validation have been visualized by Kaplan-Meier survival estimates and compared via log rank 
tests. Resulting survival curves(Figure III.2.5.3.b) show that it is possible to predict a survival spread from approxi-
mately 29% to 89% with the quinvariate model and to resolve survival homogeneously in-between. Log rank 
test  values in the legend compare all seven risk intervals to each other; top and bottom risk intervals are 
highly separate with ,  9.1 ⋅ 10 , thoroughly validating the predictive performance of the quinvariate 
GEP based predictor. 
As samples originate from four independent patient cohorts, it is also safe to assume that no systematic 
survival bias can exist that is specific only to all four analyzed DLBCL cohorts, but not to DLBCL in general. 
Hence, this leave-one-out-validated quinvariate predictor shows a generalization performance that is very 
promising for its application to future DLBCL cohorts. 
all samples 
 
Figure III.2.5.3.b) Quinvariate predictor performance for all 947 DLBCL samples based on leave-one-out validation 
Leave-one-out survival predictions for all available 947 available patients using the quinvariate model. Chosen split points to present the survival spread in seven risk 
intervals equal multiples -2.5, -1, -0.5, 0.5, 1 and 2.5 of a log(hazard	ratio	of	150%).  
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III.2.5.4 Predictions within CHOP and R-CHOP subsets 
To double-check that the predictor does not just predict survival differences because of therapy, and to show 
that it is applicable to both CHOP- and R-CHOP-treated patients as well as to both overall and progression-free 
survival, I also applied it separately to the CHOP- and R-CHOP-treated cohorts(Figure III.2.5.4). Clearly, predicted 
outcome for patients is significantly different again; top and bottom survival curves are separated with , 
1.1 ⋅ 10 for 257 CHOP-treated patients and ,  6.3 ⋅ 10  for 690 R-CHOP-treated patients, respectively. 
Comparing this result with survival dependencies predicted by standard subtypes(III.2.1.8) shows an obvious 
and strong increase in predicted survival spreads, both for CHOP and R-CHOP. (This could in part be expected, 
as subtype classification is based on just one relatively heterogeneous GEP effect(see e.g. [29].figure 3 for GSE31312), rather 
than being based on five genetically distinct correlation-based effects.) 
 CHOP R-CHOP 
 
Figure III.2.5.4) Quinvariate predictor performance for all CHOP-treated and R-CHOP-treated cohorts 
Quinvariate leave-one-out survival predictions for 257 CHOP-treated patients (left) and 690 R-CHOP-treated patients (right). Chosen split points to present the 
survival spread in five risk intervals equal multiples -1.5, -0.5, 0.5 and 1.5 of a loghazard ratio of 150%).  
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III.2.5.5 Prediction performance for FFPE and frozen cell material 
Interestingly, the survival spread between ABC DLBCL and GCB DLBCL was considerably lower for 
GSE31312 as for GSE10826 when comparing both R-CHOP treated cohorts(cf. Figure III.2.1.8).  
One difference between these cohorts is that GSE31312 is based on FFPE samples (rather than based on 
fresh frozen cell material). Hence, it is conceivable that this difference might cause that the standard 
classification into subtypes is less strongly associated with outcome in GSE31312. However, this is probably 
not the case, because survival spreads between top and bottom risk intervals that were predicted by the 
quinvariate model are very similar for both R-CHOP treated cohorts(Figure III.2.5.5). This might indicate that 
GSE10846-based gene signatures that are currently used for subtype classification(cf. Figure III.3.2.2.c) are too cohort-
specific do not generalize well, making subtype classifications difficult to reproduce for new DLBCL cohorts(also 
read III.3.2.2), irrespective of their underlying cell material. 
 GSE10846.R-CHOP GSE31312.R-CHOP 
  
Figure III.2.5.5) Quinvariate predictor performance, separately for frozen cell material and FFPE based R-CHOP cohorts 
Quinvariate leave-one-out survival predictions for 220 patients from GSE10846.R-CHOP (frozen cell material, left) and 470 patients from GSE31312.R-CHOP (FFPE, 
right). Chosen split points to present the survival spread in three risk intervals equal log(hazard ratios of 133%). 
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III.2.5.6 Predictions within ABC DLBCL and GCB DLBCL 
To demonstrate that the quinvariate predictor indeed reveals survival dependencies beyond those already 
known by standard subtype classification, I also applied it separately to ABC DLBCL samples and GCB DLBCL 
samples(Figure III.2.5.6). As expected, sample counts in risk intervals with negative loghazard	ratios) are thinned out 
for ABC DLBCL and sample counts in risk intervals with positive loghazard	ratios) are thinned out for GCB 
DLBCL, reflecting the known difference in average subtype survival. Still, significant survival dependencies 
remain on top of this, for both ABC DLBCL and GCB DLBCL and within both CHOP and R-CHOP treated cohorts: 
 CHOP & ABC DLBCL CHOP & GCB DLBCL 
 
 
 R-CHOP & ABC DLBCL R-CHOP & GCB DLBCL 
 
Figure III.2.5.6) Quinvariate model, predicted survival dependencies within standard ABC- and GCB-like DLBCL subtypes 
Quinvariate leave-one-out survival predictions shown separately for standard DLBCL subtypes and for CHOP and R-CHOP therapies.  
Chosen split points to present the survival spread in three risk intervals equal loghazard	ratios	of	150%). 
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III.2.5.7 Predictions within risk partitions of   134 
Effect   127 and hence its genetically highly correlated partner effect   131 influence survival 
hierarchically(III.2.2.3), i.e. it only affect patients in the lower risk partition of the primary effect. For this reason 
and as before(cf. III.2.2.4), predictions are additionally analyzed for each risk partition of   134 separately(Figure 
III.2.5.7) rather than for all samples simultaneously. 
The lower risk partition of   134 roughly corresponds to GCB DLBCL and its higher risk partition roughly 
corresponds to ABC DLBCL, but no samples are excluded as “unclassified” by partitioning at zero effect 
eigensignal(cf. III.2.1.3). Similar to splitting into standard subtypes(Figure III.2.5.6) and as expected by average survival, 
 CHOP & higher risk by     CHOP & lower risk by     
 
 R-CHOP & higher risk by     R-CHOP & lower risk by     
 
Figure III.2.5.7) Quinvariate model, predicted survival differences within risk partitions of   134 
Quinvariate leave-one-out survival predictions shown separately for risk partitions of 134 and for CHOP and R-CHOP therapies. Chosen split points to present the 
survival spread in three risk intervals equal log(hazard	ratios	of	150%). 
III.2 - Multivariate Survival Prediction 169 
 
samples in lower risk predictor intervals are thinned out in the higher risk partition of   134 and samples in 
higher risk predictor intervals are thinned out in its lower risk partition. 
As with the bivariate model(III.2.2.4, III.2.2.5), splitting into risk partitions of   134 allows for a cleaner separation 
by survival with lower  values compared to splitting into standard subtypes(Figure III.2.5.6), despite including all 
unclassified samples that usually have average outcome and wash out predicted survival spreads. For 
example, the two lower risk intervals for ABC DLBCL in R-CHOP are separated only with   0.019 only, but 
corresponding survival curves in the higher risk partition of   134 are already separated by   4.5 ⋅ 10 . 
This is consistent with other indications that partitioning by   134 seems to be the more natural choice for 
identification of DLBCL subtypes. This is especially interesting, because the GEP effect   134 is genetically 
rather distinct from the rediscovered COO induced effect   129 and it may point to genes that are potentially 
causal to the disease, but so far biologically unexplored in DLBCL context(cf. III.3.3.1). 
 
 
 
 
 
 
 
III.2.5.8 Predictions within risk classes by International Prognostic Index 
The international prognostic index[100] (IPI) summarizes macroscopic clinical data for survival prediction. In 
brief, the IPI score for a patient is the sum of following general conditions: IPI  age  60 Ann	Arbor	stage  3)  LDH	ratio  1)  #	extranodal	sites  2)  ECOG	performance	score  2. It can also 
predict a strong survival spread, but it cannot give any hints to molecular causes of the disease, nor could it 
robustly recommend therapies, once therapies that are specific for molecular subtypes exist. Still, for clinical 
relevance of predictors it is important to know, whether molecular effects can predict significant survival 
differences within IPI risk classes. Clinical data for IPI scores were available for the majority of patients in both 
R-CHOP cohorts and I applied the quinvariate predictor separately to risk classes determined by IPI 
scores(Figure III.2.5.8). 
As expected, a general trend can be observed that higher IPI risk classes show lower average survival and 
hence have more patients in high risk intervals of the molecular predictor. As not all patients have IPI 
annotations and due to splitting into four risk classes, remaining numbers are not very high. This is probably 
the major reason, why some neighboring curves do not show significant survival differences. However, 
survival trends are consistent with predicted molecular risks within all IPI risk classes and thus it may be 
anticipated that even neighboring curves will gain significance for future larger sample counts. 
Already now, significant differences in patient outcome between top and bottom risk intervals can be 
molecularly predicted within each IPI risk class. This demonstrates that macroscopic clinical observables 
underlying the IPI score can no longer serve as surrogates for molecular prediction, as soon as different 
therapies for different molecular subtypes are clinically available. 
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 R-CHOP & low clinical risk R-CHOP & low-intermediate clinical risk 
 
 R-CHOP & high-intermediate clinical risk R-CHOP & high clinical risk 
 
Figure III.2.5.8) Quinvariate model, predicted survival differences within IPI risk classes 
163 samples from GSE10846.R-CHOP and 415 samples from GSE31312.R-CHOP having all clinical data for IPI score computation were partitioned into: a) low clinical 
risk (IPI=0 or 1) , low-intermediate clinical risk (IPI=2), high-intermediate clinical risk (IPI=3) and a high clinical risk (IPI=4 or 5). The quinvariate predictor was 
applied to each sample subset. Chosen split points to present survival spreads in three risk intervals equal  loghazard	ratios	of	150%. 
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III.3 Biostatistical Evaluation 
To decode and to model cellular pathways that might explain why top genes of discovered 
effects are highly correlated to each other, a first step is to biologically examine all validated 
GEP effects that significantly differentiate patients with Diffuse Large B-Cell Lymphoma. 
This evaluation usually consists of two collaborative parts that may be iterated: genetic 
interpretation and experimental validation by experts in molecular biology as well as bio-
statistical evaluation of detected effects and of subsequent experiments based on available 
computable genomic and clinical knowledge. 
This section presents the initial iteration of the latter. These analyses might help to identify 
disease-specific effects that are promising targets for further experimental validation in 
molecular biology. 
Selected effects are evaluated in detail based on several clinical and genomic analyses; 
similar analyses are available at  D=Interpretation for all 135 detected effects (15304 
Excel® tables and 36588 editable EPS plots). Additionally, statistical overview tables 
are provided that describe and link most plots and sub tables to quickly find files of bio-
logical interest. 
III.3.1 Analyses and Statistical Tests 
Biostatistical analysis methods have already been introduced(cf. I.3). This section briefly describes their 
application to discovered and validated GEP effects. 
III.3.1.1 Association with clinical knowledge 
Basic and nominal clinical annotations like patient gender can be associated with effects via usual 
contingency tables: Samples are sorted based on their effect eigensignal strengths ,
 (Table III.1.5) and then 
partitioned by cutting at zero. The association between resulting binary partitions and categories of nominal 
clinical covariates is quantified by   tests. 
Besides this binary partitioning, effect eigensignal strengths ,
  may alternatively be cut at  

 standard 
deviations of all samples ,
  ,
  in a cohort  . This cuts samples into three groups for each effect and is 
useful to reveal significant associations that only exist e.g. for upper effect strengths. For each validated GEP 
effect , associations of all available clinical covariates are computed for both partitioning alternatives. 
Besides for nominal covariates, the same sample partitions are used to associate effects with patient 
outcome. More precisely, Kaplan-Meier survival estimates are computed for each sample partition and log 
rank tests are used to compare these estimates(I.3.3). These survival analyses are univariate (i.e. effect-centric) 
and are useful for validation of single GEP effects by independently observed survival. They cannot reveal 
survival dependencies based on two or more effects; to analyze these dependencies, multivariate survival 
analyses have been performed(III.2). 
All associations of individual GEP effects with available clinical knowledge about samples are provided in 
graphical and tabular form at  D=Interpretation\clinical\v(effect index)\(clinical cohort name). 
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III.3.1.2 Association with genomic knowledge 
To interpret effects biologically and their DLBCL-specificity in particular, existing knowledge about their top 
genes and their function should to be systematically collected. 
In the easiest case, the same set of genes has already been discovered in other fields of biology or medicine 
and is clearly DLBCL-unspecific, for example differential expressions between different blood cells. 
Usually, effects are only roughly associated with existing genomic knowledge and it is not trivial to see a 
biological connection or an underlying pathway that links all significant associations. Hence, often further 
biological experiments asking specific questions about individual genes in model cell lines are required to 
reverse-engineer underlying pathways step by step. 
Notably, even for effects that do not have any significant association with survival, these genomic analyses 
might still help to identify parts of the molecular pathogenesis of DLBCL, as observed patient outcome is based 
on either the CHOP or R-CHOP therapy. For example, effects might represent potential attack vectors that are 
not utilized by current therapies. On the other hand, they could also be DLBCL-unspecific effects like the 
gender induced effect. 
Gene set enrichment analyses and other basic signature statistics are utilized to reveal related sets of genes 
from a combined database comprised of 13584 known gene signatures that have been discovered and studied 
in a wide range of fields in human biology and were imported from various sources(cf. I.3.1). Genes are ranked by 
the same maximally biologically informative gene scores that were selected for cross-cohort validation(III.1.3.2). 
Hence, top genes in this gene order show both a strong differential signal between patients and are highly 
correlated to other top genes of the same effect. 
Gene ontology overrepresentation analyses(I.3.2) are utilized to reveal terms in cellular components, 
molecular functions and biological processes that are significantly related to top genes of respective effects. 
For each effect, overrepresentation is tested for several gene signatures of top-correlated or of top-anti-
correlated effect genes (genes are ranked as above and then cut by their relative correlation in 10% steps). 
These genomic analyses have also been computed for all 135 validated GEP effects and are available in effect 
subfolders at  D=Interpretation\genomic. 
An example of another complementary genomic association analysis is the correlation of top effect genes to 
copy number differences measured by array comparative genomic hybridization (aCGH). This analysis is not 
part of this work, but might reveal amplifications or losses on DNA level at or around genomic loci of effect top 
genes. Ideally, this could identify oncogenes respectively tumor suppressor genes that are the key regulators 
of validated GEP effects. 
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III.3.2 Effects Identified by Sample Annotations 
First, the quad-discovered gender effect is presented that also serves as independent control of the whole 
analysis pipeline. 
Next, effects are interrogated for their association with standard DLBCL subtypes. One particular 
unsupervisedly discovered effect is identified as the rediscovered cell of origin induced effect[4], because its 
sample axes show 95% agreement with public classifications into ABC DLBCL and GCB DLBCL for all samples. 
Several other genetically distinct effects are also significantly related to DLBCL subtypes and have markedly 
different predictive capabilities, demonstrating that a binary classification can only provide a very rough 
summary of survival trends over gene expressions. 
III.3.2.1   2: Gender effect and annotation mistakes 
 Effect overview 
The strongest effect in terms of differential expression between patients was observed for genes that 
significantly differentiate males and females(Table III.3.2.1). Naturally, this effect exists in all four detection cohorts. 
It is not DLBCL-specific. Detection ranks were #3(GSE10846.CHOP), #4(GSE10846.R-CHOP), #6(GSE4475.nonMBL) and #6(GSE31312.R-
CHOP). The average correlation of these detected effect across cohorts is the second-highest with 3,4,6,6) 
0.88(cf. III.1.2.2). This effect and its validation is also an independent control of detection, validation, annotation and 
interpretation pipelines for real world data. 
As expected, exemplary detections from two cohorts 
show(Figure III.3.2.1) that the effect signal has a binary 
nature. Clearly, patients are correctly predicted and 
sorted by gender(pink/blue). Naturally, the effect is carried 
by genes from  and  chromosomes, for example XIST 
and EIF1AY(cf. Table III.3.2.1.a). Only men can have an 
expression for  chromosome genes and consequently 
women have negative logratio) for these genes(blue). 
(All expression ratios are computed relative to cohort-
average gene expressions.) 
This is a prime example for a reflection of well-
known chromosomal features on gene expression 
level. Due to very strong foldings relative to the noise 
level, correlations of top genes with this effect are very 
high. Typical gene expression effects that are based on 
regulation networks rather than on chromosomal 
features typically cannot reach correlations ||  0.9 
due to noise. Typical correlations in these cases are 
only ||  0.5, but associated  values are still 
approximately 10  or less. 
Despite being directly related to the chromosomal 
level, it is interesting that only few of in total 1822 measured probesets for the two gender chromosomes are 
correlated to the gender effect. One conceivable explanation could be that other measured probesets are 
simply not expressed in measured samples, but this is not the case here. (Probesets with    0.4 have an 
Top genes in     
Probeset 
Gene  
Symbol 
HG19  
locus 

,  
,  
,  

,  
. 
,  
204409_s_at EIF1AY Yq11.223 2.19 0.94 1.2E-116 2.05 
205000_at DDX3Y Yq11.21 2.11 0.96 3.2E-138 2.02 
201909_at RPS4Y1 Yp11.31 2.03 0.94 3.6E-121 1.91 
206700_s_at KDM5D Yq11.222 1.62 0.93 5.9E-116 1.51 
232618_at TXLNG2P Yq11.222 1.43 0.87 4.1E-90 1.24 
236694_at TXLNG2P Yq11.222 1.39 0.87 3.7E-93 1.21 
228492_at USP9Y Yq11.21 1.38 0.87 6.3E-93 1.20 
204410_at EIF1AY Yq11.223 1.31 0.86 1.4E-76 1.13 
214131_at TXLNG2P Yq11.222 1.20 0.83 1.7E-65 0.99 
223646_s_at TXLNG2P Yq11.222 1.14 0.84 5.0E-79 0.96 
223645_s_at TXLNG2P Yq11.222 1.03 0.84 3.0E-79 0.86 
205001_s_at DDX3Y Yq11.21 0.93 0.88 1.9E-83 0.82 
230760_at ZFY Yp11.31 0.99 0.80 1.7E-65 0.79 
206624_at USP9Y Yq11.21 0.80 0.76 1.1E-49 0.61 
211149_at UTY Yq11.221 0.68 0.82 3.1E-62 0.55 
214983_at TTTY15 Yq11.21 0.65 0.79 5.7E-57 0.51 
244482_at  Yq11.223 0.61 0.69 2.6E-42 0.42 
243712_at XIST Xq13.2 -0.94 -0.69 3.3E-42 -0.65 
231592_at TSIX Xq13.2 -1.24 -0.86 4.9E-88 -1.07 
235446_at  Xq13.2 -1.36 -0.81 1.1E-69 -1.11 
224589_at XIST Xq13.2 -2.17 -0.95 9.7E-145 -2.05 
227671_at XIST Xq13.2 -2.34 -0.95 9.5E-145 -2.21 
221728_x_at XIST Xq13.2 -2.51 -0.92 6.7E-104 -2.31 
214218_s_at XIST Xq13.2 -2.58 -0.92 7.5E-105 -2.37 
224590_at XIST Xq13.2 -2.70 -0.97 1.0E-175 -2.61 
224588_at XIST Xq13.2 -3.10 -0.98 1.4E-198 -3.03 
Table III.3.2.1.a) Top genes in validated effect   2 
 (probesets) from Affymetrix U133 Plus 2.0 microarrays;  
  manufacturer annotations (NetAffxTM,[97] v33) 
 
,  Components of the consensus gene axis of effect   2
  (cf. Table III.1.5); filtered 
,   0.4. 
 
,  Consensus gene correlations; filtered 
,  0.4. 
 
,   values for the correlations (cf. II.5.2.1) 
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average logintensity) over all samples of 3.89 and show a clearly differential signal(Figure III.3.2.1). For probesets 
that are correlated less, 916/1796 show a higher average logintensity); 99 of them even have average 
logintensities) of >7. This indicates that they are expressed, but not in a gender-modulated way.) 
 Potential gender annotation mistakes 
Some patients show significant (as per  value for 
correlations to the effect’s consensus gene axis) and clearly 
defined gender on gene expression level that is different from 
their annotated gender(Table III.3.2.1.b and pink/blue classification in Figure III.3.2.1). 
Annotations for these samples should be reexamined. 
(Patient IDs together with their correlations to the effect’s 
gene axis and associated  values are available in definition 
tables for consensus effect   2 in cohort subfolders of 
 C=Consensus Effects.) 
 Survival and clinical associations 
Besides gender, no other clinical covariate was consistently 
and significantly associated with this effect. (All clinical 
correlations and contingency tables are available in c) clinical 
correlations* tables in subfolders of  D=Interpretation\clini-
cal\v002.) 
Interestingly, females were borderline significantly associated with favorable outcome in one cohort 
(GSE10846.R-CHOP  0.049, log rank test for patients partitioned at zero effect eigensignal). A study[101] showed a 
similar survival bias. However, this trend could not be validated in any of the three other cohorts 
(GSE10846.CHOP  0.68, .  0.82,   0.32). All relevant and validated DLBCL survival factors 
based on gene expressions have been systematically analyzed(III.2) and the gender effect was not significant. 
Possibly, this weak association is a shadow of age related biases in this cohort, potentially caused by general 
lower life expectancy for males. 
 Genomic associations 
Surprisingly, in the combined signatures database comprising 13586 published gene signatures from 
various sources(I.3.1), only two signatures are related to this gender effect and only remotely so. The first is the 
positional gene set chryq11(cf. online interpretation card) with 204 defined and 29 measured genes, an average logratio) 
of 0.88 and a rather low enrichment score of 0.5 (GSEA  0.002 based on 514 permutations,   0.2%). The 
second signature on the other regulation side is Disteche, escaped from X inactivation(cf. online interpretation card) with 
13 defined and measured genes, an average logratio of 0.28 and an enrichment score of 0.85 (GSEA  0.002 
based on 489 permutations,   0.2%). For comparison, the average logratio of top genes of   2 is 3.89 
and 4.34 respectively, i.e. much stronger. (The complete signature analyses for the gender effect with all 
statistics is available at  D=Interpretation\genomic\v002\SA.) 
 Inference 
Given its perfect suitability as control effect, I expected more gender-specific gene expression signatures in 
public signature databases. It might be a useful addition, especially as only a specific subset of expressed 
probesets from  and  chromosomes are actually strongly correlated to this gender effect. 
Besides its use in method validation contexts, it might be utilized for quality control of gender annotations 
when publishing large studies with gene expression measurements. 
GEP effect 
strength 
# annotated  
as males 
# annotated  
as females 
GSE10846.CHOP (163/181 patients annotated) 
 0 2 72 
 0 88 1 
 value 9.8 ⋅ 10  (  test) 
GSE10846.R-CHOP (220/233 patients annotated) 
 0 2 91 
 0 126 1 
 value 4.0 ⋅ 10  (  test) 
GSE4475 (DLBCL only, 76/166 patients) 
 0 2 35 
 0 39 0 
 value 1.3 ⋅ 10  (chi² test) 
GSE31312 (470/498 patients annotated) 
 0 9 185 
 0 262 14 
 value 1.0 ⋅ 10  (  test) 
Table III.3.2.1.b) Gender effect, contingency with clinical annotations 
Patients of each cohort were partitioned at zero eigensignal 
strength(Table III.1.5) for GEP effect   2. 
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Figure III.3.2.1) Detected gender effects 
Gender effects detected in GSE10846.R-CHOP (233 patients) and GSE31312 (498 patients). Both are part of the quad-discovered consensus gender effect. Sample 
effect strengths (orange curves in center panels) are clearly either positive or negative with a jump in-between, as can be expected for a naturally binary effect. 
Enlarged gender classifications show some mismatches between GEP based genders and annotations. Due to the obvious signal of the gender effect on GEP level, 
these are presumably annotation mistakes. 
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III.3.2.2   129: Cell of origin induced effect (standard DLBCL subtypes) 
 Identification of the cell of origin induced effect 
The COO induced effect distinguishes ABC DLBCL from GCB DLBCL(cf. [4] and Figure I.1.2.1). To test whether it has 
been unsupervisedly rediscovered, contingency tables have been computed for previously identified patient 
subtypes and for each of the 135 validated GEP effects. 
Many validated GEP effects can arrange patients with a significant bias to subtype. All effects are 
depicted(Figure III.3.2.2.a) that agree with  70% to previous subtype classifications when partitioning samples at 
zero effect eigensignal(III.3.1.1). In principle, all these GEP effects might help to comprehend DLBCL subtype 
biology. However, the smaller the agreement, the more likely it is that the effect represents a pathway that is 
not restricted to only one subtype. 
 
Figure III.3.2.2.a) Validated GEP effects that are top-associated with public sample classifications as ABC DLBCL or GCB DLBCL 
Validated GEP effects with  70%  agreement to public classifications as ABC DLBCL or GCB DLBCL from all four cohorts when partitioning samples by cutting at zero 
eigensignal of the respective consensus effect. Contingency tables for both resulting effect partitions and for public ABC/UC/GCB annotations are provided in text 
form; their  values are based on   tests. The matrix shows whether effects are genetically associated with each other (weighted correlations of their consensus gene 
axes; cf. III.1.2.1). 
With 95% agreement over all four cohorts (  2 ⋅ 10), GEP effect   129 is clearly at rank #1, thereby 
identifying it as the rediscovered cell of origin induced effect. It is followed by   25 (90% agreement,  10) that has a highly correlated consensus gene scores to the first effect with ;  0.85(cf. Eqn. III.1.3.2.b) and 
thus can be considered biologically similar (for one cohort, both consensus effects are even based on the 
identical discovered effect). 
At rank #3, a quad-discovered effect follows (  20, 88% agreement,   3 ⋅ 10). This effect is interesting, 
because it is based on rather different genes (;  0,36) and can only predict relatively weak survival 
differences(cf. III.3.4.1). This demonstrates that a binary classification into subtypes can only provide a relatively 
rough summary of genetic survival trends compared to gradual effect strengths, as no patient ordering within 
classes can be prescribed in this way. 
Effect   134 at rank #4 can still arrange patients into ABC DLBCL and GCB DLBCL with 84% agreement, 
but like   20 it is based on rather different genes (;  0.29). Because of its excellent survival 
prediction capability,   134 is evaluated in detail(cf. III.3.3.1). 
Effect   131 follows at rank #5. It is strongly correlated to effect   127 (;  0.80). Both are not 
genetically correlated to   129 (;  0.04 and ;  0.29), but these effect play an important 
role in multivariate survival analysis(III.2.2.3) and are, therefore, also presented in detail(in III.3.3.2). 
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 Effect overview 
Effect   129 has been unsupervisedly detected in two cohorts (at rank #11 in GSE10846.R-CHOP and at 
rank #12 in GSE31312.R-CHOP). Application of this effect sorts patients from GCB DLBCL to ABC DLBCL, as is 
depicted exemplary for the largest cohort(Figure III.3.2.2.b, page 179). Similar plots and definition tables are available for 
all four cohorts in  C=Consensus Effects\(cohort subfolder); they supervisedly validate the effect’s existence 
in each cohort. 
Other than for the gender effect(III.3.2.1), effect strengths for patients are gradual here. Patients in the center do 
not have sufficient correlation to the effect’s gene axis and hence their eigensignal is gray(II.4.2.1). Patients with 
effect strengths near zero therefore should be considered neither ABC DLBCL nor GCB DLBCL. (Previous 
subtype classifications implicitly assumed that every patient is either ABC DLBCL or GCB DLBCL by using a 
two-class Bayes predictor model[83] and hence could underestimate the ratio of “unclassified” patients with 
respect to the COO induced effect; cf. III.2.1.9.) 
The effect is two-sided, i.e. it is comprised both of correlated “ABC>GCB” and anti-correlated “GCB>ABC” 
genes. All correlated genes with strong folding between patients as per gene scores(III.1.3.2) 
  ⋅ 
  are 
listed(Table III.3.2.2.a) for cutoffs 
   0.4 and 
   0.4; the complete list is available in  DLBCL Master Table 
2015, gene orders.xlsx. 
Correlated genes in   129 (ABCGCB DLBCL) Anti-correlated genes in   129 (GCBABC DLBCL) 
Probeset 
Gene  
Symbol 
HG19  
locus 

,  
,  
 ,  

,  
. 
,  
Probeset 
Gene  
Symbol 
HG19  
locus 

,  
,  
,  

,  
. 
,  
44790_s_at KIAA0226L 13q14.13 1.39 0.63 3.1E-27 0.88 1554413_s_at SNX29P2 16p11.2 -1.06 -0.53 3.1E-18 -0.56 
219471_at KIAA0226L 13q14.13 1.15 0.61 3.7E-25 0.70 219753_at STAG3 7q22.1 -1.02 -0.52 3.9E-17 -0.52 
224838_at FOXP1 3p13 0.92 0.69 9.4E-34 0.63 204249_s_at LMO2 11p13 -0.96 -0.54 7.8E-19 -0.52 
224837_at FOXP1 3p13 0.79 0.66 3.7E-30 0.52 236981_at C17orf99 17q25.3 -1.12 -0.45 3.6E-13 -0.51 
223287_s_at FOXP1 3p13 0.79 0.61 1.1E-24 0.48 206310_at SPINK2 4q12 -1.05 -0.45 3.6E-13 -0.48 
235444_at FOXP1 3p13 0.74 0.59 2.0E-23 0.44 242334_at NLRP4 19q13.43 -1.14 -0.41 6.5E-11 -0.47 
212827_at IGHM 14q32.33 1.05 0.40 1.8E-10 0.42 226281_at DNER 2q36.3 -1.13 -0.41 9.1E-11 -0.46 
244413_at CLECL1 12p13.31 0.80 0.47 5.6E-14 0.37 211597_s_at HOPX 4q12 -1.00 -0.45 7.6E-13 -0.45 
229844_at FOXP1 3p13 0.62 0.60 2.0E-24 0.37 223159_s_at NEK6 9q33.3 -0.74 -0.59 6.4E-23 -0.43 
229114_at GAB1 4q31.21 0.80 0.46 9.7E-14 0.37 207599_at MMP20 11q22.2 -0.99 -0.42 1.8E-11 -0.42 
1558996_at FOXP1 3p13 0.68 0.54 4.8E-19 0.37 223158_s_at NEK6 9q33.3 -0.68 -0.61 4.0E-25 -0.41 
227198_at AFF3 2q11.2 0.82 0.45 6.3E-13 0.37 227703_s_at SYTL4 Xq22.1 -0.88 -0.46 9.5E-14 -0.41 
203753_at TCF4 18q21.2 0.66 0.55 1.7E-19 0.36 202119_s_at CPNE3 8q21.3 -0.74 -0.54 7.2E-19 -0.40 
213891_s_at TCF4 18q21.2 0.66 0.53 3.3E-18 0.35 206181_at SLAMF1 1q23.3 -0.75 -0.53 1.7E-18 -0.40 
212386_at TCF4 18q21.2 0.68 0.50 2.6E-16 0.34 231049_at LMO2 11p13 -0.77 -0.51 5.1E-17 -0.40 
222762_x_at LIMD1 3p21.31 0.61 0.56 1.7E-20 0.34 213906_at MYBL1 8q13.1 -0.94 -0.42 2.7E-11 -0.39 
225331_at CCDC50 3q28 0.64 0.52 4.0E-17 0.33 229041_s_at LOC100505746 21q22.3 -0.83 -0.47 2.0E-14 -0.39 
220230_s_at CYB5R2 11p15.4 0.74 0.44 3.5E-12 0.32 204604_at CDK14 7q21.13 -0.76 -0.50 8.9E-16 -0.38 
212382_at TCF4 18q21.2 0.60 0.52 1.3E-17 0.31 231455_at LINC00487 2p25.2 -0.86 -0.44 2.7E-12 -0.38 
1553369_at FAM129C 19p13.11 0.66 0.47 2.1E-14 0.31 244467_at SHISA8 22q13.2 -0.91 -0.41 6.0E-11 -0.37 
203313_s_at TGIF1 18p11.31 0.61 0.49 1.8E-15 0.30 242794_at MAML3 4q31.1 -0.74 -0.49 1.5E-15 -0.37 
204562_at IRF4 6p25.3 0.66 0.45 5.3E-13 0.30 202118_s_at CPNE3 8q21.3 -0.68 -0.51 9.0E-17 -0.35 
212387_at TCF4 18q21.2 0.55 0.53 2.1E-18 0.29 239697_x_at C3orf67 3p14.2 -0.78 -0.44 3.7E-12 -0.34 
222146_s_at TCF4 18q21.2 0.58 0.51 1.7E-16 0.29 244367_at  11p13 -0.66 -0.50 4.1E-16 -0.33 
212385_at TCF4 18q21.2 0.61 0.48 6.9E-15 0.29 200644_at MARCKSL1 1p35.1 -0.62 -0.51 5.3E-17 -0.32 
232739_at SPIB 19q13.33 0.60 0.48 4.5E-15 0.29 218640_s_at PLEKHF2 8q22.1 -0.60 -0.53 4.8E-18 -0.32 
1557049_at BTBD19 1p34.1 0.65 0.44 1.5E-12 0.29 219874_at SLC12A8 3q21.2 -0.68 -0.46 2.8E-13 -0.31 
228837_at TCF4 18q21.2 0.55 0.50 9.3E-16 0.27 234284_at GNG8 19q13.32 -0.75 -0.41 1.0E-10 -0.31 
230983_at FAM129C 19p13.11 0.65 0.42 2.7E-11 0.27 223624_at ZFAND4 10q11.22 -0.62 -0.50 6.6E-16 -0.31 
1565034_s_at AFF3 11q23.3 0.65 0.41 1.4E-10 0.26 230509_at SNX22 15q22.31 -0.61 -0.50 3.9E-16 -0.31 
204269_at PIM2 Xp11.23 0.52 0.48 7.6E-15 0.25 218862_at ASB13 10p15.1 -0.63 -0.49 3.2E-15 -0.30 
226304_at HSPB6 19q13.12 0.59 0.42 1.7E-11 0.25 243185_at  10p14 -0.66 -0.45 5.3E-13 -0.30 
235056_at ETV6 12p13.2 0.54 0.46 3.0E-13 0.24 212314_at SEL1L3 4p15.2 -0.57 -0.52 1.0E-17 -0.30 
205222_at EHHADH 3q27.2 0.59 0.41 8.5E-11 0.24 205570_at PIP4K2A 10p12.2 -0.59 -0.50 2.5E-16 -0.30 
212345_s_at CREB3L2 7q33 0.50 0.47 1.9E-14 0.24 1553499_s_at SERPINA9 14q32.13 -0.66 -0.44 1.3E-12 -0.29 
239973_at  7p15.3 0.52 0.45 6.7E-13 0.23 211502_s_at CDK14 7q21.13 -0.62 -0.45 4.0E-13 -0.28 
208690_s_at PDLIM1 10q23.33 0.48 0.49 2.6E-15 0.23 235213_at ITPKB 1q42.12 -0.57 -0.48 7.7E-15 -0.28 
204083_s_at TPM2 9p13.3 0.53 0.44 3.3E-12 0.23 224102_at P2RY12 3q25.1 -0.64 -0.42 1.8E-11 -0.27 
218792_s_at BSPRY 9q32 0.55 0.42 3.8E-11 0.23 235353_at SEL1L3 4p15.2 -0.57 -0.47 2.9E-14 -0.27 
233483_at TBC1D27 17p11.2 0.51 0.45 7.5E-13 0.23 200965_s_at ABLIM1 10q25.3 -0.64 -0.42 3.3E-11 -0.27 
218699_at RAB7L1 1q32.1 0.50 0.46 2.1E-13 0.23 225637_at DEF8 16q24.3 -0.66 -0.41 1.2E-10 -0.27 
235051_at CCDC50 3q28 0.49 0.46 1.4E-13 0.23 212975_at DENND3 8q24.3 -0.52 -0.50 2.2E-16 -0.26 
200953_s_at CCND2 12p13.32 0.55 0.41 1.1E-10 0.23 225622_at PAG1 8q21.13 -0.56 -0.47 2.7E-14 -0.26 
203988_s_at FUT8 14q23.3 0.55 0.41 5.7E-11 0.23 222699_s_at PLEKHF2 8q22.1 -0.55 -0.48 8.2E-15 -0.26 
244845_at  3p13 0.50 0.44 3.3E-12 0.22 227684_at S1PR2 19p13.2 -0.53 -0.50 8.5E-16 -0.26 
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213262_at SACS 13q12.12 0.47 0.46 9.2E-14 0.22 225626_at PAG1 8q21.13 -0.56 -0.46 8.9E-14 -0.26 
223218_s_at NFKBIZ 3q12.3 0.53 0.41 5.3E-11 0.22 212311_at SEL1L3 4p15.2 -0.57 -0.46 2.6E-13 -0.26 
225436_at FAM108C1 15q25.1 0.49 0.45 7.5E-13 0.22 1563621_at  7p14.2 -0.51 -0.50 4.5E-16 -0.26 
201160_s_at CSDA 12p13.2 0.50 0.43 6.8E-12 0.22 221039_s_at ASAP1 8q24.21 -0.52 -0.49 3.6E-15 -0.25 
207641_at TNFRSF13B 17p11.2 0.47 0.46 9.8E-14 0.22 217991_x_at SSBP3 1p32.3 -0.49 -0.51 1.2E-16 -0.25 
226818_at MPEG1 11q12.1 0.48 0.44 1.9E-12 0.21 1554575_a_at BPNT1 1q41 -0.50 -0.49 1.7E-15 -0.25 
233955_x_at CXXC5 5q31.2 0.49 0.43 5.1E-12 0.21 224790_at ASAP1 8q24.21 -0.51 -0.48 6.6E-15 -0.24 
223422_s_at ARHGAP24 4q21.23 0.49 0.43 8.4E-12 0.21 1568817_at  21q22.3 -0.60 -0.41 1.3E-10 -0.24 
201811_x_at SH3BP5 3p25.1 0.44 0.47 7.6E-14 0.21 230278_at  1q42.3 -0.58 -0.41 6.7E-11 -0.24 
204642_at S1PR1 1p21.2 0.44 0.46 9.2E-14 0.20 204137_at GPR137B 1q42.3 -0.57 -0.42 2.8E-11 -0.24 
228693_at CCDC50 3q28 0.48 0.42 3.9E-11 0.20 241942_at PXDNL 8q11.22 -0.57 -0.41 6.0E-11 -0.23 
203761_at SLA 8q24.22 0.44 0.45 4.4E-13 0.20 235841_at  4q31.1 -0.53 -0.44 3.2E-12 -0.23 
201810_s_at SH3BP5 3p25.1 0.46 0.43 4.6E-12 0.20 235632_at  9q33.3 -0.46 -0.50 4.4E-16 -0.23 
212654_at TPM2 9p13.3 0.43 0.46 2.3E-13 0.20 206348_s_at PDK3 Xp22.11 -0.51 -0.45 5.7E-13 -0.23 
244480_at  18q21.2 0.44 0.44 1.6E-12 0.20 224796_at ASAP1 8q24.21 -0.48 -0.47 6.2E-14 -0.22 
205965_at BATF 14q24.3 0.45 0.43 5.4E-12 0.19 210829_s_at SSBP2 5q14.1 -0.54 -0.41 7.2E-11 -0.22 
218700_s_at RAB7L1 1q32.1 0.46 0.42 2.3E-11 0.19 201209_at HDAC1 1p35.1 -0.47 -0.47 3.4E-14 -0.22 
236831_at CCDC50 3q28 0.45 0.42 4.2E-11 0.19 204891_s_at LCK 1p35.1 -0.50 -0.44 1.9E-12 -0.22 
239231_at  19p13.11 0.43 0.44 3.1E-12 0.19 210461_s_at ABLIM1 10q25.3 -0.55 -0.40 1.9E-10 -0.22 
1561167_at  12p13.2 0.45 0.41 5.2E-11 0.19 225214_at LOC100129034 9q33.3 -0.43 -0.51 7.3E-17 -0.22 
207237_at KCNA3 1p13.3 0.45 0.41 1.0E-10 0.18 238353_at RASL11A 13q12.2 -0.45 -0.49 4.0E-15 -0.22 
212097_at CAV1 7q31.2 0.41 0.44 1.6E-12 0.18 229713_at PIP4K2A 10p12.2 -0.47 -0.46 8.6E-14 -0.22 
203068_at KLHL21 1p36.31 0.41 0.43 5.3E-12 0.18 208456_s_at RRAS2 11p15.2 -0.51 -0.42 1.6E-11 -0.22 
203143_s_at KIAA0040 1q25.1 0.42 0.43 7.4E-12 0.18 229040_at LOC100505746 21q22.3 -0.48 -0.45 4.6E-13 -0.21 
205861_at SPIB 19q13.33 0.41 0.44 3.3E-12 0.18 212829_at PIP4K2A 10p12.2 -0.46 -0.47 5.7E-14 -0.21 
207655_s_at BLNK 10q24.1 0.42 0.41 1.1E-10 0.17 203723_at ITPKB 1q42.12 -0.48 -0.45 9.6E-13 -0.21 
209939_x_at CFLAR 2q33.1 0.42 0.40 2.3E-10 0.17 1555626_a_at SLAMF1 1q23.3 -0.43 -0.49 1.4E-15 -0.21 
243878_at  3p13 0.41 0.40 1.5E-10 0.17 203537_at PRPSAP2 17p11.2 -0.43 -0.49 2.3E-15 -0.21 
200599_s_at HSP90B1 12q23.3 0.40 0.42 4.1E-11 0.17 228360_at LYPD6B 2q23.1 -0.52 -0.41 1.1E-10 -0.21 
       212590_at RRAS2 11p15.2 -0.48 -0.44 3.2E-12 -0.21 
       227354_at PAG1 8q21.13 -0.48 -0.43 5.5E-12 -0.21 
       205922_at VNN2 6q23.2 -0.48 -0.43 5.2E-12 -0.21 
       212646_at RFTN1 3p25.1 -0.50 -0.42 3.7E-11 -0.21 
       222942_s_at TIAM2 6q25.2 -0.46 -0.44 1.2E-12 -0.20 
       232103_at BPNT1 1q41 -0.47 -0.43 9.1E-12 -0.20 
       1569481_s_at SNX22 15q22.31 -0.45 -0.44 1.3E-12 -0.20 
       221781_s_at DNAJC10 2q32.1 -0.43 -0.46 1.6E-13 -0.20 
       236533_at ASAP1 8q24.21 -0.44 -0.44 1.7E-12 -0.20 
       203521_s_at ZNF318 6p21.1 -0.46 -0.43 1.0E-11 -0.19 
       201425_at ALDH2 12q24.12 -0.47 -0.41 7.2E-11 -0.19 
       224791_at ASAP1 8q24.21 -0.43 -0.44 1.8E-12 -0.19 
       204890_s_at LCK 1p35.1 -0.43 -0.44 2.4E-12 -0.19 
       215886_x_at USP12 13q12.13 -0.46 -0.41 8.6E-11 -0.19 
       212974_at DENND3 8q24.3 -0.40 -0.46 1.8E-13 -0.19 
       241155_at  10p12.2 -0.42 -0.44 3.6E-12 -0.18 
       242650_at  10q11.22 -0.41 -0.45 1.1E-12 -0.18 
       235242_at  2p16.1 -0.43 -0.42 1.8E-11 -0.18 
       201201_at CSTB 21q22.3 -0.40 -0.45 6.2E-13 -0.18 
       212589_at RRAS2 11p15.2 -0.40 -0.44 1.4E-12 -0.18 
       220694_at ASAP1-IT1 8q24.21 -0.40 -0.42 3.2E-11 -0.17 
       1563513_at SYTL4 Xq22.1 -0.40 -0.40 2.2E-10 -0.16 
       221496_s_at TOB2 22q13.2 -0.40 -0.40 1.8E-10 -0.16 
Table III.3.2.2.a) Top genes in validated effect   129 
 (probesets) from Affymetrix U133 Plus 2.0 microarrays; manufacturer annotations (NetAffxTM,[97] v33) 
 
,  Components of the consensus gene axis of effect   129 (cf. Table III.1.5); filtered 
,   0.4. 
 
, , 
 ,  Consensus gene correlations of   129; filtered 
,  0.4 and  values for the correlations (cf. II.5.2.1). 
 Role in survival analysis 
Consistent with known differences in average survival of ABC DLBCL and GCB DLBCL, effect   129 has 
been found to predict the second-most significant survival differences between all DLBCL patients with   1.1 ⋅
10 (Figure III.2.5.1.a) (and if restricted to R-CHOP treated patients still with   1.8 ⋅ 10(Figure III.2.2.1.a)). It has also 
been selected and analyzed as primary variable for a bivariate Cox proportional hazard survival model(III.2.3) 
that can predict strong survival differences both for R-CHOP and CHOP-treated patients(Figure III.2.3.2). 
 Clinical associations 
Besides significant association with DLBCL subtype in all four clinical cohorts, the effect is also significantly 
associated with IPI scores (both R-CHOP treated cohorts have IPI annotations and both are significantly 
associated: GSE10846.R-CHOP  6.2 ⋅ 10 and   7.8 ⋅ 10). This is not untypical for effects with strong 
predictive performance and indicates that some molecularly explainable survival differences can already be 
predicted by macroscopic clinical variables underlying the IPI score. 
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Figure III.3.2.2.b) Rediscovered cell of origin effect (  129)  
Cell of origin consensus effect (  129), example application to GSE31312 (498 patients). Enlarged public subtype classifications show subtype reproduction quality.  
(The genomic consensus effect is applied to the cleaned signal without lab effects(cf. III.1.4.2). Samples and probesets are ordered by their effect strengths in this cohort(cf. 
Table III.1.5). Additionally, probesets are filtered by demanding a relative correlation stronger than 0.5. The effect’s bimonotonic eigensignal(panel d) is grayed for samples 
having insufficient or insignificant correlation to this effect(II.4.2.1).) 
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 Genomic associations 
Gene ontology analysis did not reveal any specific and significantly overrepresented terms; some terms like 
sequence-specific DNA binding(cf. GO:0043565, [78]) are significant, but not very specific (8/62 top genes belong to 
this term comprised of 465/20370 measured genes;   8.0 ⋅ 10  via hypergeometric test). (All gene ontology 
analyses for this effect are available at  D=Interpretation\genomic\v129\GOA.) 
Signature analyses for   129 were able to confirm rediscovery of the COO induced effect, as  
several previously published DLBCL subtype signatures are significantly and strongly enriched for its top  
genes(Table III.3.2.2). 
Enrichment plots(Figure III.3.2.2.c) for the two largest top signatures ABCgtGCB_U133AB(online interpretation card) and 
GCB_gt_ABC_U133plus(online interpretation card) visualize their significance and again confirm rediscovery of the 
standard COO induced effect.  
 The rediscovery of the COO induced effect by correlations provides a filtered view on subtype-specific genes 
Gene selection criteria for these DLBCL signatures show that they are based on (a) -tests between sample 
subsets by previously predicted subtypes, (b) deselection of genes correlated with   0.2 to a proliferation 
signature and (c) in case of GCB_gt_ABC_U133plus also deselection of genes correlated with   0.2 to a lymph 
node signature.  
Using previously predicted subtypes as basis for gene signature definition can only test every gene 
individually, but does not examine correlations between genes. Given the low information base (every subtype 
annotation essentially carries only one bit of information per patient as there are only two subtypes), 
criterion (a) probably selects many genes that are biologically unspecific with respect to DLBCL subtype 
Signatures GSEA Basic Statistics 
Signatures DB Signature Name 
# 
defined 
# mea-
sured 
Enrich- 
ment 
score 
 FDR 
Mean 
log2( 
ratio) 
 (-test 
versus 
zero) 
Down- 
reg. ratio 
Upreg. 
ratio 
StaudtSigDB_dNov2012 ABC_gt_GCB_LC 15 15 0.946 0.0019 0.2% -0.887 5.9E-07 100.0% 0.0% 
StaudtSigDB_dNov2012 ABC_gt_GCB_PMBL_MCLBL_U133AB 53 52 0.840 0.0019 0.2% -0.700 1.3E-17 100.0% 0.0% 
StaudtSigDB_dNov2012 ABC_gt_GCB_Affy 20 20 0.871 0.0020 0.2% -0.645 2.3E-06 90.1% 9.9% 
StaudtSigDB_dNov2012 ABCgtGCB_U133AB 286 281 0.701 0.0019 0.2% -0.527 1.5E-70 98.9% 1.1% 
GeneSigDB_v4_Sept2011 Lymphoma_Poulson05_48genes 48 47 0.727 0.0019 0.2% -0.501 1.9E-10 94.2% 5.8% 
MolSigDBv4_0_dMay2014 
Reactome_purine_ribonucleoside_monop
Hosphate_biosynthesis 
11 11 0.673 0.0020 0.2% -0.090 0.0031 97.6% 2.4% 
MolSigDBv4_0_dMay2014 Spindle_organization_and_biogenesis 11 11 0.744 0.0020 0.2% -0.040 0.3830 58.5% 41.5% 
MolSigDBv4_0_dMay2014 Tsai_dnajb4_targets_up 13 13 -0.766 0.0022 0.2% 0.073 0.3299 39.5% 60.5% 
MolSigDBv4_0_dMay2014 Biocarta_tcytotoxicpathway 14 12 -0.783 0.0020 0.2% 0.059 0.2917 32.2% 67.8% 
MolSigDBv4_0_dMay2014 Biocarta_thelper_pathway 14 12 -0.764 0.0020 0.2% 0.078 0.1434 22.7% 77.3% 
MolSigDBv4_0_dMay2014 Module_293 12 11 -0.795 0.0020 0.2% 0.064 0.0548 21.5% 78.5% 
MolSigDBv4_0_dMay2014 Module_143 14 13 -0.774 0.0021 0.2% 0.107 0.0810 21.3% 78.7% 
MolSigDBv4_0_dMay2014 
Reactome_translocation_of_zap_70_to_im
munologicalsynapse 
14 11 -0.682 0.0020 0.2% 0.131 0.2075 24.4% 75.6% 
HGNCSigDB_dMay2014 Histocompatibility complex 44 21 -0.791 0.0019 0.2% 0.144 0.0039 7.1% 92.9% 
MolSigDBv4_0_dMay2014 Biocarta_blymphocytepathway 11 11 -0.771 0.0021 0.2% 0.190 0.0889 20.0% 80.0% 
MolSigDBv4_0_dMay2014 
Reactome_phosphorylation_of_cd3_and_tc
r_zeta_chains 
16 13 -0.693 0.0021 0.2% 0.227 0.0342 7.3% 92.7% 
StaudtSigDB_dNov2012 GC_B_cell_BLlow_DLBCLhigh 49 48 -0.690 0.0019 0.2% 0.521 1.1E-06 11.8% 88.2% 
GeneSigDB_v4_Sept2011 Lymphoma_Chin09_65genes 47 47 -0.734 0.0019 0.2% 0.655 1.1E-09 3.6% 96.4% 
StaudtSigDB_dNov2012 GCB_gt_ABC_U133plus 307 298 -0.752 0.0021 0.2% 0.598 1.4E-75 0.4% 99.6% 
GeneSigDB_v4_Sept2011 Lymphoma_Tome05_151genes 46 44 -0.823 0.0019 0.2% 0.816 1.5E-12 4.4% 95.6% 
StaudtSigDB_dNov2012 Germinal_center_Bcell_DLBCL 59 55 -0.792 0.0021 0.2% 0.780 2.6E-15 0.0% 100.0% 
StaudtSigDB_dNov2012 
Germinal_center_B_cell_DLBCL-
survival_predictor 
37 34 -0.867 0.0020 0.2% 0.945 2.0E-11 0.4% 99.6% 
StaudtSigDB_dNov2012 GCB_gt_ABC_LC 11 10 -0.980 0.0020 0.2% 1.395 0.0001 0.0% 100.0% 
 
Table III.3.2.2.b) Top-enriched signatures by   129 
Signatures with |enrichment	score|  0.67 and at least 10 measured members are listed for genes ranked by GEP effect   129.  
All GSEA  values are based on permutation tests; hence, they are lower-bounded by 1 #permutations)⁄  and true  values might be considerably lower in this case. 
1000 permutations have been computed for each signature, i.e. approximately 500 for each enrichment sign. Percentages of down- and upregulated genes in a 
signature are weighted averages of gene regulation signs (using 1   values of -tests against zero regulation as weights). 
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biology. Deselecting genes with respect to other signatures (i.e. criteria (b) and (c)) has probably been 
performed in order to filter some of these unspecific genes out again. However, correlation between remaining 
genes is still ignored and thus many genetically distinct effects are included in and mixed by resulting gene 
signatures. Such signatures were also utilized by previous subtype classifiers[83]. 
In contrast, signal dissection forms effects based on correlation maximization(cf. II.3.2), i.e. top genes in every 
effect are as highly correlated to each other as permitted by the signal. Hence, dissection into effects with 
maximal inter-gene correlations can help to dissect pathways that were only visible in overlapped and mixed 
form in previous gene signatures.  
Interestingly, most other discovered GEP effects that are significantly related to DLBCL subtypes have rather 
uncorrelated gene axes to effect   129, i.e. their top genes are rather different from each other(cf. Figure III.3.2.2.a). 
This indicates that the unsupervisedly rediscovered GEP effect   129 does not only match previous subtypes 
form four independent cohorts best, but can also be considered a genetically filtered redefinition of above ABC-
versus-GCB-DLBCL gene signatures and presumably of corresponding subtype biology. 
Still, the known genetic heterogeneity of DLBCL remains even for this filtered view in form of a rough 
signal(see Figure III.3.2.2.b); thus correlations of top genes to the effect (and thus to each other) are only moderate. 
Other discovered effects with strong survival impact(III.3.3) like   134 are smaller and possess some top genes 
of higher correlation. Assuming that higher correlations between genes indicate tighter biological relations, 
these effects could be biologically even more specific than this filtered redefinition of the COO induced effect 
in form of   129. 
 
 
Figure III.3.2.2.c) Significant enrichment of known ABC-versus-GCB DLBCL signatures by effect   129 
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 Preliminary top genes analysis 
For probesets with 
   0.4, 151 unique genes from 22 chromosomes participate in the effect, suggesting 
that it reflects a functional genomic network, rather than just reflecting local aberrations on DNA level. For 

   0.5, 19 unique genes from 12 chromosomes remain. 
Most top genes of   129 are contained in the two above-mentioned ABC-versus-GCB-DLBCL gene 
signatures. Several have already been investigated. To illuminate the filtered redefinition of the COO induced 
effect by   129, an individual review of its top-correlated genes in context of existing research is indicated. 
To start, the most specific genes for   129 are briefly presented here. 
FOXP1 is the best-correlated gene with ,  0.69; higher correlations do not exist due to the relatively 
rough signal of this effect. This gene has already been identified for DLBCL survival predictor models before[29] 
and a recent study[102] disclosed its molecular function as oncogene in lymphomas relying on NF-B activity. It 
directly represses transcription of seven pro-apoptotic genes and its aberrant expression can complement 
(constitutive) NF-B activity, which in total may contribute to lymphomagenesis[102]. 
KIAA0226L is the second-best-correlated gene with ,  0.63. No literature that directly relates 
this gene to DLBCL has been found, but a study in molecular oncology[103] observed silencing of KIAA0226L 
(aka C13orf18) through hypermethylation in cervical cancer. Its re-expression via artificial gene-specific 
transcription factors significantly inhibited cell growth and/or induced apoptosis. However, this cannot 
explain its role in DLBCL, because KIAA0226L is expressed higher in ABC DLBCL, i.e. for patients associated 
with adverse outcome. 
On the anti-correlated side, for example LMO2 with ,  0.54 is known as a powerful prognostic 
indicator in DLBCL[104]. It is specifically upregulated in the germinal center and a study on LMO2’s 
interactome[104] revealed that it increases transcriptional activity of NFATc1. An immunohistochemical 
study[105] on LMO2 confirmed its exclusive expression in GCB DLBCL (20/20) and negativity in ABC DLBCL 
(0/15). This gene is also expressed in Hodgkin lymphoma cases (23/23) and in Burkitt’s lymphoma (9/10). 
Regarding healthy tissues, it was exclusively found in the germinal center, but not in mantle, marginal and T 
cell zones. 
 Inference 
Several genes of this rediscovered COO induced effect have already been biologically investigated with 
respect to their contribution to DLBCL lymphomagenesis. The functional interplay of identified top-correlated 
genes and the role of KIAA0226L in particular may be interesting for further investigation. However, genes in 
GEP effect   134 presented next(III.3.3.1) might be more interesting, as   134 predicts survival most 
consistently and is comprised of fewer and higher correlated top genes (for the same correlation cutoff). 
III.3 - Biostatistical Evaluation 183 
 
III.3.3 Survival Effects 
Multivariate survival analysis(III.2) has revealed that several discovered GEP effects and combinations thereof 
are significantly associated with observed patient outcome. The COO induced effect(cf. III.3.2.2) has been shown to 
be only one among several(cf. Figure III.2.5.1.a). For interpretation of constructed survival predictors, relevant GEP 
effects are presented and biostatistically evaluated here. 
Some effects could be identified as unsupervisedly rediscovered versions of genomic entities that are known 
from previous DLBCL studies. Some effects are novel. Their biostatistical evaluations can provide a basis for 
their biological interpretation. 
The discussion of each effect starts with a summary of its role in survival analysis. Then its definition and an 
overview of its signal are provided, both in graphical and tabular form. Subsequently significant genomic 
associations or clinical associations are presented. If indicated, this is followed by a preliminary discussion of 
specific top correlated genes. An effect-specific outlook may infer analytically promising experimental 
investigations that might eventually lead to advances in modeling the molecular pathogenesis of DLBCL. 
 
III.3.3.1   134: Primary survival effect in DLBCL 
 Role in survival analysis 
Already during detection and before any systematic survival analyses, one GEP effect emerged by showing 
an obvious sorting of patients by outcome. A systematic comparison(Figure III.2.5.1.a) showed that this effect can 
explain survival more consistently (with   4.5 ⋅ 10) compared to the COO induced effect(cf. III.3.2.2) (  1.1 ⋅
10), despite consisting of only 69 unique correlated top genes, whereas the COO induced effect has 151 
unique top genes for an identical correlation cutoff (||  0.4). This might indicate that it is biologically more 
specific to DLBCL. Another indication for that is the existence of a hierarchical survival effect that strongly 
affects only one risk partition of   134, whereas the other partition is unaffected(III.2.2.3). Using the COO 
induced effect as primary predictor variable did not disclose such hierarchical dependencies(cf. III.2.3.1 and III.2.3.3). 
Additionally,   134 also ranks first as primary predictor variable when training only with samples from R-
CHOP treated patients(cf. III.2.2). Because of these properties, it is evaluated here in detail. 
 Effect overview 
Effect   134 was originally detected and dissected in the GEP signal of cohort GSE31312 at rank #27. It has 
been supervisedly validated on GEP level in all three other cohorts(e.g. Figure III.3.3.1.b). (See 134* files in  C=Con-
sensus Effects\(cohort subfolders).) Additionally, it validates against survival data in all four cohorts (see
 D=Interpretation\clinical\v134\(cohort subfolders)). 
Its application to the largest patient cohort illustrates(Figure III.3.3.1.a) that this effect is comprised of 
approximately 100 correlated and only few anti-correlated probesets (with relative correlation  0.5). 
Survival as indicated by censored/progression information(green/orange) shows that higher expression of 
correlated genes is associated with better patient outcome. On the upregulated side, GCB DLBCL patients are 
overrepresented, as could be expected due to higher average survival of GCB DLBCL. Comparison of subtype 
information(yellow/pink) shows that the sample order by   134 is partially correlated, but not identical to the 
COO induced sample order(cf. Figure III.3.2.2.b). More importantly, only a weak correlation between this effect’s 
consensus gene scores and the COO consensus gene scores exists (;  0.29(cf. Eqn. III.1.3.2.b)), 
demonstrating that these effects are based on different top genes. 
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Figure III.3.3.1.a) Validated effect   134, applied to GSE31312.R-CHOP 
Primary survival effect by multi-cohort survival analysis(III.2.5) applied to GSE31312.R-CHOP (498 patients). Enlarged binary classifications show 
censored/progression follow-up information (green/orange) as well as public subtypes (yellow/pink). 
(The genomic consensus effect is applied to the cleaned signal without lab effects(cf. III.1.4.2). Samples and probesets are ordered by their effect strengths in this cohort(cf. 
Table III.1.5). Additionally, probesets are filtered by demanding a relative correlation stronger than 0.5. The effect’s bimonotonic eigensignal(panel d) is grayed for samples 
having insufficient or insignificant correlation to this effect(II.4.2.1).) 
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Figure III.3.3.1.b) Validated effect   134, applied to GSE10846.R-CHOP 
Primary survival effect by multi-cohort survival analysis(III.2.5) applied to  GSE10846.R-CHOP (233 patients). Enlarged binary classifications show 
censored/progression follow-up information (green/orange) as well as public subtypes (yellow/pink). 
(The genomic consensus effect is applied to the cleaned signal without lab effects(cf. III.1.4.2). Samples and probesets are ordered by their effect strengths in this cohort(cf. 
Table III.1.5). Additionally, probesets are filtered by demanding a relative correlation stronger than 0.5. The effect’s bimonotonic eigensignal(panel d) is grayed for samples 
having insufficient or insignificant correlation to this effect(II.4.2.1).) 
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Similar effect plots and definition tables are available for all four cohorts in C=Consensus Effects\(cohort 
subfolder); they supervisedly validate the effect’s existence in each cohort. All probesets with a relative 
correlation  0.5 to the consensus sample axis are depicted; they are ordered by their differential signal 
between samples. While this signal ordering is necessary for bimonotonic regression and effect dissection, 
highly correlated genes with relatively weak differential signal may also be biologically important to 
understand underlying pathogenic pathways(III.1.3.2). For this reason, cohort-independent genomic analyses are 
based on both differential expression and correlation strength(cf. Table III.1.5). 
 Clinical associations 
As the COO induced effect before, this effect is significantly associated with IPI scores, albeit slightly less so 
(both R-CHOP treated cohorts have IPI annotations and both are significantly associated: GSE10846.R-CHOP  3.8 ⋅
10 and   0.03). Again, this is not untypical for effects with strong predictive performance and 
indicates that some molecularly explainable survival differences can already be predicted by macroscopic 
clinical variables underlying the IPI score. 
 Genomic associations 
Using the same gene scores for ranking, gene set enrichment analyses revealed only six significantly enriched 
signatures (filtering by |enrichment	score|  0.67 as before). As could be expected by rank #4 for the association 
with subtypes(cf. Figure III.3.2.2.a), again several known ABC-versus-GCB-DLBCL gene signatures are significantly 
enriched(Table III.3.3.1.a). However, one should be cautious not to overinterpret significant enrichment as it is not 
sufficient for high correlation of signature genes to an effect(cf.  III.3.4.1). 
Signatures with a positive enrichment score are more relevant for interpretation, as the effect consists 
predominantly of top correlated and only of few and relatively weakly anti-correlated genes. None of the four 
top enriched signatures does contain all top genes of   134; however, they contain genes that are only 
weakly correlated to the effect. This implies that   134 contains a subset of known subtype-specific genes 
that are highly correlated to each other, but so far scattered over various different gene signatures or 
embedded in larger and less specific signatures. To further elucidate biological implications of this, an 
individual review of top genes of   134 is indicated. 
Like for the COO induced effect(III.3.2.2), gene ontology analysis did not reveal any specific and significantly 
overrepresented terms; some terms like the nuclear envelope(cf. GO:0005635) are significant, but not specific (4/44 
top genes belong to this term, but it is comprised of 109/20370 measured genes;   8.9 ⋅ 10 via 
hypergeometric test). 
 
Signatures GSEA Basic Statistics 
Signatures DB Signature Name 
# 
defined 
# mea-
sured 
Enrich- 
ment 
score 
 FDR Mean log2( 
ratio) 
 (-test 
versus 
zero) 
Down- 
reg. ratio 
Upreg.  
ratio 
StaudtSigDB_dNov2012 GCB_gt_ABC_LC 11 10 0.849 0.0020 0.2% -1.346 0.0009 100.0% 0.0% 
StaudtSigDB_dNov2012 
Germinal_center_B_cell_DLBCL-
survival_predictor 
37 34 0.765 0.0021 0.2% -0.987 4.9E-11 98.3% 1.7% 
StaudtSigDB_dNov2012 Germinal_center_Bcell_DLBCL 59 55 0.741 0.0020 0.2% -0.905 1.4E-15 97.0% 3.0% 
GeneSigDB_v4_Sept2011 Lymphoma_Tome05_151genes 46 44 0.736 0.0019 0.2% -0.957 2.9E-13 95.6% 4.4% 
StaudtSigDB_dNov2012 ABC_gt_GCB_LC 15 15 -0.678 0.0019 0.2% 0.439 5.6E-05 0.0% 100.0% 
MolSigDBv4_0_dMay2014 
Xu_response_to_tretinoin-
and_nsc682994_dn 
15 15 -0.688 0.0020 0.2% 0.053 0.2324 38.7% 61.3% 
 
Table III.3.3.1.a) Top-enriched signatures by   134 
Signatures with |enrichment	score|  0.67 and at least 10 measured members are listed for genes ranked by GEP effect   134.  
All GSEA  values are based on permutation tests; hence, they are lower-bounded by 1 #permutations)⁄  and true  values might be considerably lower in this case. 
1000 permutations have been computed for each signature, i.e. approximately 500 for each enrichment sign. Percentages of down- and upregulated genes in a 
signature are weighted averages of gene regulation signs (using 1   values of -tests against zero regulation as weights). 
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 Preliminary top genes analysis 
For probesets with 
  0.4, 69 unique genes from 19 chromosomes participate in the effect, suggesting 
that this effect reflects a functional genomic network, rather than just reflecting local aberrations on DNA level. 
For 
  0.5, 19 unique genes from 7 chromosomes remain. 
The most specific effect gene is FGD6 with ,FGD6  0.84 (for its top correlated probeset). Its association 
with the effect is verified by five independently measured and highly correlated probesets. FGD6 is located in 
12q22 and is a protein coding gene with validated sequence as per RefSeq[106] status(information via 
http://www.ncbi.nlm.nih.gov/gene, [107], April 2015). Literature screening did not reveal any direct association with DLBCL. A 
retrospective medical study[108] about toxic side effects of several groups of chemotherapeutic agents revealed 
that a single-nucleotide polymorphism within FGD6 (adenine instead of guanine at base pair 95490248) can 
cause severe neutropenia/leucopenia for patients of various cancers when administered with Paclitaxel and 
carboplatin agents (  2.46 ⋅ 10). This might indicate a possible functional role of FGD6 in lymphocytes and 
maybe for B cells. 
KLHL6 follows at correlation rank #2 (,
  0.75 for its top probeset); its association with this effect is 
confirmed by four independently measured probesets. It is located in 3q27.1 and is also a protein coding gene 
with validated RefSeq status. A related molecular 
immunology study[109] compared gene expressions of ex-
vivo B cells from sheep that undergo hypermutation 
during antigen-independent development with in-vitro 
B cells having the same process arrested. (Normally, 
antigen-independent hypermutation builds the primary 
antibody reservoir.) The study revealed that KLHL6 
might be involved in the germinal center B-cell 
differentiation pathway. Furthermore, KLHL6 was 
exclusively expressed in lymphoid tissues compared to 
several other human tissues. Like BCL6 (that is also 
among top genes of   134), the KLHL6 protein 
contains a domain that is known for transcriptional 
repression activity. Combining several other results like 
the relevance of receptor cross-linking in the germinal 
center differentiation program, it was hypothesized that 
KLHL6 may be involved in re-modeling actin micro-
filaments during germinal center differentiation. 
LPP follows at correlation rank #3 (,
  0.74 for 
its top probeset; supported by four other correlated 
probesets). It is a protein coding gene with reviewed 
RefSeq status and is located in 3q28. A related high 
resolution genome-wide association study[110] revealed a 
susceptibility locus in the intergenic region between 
BCL6 and LPP on 3q27 (of length ~400kB) for non-
Hodgkin lymphoma in Chinese population. This locus is 
associated with increased risk, especially in DLBCL ( 
1.14 ⋅ 10), but not in non-B cell lymphomas. 
Top genes in     
Probeset 
Gene  
Symbol 
HG19  
locus 

,  
,  
,  

,  
. 
,  
1555137_a_at FGD6 12q22 1.18 0.84 1.3E-82 0.99 
228167_at KLHL6 3q27.1 1.05 0.75 1.8E-55 0.79 
243142_at FGD6 12q22 0.94 0.83 7.6E-79 0.79 
241879_at LPP 3q28 1.03 0.72 1.2E-48 0.74 
202822_at LPP 3q28 1.00 0.74 5.4E-53 0.74 
1555275_a_at KLHL6 3q27.1 1.06 0.69 3.7E-44 0.73 
226799_at FGD6 12q22 0.89 0.82 7.8E-73 0.72 
235000_at LPP 3q28 0.92 0.72 7.2E-50 0.67 
1555136_at FGD6 12q22 0.96 0.65 6.8E-37 0.62 
224811_at LPP 3q28 0.92 0.67 5.2E-40 0.61 
1556579_s_at IGSF10 3q25.1 1.02 0.58 3.5E-28 0.59 
240866_at  3q28 0.82 0.72 2.3E-48 0.59 
219901_at FGD6 12q22 0.71 0.75 5.8E-56 0.53 
241695_s_at  3q27.1 0.72 0.73 3.7E-51 0.52 
1560397_s_at KLHL6 3q27.1 0.84 0.57 3.4E-27 0.48 
1560396_at KLHL6 3q27.1 0.92 0.50 1.8E-20 0.46 
219304_s_at PDGFD 11q22.3 0.74 0.59 2.4E-29 0.44 
239697_x_at C3orf67 3p14.2 0.84 0.52 6.2E-22 0.44 
243573_at  3q28 0.61 0.70 8.0E-46 0.43 
231455_at LINC00487 2p25.2 0.92 0.45 1.8E-16 0.42 
1569344_a_at  7p21.1 0.85 0.47 3.9E-18 0.40 
1562637_at SAMD12 8q24.12 0.69 0.55 7.3E-25 0.38 
212458_at SPRED2 2p14 0.64 0.54 7.5E-24 0.35 
1558469_at LPP 3q27.3 0.60 0.56 3.0E-26 0.34 
213906_at MYBL1 8q13.1 0.67 0.50 1.7E-20 0.33 
218331_s_at FAM208B 10p15.1 0.71 0.47 1.2E-17 0.33 
218862_at ASB13 10p15.1 0.69 0.47 5.4E-18 0.32 
240144_at DNASE1 16p13.3 0.63 0.50 6.4E-20 0.31 
238181_at  1q31.2 0.67 0.47 1.8E-17 0.31 
235521_at HOXA3 7p15.2 0.66 0.46 4.7E-17 0.30 
217966_s_at FAM129A 1q25.3 0.72 0.42 5.4E-14 0.30 
204530_s_at TOX 8q12.1 0.65 0.45 1.3E-16 0.30 
244165_at FAM208B 10p15.1 0.62 0.47 4.0E-18 0.29 
243040_at  8q24.12 0.53 0.54 7.3E-24 0.28 
244887_at  1q31.2 0.65 0.43 3.9E-15 0.28 
235800_at  10q25.3 0.63 0.44 1.3E-15 0.28 
243198_at TEX9 15q21.3 0.55 0.49 8.2E-20 0.27 
212560_at SORL1 11q24.1 0.52 0.52 1.8E-22 0.27 
225997_at MOB1B 4q13.3 0.57 0.48 1.7E-18 0.27 
227354_at PAG1 8q21.13 0.53 0.51 2.1E-21 0.27 
204680_s_at RAPGEF5 7p15.3 0.52 0.51 1.3E-21 0.27 
210712_at LDHAL6B 15q22.2 0.48 0.56 4.7E-26 0.27 
1560180_at  2p23.1 0.62 0.43 5.7E-15 0.27 
215408_at  15q22.2 0.61 0.43 6.2E-15 0.26 
231442_at ZPBP2 17q12 0.55 0.48 1.2E-18 0.26 
1556755_s_at LOC286149 8q22.1 0.54 0.47 4.5E-18 0.26 
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Other top probesets with ,__
  0.73, 
,_
  0.72 and ,_
  0.70 are located 
in genomic vicinity of either KLHL6 or LPP. 
Presumably they measure expressions of the same 
genes, because they are genomically located directly 
before or after them (with in part overlapping 
probeset sequence intervals). But they do not have a 
gene annotation so far. In any case, they seem to be 
biologically related, because sequences underlying 
243573_at(transcript AA648962) and 241695_s_at(transcript 
AA648986) were both defined with human tonsillar cells 
that were enriched for germinal center B cells by flow 
sorting(provided by L.M. Staudt, National Cancer Institute, 1997). 
The locus 3q27 is known for typical translocations in 
B-cell lymphoma, but these translocations alone could 
not predict significant survival differences in 
DLBCL[111]. However, as this study was only based on 
14/93 DLBCL patients having 3q27 translocations, the 
study size might be too small to reach significance on 
survival level. Anyhow, the low 15% incidence of these 
3q27 translocations cannot explain the consistent GEP 
signal of effect   134, as it exists in most samples. 
While both BCL6 (3q27.3) and LPP (3q28) are top 
genes of   134, the other top gene KLHL6 in genomic 
vicinity (3q27.1) is located approximately 4.3MB 
before them. This indicates that a functional relationship may be needed to establish the correlation to the 
reported 400kB short susceptibility locus between BCL6 and LPP. To further examine the possibility of a 
reflection of a chromosomal feature on GEP level, 147 additional probesets have been analyzed that are 
located between KLHL6 in 3q27.1 and LPP in 3q28. Expressions of these 147 probesets are not correlated to 
the effect, but absolute expression levels (measured by their average logintensities) over all samples) are 
higher for 35/147 probesets than average logintensities) for KLHL6 and LPP (see  DLBCL Master Table 
2015, gene orders.xlsx). If a chromosomal feature without any connection to or modulation by a functional 
genomic network was reflected by this GEP effect, these 35 expressed probesets between KLHL6 and LPP 
should also be correlated to this effect, but this is not the case. 
MYBL1 (8q13.1) is depicted at rank #1 in the effect plot(Figure III.3.3.1.a), but more due to its strongly differential 
expression, rather than by high correlation to other genes in the effect (,
  0.50; this is comparable to 
MYBL1’s moderate correlation to the COO induced effect, i.e. ,  0.42). No direct relation of this gene 
to DLBCL has been found in the literature. However, for diffuse pediatric low-grade gliomas (PLGG), MYBL1 is 
known as partially duplicated transcription factor based on gains of its 8q13.1 locus[112]. (These aberrations 
result in truncated MYBL1 transcripts. A correspondingly transformed cell line formed tumors in nude mice, 
whereas the same cell line having full-length MYBL1 wild type constructs could not form any tumors.) 
202821_s_at LPP 3q28 0.48 0.53 2.7E-23 0.26 
203284_s_at HS2ST1 1p22.3 0.58 0.44 7.8E-16 0.26 
215405_at  15q22.2 0.52 0.49 1.3E-19 0.25 
219703_at MNS1 15q21.3 0.52 0.49 1.6E-19 0.25 
1566165_at  2q31.1 0.54 0.47 8.7E-18 0.25 
235171_at LOC100505501 8q12.1 0.51 0.49 1.1E-19 0.25 
203769_s_at STS Xp22.31 0.51 0.48 5.3E-19 0.25 
228464_at MIR3685 12q22 0.44 0.55 1.0E-24 0.24 
229588_at DNAJC10 2q32.1 0.52 0.46 3.9E-17 0.24 
231181_at  8q23.2 0.58 0.41 1.7E-13 0.24 
1556758_at FAM208B 10p15.1 0.49 0.48 1.8E-18 0.23 
244185_at  12q22 0.47 0.48 1.1E-18 0.23 
232471_at  15q22.2 0.49 0.47 1.5E-17 0.23 
1568751_at RGS13 1q31.2 0.55 0.41 3.0E-13 0.22 
239691_at C12orf77 12p12.1 0.46 0.48 7.8E-19 0.22 
220168_at CASC1 12p12.1 0.49 0.45 5.6E-16 0.22 
239249_at  3q27.3 0.41 0.51 1.2E-21 0.21 
213156_at  3q13.31 0.49 0.42 1.9E-14 0.21 
215990_s_at BCL6 3q27.3 0.41 0.50 1.3E-20 0.21 
241492_at  5q31.3 0.45 0.45 2.0E-16 0.20 
230707_at SORL1 11q24.1 0.42 0.48 1.3E-18 0.20 
240777_at SYNE2 14q23.2 0.46 0.44 2.0E-15 0.20 
1554168_a_at SH3KBP1 Xp22.12 0.45 0.44 7.2E-16 0.20 
203140_at BCL6 3q27.3 0.42 0.47 3.4E-18 0.20 
232125_at  3q13.31 0.47 0.41 7.4E-14 0.20 
219551_at EAF2 3q13.33 0.48 0.40 5.3E-13 0.19 
214276_at KLF12 13q22.1 0.42 0.47 1.1E-17 0.19 
1566242_at  7q22.1 0.41 0.46 3.9E-17 0.19 
212640_at PTPLB 3q21.1 0.41 0.45 1.4E-16 0.18 
225626_at PAG1 8q21.13 0.46 0.40 4.8E-13 0.18 
227713_at KATNAL1 13q12.3 0.45 0.41 2.7E-13 0.18 
1554122_a_at HSD17B12 11p11.2 0.44 0.41 1.4E-13 0.18 
239516_at  1q41 0.44 0.41 2.7E-13 0.18 
209967_s_at CREM 10p11.21 0.42 0.41 7.5E-14 0.17 
224586_x_at SUB1 5p13.3 -0.44 -0.49 2.9E-19 -0.21 
1566734_at LOC283454 12q24.22 -0.54 -0.44 8.2E-16 -0.24 
212664_at TUBB4A 19p13.3 -0.68 -0.49 7.2E-20 -0.34 
Table III.3.3.1.b) Top genes in validated effect   134  
 (probesets) from Affymetrix U133 Plus 2.0 microarrays;  
  manufacturer annotations (NetAffxTM,[97] v33) 
 
,  Components of the consensus gene axis of effect   134 
  (cf. Table III.1.5); filtered  0.4. 
 
,  Consensus gene correlations of   134; filtered  0.4. 
 
,   values for the correlations (cf. II.5.2.1) 
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For comparison, the probesets discussed for the three top genes are correlated only with ,FGD6
  0.22, 
,
  0.27 and ,
  0.25 to the COO induced effect   129, underlining that these two GEP effects 
describe genetically distinct or at the most partially correlated biology. 
 Inference 
As KLHL6 proteins contain a domain that is known for transcriptional repression activity and might be 
involved in the germinal center B-cell differentiation pathway[109], it could potentially be a tumor suppressor 
gene whose expression is required to switch off the hypermutation program in a subset of DLBCL cells. This 
would be consistent with significantly adverse patient outcome for lower KLHL6 expression. As they are 
linked by high GEP correlation, the same biological function might be associated with FGD6 and other top-
correlated genes of   134. 
These hypotheses about potential tumor suppressor genes could possibly be investigated by overexpression 
experiments in DLBCL cell lines that show low expression of effect   134. To identify these cell lines, they 
could be screened for their protein levels of KLHL6 and FGD6. Ideally, the proliferation of cells with low or 
nonexistent levels of these proteins can be stopped by corresponding overexpression experiments. 
 
III.3.3.2  ∈ 127, 131: A hierarchical survival effect prevailing in GCB DLBCL 
 Role in survival analysis 
Effect   127 is the best secondary predictor variable with   5.6 ⋅ 10  on top of the primary effect  
134 for the bivariate model trained with all samples from R-CHOP treated patients(III.2.2.1). It predicts 
hierarchical survival dependencies(III.2.2.3) that exclusively exist in the lower risk partition of the primary 
effect(Figure III.2.2.3.a). It can also significantly predict survival differences between GCB DLBCL patients, but not 
between ABC DLBCL patients. More precisely(cf. Figure III.2.2.3.b), 89/327 R-CHOP treated GCB DLBCL patients in the 
high risk interval of   127 have an average survival of only 55.1% while 218/327 patients in the baseline 
risk interval have an average survival of 78.4% (  5.6 ⋅ 10, log rank test). From the remaining 20/327 GCB 
DLBCL patients in the low risk interval of effect   127  17/20 survived (average survival of 85%, still 
significant with   0.018 relative to the high risk interval, despite the low sample number). 
Effect   131 qualified as best secondary variable on top of effect   134 with   1.6 ⋅ 10 for the 
quinvariate predictor model trained with all samples(III.2.5.1). Here,   127 followed on rank #2 with   2.0 ⋅
10 . Due to the high correlation of their consensus gene scores (;)
  0.80(cf. Eqn. III.1.3.2.b)) both effects share 
many top probesets (for one cohort, they are even based on the identical detected effect). Additionally, their 
sample eigensignal strengths(cf. Table III.1.5) from all four cohorts are correlated with 0.90, i.e. sample arrangements 
by either GEP effect are highly similar. Hence, it suffices to evaluate   127 in detail here; results should be 
transferrable to   131. 
To provide a direct validation of GEP effect   127 on patient survival level (rather than as secondary 
variable within larger predictor models), I fitted additional univariate Cox models that are only based on effect 
  127 to each of the four GCB DLBCL sub cohorts separately. Independent and highly significant validations 
succeeded based on both R-CHOP treated GCB DLBCL sub cohorts: ..  1.0 ⋅ 10  and 
..  5.4 ⋅ 10 . However, these analyses revealed another striking difference, this time 
between R-CHOP and CHOP therapy, as for CHOP-treated GCB DLBCL samples ..  0.44 
and  ..  0.77 only. The same difference (significant in R-CHOP.GCB, but not in CHOP.GCB) 
exists for   131. 
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Figure III.3.3.2) Validated effect   127, applied to GSE31312  
Secondary survival effect by R-CHOP based survival analysis(III.2.2) applied to GSE31312.R-CHOP (498 patients); it is genetically highly correlated to effect   131 , the 
secondary survival effect for survival analyses based on all samples(III.2.5). Enlarged binary classifications show censored/progression follow-up information 
(green/orange) as well as public subtypes (yellow/pink). At the right/lower tail, more GCB DLBCL patients with deaths or progressions were observed than could be 
expected by average GCB DLBCL survival.  
(The genomic consensus effect is applied to the cleaned signal without lab effects(cf. III.1.4.2). Samples and probesets are ordered by their effect strengths in this cohort(cf. 
Table III.1.5). Additionally, probesets are filtered by demanding a relative correlation stronger than 0.5. The effect’s bimonotonic eigensignal(panel d) is grayed for samples 
having insufficient or insignificant correlation to this effect(II.4.2.1).) 
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When sorting all patients by   127, subtypes are separated(cf. Figure III.3.2.2.a) with 72% agreement (  3.2 ⋅
10) and for   131 even with 83% agreement (  8.9 ⋅ 10). This trend together with the adverse 
outcome of ABC DLBCL compared to GCB DLBCL overlaps and hides the opposite survival trend within GCB 
DLBCL. Hence,   127 cannot predict a strong survival trend when applied to all DLBCL samples. This 
demonstrates that a multivariate survival analysis was necessary to reveal these dependencies and also shows 
that significant association of an effect to subtypes cannot provide a biologically complete characterization of 
underlying genes. With the background knowledge of these two opposite survival trends, they can now even 
be noticed visually: While the subtype trend is clearly visible, more GCB DLBCL patients had a progression or 
died in the upper/right interval than could be expected by average GCB DLBCL survival(Figure III.3.3.2). 
 Effect overview 
Effect   127 was unsupervisedly detected at rank #41 in GSE10846.R-CHOP and at rank #11 in GSE31312. 
It has been supervisedly validated on GEP level in all four cohorts (see 127* files at  C=Consensus 
Effects\(cohort subfolders)). 
Top probesets of effect   127 are depicted(cf. Figure III.3.3.2) for a relative correlation  0.5. It has a two-sided 
gradual gene expression eigensignal with approximately 65 correlated and 15 anti-correlated top probesets. 
Higher expressions of correlated genes (  0) are associated with adverse outcome. Consequently, lower 
expressions of anti-correlated genes (  0) are also associated with adverse outcome. As summarized 
above, this association exists within the lower risk partition of effect   134 and within GCB DLBCL, but 
neither in the high risk partition of   134 nor in ABC DLBCL. 
 Genomic associations 
Gene ontology analysis did no not reveal any significantly overexpressed and specific terms. On gene set 
level, 4/6 top enriched signatures are related to differential expression of Burkitt’s lymphoma (BL) relative  
to DLBCL: 
GCB DLBCL patients with adverse outcome have downregulated Hummel_Burkittslymphoma_dn(online 
interpretation card, [95]) and upregulated Hummel_Burkittslymphoma_up(online interpretation card, [95]). Superficially, this 
might suggests that these GCB DLBCL patients are misclassified BL rather than DLBCL cases. However, 
molecularly similarly determined BL patients showed a much higher 5-years survival of approximately 
80%[95.figure 3] that makes this conclusion questionable. Furthermore, even LymphomaHummel06_24genes(online 
interpretation card, [95]) with enrichment score 0.95 does not contain any of the GEP effect’s top genes(as listed in Table 
III.3.3.2.b), i.e. all signature genes are correlated with    0.4. As before, enrichment results are not specific 
enough and top correlated genes of this effect need to be analyzed individually to further elucidate its 
biological meaning. 
Signatures GSEA Basic Statistics 
Signatures DB Signature Name 
# 
defined 
# mea-
sured 
Enrich- 
ment 
score 
 FDR 
Mean log2( 
ratio) 
 (-test 
versus 
zero) 
Down- 
reg. ratio 
Upreg.  
ratio 
GeneSigDB_v4_Sept2011 Lymphoma_Hummel06_24genes 14 14 -0.950 0.0020 0.2% 0.314 0.0018 8.7% 91.3% 
MolSigDBv4_0_dMay2014 Hummel_Burkittslymphoma_dn 15 15 -0.883 0.0021 0.2% 0.316 0.0008 8.1% 91.9% 
StaudtSigDB_dNov2012 ABC_gt_GCB_LC 15 15 -0.755 0.0019 0.2% 0.464 8.3E-06 5.4% 94.6% 
HGNCSigDB_dMay2014 
Protein tyrosine phosphatases / 
Class I Cys-based PTPs: MAP kinase 
phosphatases 
11 11 -0.685 0.0019 0.2% 0.180 0.0502 11.5% 88.5% 
MolSigDBv4_0_dMay2014 Hummel_Burkittslymphoma_up 43 43 0.725 0.0021 0.2% -0.311 9.6E-06 91.5% 8.5% 
StaudtSigDB_dNov2012 GC_B_cell_BLhigh_DLBCLlow 36 35 0.734 0.0021 0.2% -0.550 2.0E-08 98.4% 1.6% 
 
Table III.3.3.2.a) Top-enriched signatures by   127 
Signatures with |enrichment	score|  0.67 and at least 10 measured members are listed for genes ranked by GEP effect   127.  
All GSEA  values are based on permutation tests; hence, they are lower-bounded by 1 #permutations)⁄  and true  values might be considerably lower in this case. 
1000 permutations have been computed for each signature, i.e. approximately 500 for each enrichment sign. Percentages of down- and upregulated genes in a 
signature are weighted averages of gene regulation signs (using 1   values of -tests against zero regulation as weights). 
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 Preliminary top genes analysis 
For probesets with 
   0.4, 71 unique genes from 
19 chromosomes participate in the effect, suggesting 
that it reflects a functional genomic network, rather than 
just reflecting local aberrations on DNA level. For 
  
0.5, 14 unique genes from 14 chromosomes remain. 
On the co-regulated side, several probesets with high 
correlations to the effect are available. The list is led by 
BACH2 (,  0.86, 6q15). Three unannotated 
probesets that measure transcribed sequences in direct 
genomic vicinity to BACH2 (with no other measured 
probeset in-between) are also highly correlated. 
Because their annotated sequence intervals are 
overlapped by BACH2-annotated probesets, they 
potentially still measure BACH2 RNA. 
A recent study[113] performed parallel to this work has 
already tested immunohistochemical BACH2 expression 
for its prognostic value in DLBCL. (Such prognostic 
factors are important in order to optimize therapeutic 
strategies, as molecular analyses are not readily 
available in clinical practice.) Indeed, for a cohort size of 
76 DLBCL patients, the BACH2-low group (  36) 
showed an average overall survival of 91% that was 
significantly higher (  0.026) than for the BACH2-high 
group (  40) with 72% average overall survival. 
Progression free survival showed the same trend ( 0.068). However, there was no significant difference 
between GCB DLBCL and non-GCB DLBCL classes. Non-
GCB DLBCL overall survival was even higher on average 
than GCB DLBCL overall survival. This fact and the small 
study size made it impossible to recognize that BACH2 
belongs to a hierarchical survival effect. 
Interestingly, the study also summarizes inconsistent 
findings from previous studies with respect to the 
survival impact of BACH2 expression in DLBCL. These 
inconsistencies are probably caused by and may be 
explained by this hierarchical survival impact of   127. 
(Its anti-aligned survival trend relative to the over-
lapping global subtype trend for the same genes might 
cause confusing and misleading results for univariate 
analyses.) 
Top genes in     
Probeset 
Gene  
Symbol 
HG19  
locus 

,  
,  
,  

,  
. 
,  
221234_s_at BACH2 6q15 1.46 0.86 1.3E-62 1.25 
236796_at  6q15 1.40 0.86 2.5E-64 1.21 
236307_at  6q15 1.36 0.82 1.6E-53 1.12 
209995_s_at TCL1A 14q32.13 1.48 0.51 9.5E-16 0.76 
212094_at PEG10 7q21.3 1.46 0.51 3.6E-15 0.74 
39318_at TCL1A 14q32.13 1.44 0.51 3.4E-15 0.73 
224990_at C4orf34 4p14 1.14 0.57 6.6E-20 0.65 
229513_at STRBP 9q33.3 0.93 0.68 9.8E-31 0.64 
1556451_at  6q15 0.80 0.75 2.3E-40 0.61 
201691_s_at TPD52 8q21.13 1.01 0.59 1.6E-21 0.60 
227052_at  4p14 1.04 0.55 3.3E-18 0.57 
227173_s_at BACH2 6q15 0.77 0.73 2.8E-36 0.56 
235380_at  10q11.21 0.92 0.53 1.8E-16 0.48 
238919_at  13q21.32 1.13 0.41 3.5E-10 0.47 
212092_at PEG10 7q21.3 0.93 0.50 1.2E-14 0.46 
224989_at  4p14 0.94 0.49 5.7E-14 0.46 
206864_s_at HRK 12q24.22 0.95 0.47 2.8E-13 0.45 
223245_at STRBP 9q33.3 0.75 0.60 2.1E-22 0.45 
233252_s_at STRBP 9q33.3 0.73 0.58 2.0E-20 0.42 
1566734_at LOC283454 12q24.22 0.99 0.42 1.9E-10 0.42 
221908_at RNFT2 12q24.22 0.78 0.53 7.3E-17 0.41 
212503_s_at DIP2C 10p15.3 0.91 0.44 1.5E-11 0.40 
1554161_at SLC25A27 6p12.3 0.76 0.53 1.6E-16 0.40 
206896_s_at GNG7 19p13.3 0.81 0.49 3.3E-14 0.40 
201690_s_at TPD52 8q21.13 0.74 0.53 5.2E-17 0.39 
208651_x_at CD24 Yq11.222 0.90 0.43 5.9E-11 0.39 
228818_at  8q21.13 0.75 0.52 6.2E-16 0.39 
266_s_at CD24 Yq11.222 0.94 0.40 9.3E-10 0.38 
216379_x_at CD24 6q21 0.89 0.41 5.5E-10 0.36 
236414_at  8q21.13 0.61 0.57 6.1E-20 0.35 
201689_s_at TPD52 8q21.13 0.69 0.50 7.1E-15 0.35 
209771_x_at CD24 Yq11.222 0.85 0.40 1.3E-09 0.34 
227798_at SMAD1 4q31.21 0.85 0.40 1.4E-09 0.34 
209590_at BMP7 20q13.31 0.73 0.45 2.9E-12 0.33 
227407_at TAPT1 4p15.32 0.65 0.50 3.9E-15 0.33 
238712_at  3p13 0.65 0.49 2.1E-14 0.32 
203434_s_at MME 3q25.2 0.76 0.40 1.2E-09 0.31 
204165_at WASF1 6q21 0.66 0.46 1.1E-12 0.30 
223246_s_at STRBP 9q33.3 0.57 0.53 5.6E-17 0.30 
232286_at  2q11.2 0.74 0.41 7.6E-10 0.30 
222336_at C4orf34 4p14 0.63 0.48 1.8E-13 0.30 
227533_at  1q25.2 0.59 0.51 2.3E-15 0.30 
225978_at RIMKLB 12p13.31 0.70 0.42 1.1E-10 0.30 
223522_at MIR600HG 9q33.3 0.52 0.57 1.0E-19 0.30 
1552774_a_at SLC25A27 6p12.3 0.54 0.54 2.5E-17 0.29 
1566880_at  2q11.2 0.59 0.49 4.2E-14 0.29 
226164_x_at RIMKLB 12p13.31 0.58 0.49 3.4E-14 0.29 
229670_at  1q24.2 0.63 0.45 9.7E-12 0.28 
241577_at  2q11.2 0.63 0.44 1.9E-11 0.28 
239884_at CADPS 3p14.2 0.64 0.43 4.6E-11 0.28 
225999_at RIMKLB 12p13.31 0.61 0.45 7.4E-12 0.27 
225421_at PM20D2 6q15 0.55 0.49 2.9E-14 0.27 
1557814_a_at  5q14.1 0.51 0.50 4.1E-15 0.26 
236655_at TPD52 8q21.13 0.52 0.50 1.0E-14 0.26 
239862_at  8q21.13 0.52 0.48 1.2E-13 0.25 
242090_x_at  NA 0.57 0.43 6.3E-11 0.25 
229552_at LOC283454 12q24.22 0.58 0.42 1.9E-10 0.24 
208754_s_at NAP1L1 12q21.2 0.50 0.48 1.0E-13 0.24 
242681_at  1p36.22 0.56 0.43 5.9E-11 0.24 
231817_at USP53 4q26 0.57 0.42 2.8E-10 0.24 
233251_at STRBP 9q33.3 0.46 0.51 2.5E-15 0.23 
202478_at TRIB2 2p24.3 0.53 0.43 3.8E-11 0.23 
229344_x_at RIMKLB 12p13.31 0.48 0.47 3.3E-13 0.23 
215221_at  3p13 0.44 0.51 1.9E-15 0.23 
225763_at RCSD1 1q24.2 0.54 0.40 1.0E-09 0.22 
219655_at C7orf10 7p14.1 0.51 0.43 9.4E-11 0.22 
235310_at GCET2 3q13.2 0.53 0.41 6.7E-10 0.22 
218988_at SLC35E3 12q15 0.52 0.41 3.9E-10 0.21 
228991_at CDK13 7p14.1 0.44 0.48 1.2E-13 0.21 
228081_at CCNG2 4q21.1 0.46 0.45 3.5E-12 0.21 
227369_at SERBP1 1p31.3 0.51 0.41 5.7E-10 0.21 
238484_s_at SSBP2 5q14.1 0.47 0.44 2.6E-11 0.21 
241933_at QRSL1 6q21 0.45 0.44 1.0E-11 0.20 
201688_s_at TPD52 8q21.13 0.50 0.40 9.5E-10 0.20 
238483_at SSBP2 5q14.1 0.46 0.43 5.2E-11 0.20 
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The second gene in terms of correlation is STRBP 
(,  0.68, 9q33.3). Regarding STRBP, no B cell 
or lymphomagenesis related literature could be found. 
Other co-regulated probesets for TCL1A (, 
0.51, 14q32.13), PEG10 (,  0.51, 7q21.3) and 
C4orf34 (,  0.57, 4p14) show strong 
differential expressions, but not as high correlation to 
the effect. 
The anti-regulated side is led by LINC00152 
(,  0.58, 2p11.2); this is a long intergenic 
non-protein-coding RNA. No direct link to DLBCL could 
be located, but LINC00152 was found to be 
significantly expressed in gastric cancer[114] compared 
to normal adjacent tissue (fold change  1.93,   6.9 ⋅
10). It has subsequently been suggested as 
biomarker[115] for gastric cancer, because its 
expression levels were significantly increased 
compared to mucosa from healthy controls (  0.004) 
as well as when comparing gastric juice between 
gastric cancer patients and normal controls (  0.002). 
Interestingly, another study[116] showed that LINC00152 is being significantly and strongly upregulated in 
HeLa cells in response to chemical stressors, especially by Cisplatin (fold change of 32). Hence, it was 
suggested as surrogate indicator of general or specific cell stress. 
Other anti-regulated genes include BATF (,  0.53, 14q24.3) and IRF4 (,  0.49, 6p25.3). 
These genes are related to T cell lymphomas and inhibiting IRF4 (and MYC) caused toxicity in ALCL cell lines[76]. 
While these properties might be transferrable to ABC DLBCL cells (given their relative overexpression of IRF4 
and BATF), for the GCB DLBCL subgroup in question low expressions of these genes are associated with 
significantly adverse patient outcome. 
 Inference 
To elucidate the biological pathway underlying   127 and the cause of its hierarchical survival impact 
relative to effect   134, further biological experiments might potentially be helpful. Analytically, BACH2 
seems to be a promising oncogene candidate for the lower risk partition of   134, i.e. predominantly for GCB 
DLBCL patients. To test this hypothesis, GCB DLBCL cell lines with high BACH2 protein expression could be 
selected for BACH2 knockdown experiments. 
Additionally, it might be biologically illuminating to investigate the cause why the survival impact of   127 
is highly significant for GCB DLBCL patients following R-CHOP therapy, but not for the CHOP therapy. The 5-
years survival in the higher risk partition of   127 for R-CHOP-treated GCB DLBCL patients equals 
approximately 55%. This is comparable to GCB DLBCL 5-years survival following CHOP therapy. Hence, one 
conceivable hypothesis pending further validation might be that GCB DLBCL patients in this higher risk 
partition of   127 cannot profit from Rituximab. 
 
236199_at  10q11.21 0.43 0.46 2.5E-12 0.20 
218949_s_at QRSL1 6q21 0.48 0.40 1.0E-09 0.20 
244185_at  12q22 0.44 0.44 2.7E-11 0.19 
1557452_at  5q14.1 0.42 0.44 1.8E-11 0.19 
223624_at ZFAND4 10q11.22 0.44 0.42 2.6E-10 0.18 
230624_at SLC25A27 6p12.3 0.45 0.40 1.1E-09 0.18 
237187_at  12q24.22 0.44 0.41 8.6E-10 0.18 
214042_s_at RPL22 3q26.2 0.43 0.42 2.2E-10 0.18 
201678_s_at C3orf37 3q21.3 0.44 0.40 1.3E-09 0.18 
240176_at  2p11.2, 2q13 -0.41 -0.42 2.1E-10 -0.17 
221658_s_at IL21R 16p12.1 -0.43 -0.41 4.1E-10 -0.18 
213622_at COL9A2 1p34.2 -0.42 -0.43 3.6E-11 -0.18 
244612_at  NA -0.45 -0.41 3.6E-10 -0.19 
202644_s_at TNFAIP3 6q23.3 -0.48 -0.40 8.9E-10 -0.19 
235668_at PRDM1 6q21 -0.46 -0.43 8.0E-11 -0.20 
219424_at EBI3 19p13.3 -0.47 -0.42 1.3E-10 -0.20 
238567_at SGPP2 2q36.1 -0.53 -0.43 9.0E-11 -0.23 
216942_s_at CD58 1p13.1 -0.58 -0.44 2.4E-11 -0.25 
1562056_at  2p11.2, 2q13 -0.54 -0.51 1.4E-15 -0.28 
220990_s_at VMP1 17q23.1 -0.57 -0.50 8.1E-15 -0.28 
226560_at  2q36.1 -0.64 -0.47 3.7E-13 -0.30 
211744_s_at CD58 1p13.1 -0.71 -0.47 4.2E-13 -0.33 
205173_x_at CD58 1p13.1 -0.72 -0.46 1.1E-12 -0.33 
205965_at BATF 14q24.3 -0.63 -0.53 4.2E-17 -0.33 
204562_at IRF4 6p25.3 -0.71 -0.49 4.4E-14 -0.35 
225799_at LINC00152 2p11.2 -0.69 -0.58 1.3E-20 -0.40 
Table III.3.3.2.b) Top genes in validated effect   127  
 (probesets) from Affymetrix U133 Plus 2.0 microarrays;  
  manufacturer annotations (NetAffxTM,[97] v33) 
 
,  Components of the consensus gene axis of effect   127  
  (cf. Table III.1.5); filtered 
,   0.4. 
 
,  Consensus gene correlations; filtered 
,  0.4. 
 
,   values for the correlations (cf. II.5.2.1) 
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III.3.3.3   105: KIAA1217 (2nd predictor variable for the COO based model) 
 Role in survival analysis 
Effect   105 facilitates survival prediction 
on top of the standard COO induced effect with   4.5 ⋅ 10(Figure III.2.3.1). 
Like   127 relative to   134, the survival 
trend predicted by this effect is anti-aligned to 
subtype sorting by   129(Table III.2.3.2) with a 
Cox coefficient of   0.321. This can even 
be seen in its GEP definition plot(Figure III.3.3.3), as 
ABC DLBCL samples are overrepresented on 
the right side, while more progression events 
and deaths are observed on the opposite side.  
Hence, a lower KIAA1217 expression 
corresponds to higher risk and adverse 
outcome for a subset of DLBCL patients. 
 Effect overview 
Two unsupervised detections underlie this 
consensus effect (rank #71 in GSE10846-
CHOP and rank #92 in GSE31312.R-CHOP). 
They have correlated probesets from some 
additional genes, but after soft intersection by 
consensus gene axis construction(cf. III.1.3), 
KIAA1217 is the only remaining top 
correlated gene. More precisely, 7 indepen-
dently measured probesets that are 
correlated with 
   0.4 remain(cf. Table 
III.3.3.3.a), some of which are unannotated, but all 
are located in direct genomic vicinity to 
KIAA1217 in 10p12.1. 
Hence it cannot be excluded that this effect 
is a reflection of a chromosomal feature in the 
GEP signal. 
 
 Preliminary top gene analysis 
KIAA1217 is a protein-coding gene with 
validated RefSeq[106] status(cf. gene ID 56243), but no 
B cell or lymphomagenesis related literature 
could be found about this gene. 
 
 
Figure III.3.3.3) Validated effect   105, applied to GSE31312  
The secondary survival effect for the predictor based on the COO induced effect(III.2.3) is 
applied to cohort GSE31312.R-CHOP (498 patients). Enlarged binary classification stripes 
show censored/progression follow-up information (green/orange) as well as public 
subtypes (yellow/pink). 
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 Inference 
Due to its high genomic specificity and the lack of 
strongly correlated genes from other chromosomes, 
this GEP effect may reflect e.g. a DNA level aberration; 
copy number measurements(e.g. from GSE11318, [11]) for its 
locus could clarify this. 
Due to its prognostic value on top of the COO induced 
effect and its anti-aligned survival effect, analyzing 
KIAA1217 experimentally might also be interesting. 
To this end, DLBCL cell lines could first be screened for 
low KIAA1217 protein levels relative to DLBCL 
average. Ideally, proliferation of a subset of these cell 
lines could be reduced by KIAA1217 overexpression 
experiments. 
However, this effect cannot explain any strong 
survival dependencies on top of the primary survival 
effect   134; it only ranks #37 with   0.006(cf. Figure 
III.2.5.1.b). Therefore, experiments for this gene seem to be 
of second priority from an analytical point of view. 
III.3.3.4   5: A stromal effect (CHOP based model, 1st predictor variable) 
 Role in survival analysis 
Sorting patients by the eigensignal of effect   5 
shows the most consistent survival prediction (  2.2 ⋅
10) of all discovered GEP effects for CHOP-treated 
patients(Figure III.2.4.1.a). But for R-CHOP treated patients it 
only ranks #14th (  8.4 ⋅ 10). 
 Effect overview 
The effect has been unsupervisedly quad-discovered 
effect with detection ranks #1(GSE10846.CHOP), #1(GSE10846.R-
CHOP), #1(GSE4475.nonMBL) and #2(GSE31312.R-CHOP). It is one of the 
largest discovered GEP effects in terms of number of 
correlated and differentially expressed genes. It is the 
largest effect that is associated with a significant 
survival impact. 
Higher expressions of this effect correspond to lower 
risk and more favorable outcome(cf. Table III.2.4.2). 
The effect has a one-sided eigensignal(Figure III.3.3.4.d, page 199) 
that has more than 650 probesets correlated stronger 
than 
   0.5. To unveil its biological meaning, I focus 
this evaluation on its top genes only(Table III.3.3.4.a). 
Top genes in   105 
Probeset 
Gene  
Symbol 
HG19  
locus 
,  ,  ,  ,  . ,  
231807_at KIAA1217 10p12.1 1.26 0.92 5.9E-68 1.16 
1554438_at KIAA1217 10p12.1 1.01 0.87 5.7E-51 0.88 
232762_at KIAA1217 10p12.1 0.79 0.86 3.7E-49 0.69 
244147_at  10p12.1 0.58 0.78 6.8E-34 0.45 
214912_at  10p12.2 0.60 0.74 1.9E-29 0.45 
242846_at  10p12.2 0.45 0.69 8.4E-24 0.31 
1562966_at KIAA1217 10p12.1 0.50 0.61 1.7E-17 0.30 
235333_at B4GALT6 18q12.1 0.51 0.37 1.1E-06 0.19 
203562_at FEZ1 11q24.2 0.59 0.31 5.8E-05 0.18 
241163_at  3q26.31 0.50 0.31 5.7E-05 0.16 
229070_at ADTRP 6p24.1 0.48 0.31 6.1E-05 0.15 
224374_s_at EMILIN2 18p11.32 0.38 0.35 5.2E-06 0.13 
225202_at RHOBTB3 5q15 0.40 0.32 3.8E-05 0.13 
232352_at ISL2 15q24.3 0.37 0.34 8.4E-06 0.13 
226099_at ELL2 5q15 0.37 0.32 3.0E-05 0.12 
225662_at ZAK 2q31.1 0.36 0.32 3.9E-05 0.12 
204083_s_at TPM2 9p13.3 0.37 0.30 1.1E-04 0.11 
206034_at SERPINB8 18q22.1 0.31 0.35 4.1E-06 0.11 
202950_at CRYZ 1p31.1 0.36 0.30 1.0E-04 0.11 
206490_at DLGAP1 18p11.31 0.34 0.30 9.8E-05 0.10 
233002_at PPP4R4 14q32.12 0.33 0.30 1.0E-04 0.10 
213060_s_at CHI3L2 1p13.3 -0.42 -0.31 7.1E-05 -0.13 
Table III.3.3.3.a) Top genes in validated effect   105 
 (probesets) from Affymetrix U133 Plus 2.0 microarrays;  
  manufacturer annotations (NetAffxTM,[97] v33) 
 ,  Components of the consensus gene axis of effect   105  
  (cf. Table III.1.5); filtered ,   0.3. 
 
,  Consensus gene correlations; filtered 
,  0.3. 
 
,   values for the correlations (cf. II.5.2.1) 
Top genes in   5 
Probeset 
Gene  
Symbol 
HG19  
locus 
,  ,  ,  ,  . ,  
202404_s_at COL1A2 7q21.3 1.88 0.96 7.5E-125 1.81 
201852_x_at COL3A1 2q32.2 1.87 0.96 6.5E-120 1.78 
1555778_a_at POSTN 13q13.3 2.02 0.88 4.2E-84 1.78 
211161_s_at COL3A1 NA 1.80 0.95 7.0E-117 1.72 
202310_s_at COL1A1 17q21.33 1.80 0.94 7.9E-104 1.69 
202311_s_at COL1A1 17q21.33 1.85 0.91 4.3E-88 1.69 
215076_s_at COL3A1 2q32.2 1.72 0.95 4.9E-114 1.63 
210809_s_at POSTN 13q13.3 1.85 0.87 1.4E-71 1.61 
212464_s_at FN1 2q35 1.66 0.93 3.1E-96 1.53 
227140_at INHBA 7p14.1 1.72 0.87 5.9E-81 1.50 
221730_at COL5A2 2q32.2 1.58 0.93 1.2E-101 1.48 
202403_s_at COL1A2 7q21.3 1.55 0.95 9.3E-118 1.48 
221729_at COL5A2 2q32.2 1.56 0.94 1.8E-105 1.47 
212489_at COL5A1 9q34.3 1.58 0.91 2.6E-88 1.44 
211719_x_at FN1 2q35 1.54 0.93 4.1E-97 1.43 
212354_at SULF1 8q13.2 1.54 0.90 8.4E-85 1.39 
216442_x_at FN1 2q35 1.50 0.93 4.6E-99 1.39 
210495_x_at FN1 2q35 1.49 0.93 8.5E-97 1.38 
225664_at COL12A1 6q13 1.63 0.84 1.8E-69 1.37 
225681_at CTHRC1 8q22.3 1.56 0.86 2.3E-76 1.35 
209335_at DCN 12q21.33 1.53 0.87 3.8E-70 1.33 
221731_x_at VCAN 5q14.3 1.47 0.90 2.0E-83 1.33 
203083_at THBS2 6q27 1.43 0.92 7.3E-92 1.32 
201744_s_at LUM 12q21.33 1.47 0.89 4.1E-77 1.31 
211896_s_at DCN 12q21.33 1.49 0.87 2.8E-70 1.29 
212353_at SULF1 8q13.2 1.51 0.85 1.6E-64 1.29 
209596_at MXRA5 Xp22.33 1.45 0.88 1.4E-73 1.28 
204620_s_at VCAN 5q14.2 1.38 0.89 4.7E-79 1.23 
202620_s_at PLOD2 3q24 1.39 0.87 3.0E-72 1.22 
201893_x_at DCN 12q21.33 1.36 0.89 4.0E-77 1.21 
201069_at MMP2 16q12.2 1.40 0.86 3.6E-68 1.20 
215646_s_at VCAN 5q14.3 1.39 0.85 1.0E-63 1.18 
212488_at COL5A1 9q34.3 1.33 0.89 2.7E-76 1.18 
211813_x_at DCN 12q21.33 1.33 0.88 1.8E-72 1.17 
203325_s_at COL5A1 9q34.3 1.29 0.88 2.8E-75 1.14 
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 Identification by gene ontology 
For so far presented survival effects  ∈129, 134, 127, 131, 105 no highly significant gene 
ontology terms existed. For   5 however, several GO 
terms are significantly overrepresented for cellular 
components(cf. Figure III.3.3.4.a), molecular functions and 
biological processes(cf. Figure III.3.3.4.b). The top 30-40 genes 
of this effect already suffice for significance. Based on 
these results,   5 can be interpreted as a measure-
ment of extracellular matrix structural constituents(cf. 
GO:0005201) with   2.2 ⋅ 10  and of related terms for 
the extracellular matrix. 
Small GO terms might serve as starting points for a 
biologically more specific interpretation. For example, 
the molecular function of platelet-derived growth 
factor binding(cf. GO:0048407) is significant (5 of the top 34 
genes belong to this term, while the term contains only 
11 genes in total from all measured 20370 genes; this 
results in   4.4 ⋅ 10 via hypergeometric test). 
201438_at COL6A3 2q37.3 1.23 0.92 1.6E-90 1.13 
1556499_s_at COL1A1 17q21.33 1.27 0.88 7.8E-84 1.12 
224694_at ANTXR1 2p13.3 1.32 0.83 1.2E-65 1.09 
204619_s_at VCAN 5q14.2 1.22 0.86 8.3E-69 1.06 
226777_at ADAM12 10q26.2 1.30 0.80 6.9E-59 1.04 
229218_at COL1A2 7q21.3 1.18 0.86 9.7E-76 1.02 
203131_at PDGFRA 4q12 1.21 0.83 5.1E-58 1.00 
213905_x_at BGN Xq28 1.13 0.87 5.3E-71 0.99 
203477_at COL15A1 9q22.33 1.18 0.81 2.3E-53 0.95 
227399_at VGLL3 3p12.1 1.19 0.80 8.8E-59 0.95 
207173_x_at CDH11 16q21 1.12 0.83 1.1E-57 0.93 
202766_s_at FBN1 15q21.1 1.08 0.85 4.9E-64 0.92 
202237_at NNMT 11q23.2 1.09 0.84 3.9E-60 0.91 
212344_at SULF1 8q13.2 1.05 0.85 7.4E-64 0.90 
225242_s_at CCDC80 3q13.2 1.10 0.81 7.6E-61 0.89 
201261_x_at BGN Xq28 1.03 0.86 3.9E-67 0.89 
211571_s_at VCAN 5q14.2 1.06 0.83 8.0E-59 0.88 
201505_at LAMB1 7q31.1 1.08 0.81 4.9E-54 0.88 
232458_at COL3A1 2q32.2 1.07 0.81 2.2E-60 0.87 
210986_s_at TPM1 15q22.2 1.07 0.81 5.8E-53 0.86 
209955_s_at FAP 2q24.2 0.99 0.85 3.1E-65 0.85 
212667_at SPARC 5q33.1 1.01 0.82 2.2E-56 0.83 
208782_at FSTL1 3q13.33 0.94 0.86 1.4E-68 0.81 
202202_s_at LAMA4 6q21 0.95 0.84 2.3E-62 0.80 
227628_at GPX8 5q11.2 0.95 0.82 7.4E-64 0.78 
228141_at GPX8 5q11.2 0.95 0.82 2.0E-62 0.77 
200665_s_at SPARC 5q33.1 0.92 0.83 9.8E-59 0.77 
204517_at PPIC 5q23.2 0.93 0.81 1.6E-53 0.75 
202619_s_at PLOD2 3q24 0.91 0.82 6.4E-55 0.74 
210139_s_at PMP22 17p12 0.87 0.83 1.2E-58 0.73 
202351_at ITGAV 2q32.1 0.87 0.81 8.4E-55 0.71 
211651_s_at LAMB1 7q31.1 0.81 0.80 1.0E-51 0.65 
Table III.3.3.4.a) Top genes in validated effect   5 
 (probesets) from Affymetrix U133 Plus 2.0 microarrays;  
  manufacturer annotations (NetAffxTM,[97] v33) 
 ,  Components of the consensus gene axis of effect   5  
  (cf. Table III.1.5); filtered ,   0.8. 
 
,  Consensus gene correlations; filtered 
,  0.8. 
 
,   values for the correlations (cf. II.5.2.1) 
Figure III.3.3.4.a) Gene ontology overrepresentation analyses of cellular components in effect   5 
All  values are based on hypergeometric tests. A  value of zero indicates an underflow, i.e.   2.2 ⋅ 10 , which is the numeric resolution limit for differences to 
one; the true  value is never exactly zero. 
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Figure III.3.3.4.b) Gene ontology overrepresentation analyses of biological processes and molecular functions in effect   5 
All  values are based on hypergeometric tests. A  value of zero indicates an underflow, i.e.   2.2 ⋅ 10 , which is the numeric resolution limit for differences to 
one; the true  value is never exactly zero. 
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Another example is the biological process of leukocyte migration(cf. GO:0050900) (with COL1A1, COL1A2 and FN1, 
three of the top 7 genes belong to this term, while 107 genes from all measured 20370 genes are directly 
annotated with this term; this results in with   4.9 ⋅ 10 via hypergeometric test). (All GO results including 
associated gene IDs are available in graphical and tabular form in  D=Interpretation\genomic\v005\GOA.) 
 Signature analyses 
Many known signatures are significantly enriched for top genes of   5. Only those with enrichments 
stronger than 0.8 are listed(Table III.3.3.4.b). The full signature analyses table is available at  D=Interpretation\ge-
nomic\v005\SA. 
Signatures GSEA Basic Statistics 
Signatures DB Signature Name 
# 
defined 
# mea-
sured 
Enrich- 
ment 
score 
 FDR 
Mean log2( 
ratio) 
 (-test 
versus zero) 
Down- 
reg. ratio 
Upreg.  
ratio 
MolSigDBv4_0_dMay2014 Ffarmer_breast_cancer_cluster_5 19 19 0.982 0.0019 0.2% -1.697 4.2E-11 100.0% 0.0% 
MolSigDBv4_0_dMay2014 Gnf2_cdh11 25 25 0.937 0.0019 0.2% -1.562 1.2E-11 100.0% 0.0% 
StaudtSigDB_dNov2012 Normal_mesenchymal-1_Node1643 77 77 0.936 0.0021 0.2% -1.368 2.3E-34 100.0% 0.0% 
MolSigDBv4_0_dMay2014 
Anastassiou_cancer_mesenchymal_-
transition_signature 
64 64 0.921 0.002 0.2% -1.654 8.7E-29 99.7% 0.3% 
StaudtSigDB_dNov2012 Lymph_node_LymphDx 56 56 0.902 0.0021 0.2% -1.183 1.5E-19 98.2% 1.8% 
StaudtSigDB_dNov2012 Lymph_node_High_vs_low 651 645 0.871 0.002 0.2% -0.872 4.9E-188 99.5% 0.5% 
MolSigDBv4_0_dMay2014 GNF2_PTX3 36 36 0.860 0.002 0.2% -1.346 8.5E-13 100.0% 0.0% 
StaudtSigDB_dNov2012 Stromal-1_DLBCL_survival_predictor 263 248 0.855 0.0021 0.2% -0.997 6.9E-76 98.4% 1.6% 
GeneSigDB_v4_Sept2011 Lymphoma_Piccaluga07_64genes 60 59 0.839 0.002 0.2% -1.026 1.4E-18 98.3% 1.7% 
GeneSigDB_v4_Sept2011 Breast_Miller07_19genes 17 17 0.837 0.002 0.2% -1.267 7.2E-06 98.5% 1.5% 
StaudtSigDB_dNov2012 Lymph_node_U133plus 217 215 0.828 0.0022 0.2% -0.843 5.1E-60 98.8% 1.2% 
GeneSigDB_v4_Sept2011 StemCell_Menicanin09_13genes 12 12 0.813 0.002 0.2% -1.084 1.2E-03 95.2% 4.8% 
GeneSigDB_v4_Sept2011 Prostate_Chambers09_40genes 28 28 0.805 0.0019 0.2% -1.195 1.8E-08 100.0% 0.0% 
GeneSigDB_v4_Sept2011 Lymphoma_VanLoo09_11genes 11 11 -0.810 0.0019 0.2% 0.265 5.7E-03 6.3% 93.7% 
MolSigDBv4_0_dMay2014 RRNA_metabolic_process 16 16 -0.817 0.0019 0.2% 0.252 3.8E-07 0.0% 100.0% 
MolSigDBv4_0_dMay2014 Ribosome_biogenesis_and_assembly 18 18 -0.880 0.0019 0.2% 0.246 5.7E-08 0.0% 100.0% 
MolSigDBv4_0_dMay2014 RRNA_processing 15 15 -0.880 0.002 0.2% 0.265 2.1E-07 0.0% 100.0% 
 
Table III.3.3.4.b) Top-enriched signatures by   5 
Signatures with |enrichment	score|  0.8 and at least 10 measured members are listed for genes ranked by GEP effect   5.  
All GSEA  values are based on permutation tests; hence, they are lower-bounded by 1 #permutations⁄  and true  values might be considerably lower in this case. 
1000 permutations have been computed for each signature, i.e. approximately 500 for each enrichment sign. Percentages of down- and upregulated genes in a 
signature are weighted averages of gene regulation signs (using 1   values of -tests against zero regulation as weights). 
Given the size of effect   5 and the high correlation of top genes to it (and thus between each other), it is 
interesting that several significantly and highly enriched signatures are relatively small. As any definition that 
includes only some but not all highly correlated genes 
would be biased, I would have expected larger 
signatures. (Maybe these signatures were defined in a 
constraint signal context or were intersected with 
biologically motivated tertiary signatures.) 
 Role as “stromal-1” signature in a previous CHOP-
based DLBCL survival predictor 
One of the larger listed top signatures is the 
stromal-1 signature(online interpretation card, Figure III.3.3.4.c) that 
has already been identified for a previous DLBCL 
survival predictor[5] and has also been associated with 
the extracellular matrix. The previous predictor was 
trained with samples from CHOP-treated patients 
only. Hence, it is consistent that it included effect  5, as it shows the most consistent survival prediction 
for CHOP-treated patients(Figure III.2.4.1.a).  
Figure III.3.3.4.c) Significant enrichment of the stromal-1 signature[5] 
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Figure III.3.3.4.d) Validated effect   5, applied to GSE10846.CHOP 
Primary survival effect by CHOP based multi-cohort survival analysis(III.2.4) applied to GSE10846.CHOP (181 patients). Enlarged binary classification stripes show 
censored/progression follow-up information (green/orange) as well as public subtypes (yellow/pink). 
(The genomic consensus effect is applied to the cleaned signal without lab effects(cf. III.1.4.2). Samples and probesets are ordered by their effect strengths in this cohort(cf. 
Table III.1.5). Additionally, probesets are filtered by demanding a relative correlation stronger than 0.5. The effect’s bimonotonic eigensignal(panel d) is grayed for samples 
having insufficient or insignificant correlation to this effect(II.4.2.1).)  
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 Top genes overview 
For probesets with 
   0.4, 783 unique genes from 24 chromosomes participate in the effect. This clearly 
indicates that it does not just reflect genomically local aberrations on DNA level, as could be expected by its 
identified biological function. Even for 
   0.5, 417 unique genes from 23 chromosomes remain. 
As the biological function of this effect has already been identified by gene ontology terms, an individual 
analysis of its top-correlated genes has not been performed. 
 Inference 
Gene ontology terms and gene signatures with significant enrichment only concern small subsets of the 
effect’s correlated top genes. Hence, they may not be able to biologically describe this large effect completely. 
Maybe a common yet unidentified biological cause exists that regulates all these genes coordinately, resulting 
in observed correlations. It might be biologically interesting to search for such a common cause. 
As previously quantified, the predictive value of this stromal effect is limited in the Rituximab era. If this 
prognostic difference between CHOP and R-CHOP therapies validates biologically, it might be interesting to 
find the cause, why Rituximab seems to predominantly help patients with lower expressions of   5. 
Already in the CHOP era, this effect seems to have measured an effect of the tumor microenvironment. 
Additionally, it did not qualify as one of the best five survival effects when training with all samples. (Survival 
dependencies explained by   5 can already be explained by the selected primary and secondary predictor 
variables  ∈ 134, 131(cf. III.2.5.1).) Hence and analytically,   5 seems to be of second priority towards 
disclosing DLBCL’s molecular pathogenesis. 
 
 
 
 
 
 
 
III.3.3.5   44: Another stromal effect with a hierarchical survival  
 dependency and revisiting a previous DLBCL survival predictor 
 Role in survival analysis 
Effect   44 facilitates a significant additional survival prediction (  2.5 ⋅ 10) on top of effect   5 for CHOP treated DLBCL patients(Figure III.2.4.1.b). Like   127 relative to   134, this survival trend is anti-
aligned(Table III.2.4.2) to the primary CHOP predictor variable   5. 
The survival dependency predicted by this effect is hierarchical. More precisely, it can predict significant 
survival differences within the higher risk partition of   5, but not within the lower risk partition of this 
stromal effect. The same hierarchical effect is still strong and significant following R-CHOP therapy(cf. Figure III.2.4.3). 
A subtype-specific analysis of   44 revealed the same but considerably weaker survival dependency(cf. Figure 
III.2.4.4), suggesting that not the COO induced effect, but effect   5 is required to biologically understand 
this hierarchy. 
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 Effect overview 
The effect has been unsupervisedly discovered in three of four cohorts with detection ranks #5(GSE10846.CHOP), 
#18(GSE10846.R-CHOP) and #32(GSE31312.R-CHOP). It has been supervisedly validated on GEP level in all four cohorts (see 
44* files in  C=Consensus Effects\(cohort subfolder)). 
Its signal is one-sided(Figure III.3.3.5) with approximately 100 top probesets (with relative correlation  0.5).  
Higher expressions of this effect correspond to higher risk (for a subset of DLBCL patients that shows higher 
risk with respect to effect   5). 
 Clinical associations 
Besides associations to survival, it is interesting that in all three cohorts with ECOG data, ECOG performance 
is significantly and consistently associated with this effect for ABC DLBCL patients, but not so for GCB DLBCL 
patients. More precisely, significantly more ABC DLBCL patients with ECOG state  1 are found in the lower 
expression and lower risk partition of   44 (GSE10846.CHOP.ABC  0.01, GSE10846.R-CHOP.ABC  0.02 and 
GSE31312.R-CHOP.ABC  0.03;   tests based on contingency tables), whereas this is not the case for GCB DLBCL 
(GSE10846.CHOP.GCB  0.73, GSE10846.R-CHOP.GCB  0.10 and GSE31312.R-CHOP.GCB  0.99). This is consistent with the 
effect’s hierarchical prediction of survival, as the majority of samples in the higher risk partition of the stromal 
effect   5 are classified as ABC DLBCL. However and again, only partitioning by   5 and not by the COO 
induced effect can reveal this hierarchical survival dependency in a clear-cut way(compare Figure III.2.4.3 with Figure III.2.4.4). 
 Genomic associations 
Gene ontology analyses showed some significantly and specifically overrepresented biological processes, 
but no molecular functions or cellular components. The two most specific GO terms are positive regulation of 
macrophage derived foam cell differentiation(cf. GO:0010744) (3/14 top genes belong to this term, while it is 
comprised of 14/20370 measured genes;   9.4 ⋅ 10  via hypergeometric test) and triglyceride catabolic 
process(cf. GO:0019433) (3/14 top genes belong to this term, while it is comprised of 19/20370 measured genes; 
  2.5 ⋅ 10 via hypergeometric test). All gene ontology analyses for this effect are available at 
 D=Interpretation\genomic\v44\GOA. 
Gene set enrichment analyses(Table III.3.3.5.a) revealed that   44 is the unsupervisedly rediscovered version of 
the stromal-2 signature(online interpretation card, [5]) from a previous CHOP-based DLBCL survival predictor; this effect 
has been associated with tumor blood vessel density[5]. 
 
Signatures GSEA Basic Statistics 
Signatures DB Signature Name 
# 
defined 
# mea-
sured 
Enrich- 
ment 
score 
 FDR Mean log2( 
ratio) 
 (-test 
versus zero) 
Down- 
reg. ratio 
Upreg.  
ratio 
StaudtSigDB_dNov2012 Stromal-2_DLBCL_survival_predictor 62 60 0.853 0.0021 0.2% -0.879 3.1E-21 100.0% 0.0% 
GeneSigDB_v4_Sept2011 Stomach_Yu04_17genes 13 11 0.687 0.0020 0.2% -0.947 0.0033 86.4% 13.6% 
MolSigDBv4_0_dMay2014 Nakayama_soft_tissue_tumors_pca2_dn 80 80 0.794 0.0020 0.2% -0.586 6.0E-15 97.8% 2.2% 
HGNCSigDB_dMay2014 Metallothioneins 19 10 0.782 0.0021 0.2% -0.368 0.0021 87.3% 12.7% 
MolSigDBv4_0_dMay2014 
Schaeffer_prostate_development_and 
cancer_box4_up 
11 11 0.679 0.0020 0.2% -0.466 0.0431 91.2% 8.8% 
GeneSigDB_v4_Sept2011 Lymphoma_Blenk08_16genes 11 11 -0.691 0.0019 0.2% 0.385 1.1E-07 0.0% 100.0% 
 
Table III.3.3.5.a) Top-enriched signatures by   44 
Signatures with |enrichment	score|  0.67, a mean logratio)  0.2 and at least 10 measured members are listed for genes ranked by GEP effect   44.  
All GSEA  values are based on permutation tests; hence, they are lower-bounded by 1 #permutations)⁄  and true  values might be considerably lower in this case. 
1000 permutations have been computed for each signature, i.e. approximately 500 for each enrichment sign. Percentages of down- and upregulated genes in a 
signature are weighted averages of gene regulation signs (using 1   values of -tests against zero regulation as weights). 
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Figure III.3.3.5) Validated effect   44, exemplary application to GSE10846.R-CHOP 
Second survival effect by CHOP based survival analysis(III.2.4) applied to GSE10846.R-CHOP (233 patients). The survival trend (that overlaps the trend of effect   5 
with opposite sign) is hardly visible in the classification stripe showing censored/progression follow-up information (green/orange) for R-CHOP. 
(The genomic consensus effect is applied to the cleaned signal without lab effects(cf. III.1.4.2). Samples and probesets are ordered by their effect strengths in this cohort(cf. 
Table III.1.5). Additionally, probesets are filtered by demanding a relative correlation stronger than 0.5. The effect’s bimonotonic eigensignal(panel d) is grayed for samples 
having insufficient or insignificant correlation to this effect(II.4.2.1).) 
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 Top genes overview 
For probesets with 
   0.4, 102 unique genes 
from 22 chromosomes participate in the effect, clearly 
indicating that it does not just reflect local aberrations 
on DNA level, as could be expected by its identified 
biological function. Even for 
   0.5, 42 unique 
genes from 17 chromosomes remain. 
As the effect has already been identified as the 
rediscovered stromal-2 signature, literature 
screening for individual top genes is not performed. 
 
 Revisiting a previous CHOP-based survival predictor 
A previous DLBCL survival predictor utilized a 
trivariate Cox model[5]. It is based on genes that were 
supervisedly selected utilizing CHOP survival data[5.SI]. 
Restricting the analysis to this gene selection, 
signature candidates were formed by hierarchical 
clustering. 
All three explanatory variables of this previous 
predictor have been unsupervisedly rediscovered by 
signal dissection: 
(a) the “Germinal center B cell DLBCL survival 
predictor” signature is enriched with score 0.867 by top genes of effect   129,  
(b) the “stromal-1” signature is enriched with 
score 0.855 by top genes of effect   5 and 
(c) the “stromal-2” signature is enriched with 
score 0.853 by top genes of this effect   44. 
Interestingly, effects  ∈ 5, 44 already suffice to 
explain CHOP patient survival(Figure III.2.4.2) to an extent 
that the standard COO induced effect   129 did not 
show any significant additional explanatory value 
(  0.26). (Effect   134 was still able to contribute 
with   1.5 ⋅ 10 on top of  ∈ 5, 44 in CHOP, but 
was not selected because of the chosen tight 
significance threshold at 10.) 
Because of only 181 available follow-up events for 
GSE10846.CHOP, the supervised gene selection 
procedure underlying this previous predictor might 
have selected many genes that are not specific to 
DLBCL(cf. III.2.1.2).  
Top genes in     
Probeset 
Gene  
Symbol 
HG19  
locus 
,  ,  ,  ,  . ,  
207175_at ADIPOQ 3q27.3 1.69 0.87 2.3E-53 1.47 
203980_at FABP4 8q21.13 1.64 0.85 3.3E-49 1.40 
209613_s_at ADH1B 4q23 1.49 0.81 1.9E-41 1.22 
209612_s_at ADH1B 4q23 1.15 0.70 6.2E-26 0.80 
228766_at CD36 7q21.11 1.14 0.67 9.6E-24 0.76 
218087_s_at SORBS1 10q24.1 0.89 0.68 1.0E-24 0.61 
235978_at FABP4 8q21.13 0.82 0.74 1.1E-30 0.61 
209555_s_at CD36 7q21.11 0.97 0.62 1.5E-19 0.60 
225207_at PDK4 7q21.3 0.88 0.66 8.8E-23 0.58 
205913_at PLIN1 15q26.1 0.71 0.76 1.2E-33 0.54 
1565162_s_at MGST1 12p12.3 1.02 0.51 1.0E-12 0.52 
201348_at GPX3 5q33.1 0.92 0.56 1.4E-15 0.51 
203548_s_at LPL 8p21.3 0.85 0.61 1.6E-18 0.51 
224918_x_at MGST1 12p12.3 0.95 0.54 4.5E-14 0.51 
203649_s_at PLA2G2A 1p36.13 0.90 0.56 9.6E-16 0.51 
214091_s_at GPX3 5q33.1 0.84 0.61 2.0E-18 0.51 
206488_s_at CD36 7q21.11 0.81 0.59 4.3E-17 0.48 
225987_at STEAP4 7q21.12 0.79 0.59 3.3E-17 0.46 
205498_at GHR 5p13.1 0.65 0.71 5.9E-28 0.46 
229476_s_at THRSP 11q14.1 0.69 0.65 1.3E-21 0.45 
231736_x_at MGST1 12p12.3 0.85 0.51 7.8E-13 0.44 
204955_at SRPX Xp11.4 0.69 0.63 2.5E-20 0.43 
203549_s_at LPL 8p21.3 0.73 0.59 4.1E-17 0.43 
222513_s_at SORBS1 10q24.1 0.63 0.66 1.3E-22 0.42 
219140_s_at RBP4 10q23.33 0.64 0.65 5.5E-22 0.42 
208383_s_at PCK1 20q13.31 0.75 0.52 5.5E-13 0.39 
204154_at CDO1 5q22.3 0.69 0.54 2.3E-14 0.37 
209763_at CHRDL1 Xq23 0.65 0.57 2.3E-16 0.37 
215049_x_at CD163 12p13.31 0.74 0.48 3.0E-11 0.36 
203571_s_at C10orf116 10q23.2 0.61 0.59 4.0E-17 0.36 
201540_at FHL1 Xq26.3 0.61 0.58 1.2E-16 0.35 
202992_at C7 5p13.1 0.70 0.49 8.7E-12 0.34 
49452_at ACACB 12q24.11 0.67 0.49 1.2E-11 0.33 
206157_at PTX3 3q25.32 0.64 0.49 1.9E-11 0.31 
43427_at ACACB 12q24.11 0.60 0.51 7.5E-13 0.31 
204719_at ABCA8 17q24.2 0.60 0.51 6.4E-13 0.31 
1552509_a_at CD300LG 17q21.31 0.45 0.67 4.0E-23 0.30 
204894_s_at AOC3 17q21.31 0.53 0.56 1.0E-15 0.30 
238066_at RBP7 1p36.22 0.54 0.55 7.9E-15 0.30 
214456_x_at SAA1 11p15.1 0.53 0.55 5.6E-15 0.29 
203645_s_at CD163 12p13.31 0.65 0.45 1.1E-09 0.29 
226304_at HSPB6 19q13.12 0.53 0.53 9.8E-14 0.28 
205382_s_at CFD 19p13.3 0.56 0.46 2.1E-10 0.26 
209699_x_at AKR1C2 10p15.1 0.45 0.57 5.0E-16 0.26 
210299_s_at FHL1 Xq26.3 0.52 0.49 1.1E-11 0.26 
207277_at CD209 19p13.2 0.48 0.50 2.1E-12 0.24 
228854_at  11q23.2 0.60 0.41 3.8E-08 0.24 
203305_at F13A1 6p25.1 0.55 0.44 2.9E-09 0.24 
201785_at RNASE1 14q11.2 0.48 0.48 2.6E-11 0.23 
216333_x_at TNXA 6p21.33 0.40 0.57 7.5E-16 0.23 
218736_s_at PALMD 1p21.2 0.43 0.53 1.5E-13 0.23 
209614_at ADH1B 4q23 0.42 0.54 3.4E-14 0.23 
202291_s_at MGP 12p12.3 0.53 0.40 4.7E-08 0.21 
219295_s_at PCOLCE2 3q23 0.48 0.44 2.3E-09 0.21 
212097_at CAV1 7q31.2 0.48 0.43 3.4E-09 0.21 
219607_s_at MS4A4A 11q12.2 0.50 0.42 1.4E-08 0.21 
222717_at SDPR 2q32.3 0.41 0.50 2.7E-12 0.21 
205559_s_at PCSK5 9q21.13 0.42 0.48 4.4E-11 0.20 
225575_at LIFR 5p13.1 0.43 0.46 3.7E-10 0.20 
205392_s_at CCL14 17q12 0.41 0.48 5.0E-11 0.19 
201010_s_at TXNIP 1q21.1 0.42 0.44 1.7E-09 0.19 
208607_s_at SAA1 11p15.1 0.44 0.41 3.4E-08 0.18 
219519_s_at SIGLEC1 20p13 0.43 0.42 1.5E-08 0.18 
228335_at CLDN11 3q26.2 0.42 0.42 9.3E-09 0.18 
208131_s_at PTGIS 20q13.13 0.42 0.41 2.0E-08 0.17 
202409_at IGF2 11p15.5 0.41 0.40 6.1E-08 0.16 
Table III.3.3.5.b) Top genes in validated effect   44 
 (probesets) from Affymetrix U133 Plus 2.0 microarrays;  
  manufacturer annotations (NetAffxTM,[97] v33) 
 
,  Components of the consensus gene axis of effect   44  
  (cf. Table III.1.5); filtered 
,   0.4. 
 
,  Consensus gene correlations; filtered 
,  0.4. 
 
,   values for the correlations (cf. II.5.2.1) 
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More importantly, this previous model reserved all R-CHOP treated patients for validation purposes and 
therefore discovered GEP effects for survival prediction that are optimal for CHOP(as confirmed by this work in III.2.4.1), but 
unfortunately suboptimal for the Rituximab-added therapy(cf. III.2.2.1 and III.2.5.1). 
In contrast, signal dissection discovers effects unsupervisedly based on GEP information only. Hence, all 
survival associations can be regarded as independent validation of these GEP effects. More importantly, this 
allows using all available survival data via leave-one-out validation(III.2.5.3) for predictor construction. The 
unbiased predictor construction procedure(cf. III.2.5.1) consequently can identify DLBCL survival effects based on 
survival data from much more patients. Correspondingly low  values indicate that GEP survival effects 
identified in this way can explain observed survival more reliably and are relevant for both CHOP and R-CHOP 
therapies(cf. III.2.5.4). 
Furthermore, discovered GEP effects always include as many top genes as correlations between gene 
expressions exist in the signal, i.e. they are not restricted to genes preselected with limited survival 
information. Hence, also GEP effects could be discovered that are not associated with outcome following 
contemporary therapies, but that might still reveal biologically interesting molecular differences between 
DLBCL patients(e.g. III.3.4.3). 
 Inference 
Both stromal effects  ∈ 5, 44 seem to concern the microenvironment, rather than gene expressions 
originating from DLBCL tumor cells. Additionally, effect   5 is associated with a strong survival dependency 
following CHOP therapy, but no longer following current standard R-CHOP therapy. However, both effects 
together predict a hierarchical survival dependency for a subset of DLBCL that is still strong following R-CHOP 
therapy(cf. Figure III.2.4.3). It might be biologically interesting to understand this hierarchical relation between these 
stromal effects. Still, in order to investigate the molecular pathogenesis of DLBCL, other discovered survival 
effects may provide more direct information.  
 
 
 
 
III.3.3.6   19: A T cell related effect (quinvariate model, 3rd predictor variable) 
 Role in survival analysis 
Effect   19 facilitates significant (  7.4 ⋅ 10) survival prediction on top of survival already explained by 
effects  ∈ 134, 131(Figure III.2.5.1.c). Together with   75 it additionally shows a complex hierarchical 
dependency for effect   3(as described in III.3.3.8). 
 Effect overview 
Effect   19 is another unsupervisedly quad-discovered effect. Detection ranks are #47(GSE10846.CHOP), 
#29(GSE10846.R-CHOP), #29(GSE4475.nonMBL) and #57(GSE31312.R-CHOP). It has a one-sided gradual signal(e.g. Figure III.3.3.6.a) with 
approximately 75 probesets (relative correlation  0.5). 
Higher expressions correspond to lower risk(Table III.2.5.2) for a subset of patients. 
 Clinical associations 
Clinically, it is interesting that in all three cohorts with LDH data, LDH ratios are significantly and consistently 
associated with effect   19 for GCB DLBCL patients, but not so for ABC DLBCL patients.   More precisely, the 
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Figure III.3.3.6.a) Validated effect    19, applied to GSE10846.R-CHOP 
Third survival effect by multi-cohort based survival analysis(III.2.5) applied to GSE10846.R-CHOP (233 patients). 
(The genomic consensus effect is applied to the cleaned signal without lab effects(cf. III.1.4.2). Samples and probesets are ordered by their effect strengths in this cohort(cf. 
Table III.1.5). Additionally, probesets are filtered by demanding a relative correlation stronger than 0.5. The effect’s bimonotonic eigensignal(panel d) is grayed for samples 
having insufficient or insignificant correlation to this effect(II.4.2.1).) 
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partition with lower average expression contains significantly more GCB DLBCL patients with LDH ratio  1 
(GSE10846.CHOP.GCB  0.01, GSE10846.R-CHOP.GCB  7.7 ⋅ 10 and GSE31312.R-CHOP.GCB  0.03;   tests based on 
contingency tables). This is consistent with the overall survival trend predicted by   19, i.e. higher 
expression is associated with more favorable outcome (Table III.2.5.2). However, this association does not reliably 
exist for ABC DLBCL patients (GSE10846.CHOP.ABC  0.06, GSE10846.R-CHOP.ABC  0.67 and GSE31312.R-CHOP.ABC  0.59), 
indicating a subtype-specific survival dependency. 
 Genomic associations 
Gene ontology overrepresentation analyses reveal an overrepresentation of T cell co-stimulation(cf. GO:0031295) 
with   5.1 ⋅ 10(Figure III.3.3.6.b). This term contains genes responsible for antigen-independent signaling for T 
cell activation, i.e. an alternative to T cell receptor signaling. 
Figure III.3.3.6.b) Gene ontology overrepresentation analyses of biological processes in effect    19 
All  values are based on hypergeometric tests; cf. I.3.2. 
 
Signature analyses(Table III.3.3.6.a) confirm this association with T cells. For example, the Biocarta pathway about 
surface molecules of T helper cells(online interpretation card) is significantly enriched. 
Signatures GSEA Basic Statistics 
Signatures DB Signature Name 
# 
defined 
# mea-
sured 
Enrich- 
ment 
score 
 FDR 
Mean log2( 
ratio) 
 (-test 
versus zero) 
Down- 
reg. ratio 
Upreg.  
ratio 
MolSigDBv4_0_dMay2014 Biocarta_Thelper_pathway 14 12 0.886 0.0021 0.2% -1.088 0.0002 100.0% 0.0% 
StaudtSigDB_dNov2012 T_cell 15 14 0.851 0.0020 0.2% -1.215 7.9E-06 93.0% 7.0% 
MolSigDBv4_0_dMay2014 Biocarta_Tcytotoxic_pathway 14 12 0.802 0.0021 0.2% -1.157 7.6E-05 100.0% 0.0% 
MolSigDBv4_0_dMay2014 Biocarta_TCRA_pathway 13 11 0.801 0.0020 0.2% -0.906 0.0001 100.0% 0.0% 
MolSigDBv4_0_dMay2014 Watanabe_ulcerative_colitis_with-cancer_dn 14 14 0.670 0.0020 0.2% -0.728 1.8E-05 97.2% 2.8% 
MolSigDBv4_0_dMay2014 GNF2_ATM 30 30 0.689 0.0019 0.2% -0.564 2.3E-06 96.0% 4.0% 
 
Table III.3.3.6.a) Top-enriched signatures by   19 
Signatures with |enrichment	score|  0.67 and at least 10 measured members are listed for genes ranked by GEP effect   19. 
All GSEA  values are based on permutation tests; hence, they are lower-bounded by 1 #permutations)⁄  and true  values might be considerably lower in this case. 
1000 permutations have been computed for each signature, i.e. approximately 500 for each enrichment sign. Percentages of down- and upregulated genes in a 
signature are weighted averages of gene regulation signs (using 1   values of -tests against zero regulation as weights). 
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 Top genes overview 
For probesets with 
   0.4(cf.Table III.3.3.6.b), 70 unique 
genes from 18 chromosomes participate in the effect, 
suggesting that it reflects a genomic regulation 
network and not just local aberrations on DNA level, 
as could be expected by its identified function in T cell 
regulation. Even for 
   0.5, 33 unique genes from 
12 chromosomes remain. 
A brief recherché for individual top correlated 
genes(information via http://www.ncbi.nlm.nih.gov/gene, [107], April 2015) 
confirms the association with T cells: CTLA4 can 
cause inhibitory signals to T cells[117], ICOS stands for 
“inducible T-cell co-stimulator”, CD28 belongs to one 
of the dominant co-stimulatory pathways[118] and 
TOX2 is an essential regulator of T-cell differen-
tiation[119]. 
While the top three genes are all located in 2q33.2, 
many other measured and expressed probesets from 
this locus are not correlated to the effect, making a 
DNA level aberration unlikely (see  DLBCL Master 
Table 2015, gene orders.xlsx). 
 
 Inference 
Based on gene ontology analyses and confirmed by 
other analyses, this effect is related to T cells, 
probably to antigen-independent T cell co-stimu-
lation (  5.1 ⋅ 10). 
To rule out a potential triggering aberration, copy 
number measurements(e.g. from GSE11318, [11]) for 2q33.2 
could be interrogated. 
The role of effect   19 in DLBCL is probably easier 
to conceive in context of expressions of other effects. 
For example, it plays a key role in selecting DLBCL 
patients that show a strong survival dependency on 
effect   3, as will be described in III.3.3.8. This may 
also help to interpret this effect, maybe validate its 
association with T cells and ideally unveil their role in 
DLBCL. 
Top genes in     
Probeset 
Gene  
Symbol 
HG19  
locus 

,  
,  
 ,  

,  
. 
,  
236341_at CTLA4 2q33.2 1.23 0.90 3.8E-55 1.10 
234362_s_at CTLA4 2q33.2 0.90 0.86 2.1E-44 0.77 
210439_at ICOS 2q33.2 0.81 0.82 3.0E-35 0.67 
231794_at CTLA4 2q33.2 0.75 0.81 4.4E-37 0.61 
221331_x_at CTLA4 2q33.2 0.69 0.83 2.6E-37 0.58 
206545_at CD28 2q33.2 0.65 0.76 5.3E-28 0.50 
228737_at TOX2 20q13.12 0.76 0.53 1.8E-12 0.41 
229327_s_at  16q23.2 0.64 0.55 4.4E-13 0.35 
211796_s_at TRBC1 7q34 0.53 0.64 1.8E-17 0.34 
213193_x_at TRBC1 7q34 0.48 0.69 4.6E-21 0.33 
210915_x_at TRBC1 7q34 0.47 0.70 9.1E-22 0.33 
236787_at  2p11.2 0.66 0.48 3.1E-10 0.32 
213135_at TIAM1 21q22.11 0.54 0.58 4.6E-14 0.32 
209348_s_at MAF 16q23.2 0.52 0.58 4.6E-14 0.30 
206363_at MAF 16q23.2 0.48 0.61 8.1E-16 0.29 
214228_x_at TNFRSF4 1p36.33 0.45 0.64 1.2E-17 0.29 
213539_at CD3D 11q23.3 0.41 0.66 7.8E-19 0.27 
210116_at SH2D1A Xq25 0.47 0.56 7.5E-13 0.26 
214551_s_at CD7 17q25.3 0.42 0.61 1.7E-15 0.26 
211005_at LAT 16p11.2 0.40 0.65 7.8E-18 0.26 
219528_s_at BCL11B 14q32.2 0.40 0.64 8.4E-18 0.26 
214049_x_at CD7 17q25.3 0.38 0.67 3.0E-19 0.25 
204777_s_at MAL 2q11.1 0.49 0.51 2.0E-10 0.25 
230469_at RTKN2 10q21.2 0.53 0.46 1.8E-09 0.25 
220485_s_at SIRPG 20p13 0.39 0.62 2.3E-16 0.24 
205831_at CD2 1p13.1 0.38 0.64 3.0E-17 0.24 
207949_s_at ICA1 7p21.3 0.42 0.57 3.4E-13 0.24 
210547_x_at ICA1 7p21.3 0.39 0.60 3.6E-15 0.23 
203828_s_at IL32 16p13.3 0.41 0.56 8.1E-13 0.23 
224211_at FOXP3 Xp11.23 0.42 0.52 5.5E-12 0.22 
209670_at TRAC 14q11.2 0.36 0.59 1.0E-14 0.22 
209671_x_at TRAC 14q11.2 0.37 0.58 9.2E-14 0.21 
210972_x_at TRAV20 14q11.2 0.37 0.57 1.4E-13 0.21 
227361_at HS3ST3B1 17p12 0.47 0.44 1.5E-08 0.21 
213958_at CD6 11q12.2 0.30 0.68 4.6E-20 0.21 
202524_s_at SPOCK2 10q22.1 0.36 0.55 1.1E-12 0.20 
209604_s_at GATA3 10p14 0.36 0.55 2.6E-12 0.20 
219423_x_at TNFRSF25 1p36.31 0.37 0.52 2.9E-11 0.20 
211902_x_at YME1L1 14q11.2 0.35 0.56 8.9E-13 0.20 
211339_s_at ITK 5q33.3 0.44 0.44 6.2E-08 0.19 
54632_at THADA 2p21 0.41 0.47 3.7E-09 0.19 
222895_s_at BCL11B 14q32.2 0.37 0.51 2.7E-11 0.19 
229247_at FBLN7 2q13 0.38 0.49 1.6E-10 0.19 
240070_at TIGIT 3q13.31 0.40 0.46 2.7E-09 0.18 
236226_at BTLA 3q13.2 0.43 0.42 9.4E-08 0.18 
216033_s_at FYN 6q21 0.38 0.47 3.6E-09 0.18 
224832_at DUSP16 12p13.2 0.33 0.54 8.3E-13 0.18 
205456_at CD3E 11q23.3 0.31 0.55 1.7E-12 0.17 
220212_s_at THADA 2p21 0.33 0.52 7.4E-11 0.17 
214032_at ZAP70 2q11.2 0.35 0.49 1.2E-09 0.17 
210031_at CD247 1q24.2 0.36 0.47 6.5E-09 0.17 
210073_at ST8SIA1 12p12.1 0.35 0.47 3.3E-09 0.17 
202747_s_at ITM2A Xq21.1 0.35 0.47 3.1E-09 0.16 
223377_x_at CISH 3p21.2 0.36 0.45 7.9E-09 0.16 
223851_s_at TNFRSF18 1p36.33 0.31 0.52 8.3E-12 0.16 
226333_at IL6R 1q21.3 0.40 0.40 3.5E-07 0.16 
1555613_a_at ZAP70 2q11.2 0.35 0.45 4.7E-09 0.16 
211210_x_at SH2D1A Xq25 0.32 0.50 5.1E-10 0.16 
211828_s_at TNIK 3q26.2 0.35 0.45 3.2E-08 0.16 
214735_at IPCEF1 6q25.2 0.32 0.48 1.4E-09 0.15 
212062_at ATP9A 20q13.2 0.36 0.43 1.2E-07 0.15 
202746_at ITM2A Xq21.1 0.38 0.41 4.8E-07 0.15 
212473_s_at MICAL2 11p15.3 0.34 0.45 3.6E-08 0.15 
230489_at CD5 11q12.2 0.31 0.48 2.9E-10 0.15 
206118_at STAT4 2q32.2 0.30 0.49 8.7E-10 0.15 
230488_s_at DBH-AS1 9q34.2 0.36 0.40 2.8E-07 0.14 
218573_at MAGEH1 Xp11.21 0.34 0.42 2.8E-07 0.14 
203508_at TNFRSF1B 1p36.22 0.33 0.42 1.8E-07 0.14 
222317_at PDE3B 11p15.2 0.33 0.42 3.0E-07 0.14 
239288_at TNIK 3q26.31 0.31 0.40 3.6E-07 0.12 
Table III.3.3.6.b) Top genes in validated effect   19 
 (probesets) from Affymetrix U133 Plus 2.0 microarrays;  
  manufacturer annotations (NetAffxTM,[97] v33) 
 
,  Components of the consensus gene axis of effect   19  
  (cf. Table III.1.5); filtered 
,   0.3. 
 
,  Consensus gene correlations; filtered 
,  0.4. 
 
,   values for the correlations (cf. II.5.2.1) 
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III.3.3.7   75: BCL2 (quinvariate model, 4th predictor variable) 
 Role in survival analysis 
Effect   75 is capable of predicting significant survival differences (  3.6 ⋅ 10) on top of already 
explained survival by effects  ∈ 134, 131, 19. Together with   19 it additionally reveals a complex 
hierarchical dependency of effect   3(as described in III.3.3.8). 
 Effect overview 
Two unsupervised detections underlie this consensus effect (with ranks #136 in GSE10846.R-CHOP and #43 
in GSE31312.R-CHOP). It has been supervisedly validated in all four cohorts(e.g. Figure III.3.3.7). Detected effects 
contain several correlated genes, but after soft intersection by consensus gene axis construction(cf. III.1.3) BCL2 
is the only remaining gene that is highly correlated to this effect. Eight top-correlated probesets(Table III.3.3.7.a) 
support this effect; all measure BCL2 or are overlapped by BCL2-annotated probesets in locus 18q21.33. 
Hence it cannot be excluded that this effect is a reflection of a chromosomal feature in the GEP signal; 
examination of DNA measurements like array comparative genomic hybridization might clarify this. 
Higher expressions of BCL2 correspond to higher risk and adverse outcome(cf. III.2.5.1) for a DLBCL subset. 
  Preliminary top gene analysis 
Direct literature screening for BCL2 revealed that it 
is an already well-known player in several 
lymphomas, for example in follicular lymphoma[120]. 
Functionally, Bcl-2 proteins are mainly located in the 
outer mitochondrial membrane and bind Bax/Bak 
proteins that can make the mitochondrial membrane 
permeable as soon as they are released, thereby 
triggering apoptosis[121]. Consistent with adverse 
outcome for higher expression of   75, over-
expressed BCL2 has an anti-apoptotic effect and can 
cause chemotherapy resistance in various human 
cancers; hence complementing chemotherapy with 
BCL2-specific agents like small molecule Bcl-2 protein 
inhibitors has been suggested for clinical trials[121]. 
With respect to DLBCL, a review in clinical oncology[122] reported poor prognosis with standard R-CHOP 
therapy for patients having a (14; 18) translocation of BCL2 together with a MYC gene rearrangement 
(“double-hit DLBCL”). The review concluded from several other studies that a) only concurrent expression of 
BCL2 and MYC is important for outcome rather than MYC expression alone and that b) the incidence for 
double-overexpression is 20%-30% in DLBCL, if measured by immunohistochemistry. Routine evaluation of 
MYC and BCL2 by immunohistochemistry was recommended for clinical management. While it was clear that 
R-CHOP should be replaced for double-hit patients, the review concluded (in 2012) that no optimal therapy is 
known and double-hit patients should be referred for clinical trials wherever possible. 
 Inference 
The unsupervisedly (re)discovered BCL2 GEP effect plays a known important role for a subset of DLBCL 
patients having a (14; 18) translocation. This might be helpful when interpreting the complex survival 
dependency of   3 in context of this effect and   19 that only exists for low BCL2 expression(cf. III.3.3.8). 
Another study has already revealed significantly more favorable outcome for GCB DLBCL patients with high 
Top genes in   75 
Probeset 
Gene  
Symbol 
HG19  
locus 

,  
,  
,  

,  
. 
,  
244035_at  18q21.33 1.31 0.90 1.8E-68 1.17 
203685_at BCL2 18q21.33 1.33 0.80 5.1E-44 1.06 
232614_at  18q21.33 1.12 0.90 3.0E-69 1.01 
232210_at  18q21.33 1.06 0.87 1.3E-60 0.93 
237837_at  18q21.33 0.79 0.65 9.3E-24 0.51 
203684_s_at BCL2 18q21.33 0.61 0.73 8.9E-33 0.45 
207005_s_at BCL2 18q21.33 0.62 0.72 2.3E-31 0.44 
207004_at BCL2 18q21.33 0.39 0.45 8.6E-11 0.17 
211352_s_at NCOA3 20q13.12 0.33 0.36 3.0E-07 0.12 
1554636_at  19q13.43 0.32 0.30 2.5E-05 0.10 
206951_at HIST1H4I 6p22.2 -0.32 -0.32 8.1E-06 -0.10 
1554878_a_at ABCD3 1p21.3 -0.37 -0.31 1.0E-05 -0.12 
Table III.3.3.7.a) Top genes in validated effect   75 
 (probesets) from Affymetrix U133 Plus 2.0 microarrays;  
  manufacturer annotations (NetAffxTM,[97] v33) 
 
,  Components of the consensus gene axis of effect   75  
  (cf. Table III.1.5); filtered 
,   0.3. 
 
,  Consensus gene correlations; filtered 
,  0.3. 
 
,   values for the correlations (cf. II.5.2.1) 
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BCL2 expression and high NF-κB expression(cf. Figure I.3.3 and [81]). It might be biologically interesting to search for a 
potential common molecular mechanism involving BCL2 that may link both observations. 
        
Figure III.3.3.7) Validated effect    75, applied to GSE10846.R-CHOP and GSE4475 
Fourth survival effect by multi-cohort based survival analysis(III.2.5) applied to GSE10846.R-CHOP (233 patients) and GSE4475 (all 166 patients, including BL patients). 
(The genomic consensus effect is applied to the cleaned signal without lab effects(cf. III.1.4.2). Samples and probesets are ordered by their effect strengths in this cohort(cf. 
Table III.1.5). Additionally, probesets are filtered by demanding a relative correlation  0.5. The effect’s bimonotonic eigensignal(panel d) is grayed for samples having insuf-
ficient or insignificant correlation to this effect(II.4.2.1). Missing probesets for the consensus gene axis due to an older microarray design in GSE4475 are also grayed.) 
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III.3.3.8   3: A zinc-related effect (quinvariate model, 5th predictor variable) 
 Role in survival analysis 
The final explanatory variable for the quinvariate predictor is effect   3. With   2.5 ⋅ 10(III.2.5.1), it can 
predict significant survival differences on top of already explained survival by effects  ∈ 134, 131, 19, 75. In 
the final quinvariate model(cf. Table III.2.5.2) it contributes with a Cox  value of 6.3 ⋅ 10. 
 Effect overview 
Effect   3 has been unsupervisedly quad-discovered with detection ranks #204(GSE10846.CHOP), #32(GSE10846.R-
CHOP), #24(GSE4475.nonMBL) and #42(GSE31312.R-CHOP). It has a one-sided gradual signal with few co-regulated genes that 
show a clear and homogeneous folding between patients in all cohorts(Figure III.3.3.8.b). 
Higher expression corresponds to higher risk(Table III.2.5.2) for a subset of DLBCL patients stratified by other 
predictor variables. A hierarchical survival analysis below clarifies this subset. 
 Genomic associations 
Via gene ontology overrepresentation(Figure III.3.3.6.b), it was possible to locate this effect in the perinuclear region 
of the cytoplasm(cf. GO:0005737) (  2.0 ⋅ 10, hypergeometric test) where it is involved in negative regulation 
of growth(cf. GO:0045926) (  2.2 ⋅ 10). 
Interestingly, top genes of this effect also represent the majority of genes involved in cellular response to 
cadmium ion(cf. GO:0071276) (  1.6 ⋅ 10) and in cellular response to zinc ion(cf. GO:0071294) (  2.2 ⋅ 10). This 
zinc association seems highly specific, as this GO term is comprised of only 10/20370 measured genes and 
7/8 top genes of the discovered effect belong to it. 
 
Figure III.3.3.8.a) Gene ontology overrepresentation analyses of biological processes and cellular components for effect    3 
All  values are based on hypergeometric tests; cf. I.3.2. (A  value of zero indicates an underflow, i.e.   2.2 ⋅ 10 , which is the numeric resolution limit for 
differences to one; the true  value is never exactly zero.) 
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Figure III.3.3.8.b) Validated effect    3, applied to GSE10846.R-CHOP and GSE31312.R-CHOP 
The fifth and last significant survival effect by multi-cohort based survival analysis(III.2.5) is depicted for cohorts GSE10846.R-CHOP (233 patients) and GSE31312.R-
CHOP (498 patients). 
(The genomic consensus effect is applied to the cleaned signal without lab effects(cf. III.1.4.2). Samples and probesets are ordered by their effect strengths in this cohort(cf. 
Table III.1.5). Additionally, probesets are filtered by demanding a relative correlation stronger than 0.5. The effect’s bimonotonic eigensignal(panel d) is grayed for samples 
having insufficient or insignificant correlation to this effect(II.4.2.1).) 
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Signature analyses reveal two significantly enriched gene signatures that contain top genes of   3; both 
are strongly differentially expressed: 
Consistent with gene ontology findings, the Metallothioneins signature(online interpretation card) describes a family 
of genes that are involved in the metal metabolism of cells[123]. 
Genes in signature Lung_Magda08_21genes(online interpretation card) were upregulated in human lung cancer cell 
line A549 after treatment with zinc ionophores[124]. As zinc ionophores significantly inhibited proliferation for 
these cells, they were suggested as anti-cancer agents in this context. In contrast, DLBCL patient outcome is 
inferior for higher expression of this effect. 
 
 Preliminary top genes analysis 
The effect contains nine top-correlated genes from 
four genomic loci and two chromosomes. 
All top genes are named MT*, where MT abbreviates 
metallothionein. Thionein proteins can bind several 
metals; the complex is then called metallothionein. By 
binding physiologically important metals like zinc or 
by providing a metal storage buffer, they can play a 
role in cellular functions. A dynamic equilibrium 
between thionein acceptors and metallothionein 
donors regulates the availability of zinc[125], for 
example for protein synthesis. 
Seven top genes are from either 16q12.2 or from 
16q13. In principle, a reflection of a chromosomal 
feature in the GEP signal cannot be ruled out. However, 
given the association of these genes to the same known 
function, a genetic regulation network seems more likely to be involved in their coordinate expression. 
Interrogating copy number measurements(e.g. from GSE11318, [11]) for these loci could potentially provide more 
clarity. 
 Hierarchical survival analysis demarcates a DLBCL subset that is influenced by this effect 
As standalone univariate predictor, effect   3 only explains a weak survival trend with   0.0601 on top 
of age and therapy (likelihood ratio test; trained with all samples). However, its additional explanatory value 
increased by orders of magnitudes after incorporating effect   19 into the model (  1.2 ⋅ 10, likelihood 
ratio test) and increased further after incorporating   75. Hence, it should be biologically interpreted in 
context of these other GEP effects. 
Signatures GSEA Basic Statistics 
Signatures DB Signature Name 
# 
defined 
# mea-
sured 
Enrich- 
ment 
score 
 FDR 
Mean  
log2(ratio) 
 (-test 
versus zero) 
Down- 
reg. ratio 
Upreg.  
ratio 
HGNCSigDB_dMay2014 Metallothioneins 19 10 0.897 0.0019 0.2% -1.375 0.0003 100.0% 0.0% 
GeneSigDB_v4_Sept2011 Lung_Magda08_21genes 16 13 0.610 0.0020 0.2% -1.042 0.0004 97.3% 2.7% 
 
Table III.3.3.8.a) Top-enriched signatures by   3 
Signatures with |enrichment	score|  0.5, a mean |log(ratio)|  0.33 and at least 10 measured members are listed for genes ranked by GEP effect   3. 
All GSEA  values are based on permutation tests; hence, they are lower-bounded by 1 (#permutations)⁄  and true  values might be considerably lower in this case. 
1000 permutations have been computed for each signature, i.e. approximately 500 for each enrichment sign. Percentages of down- and upregulated genes in a 
signature are weighted averages of gene regulation signs (using 1   values of -tests against zero regulation as weights). 
Top genes in     
Probeset 
Gene  
Symbol 
HG19  
locus 

,  
,  
,  

, 	
. 
,  
206461_x_at MT1H 16q13 1.07 0.96 8.8E-98 1.03 
204745_x_at MT1G 16q13 1.00 0.94 1.4E-79 0.94 
208581_x_at MT1X 16q13 0.97 0.93 1.5E-76 0.91 
204326_x_at MT1X 16q13 0.95 0.92 1.9E-69 0.87 
212859_x_at MT1E 16q12.2 0.92 0.90 2.4E-62 0.83 
211456_x_at MT1P2 1q43 0.87 0.92 1.9E-69 0.80 
217165_x_at MT1F 16q12.2 0.85 0.88 7.0E-56 0.74 
213629_x_at MT1F 16q12.2 0.83 0.87 4.4E-54 0.73 
212185_x_at MT2A 16q12.2 0.81 0.89 3.9E-58 0.72 
217546_at MT1M 16q12.2 0.99 0.73 3.1E-29 0.72 
216336_x_at MT1E 1p35.1 0.73 0.87 8.6E-55 0.64 
210524_x_at  17q23.3 0.66 0.81 5.0E-40 0.53 
216504_s_at SLC39A8 4q24 0.37 0.31 4.9E-05 0.11 
228945_s_at SLC39A8 4q24 0.34 0.31 2.1E-05 0.11 
202437_s_at CYP1B1 2p22.2 0.30 0.30 5.5E-05 0.09 
Table III.3.3.8.b) Top genes in validated effect   3 
 (probesets) from Affymetrix U133 Plus 2.0 microarrays;  
  manufacturer annotations (NetAffxTM,[97] v33) 
 
,  Components of the consensus gene axis of effect   3  
  (cf. Table III.1.5); filtered 
,   0.3. 
 
,  Consensus gene correlations; filtered 
,  0.3. 
 
,   values for the correlations (cf. II.5.2.1) 
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 low BLC2 expression and high “T cell co-stimulation” high BLC2 expression or low “T cell co-stimulation” 
 all available samples 
   
 ABC DLBCL 
   
 GCB DLBCL 
   
Figure III.3.3.8.c) Survival dependency on effect   3 for low BCL2 expression and high “T cell co-stimulation”. 
On the left, 173 samples from all four cohorts with low BCL2 expression (negative logratios) for   75) and high “T cell co-stimulation” (positive log(ratios) for 
  19) are split into subgroups of significantly different survival by effect   3 (hazards predicted by leave-one-out validation). On the right, hazards are predicted 
with the same predictor variable   3 (and with   0.37) for samples with high BCL2 expression or low “T cell co-stimulation”. Here, no significant survival 
difference exists for identical risk intervals. (Chosen split points to present the survival spread in three risk intervals equal ±loghazard ratios of 125%).) 
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To elucidate this complex survival dependency, further manual combinations of effects and hierarchical 
survival analyses have been performed. These investigations revealed a DLBCL subset of 173/947 cases 
(18.3%) defined by low expression of BCL2 (i.e. the lower risk partition of effect   75(cf. III.3.3.7)) and by high 
expression of the “T cell co-stimulation” effect (i.e. also the lower risk partition of effect   19(cf. III.3.3.6)). 
For this subset, a simple univariate Cox predictor model based only on effect   3 can predict significant 
survival differences (  0.37,   3.2 ⋅ 10 using all 173 samples for training), whereas for remaining DLBCL 
patients (having high expression of BCL2 or low expression of “T cell co-stimulation”) effect   3 cannot 
predict any significant survival differences. 
To visualize and validate this, leave-one-out validation(cf. III.2.5.3) has been applied to this subset of 173 cases, 
Kaplan-Meier survival estimates for risk intervals have been computed and resulting survival curves have 
been compared by log rank tests(Figure III.3.3.8.c). The subset for low BLC2 expression and high “T cell co-
stimulation” is clearly split into groups of significantly different survival, including a small group of particularly 
favorable prognosis for lowest metallothionein expressions (95.5% average survival). 
This trend is also visible when additionally restricting to ABC DLBCL or to GCB DLBCL. However, remaining 
sample counts for this three-level hierarchy are too low to reach log rank significance between all neighboring 
risk intervals. Additionally, no ABC DLBCL samples with very low metallothionein expressions exist (hence, 
only two survival curves result for identical risk cutoffs). 
In contrast, for high BLC2 expression or low “T cell co-stimulation”, expressions of metallothioneins cannot 
predict any significant survival differences (and neither after restricting by subtype). 
 The role of zinc for B cells 
Consistent with observed favorable outcome for a subset of DLBCL patients for low levels of 
metallothioneins, a review on zinc related pathways in immunity[126] summarized zinc’s complex involvement 
in T and B cell activity: 
• Zinc deficiency can lead to decreased (non-malignant) lymphocyte count and function. 
• Different sensibility to zinc deprivation points to an effect on cellular development of B cells, rather than 
a functional dependency of mature B cells on zinc. 
• More precisely, zinc deficiency is assumed to increase the rate of apoptosis during elimination of 
autoreactive(cf. I.1.2.2) B cells. 
• Consistently, on organism level it has been observed that loss of lymphoid tissue during zinc deprivation 
exceeds that of other tissues. 
• Numerous additional zinc-related pathways in context of NF-κB, MAPK, PI3K, NFAT and IRAK are 
described that can cause zinc to show complex opposing functions, depending on its concentration and 
on the cellular environment, especially with respect to T cells. 
 Inference 
In summary, high metallothionein expression is associated with adverse outcome for DLBCL patients with 
low BCL2 expression(III.3.3.7) and high “T cell co-stimulation”(III.3.3.6). Low metallothionein expression in this 
subset is associated with 95.5% average survival(cf. Figure III.3.3.8.c). 
The molecular mechanisms for metallothionein overexpression are currently unclear. The gene ontology 
result for cellular response to zinc ion and published data for a lung cancer experiment using zinc 
ionophores[124] indicate that the expression of this effect may directly correlate with zinc concentrations. In 
this context, a correlation of patient zinc blood levels with average expressions of this effect could potentially 
be interesting. 
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III.3.4 Effects without Strong Survival Impact 
As patient outcome is dependent on therapy, effects may be relevant to understand causes of DLBCL, even if 
their differential expression cannot predict significant survival differences. Ideally, some of these discovered 
effects might be utilized therapeutically by novel agents in the future. Other effects without survival 
association might be DLBCL-unspecific. 
Three more effects with interesting statistical properties have been selected and are briefly evaluated here. 
Analyses for several more effects with significant associations to gene ontology terms or to gene signatures 
can be browsed via  DLBCL Master Table 2015, main overview.xlsx. Additionally, some effects with clearly 
differential signal between DLBCL patients but without any known associations can be found there. 
III.3.4.1   20: Another perspective on DLBCL subtypes 
 Role in survival analysis 
Sorting patients by effect   20 reproduces published DLBCL subtypes with 88% agreement and with  
3.4 ⋅ 10 (cf. Figure III.3.2.2.a). Kaplan-Meier survival estimates for sets of patients that result from cutting effect  
20 at its average expression (i.e. at zero eigensignal) are significantly different for both R-CHOP treated cohorts 
(with GSE10846.R-CHOP.KM  7.8 ⋅ 10 and GSE31312.R-CHOP.KM  0.05, log rank tests). This is consistent with known 
differences in average survival of ABC DLBCL and GCB DLBCL. 
However, the effect does not predict any consistent survival trend on top of age and therapy. With   0.065 
(likelihood ratio test) it only ranks 68/135(cf. Figure III.2.5.1.a) in multivariate analysis. Fitting univariate Cox survival 
models for both R-CHOP-treated cohorts results in GSE10846.R-CHOP.Cox  0.03 and GSE31312.R-CHOP.Cox  0.71. For 
comparison, the same univariate Cox survival analyses for effect   134 result in ν134,	GSE10846.R-CHOP.Cox  1.1 ⋅
10 and ν134,	GSE31312.R-CHOP.Cox  1.6 ⋅ 10. Cox models test for a consistent survival trend over the effect’s 
average expression (quantified by its eigensignal strengths(cf. Table III.1.5)), rather than comparing the average 
survival of sets of patients.  
These results indicate that compatible survival trends over average effect expression within subsets of ABC 
DLBCL or GCB DLBCL are predicted by effect   134, but not so by effect   20. Visually consistent(cf. Figure 
III.3.4.1.a), there is no overrepresentation of ABC DLBCL samples with observed progressions (or deaths) on the 
left and neither an overrepresentation of censored GCB DLBCL samples on the right. Hence, no consistent and 
strong survival trend exists over sample eigensignal strengths of   20, despite the obvious arrangement 
by subtype. 
Similar to effects   127 and   131(cf. III.3.3.2), this effect gains in predictive value after including effect  
134 in the multivariate predictor, indicating that expression of   20 is associated with two opposing survival 
trends for two overlapping subsets of DLBCL. However, it still only ranks 9th(cf. Figure III.2.5.1.b) with   2.1 ⋅ 10 . 
After including   131 or   127 in the predictor model as well, no significant additional explanatory value 
remains for   20. 
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Figure III.3.4.1.a) The quad-discovered effect   20 is significantly associated with DLBCL subtypes, but not with a consistent survival trend 
Effect   20	applied to GSE31312 (498 patients). Enlarged public subtype classifications (yellow/pink) show a significant arrangement from ABC DLBCL to GCB 
DLBCL. Despite that, no clear survival trend exists (green/orange). 
(The genomic consensus effect is applied to the cleaned signal without lab effects(cf. III.1.4.2). Samples and probesets are ordered by their effect strengths in this 
cohort(cf. Table III.1.5). Additionally, probesets are filtered by demanding a relative correlation stronger than 0.5. The effect’s bimonotonic eigensignal(panel d) is grayed for 
samples having insufficient or insignificant correlation to this effect(II.4.2.1).) 
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 Effect overview 
Effect   20 has been unsupervisedly quad-discovered with detection ranks #6(GSE10846.CHOP), #27(GSE10846.R-
CHOP), #4(GSE4475.nonMBL) and #15(GSE31312.R-CHOP). The effect has a well-defined signal of moderate size(e.g. Figure III.3.4.1.a) in 
all four cohorts (approximately 70 top probesets for relative correlation  0.5). A detailed list of top genes is 
available in  DLBCL Master Table 2015, gene orders.xlsx. 
Its top genes are partially correlated to the hierarchical survival effect  ∈ 127, 131(cf. III.3.3.2) (with ; 0.57 and (;)  0.31(cf. Eqn. III.1.3.2.b)). It is also partially correlated to the relatively large rediscovered COO 
induced effect(III.3.2.2) (with (;)
  0.36). This indicates that several of its top genes may be biologically 
relevant in contexts of these other GEP effects. However, described survival characteristics of effect   20 
indicate that the average expression of its particular composition of top genes is not as specific to true 
biological effects as these partially correlated other effects. 
 Genomic associations 
The same ABC-versus-GCB signatures that were significantly enriched for the COO induced effect  
129(Figure III.3.2.2.c) are nearly as strongly enriched for top genes of   20(Figure III.3.4.1.b): 
 
Figure III.3.4.1.b) Significant enrichment of known ABC-versus-GCB DLBCL signatures by effect   20 
 
 
 Inference 
Results for this effect demonstrate that significant association with and high agreement with binary DLBCL 
subtypes is not sufficient information to reliably infer consistent trends of patient survival over average effect 
expression. (Significantly different average survival for corresponding patient partitions may be inferred.) 
Hence, depicted signatures ABCgtGCB_U133AB(online interpretation card) and GCB_gt_ABC_U133plus(online interpretation 
card) may contain genes that are not necessarily associated with a consistent survival trend, as these genes were 
identified based on previously assigned subtype classes(cf. page  180 for details). 
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This is confirmed by the enrichment of these signatures for both the COO induced effect   129(cf. III.3.2.2) (that 
is associated with a strong survival trend with   1.1 ⋅ 10) and likewise enrichment for the current effect 
  20, although it only has   0.065 for the same test(cf. Figure III.2.5.1.a). 
Consequently and in general, significant enrichment of the same signatures for two different effects does not 
necessarily indicate that these effects represent biologically similar functions. Hence, results from signature 
enrichment analyses should be interpreted with care. In particular, the biological specificity of enriched 
signatures should be independently verified in the respective context, if possible. 
Furthermore, to quantify whether a small gene signature is associated with a particular effect, individual 
correlations of signature genes to the effect’s sample axis might provide a biologically more specific answer. 
These correlations may complement enrichment or overrepresentation analyses on signature level. 
(However, they can only be computed in context of a concrete patient cohort and are not available for pure 
genomic association analyses.) 
 
 
 
 
 
 
 
 
III.3.4.2   7: Presumably the main blood concentration effect 
 Effect overview 
This one-sided effect(Figure III.3.4.2) consists of approximately 800 top probesets (relative correlation  0.5) and 
is one of the largest discovered effects. It has been unsupervisedly quad-discovered with detection ranks 
#2(GSE10846.CHOP), #2(GSE10846.R-CHOP), #3(GSE4475.nonMBL) and #1(GSE31312.R-CHOP).  
It is not associated with patient outcome following (R-)CHOP therapy. 
 Effect identification 
Due to the effect’s size, many gene ontology terms are overrepresented and many signatures are enriched, 
including many signatures from specific leukemia and immune contexts. All of them are of much smaller size 
and hence are not representative for the full effect. Furthermore, they describe different biology. There should 
be a common explanation for such high correlations between so many genes. 
While unsupervised quad-discovery rules lab-specific technical effects out, it may be speculated that the 
effect represents differences in frequency of another cell type from the microenvironment that has been 
inadvertently included in measured tumor samples. This could affect all four patient cohorts and could explain 
the large number of correlated genes, as simply all genes expressed in this other cell type would be ordered 
by relative frequencies of this cell type in measured samples. However, this is just a hypothesis that seems 
plausible because of the large size of this effect that I have only seen between different cell types so far. Instead 
of a single cell type, it might also be an indirect measurement of a common mixture of cell types. 
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Figure III.3.4.2) One of the largest quad-discovered GEP effects that presumably represents blood concentrations in tumor samples 
Effect   7	applied to GSE10846.R-CHOP (233 patients); 1 patient id hidden from the plot as it has insufficient or insignificant correlation to this effect(cf. II.4.2.1).  
(The genomic consensus effect is applied to the cleaned signal without lab effects(cf. III.1.4.2). Samples and probesets are ordered by their effect strengths in this cohort(cf. 
Table III.1.5). Additionally, probesets are filtered by demanding a relative correlation stronger than 0.5. The effect’s bimonotonic eigensignal(panel d) is grayed for samples 
having insufficient or insignificant correlation to this effect(II.4.2.1).) 
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Screening significant signatures with this hypothesis in mind revealed that several different blood modules 
are significantly enriched: 
Signatures GSEA Basic Statistics 
Signatures DB Signature Name 
# 
defined 
# mea-
sured 
Enrich- 
ment 
score 
 FDR Mean log2( 
ratio) 
 (-test 
versus zero) 
Down- 
reg. ratio 
Upreg.  
ratio 
StaudtSigDB_dNov2012 Dendritic_cell_CD16pos_blood 42 41 0.659 0.0020 0.2% -0.635 1.7E-09 91.9% 8.1% 
StaudtSigDB_dNov2012 Blood_Module-1.5_Myeloid_lineage-1 110 108 0.583 0.0020 0.2% -0.611 6.3E-25 92.3% 7.7% 
StaudtSigDB_dNov2012 Blood_Module-3.1_Interferon_inducible 94 93 0.694 0.0020 0.2% -0.526 5.4E-18 91.8% 8.2% 
StaudtSigDB_dNov2012 Blood_Module-2.1_Cytotoxic_cells 160 155 0.586 0.0021 0.2% -0.551 1.5E-25 87.1% 12.9% 
StaudtSigDB_dNov2012 Blood_Module-2.6_Myeloid_lineage-2 145 143 0.543 0.0020 0.2% -0.461 5.3E-22 87.8% 12.2% 
StaudtSigDB_dNov2012 Blood_Module-1.3_B_cells 55 53 -0.577 0.0020 0.2% 0.496 2.0E-11 8.8% 91.2% 
 
Table III.3.4.2) Blood module signatures that are significantly enriched for   7 
All GSEA  values are based on permutation tests; hence, they are lower-bounded by 1 #permutations)⁄  and true  values might be considerably lower in this case. 
1000 permutations have been computed for each signature, i.e. approximately 500 for each enrichment sign. Percentages of down- and upregulated genes in a 
signature are weighted averages of gene regulation signs (using 1   values of -tests against zero regulation as weights). 
This might indicate that this effect is just an indirect measurement of blood concentrations in tumor samples 
and that these concentration differences cause the discovered broad correlation effect. Only moderate 
enrichment of these signatures could be caused by slightly changing mixture ratios of different blood cells 
form patient to patient. 
Interestingly, Blood_Module-1.3_B_cells(cf. online interpretation card, [127]) is anti-correlated to all other enriched blood 
modules, indicating that the effect does not only measure different levels of blood concentration, but a relative 
concentration of B cells and other blood cells. 
 Inference 
Assuming that this effect indeed measures relative concentrations of B cells to other blood modules, it may 
be interesting to find out whether these concentration ratios have already been introduced by tumor sampling. 
If this can be excluded, the effect might allow indirect insights on how different forms of DLBCL influence their 
tumor microenvironment. 
 
 
 
 
III.3.4.3   4: A strong immunoglobulin effect 
 Effect overview 
Effect   4 shows a strongly differential one-sided signal(Figure III.3.4.3, p222) and was also unsupervisedly 
discovered in all four DLBCL cohorts (with detection ranks #9(GSE10846.CHOP), #9(GSE10846.R-CHOP), #12(GSE4475.nonMBL) and 
#14(GSE31312.R-CHOP)). It is not associated with patient outcome following (R-)CHOP therapy. 
 Top genes overview 
Interestingly, most of this effect’s top-correlated genes 
originate from only three loci: 2p11.2, 14q32.33 and 
22q11.22(cf. Table III.3.4.3.a). Such overrepresented and 
specific loci might indicate a reflection of chromosomal 
features. To test for potential triggering aberrations, 
copy number measurements(e.g. from GSE11318, [11]) for these 
loci could be interrogated. 
Top genes in     
Probeset 
Gene  
Symbol 
HG19  
locus 

,  
,  
,  

,  
. 
,  
215176_x_at  2p11.2 2.21 0.95 1.6E-99 2.10 
211645_x_at  2p11.2 2.18 0.96 1.4E-109 2.09 
216576_x_at IGKC 2p11.2 2.04 0.95 8.5E-98 1.93 
234764_x_at IGLC1 22q11.22 2.11 0.80 8.9E-50 1.68 
216401_x_at  2p11.2 1.66 0.94 1.9E-92 1.56 
216207_x_at IGKC 2p11.2 1.57 0.94 3.0E-93 1.48 
217157_x_at IGKC 2p11.2 1.60 0.92 2.2E-80 1.47 
217378_x_at LOC100130100 2q13 1.55 0.93 1.2E-85 1.44 
216510_x_at IGHA1 14q32.33 1.65 0.79 1.5E-42 1.30 
217148_x_at IGLC1 22q11.22 1.81 0.69 8.1E-29 1.25 
211644_x_at IGKC 2p11.2 1.73 0.72 5.2E-32 1.24 
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However, as most top genes from all three loci are 
coding immunoglobulins, their consistent regulation 
might also be associated with a common function or 
cell type. 
 
 Genomic associations 
The gene ontology term for antigen binding(cf. 
GO:0003823) is significantly overrepresented with  
2.2 ⋅ 10  (7 of the effect’s top 17 genes belong to this 
term, while only 25 genes of all 20370 measured 
genes belong to it; hypergeometric test). 
Signature analyses revealed several significantly yet 
moderately enriched signatures, including several 
immunoglobulin gene families and Blood_Module-
1.1_Plasma_cells(cf. online interpretation card, [127]) (enrichment 
score 0.591,   0.0021, 486 permutations). 
 
 Inference 
Signature enrichment suggests that correlated 
expressions of genes in this effect might reflect 
concentrations of blood plasma cells that might 
produce and secrete soluble antibodies (immuno-
globulins). 
In this case and assuming that no bias with respect 
to plasma cell concentrations has been introduced by 
tumor sampling,   4 might measure an indirect 
effect of different forms of DLBCL on the micro-
environment. (Biases due to the way of sampling are 
unlikely here, because in all four independent cohorts 
approximately one third of patients overexpresses 
this effect relative to baseline and approximately two 
thirds have lower expression than baseline(cf. Figure 
III.3.4.3). In case of random fluctuations of plasma cell 
concentrations by tumor sampling, a baseline that is 
near the median would be more likely.) 
However, the link to plasma cells by enrichment 
requires further biological validation, because only 
approximately 25% of this signature’s genes are 
strongly differentially expressed by   4. Hence, also 
a more direct role of this effect in DLBCL cannot be 
excluded. 
214768_x_at IGKC 2p11.2 1.57 0.79 2.2E-43 1.24 
211430_s_at IGHG1 14q32.33 1.72 0.71 1.6E-31 1.23 
217480_x_at LOC100287723 (multiple) 1.35 0.91 3.1E-76 1.23 
216557_x_at IGHA1 14q32.33 1.43 0.77 2.9E-39 1.10 
217281_x_at IGH@ 14q32.33 1.40 0.77 1.2E-39 1.08 
216984_x_at IGLC1 22q11.22 1.52 0.70 4.4E-30 1.07 
211643_x_at IGKC 2p11.2 1.40 0.76 3.1E-38 1.06 
217022_s_at IGH@ 14q32.33 1.55 0.64 5.1E-24 1.00 
211650_x_at IGH@ 14q32.33 1.28 0.78 1.1E-40 0.99 
211798_x_at IGLJ3 22q11.22 1.33 0.74 4.1E-35 0.98 
214973_x_at IGHD 14q32.33 1.35 0.73 2.8E-33 0.98 
214777_at  2p11.2 1.52 0.64 5.2E-24 0.97 
216491_x_at IGHM 14q32.33 1.40 0.67 3.4E-27 0.94 
217258_x_at IGLV1-44 22q11.22 1.27 0.71 9.9E-32 0.91 
224342_x_at LOC96610 22q11.22 1.23 0.72 9.7E-36 0.88 
217227_x_at IGLV1-44 22q11.22 1.20 0.72 4.7E-33 0.87 
211637_x_at IGH@ 14q32.33 1.23 0.66 2.7E-26 0.82 
217179_x_at  22q11.22 1.24 0.66 2.5E-25 0.81 
214669_x_at IGKC 2p11.2 1.26 0.63 9.2E-23 0.79 
217235_x_at IGLL5 22q11.22 1.20 0.65 5.6E-25 0.78 
224795_x_at IGKC 15q21.3 1.31 0.59 4.5E-22 0.78 
211881_x_at IGLJ3 22q11.22 1.04 0.73 3.2E-34 0.76 
221651_x_at IGKC 2p11.2 1.30 0.58 4.5E-19 0.76 
221671_x_at IGKC 2p11.2 1.28 0.58 4.9E-19 0.74 
214836_x_at IGKC 2p11.2 1.17 0.63 3.2E-23 0.74 
211868_x_at IGH@ 14q32.33 1.05 0.68 2.1E-28 0.72 
211641_x_at IGHA1 14q32.33 0.93 0.75 2.9E-37 0.71 
215214_at IGLC1 22q11.22 1.00 0.68 1.0E-27 0.68 
209138_x_at IGLC1 22q11.22 1.28 0.52 6.4E-15 0.67 
211908_x_at IGK@ 14q32.33 0.92 0.72 4.1E-33 0.67 
234884_x_at IGLC1 22q11.22 1.01 0.65 4.7E-28 0.66 
214677_x_at IGLC1 22q11.22 1.30 0.49 2.5E-13 0.64 
211634_x_at IGHM 14q32.33 1.00 0.61 1.8E-21 0.61 
216542_x_at IGHA1 14q32.33 0.83 0.73 7.5E-34 0.61 
216560_x_at IGLC1 22q11.22 1.05 0.57 3.4E-18 0.60 
211639_x_at IGH@ 14q32.33 0.98 0.58 2.6E-19 0.57 
215121_x_at IGLC1 22q11.22 1.14 0.49 2.7E-13 0.56 
234366_x_at IGLC1 22q11.22 0.92 0.61 2.1E-23 0.56 
214916_x_at IGHA1 14q32.33 0.92 0.61 5.2E-21 0.56 
216829_at IGKC 2p11.2 0.75 0.71 4.0E-31 0.54 
215379_x_at IGLV1-44 22q11.22 1.06 0.50 1.5E-13 0.52 
216853_x_at IGLC1 22q11.22 0.89 0.56 2.1E-17 0.50 
217360_x_at IGHA1 14q32.33 0.69 0.70 3.0E-30 0.49 
215949_x_at IGHM 14q32.33 0.73 0.66 6.0E-26 0.49 
211635_x_at IGHA1 14q32.33 0.83 0.58 3.2E-19 0.49 
211640_x_at IGHG1 14q32.33 0.78 0.62 2.3E-22 0.48 
212592_at IGJ 4q13.3 1.18 0.41 3.5E-09 0.48 
215946_x_at IGLL3P 22q11.23 0.89 0.50 6.4E-14 0.45 
216412_x_at IGLC1 22q11.22 0.71 0.60 9.2E-21 0.43 
211633_x_at  14q32.33 0.70 0.59 5.5E-20 0.42 
237625_s_at  2p11.2 0.94 0.43 2.2E-11 0.41 
213502_x_at GUSBP11 22q11.23 0.84 0.48 1.7E-12 0.40 
216430_x_at IGLV1-44 22q11.22 0.62 0.61 4.9E-21 0.38 
217384_x_at IGHV3-48 14q32.33 0.56 0.66 5.7E-26 0.37 
216365_x_at IGLC1 22q11.22 0.72 0.51 3.1E-14 0.37 
234851_at IGLC1 22q11.22 0.60 0.58 2.7E-21 0.35 
234792_x_at IGHA1 14q32.33 0.57 0.58 6.7E-21 0.33 
216541_x_at IGHG1 14q32.33 0.60 0.52 4.0E-15 0.32 
235965_at  7q21.3 0.64 0.47 3.3E-13 0.30 
234707_x_at IGLV1-44 22q11.22 0.68 0.43 4.2E-11 0.29 
217236_x_at IGH@ 14q32.33 0.47 0.59 1.3E-19 0.28 
217239_x_at LOC100508797 14q32.33 0.48 0.57 3.2E-18 0.27 
211647_x_at IGHG1 14q32.33 0.48 0.56 2.9E-17 0.27 
211649_x_at IGHA1 14q32.33 0.46 0.53 2.1E-15 0.24 
216708_x_at CKAP2 22q11.22 0.49 0.47 2.6E-12 0.23 
200670_at XBP1 22q12.1 0.54 0.42 7.3E-10 0.23 
217145_at IGKC 2p11.2 0.42 0.51 4.7E-14 0.21 
216517_at IGKC 2p11.2 0.45 0.44 8.9E-11 0.20 
229721_x_at DERL3 22q11.23 0.45 0.44 1.2E-11 0.20 
201287_s_at SDC1 2p24.1 0.43 0.45 5.4E-11 0.19 
Table III.3.4.3.a) Top genes in validated effect   4 
 (probesets) from Affymetrix U133 Plus 2.0 microarrays;  
  manufacturer annotations (NetAffxTM,[97] v33) 
 
,  Components of the consensus gene axis of effect   4  
  (cf. Table III.1.5); filtered 
,   0.4. 
 
,  Consensus gene correlations; filtered 
,  0.4. 
 
,   values for the correlations (cf. II.5.2.1) 
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Figure III.3.4.3) A quad-discovered immunoglobulin effect  
Effect   4 applied to GSE10846.R-CHOP (233 patients); 6 patients are hidden from the plot as they have insufficient or insignificant correlation to this effect(cf. II.4.2.1). 
(The genomic consensus effect is applied to the cleaned signal without lab effects(cf. III.1.4.2). Samples and probesets are ordered by their effect strengths in this cohort(cf. 
Table III.1.5). Additionally, probesets are filtered by demanding a relative correlation stronger than 0.5. The effect’s bimonotonic eigensignal(panel d) is grayed for samples 
having insufficient or insignificant correlation to this effect(II.4.2.1).) 
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A novel method for signal dissection into interpretable patterns has been designed, 
developed and successfully validated against synthetic and real-world data. Its search 
strategy for interactions is based on an extremum principle for correlations. Its bimonotonic 
effect model allows the regression of a broad class of nonlinear gene regulations. With its 
capability to dissect even partially correlated effects precisely, it goes conceptually beyond 
standard methods like principle components analysis and hierarchical clustering. 
All known major GEP effects for DLBCL that are significantly associated with patient 
survival have been rediscovered. Additionally, novel genetic effects with greater predictive 
power have been discovered. They can predict significant survival differences within known 
disease subtypes and within clinical risk classes by international prognostic index. 
Comprehensive biostatistical evaluations for discovered survival effects reveal hierarchical 
dependencies and pinpoint molecular heterogeneities. Effect correlations identify potential 
oncogenes or tumor suppressor genes. Together, these results may help to clarify the 
molecular pathogenesis of DLBCL. 
Signal dissection can be readily applied to other cancer entities as well. Moreover, its concept 
of interaction may have the potential to lead to more interpretable insights into signals from 
many other fields of science, for instance, into spectral energy distributions of stars. 
 Key concepts and scope of application 
Mathematically, signal dissection is applicable to any high-dimensional multi-sample signal ∈ (cf. II.2.1.1) 
consisting of  samples (e.g. tumor biopsies) of a system with  dimensions (e.g. genes). However, for resulting 
effects to be interpretable, its concept of interaction and detection must be compatible with the analyzed 
system. There are three key concepts driving signal dissection that determine its scope of application and 
distinguish it from principal components analysis (PCA). 
Correlation maximization principle: Initially, the search strategy(II.3) detects effect axes similar to principal 
components, but it utilizes a different generic concept of interactions for detection(cf. I.1.3.4). Rather than looking 
for maximal signal variance and minimal cross-effect covariance as done by PCA(cf. I.2.2.2), it maximizes the within-
effect correlation(II.3.1.6). Searching for maximal correlation instead of maximal variance optimizes specificity of 
resulting effects. Generally, for signal dissection to be applicable, it must make sense to ask for non-local 
correlations between arbitrary system dimensions and between arbitrary samples. For genes, this is the case, 
as their extrinsic order by genomic sequence does not prevent non-neighboring genes from being coordinately 
expressed by a shared pathway that is active in measured cells. Discovered effect axes then summarize laws 
of gene regulation mediated by such pathways (or by other causes) as linear combinations of genes. 
Generic bimonotonic effect model: A bimonotonic effect model(II.2.1.2) and a corresponding bimonotonic 
regression algorithm(II.4.1) is utilized to empirically estimate an particular effect’s own contributions to the 
measured signal sum of superposed effects(II.2.1.1). The resulting effect eigensignal can be parameterized as 
either the effect’s gene curve in gene space or the effect’s sample curve in sample space(II.2.2.3). Effect curves 
extend the linear concept of gene and sample axes. This also extends the method’s applicability to a broad class 
of nonlinear effects that are monotonic with respect to projections on effect axes, e.g. biological activation 
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thresholds or saturations(II.1.1.2). In contrast, usual projections along gene axes can only explain the linear 
component of an effect’s law of gene regulation. Hence, a naïve dissection by projection would split the effect 
by leaving its nonlinear parts in the signal. This would trigger later discoveries of hard-to-interpret secon-
dary effects. 
Effect focusing and precise dissection: Weighted uncentered correlations(cf. II.2.3.1) to converged gene and 
sample axes and their statistical significance(II.5.2.1) define the final focus of a discovered effect, i.e. its 
participating genes and affected samples. Utilizing this focus as dissection strengths and together with 
regressed effect curves, this allows the precise and exclusive dissection of the effect(II.4.2). Signal parts from 
other potentially overlapping effects (that may regulate the same genes in the same samples by other laws) 
are left untouched for their later separate discovery(e.g. Figure II.4.2.2.b). This makes the method even applicable in 
context of partially correlated effects, for instance to all four effects in the 3D concept example(II.6.1). In contrast, 
the dissection of such effects is not possible with PCA or with other methods that are equivalent to projections 
or to orthogonal coordinate transformations of the gene or sample space. (This is conceptually impossible for 
these methods, because after three full projections in 3D only a point signal remains, but there are four distinct 
effect axes in this signal(cf. II.6.1).) 
Signal dissection utilizes these concepts iteratively to detect, extract, quantify and summarize distinct laws 
of gene regulation by effect curves. Other than traditional techniques like hierarchical clustering that can just 
reorganize genes and samples into groups once, dissection modifies the signal itself by “peeling off” correlated 
and potentially overlapped signal parts. The sum of all detected and dissected effects reconstructs the complete 
signal, except for noise(cf. II.2.1.1). If needed, a traditional clustering can be readily derived from each effect by 
choosing a cutoff. Hence, signal dissection effectively also realizes and describes a set of alternate clusterings 
of genes and samples by shared gene regulation effects. 
 
 Solution overview 
As introduced(I.1), the practical aim is to bridge the increasing gap between overwhelmingly detailed signals 
based on modern measurement technology and expert modeling of underlying (and typically complex) 
systems. To this end, signal dissection contributes an interpretable summarization of measured signals. More 
precisely, it contributes a superposition(II.2.1.1) of specific effects of interaction that are observable by 
correlations(II.2.1.2). However, a complete solution for this aim needs some additional steps. 
For validation purposes, two or more independent sample sets have to be measured for the analyzed system; 
this is depicted by three exemplary patient cohorts in the solution scheme(unterhalb). First, the signal for each 
cohort is dissected independently. Important steps of signal dissection are illustrated again. Next, resulting 
sets of effects are validated across cohorts; this enables filtering out systematic errors like lab-specific effects. 
Hence, validated effects most probably originate from true interactions in the analyzed system. Finally and as 
optimal preparation for expert interpretation and modeling, several statistical methods are utilized to 
associate validated effects with available sources of computable knowledge. 
This solution has been applied to more than 1000 tumor samples from DLBCL patients(III.1.1.1). All gene 
expression effects that can distinguish patients of DLBCL have been unsupervisedly discovered and 
validated(III.1.2) across four independent patient cohorts. As signal dissection is complete(II.2.1.1), there are no 
significant(II.5) GEP correlation effects left in remaining signals. Several validated effects are significantly 
associated with patient outcome. Genetically novel survival effects are summarized below. To the best of my 
knowledge, this is the most comprehensive unsupervised gene expression analysis of DLBCL to date. 
Conclusion 225 
 
 
Solution scheme (exemplary for gene expressions in bioscience) 
(a) Gene expressions have been measured for independent patient cohorts. (b) Signal dissection and its exploratory search strategy detect effects. (c) Discovered 
effects are validated across independent cohorts. (d) Applying validated consensus gene effects classifies samples. (e) Genomic associations to consensus gene axes 
and clinical associations to consensus sample axes provide the basis for expert assessment and interpretation of effects. 
Measurements: Gene expressions for patient cohorts of the disease 
Discovery: Signal dissection (for each independent cohort) 
, 
Cross-cohort validation 
, , 
Consensus effects 
, 
An initial or a 
new patient 
cohort 
Consensus 
sample order 
, , , 
Signal Cleaning 
(dissect as above 
and remove all 
effects that failed 
validation; III.1.4.1) 
Filter out systematic errors 
(cohort-specific lab effects) 
Remaining signal 
 ≡    
(may still contain 
information about 
superposed effects) 
Unexplained  
signal  
Consensus gene axes (most probab-
ly of biological origin; cf. III.1.3) 
Statistical evaluation (III.3) and effect identification 
Significantly over-
represented loci 
Significant clinical 
associations 
Significantly en-
riched signatures 
Consensus sample axes Consensus gene axes 
Log rank 
tests 
Genomic 
order 
Clinical data 
(e.g. gender) 
Hypergeo-
metric tests 
Follow up 
events 
Contingency 
tables 
Gene Set 
Enrichment 
Analyses 
Known gene 
signatures 
Stop, once no 
significant effects 
remain 
Sort by projections on 
effect axes (II.4.1.1) 
, 
Search strategy (II.3) 
Unsupervised validation (independent discovery in multiple cohorts) or 
supervised validation (apply detected gene axes to other cohorts) (III.1.2) 
Classification 
(compute eigensignals 
as above, but utilize 
discovered consensus 
gene axes instead of 
the search strategy; 
cf. III.1.4.2) 
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 Method validation and comparison 
Several synthetic data scenarios have been designed to validate signal dissection thoroughly: A versatility 
test(II.6.2) has simulated overlapping effects of various size, shape and signal strength that mimic known 
biological or technical real world effects. A superposition scenario(II.6.3) has tested the maximum dissectible 
amount of overlapping effects. Several tests have been designed to test diverse detection limits(II.6.4): the limit 
of weak signals relative to simulated noise, the limit of acceptable missing values and the limit of an acceptable 
number of noise genes for the detection of small effects.  
A systematic comparison with PCA has proven that signal dissection leads to more interpretable results, i.e. 
the method is able to rediscover more simulated effects with significantly higher correlations to true simulated 
effect axes(cf. II.6.2.5). In particular, signal dissection has clear advantages for overlapping effects of similar size, 
which are common for real world gene expression signals. Here, PCA’s interaction concept of maximal 
variance guides to genes that are expressed by the highest number of overlapping effects. Consequently, 
resulting principal components represent uninterpretable linear combinations of overlapping yet distinct 
effects, rather than to dissect the signal into true simulated effects(cf. Figure II.6.3.1.a).  
Furthermore, signal dissection can still detect effects for high ratios of missing values(e.g. Figure II.6.4.4.b). To a 
certain extent, it can even restore missing signals from correlations(cf. Figure II.6.4.4.d). (PCA does not support signals 
with missing values.) 
 
 Real-world validation and rediscovered biological effects 
Signal dissection has also been successfully validated against real-world data. For instance, the gender GEP 
effect has been unsupervisedly discovered in all four dissected DLBCL patient cohorts(III.3.2.1). This is already an 
independent control of detection, validation, annotation and interpretation pipelines. 
Due to the completeness of signal dissection(II.2.1.1), additionally all major previously discovered DLBCL GEP 
effects have been unsupervisedly rediscovered. All are known for their association with patient outcome. The 
biologically most important one is the cell-of-origin (COO) induced effect. It identifies two patient subgroups 
as molecularly distinct DLBCL subtypes(III.3.2.2, index ν=129). These subtypes are associated with significantly 
different survival and are hard to distinguish on morphological level. Hence, this molecular effect is possibly 
needed for precise therapy decisions, when subtype-specific agents become available. Secondly, a stromal 
effect has been rediscovered that is associated with the extracellular matrix(III.3.3.4, index ν=5). Thirdly, another 
stromal effect has been rediscovered that has previously been associated with the tumor blood-vessel 
density(III.3.3.5, index ν=44). 
 
 Genetically novel effects and survival prediction 
Several more genetically distinct GEP effects have been discovered that are significantly associated with 
survival(III.2.5.1). In particular, one genetically novel effect(III.3.3.1, index ν=134) can predict observed survival even more 
consistent(Figure III.2.5.1.a) than the COO induced effect. 
Via iterative selection of GEP effects that provide the highest additional explanatory value for observed 
patient outcome, a quinvariate Cox survival predictor has been constructed(III.2.5). Based on leave-one-out 
validation, predicted survival probabilities show a homogeneous predictor performance from 29% to 89% 
average survival(cf. Figure III.2.5.3.b). Comparison with survival dependencies that are predicted by known DLBCL 
subtypes(III.2.1.8) shows an obvious and strong increase in the predicted survival spread, both for the former 
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standard CHOP and the current standard R-CHOP chemotherapy(III.2.5.4). Furthermore, it can predict significant 
survival differences within known DLBCL subtypes(III.2.5.6) and within risk classes by international prognostic 
index (IPI)(III.2.5.8). This suggests that discovered GEP effects register so far unknown DLBCL biology and identify 
relevant genetic heterogeneity. Additionally, this demonstrates that macroscopic clinical observables 
underlying the IPI score presumably can no longer serve as surrogates for molecular predictors, as soon as 
different therapies for specific molecular subtypes become clinically available. The latter is a concrete goal 
towards precision medicine(I.1.2.4). 
 
 Biostatistical evaluation of major novel survival effects 
It is not yet clear which precise molecular mechanisms cause these survival differences. Towards 
understanding them, all discovered major survival effects(III.3.3) have been biostatistically evaluated. Genomic 
associations of effects with existing knowledge, clinical associations with patient covariates and in particular 
hierarchical survival dependencies between effects have been analyzed. These results and suggested 
biological validation experiments may help to advance the investigation of DLBCL’s molecular pathogenesis. 
Selected results and inferred biological hypotheses are summarized below. 
Effect   134(III.3.3.1) is the primary survival factor in DLBCL, as it can predict survival most consistently with 
  4.5 ⋅ 10. The COO induced effect(cf. III.3.2.2) follows at rank #2 with   1.1 ⋅ 10(Figure III.2.5.1.a). Top genes of 
these two effects are only weakly correlated (;)
  0.29). With only 69 unique correlated top genes, 
effect   134 is more specific than the COO induced effect with 151 unique top genes for the same correlation 
cutoff. One of the novel effect’s top genes is KLHL6. As KLHL6 proteins contain a domain that is known for 
transcriptional repression activity and might be involved in the germinal center B-cell differentiation 
pathway[109], it could potentially be a tumor suppressor gene. This would be consistent with significantly 
adverse patient outcome for lower KLHL6 expression. As they are linked by high GEP correlation, the same 
biological functions might be associated with FGD6 and other top-correlated genes of   134. These 
hypotheses about potential tumor suppressor genes could possibly be investigated by overexpression 
experiments in DLBCL cell lines that show low expression of effect   134. To identify these cell lines, they 
could be screened for their protein levels of KLHL6 and FGD6. Ideally, the proliferation of cells with low or 
nonexistent levels of these proteins can be stopped by corresponding overexpression experiments. 
Effect   127(III.3.3.2) is the best secondary predictor variable with   5.6 ⋅ 10 on top of the primary effect 
  134 when training with samples from all R-CHOP treated patients(III.2.2.1). It predicts hierarchical survival 
dependencies(III.2.2.3) that exclusively exist in the lower risk partition of the primary effect(Figure III.2.2.3.a). To 
elucidate the biological pathway underlying   127, further biological experiments might potentially be 
helpful. Analytically, BACH2 seems to be a promising oncogene candidate for the lower risk partition of  
134, i.e. predominantly for GCB DLBCL patients. To test this hypothesis, GCB DLBCL cell lines with high BACH2 
protein expression could be selected for BACH2 knockdown experiments. 
Effect   3(III.3.3.8) contributes to the final quinvariate model(cf. Table III.2.5.2) with a Cox  value of 6.3 ⋅ 10. It 
measures metallothionein expressions and predicts significant survival differences in context of two other 
effects. High metallothionein expression is associated with adverse outcome for DLBCL patients with low 
BCL2 expression(III.3.3.7) and high “T cell co-stimulation”(III.3.3.6). Low metallothionein expression in this subset is 
associated with 95.5% average survival(cf. Figure III.3.3.8.c). The molecular mechanisms for metallothionein 
overexpression are currently unclear. The gene ontology result for cellular response to zinc ion and published 
data for a lung cancer experiment using zinc ionophores[124] indicate that the expression of this effect may 
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directly correlate with zinc concentrations. In this context, a correlation of patient zinc blood levels with 
average expressions of this effect could potentially be interesting. 
Besides major survival effects(III.3.3), several additional effects with differential gene expressions have been 
discovered and validated across DLBCL patient cohorts. Some of these effects describe ordinary human gene 
expression differences like the quad-discovered gender effect(III.3.2.1) or a presumed blood concentration 
effect(III.3.4.2). Further disease-specific effects might also be among these effect, because current chemotherapies 
may have no or only a constant impact on their underlying pathways. All biostatistical analyses have been 
performed for these effects as well and are provided on disc(page 231). 
 
 
 
 
 
 
 
 
 
 Dissecting other cancer entities 
Given validated and biologically relevant results for DLBCL, a promising research perspective is the 
dissection of gene expression signals for other cancer entities. With a multitude of gene expression cohorts for 
various cancers already publicly available via the NCBI Gene Expression Omnibus([63], http://www.ncbi.nlm.nih.gov/geo) or 
via the Cancer Genome Atlas(see TCGA Research Network, http://cancergenome.nih.gov), this perspective has enormous scope. 
Furthermore, the recent(January 2015) United States Government Precision Medicine Initiative has the aim to 
measure genomic data for up to one-million samples[15], an unprecedented amount of genomic data. This is 
ideal for signal dissection and may even allow the discovery of effects that concern only tiny fractions of 
samples for a particular disease. This initiative also underlines the priority of this research field[14] and the 
potential of signal dissection in particular. 
 
 Biologically more specific genomic associations 
The conceptual problem of representing effects by flat sets(cf. II.1.2.6) has been demonstrated for DLBCL 
subtypes: Several genetically distinct GEP effects are significantly associated with ABC DLBCL and GCB DLBCL, 
but they show strikingly different predictive power with respect to patient outcome(e.g. III.3.4.1). The same 
problem does not only concern sets of samples. Information is likewise lost when representing genomic effects 
by sets of genes, as is commonly done for gene signatures today. This can result in significant enrichments of 
the same signature for genetically distinct effects with distinct biological characteristics. For instance, the 
same ABC-versus-GCB signatures are significantly enriched for validated effects   129,   134 and   20, 
although these effects have clearly different top genes and again strikingly different predictive power. In brief, 
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flat sets for sample clusters or gene signatures do not encode enough information about biological effects to 
enable specific associations. 
In contrast, signal dissection quantifies effects with much more information as is stored by flat sets. For 
example, gene axes store regulation strengths mediated by the underlying pathway for each single gene. 
Additionally, gene correlations describe the consistency of these regulations over all samples for each single 
gene. Based on these information and the associated effect foci, a precise cross-cohort validation of effects can 
be facilitated(III.1.2.1). More precisely, this task is realized by weighted uncentered correlations(II.2.3.1) that can be 
complemented with measures of statistical significance(II.5.2). 
The same effect comparison method could also be utilized to replace gene set enrichment analyses in order 
to facilitate biologically more specific associations. An effects database similar to large public gene signature 
databases does not yet exist, but discovered DLBCL effects could provide a start. Many gene signatures are 
based on supervised analyses(I.2.1) or on hierarchical clustering(I.2.2.1) of gene expression signals that are already 
stored in public databases. Hence and in principle, such an effects database could be built semi-automatically 
by dissection of these stored gene expression signals, although this would require a tremendous amount of 
computation. 
 
 Towards standalone microarray classification for clinical applications 
To utilize results like survival predictors(III.2) for clinical applications, e.g. for therapy decisions and towards 
precision medicine, standalone microarray measurements for tissue samples from single patients should be 
robustly classifiable. The technological problem here is that absolute gene expression intensities may vary 
strongly by chip design and by lab, for example due to different measurement protocols or due to different 
sequences probed for the same genes. Not all sources for these differences are known. Typically, this problem 
is solved by measuring sufficiently large patient cohorts with exactly the same microarrays in exactly the same 
lab. Then gene expression ratios relative to average gene intensities in this cohort are analyzed to avoid 
problems originating from technology-specific gene offset intensities. For a clinical application based on only 
one standalone microarray however, this is not possible (all ratios would equal one). Hence, a way to dissect 
all technological offsets precisely from this standalone microarray is required in order to compare the 
remaining biological signal with known and validated biological effects (e.g. with the COO effect for DLBCL 
subtype classification). 
Assuming that lab effects and offset effects are systematic errors and only a finite number of them exists, it 
may be possible to achieve this by signal dissection. First, raw gene expression signals for many patient 
cohorts that were measured by various microarray designs in different labs need to be dissected. Resulting 
systematic lab effects, i.e. all effects that do not validate across biologically equal cohorts, but do validate across 
technologically equal and biologically different cohorts, are recorded in a database. Now the standalone 
microarray could be tested for similar effects by computing correlations with gene axes of recorded and 
validated technical effects. Top-correlated offset effects or other lab effects could then be dissected from its 
signal, which should result in effective logratio) that can subsequently be classified with validated biological 
effects. To quantify the confidence of such classifications,  values for weighted uncentered correlations could 
be utilized. 
Such a normalization by dissection of known technical effects may be much more precise compared to global 
normalization methods like quantile normalization. This could provide a tool for precision medicine that can 
utilize existing molecular knowledge for future therapy decisions in clinical settings, even for cost-effective 
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standalone microarray measurements. Furthermore, this lab effects database could help to identify 
technological causes of lab effects in order to improve experimental reproducibility in the first place. 
 
 Beyond bioscience 
Throughout this work, DLBCL was selected as concrete biological application for signal dissection. Therefore 
and lastly, let the following analogy illustrate the method’s general applicability and potential beyond 
biosciences, whenever intrinsic data orders by correlations are of interest. 
System Bioscience example Astrophysics example 
Samples  
or system instances 
tumor biopsies from patients 
stars or quasars (i.e. centers  
of active galaxies) 
Dimensions  
or system parts 
all known genes 
e.g. known spectral lines for all elements or 
other light-emitting entities (or simply an 
equidistantly discretized light spectrum) 
Extrinsic order that tolerates 
non-local correlations 
order of genes by genomic sequence order of spectral lines by energy 
Observable signal 
gene expressions (i.e. mRNA molecule 
concentrations in cells) 
light intensities in spectral intervals  
(spectral energy distributions) 
Signal dissection   
Discovered effect curves 
empirical laws of coordinated  
and specific gene regulation 
empirical laws of coordinated  
and specific light emission 
Classification of samples by 
their correlations to effects 
disease subtypes, i.e. groups of  
patients that may share the same  
drivers of pathogenesis 
classes of stars that maintain common 
reactions and may share a similar  
element composition 
Modeling by experts   
Underlying system 
interactions 
gene-regulating pathways 
(e.g. for the process of cell division) 
light-emitting physical reaction  
pathways (e.g. for nuclear fusion) 
General applicability of signal dissection by analogy 
 
Similar to the explorative detection of so far unknown biological processes in cells, signal dissection could 
yield so far unknown light-emitting reactions in stars. Patients belonging to the same disease subtype 
correspond to stars that maintain a common reaction. This could be utilized for star classification, for example. 
Finally, reverse engineering of biological pathways by molecular biologists corresponds to reverse 
engineering of physical reaction chains in stars by astrophysicists. 
Similar to bioscience, large and growing spectral data volumes are already publicly available, for example 
via the Sloan Digital Sky Survey(SDSS, see http://www.sdss.org). Consistent with results for synthetic test scenarios(e.g. Figure 
II.6.3.1.a), principal components in astrophysics are already known to be hard to interpret in terms of their 
physical properties(cf. I.1.4.1). Hence, application of signal dissection to light spectra of measured stars or quasars 
might be a promising research perspective as well. 
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All dissection results for DLBCL, all 135 validated consensus GEP effects(III.1) and all performed 
biostatistical analyses for each consensus effect(see III.3 for examples) are provided on disc in both 
graphical and tabular format. Files of biological interest can be located quickly via master 
tables. Additionally, dissection results for all method validation scenarios(cf. II.6) are provided.  
 Master tables 
Master tables in the root folder provide a convenient access to all results for DLBCL by linking to them. 
The main overview table lists all 135 validated DLBCL consensus effects, links to their signal plots for each 
patient cohort, followed by links to their genomic analyses like signature analyses tables and gene ontology 
analyses folders. The next column group lists and links to survival analyses and to associations with clinical 
covariates like gender or IPI scores. These analyses are provided separately for all patients and for ABC DLBCL 
and GCB DLBCL subsets. The last column group shows related effects having similar top genes in form of their 
consensus gene axis correlations. 
The gene orders master table lists consensus gene axes and consensus gene correlations for all measured 
probesets and for each effect. Annotation columns like genomic alignments and probeset IDs allow comparing 
genomic loci of top genes and allow retrieving exact sequences that underlie correlated gene expressions. 
In the sample orders master table, patients from all four cohorts are listed together with their consensus 
sample axes and consensus sample correlations for each effect. These columns allow sorting all patients by 
 
Blu-ray disc) All dissection results and biostatistical analyses in digital form (ca. 18.2 GB, ca. 65.000 files) 
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their involvement in a given effect. Another column group in this table lists all available clinical data about 
those samples, including available follow-up information. 
(Master tables were tested to work on a Windows® 7 PC with Excel® 2013 and 8GB RAM. Weaker PCs or 
older versions of Excel® might have problems due to the large table size. In this case, the directory structure 
described below allows opening smaller result files for individual effects manually.) 
 Directors structure 
 A=Detection 
• Contains cohort subfolders for GSE10846.CHOP, GSE10846.R-CHOP, GSE4475 and GSE31312. 
• For each discovered and dissected effect, several files exist, named with the effect’s dissection rank. 
Most importantly, files named like 007, effect overview.eps show the effect’s heatmap, its regressed 
eigensignal and the remaining signal for further dissection. Files named like 007, definition.xlsx 
contain converged gene and sample axes, correlations and  values for an effect, both before and 
after dissection to control dissection efficacy. 
 B=Validation and Consensus Eigenorders 
• \A=cohorts vs cohorts: Contains gene order correlations between detected effects of all cohorts based 
on product gene scores(cf. III.1.3.2). These correlations are the basis for unsupervised cross-cohort 
validation of detected GEP effects. 
• \validatedEffects: Contains scatter plots for validated effect tuples. 
 C=Consensus Effects 
• Contains cohort subfolders for GSE10846.CHOP, GSE10846.R-CHOP, GSE4475 and GSE31312. 
• For each validated effect, similar files exist as for detection. However, this time each validated effect 
is applied to and dissected from the cohort’s initial GEP signal (except for cleaned lab effects). 
 D=Interpretation 
• \genomic 
• Contains effect subfolders named like v007. 
• \SA: These subfolders contain signature analyses, together with enrichment plots and 
heatmaps for strongly enriched signatures (genes ranked by product gene scores(cf. III.1.3.2)). 
• \GOA: Contains gene ontology overrepresentation analyses for effect top gene signatures of 
various size. Analyses are available for term trees of biological processes, molecular functions 
and cellular components. (Not available if the effect has less than five top genes.) 
• \clinical 
• Contains effect subfolders named like v007. 
• Clinical cohort subfolders like GSE10846_RCHOP.GCB.PFS 
• Kaplan-Meier survival estimates for patient subsets cut by the effect’s sample 
scores(cf. III.3.1.1). Excel files contain plots in tabular form. 
• Excel filed for clinical correlations contain contingency sub tables for each covariate. 
• \comparisons: Contains Kaplan-Meier survival estimates for standard ABC DLBCL, unclassified 
and GCB DLBCL patient subsets for comparison. 
 Method Validation 
• Contains subfolders for various synthetic data scenarios for method validation(II.6). 
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Symbols 
 Spaces and the initial signal 
 Number of measured dimensions or genes 
 Number of measured samples   Signal space, i.e. the matrix space  ≡ ,…,…|, ∈ . The complete gene expression signal 
measured for a patient cohort is one element in this signal space, for example. 
  Initial signal matrix ∈     Gene vector space over  , spanned by  gene basis vectors |  1 … . Contains measured samples | with their expressions  | for all genes   1 … . See II.2.2.1 for details.   Sample vector space over  , spanned by  sample basis vectors |   1 … . Contains measured genes |  with their expressions  |  for all samples   1 …  . See II.2.2.1 for details.   External measurement or reference order of genes; without loss of generality  ≡ 1,2, … ,    External measurement or reference order of samples; without loss of generality  ≡ 1,2, … ,  | ,  Abbreviation for the vector | ∈   with components ∀  1 … :  | ≡ ,  |,  Abbreviation for the vector | ∈   with components ∀  1 … :  | ≡ ,  
,  Permuted matrix for sort vectors , , i.e. ,  ≡ , …,…. Sort vectors are 
permutations of row indices   or column indices  , respectively. In particular,  ,    . 
 
 Basic operations and functions |,  Vector | and its coordinate array, e.g. for | ∈   the column array    |, ∈    Matrix multiplication, defined as ∑ ,, , . E.g. for a row vector  ∈   and a column vector  ∈ the scalar ∑ ,,… ∈ . In case of a column vector  ∈   and a row vector  ∈   the 
matrix …,… ∈  . |,   Dual vector for | and transpose operation for its coordinate array . E.g. for | ∈   the dual vector  
is | ∈ ∗; it is computed on coordinate level via transposition and hence equals the row vector   |, ∈  . 	.  Hadamard product (i.e. component-wise multiplication); yields a vector or matrix of the same size. 
|	 Scalar product aka dot product; for |, | ∈   defined on coordinate level as  ∈ . 
‖‖ Euclidean vector norm ‖‖ ≡ |  ∑   ⁄  |⨂| Tensor product aka outer product; e.g. for | ∈  , | ∈   defined as  ∈  . 
̂ Uncentered standard deviation of , i.e. E  0, where E  denotes the expectation estimator. 
 
 Central measures of interaction ||  Weighted projections of a vector | in direction of an axis | using dimension weights |. Equals the 
normalized weighted scalar product defined as . |.  ‖. ‖⁄ . See II.2.3.2 for details. 
||  Weighted uncentered correlation aka the weighted cosine distance between | and | using dimension 
weights |. Defined as  . |.  ‖ . ‖‖. ‖)⁄ . See II.2.3.1 for details. 
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 Search strategy and effect axes convergence 
,  Index of the detection iteration and of the effect detected by it. The total number of detected effects before 
termination is denoted by  . 
 Input signal for detection iteration  that ultimately yields the remaining signal   after dissecting effect  . 
(See the signal model in II.2.1.1.) 

  Standardized signal matrix with uncentered variances equaling one for all rows and columns (cf. II.3.1.1). 
 
, , , Gene index , ∈ 1,  ⊂  respectively sample index , ∈ 1,  ⊂  selected as initial representative 
for effect  by the search strategy (cf. II.3.1). |, |   Gene and sample effect axes. Based on the selected initial gene or sample and its twin axis (cf. II.3.1.3).  , |  Initial gene and sample weights based on the standardized signal (cf. II.3.1.2). |, |   Gene and sample correlations to the respective effect axis (cf. II.3.1.4). |, |  Gene and sample  values for correlations (cf. II.5.2.1). |, | Gene and sample weights aka the effect focus. Based on correlations and their significance (cf. II.3.1.4). 
  Scalar effect score based on correlations of genes and samples with the effect and on the effect size (II.3.1.6). 
 
,  Iteration index of effect axes convergence (cf. II.3.2); equals the number of representatives utilized so far for 
definition of the effect’s axes.  denotes the number of representatives considered sufficient (cf. II.3.2.3). |, |  Gene axis and sample axis for representative  (cf. II.3.1.3). |, |  Accumulated gene axis and accumulated sample axis for representatives 1 …  (cf. II.3.2.3). |, | , |, |, |, |, |, | Converged effect axes based on  selected representative genes or samples, 
final correlations to these axes and their significance, and the final effect focus for effect  . (The index  is 
clear from the context and suppressed for readability reasons.) 
 
 Bimonotonic regression, effect eigensignal and its dissection ,      Index of outer regression iterations (cf. II.4.1) and the converged iteration     (cf. II.4.1.5). , , ,  Effect strengths for effect  in regression iteration . Defined as projections of all genes and samples on the 
respective final effect axis or on the regressed effect curves (cf. II.4.1.1). , , ,  Empirical effect eigenorder based on effect strengths (cf. II.4.1.2 and also see the effect model in II.2.1.2). , , ,  Current signal in the empirical eigenorder. ,      Index of inner bimonotonic regression iterations (cf. II.4.1.3) (and convergence iteration     ). ,    Result of the converged iterative bimonotonic regression of the signal in empirical eigenorder (cf. II.4.1.3). ,     Adaptive smoothing of the result from bimonotonic regression using rescaling and 2D Fourier  
transformations (cf. II.4.1.4). 
  Dissection strengths of the effect, defined based on the product effect focus (cf. II.4.2.1). 
   Eigensignal of detected effect  (cf. II.4.2.1 and also see the effect model in II.2.1.2). 
 
 Effect validation and sores for biostatistical association analyses       Number of independently dissected cohorts that are available for validation (cf. III.1.2.2). | |.   Gene scores based on the gene axis and gene correlations; defined as ∑  	 	 . Used as 
basis for cross-cohort comparison of effects (cf. III.1.2.1), to compare consensus gene effects (cf. III.1.3.2) and 
to associate effects with genomic knowledge (cf. Table III.1.5). 
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,; ,) Correlations between gene scores of effects   from cohort    and   from cohort   (cf. III.1.2.1).  ,,    For each possible effects tuple, the counts of significant pairwise correlations between effects from different 
cohorts, their average correlation to each other and a validation score (cf. III.1.2.2). 
  Validation index for all unsupervisedly (cf. III.1.2.2) and selected supervisedly (cf. III.1.2.3) validated effects. 

, , 
,, 
,   Consensus gene axes, correlations and weights for detected effects for validation index  (III.1.3.1). 
 ,   Cleaned signal of cohort   (cf. III.1.4.1). 
 ,   Eigensignal of consensus effect  in cohort   (cf. III.1.4.2). 
| ,   Sample eigensignal strengths of consensus effect  in cohort   (cf. III.1.4.2). Used to associate effects with 
clinical knowledge (cf. Table III.1.5). 
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